[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"fda-warning-letters-search:[\"Diversatek Healthcare\",\"\",\"\",\"\",\"\",1]":3,"fda-latest-sync-dates":344},{"warningLetters":4,"total":343},[5,33,58,77,98,122,141,160,181,199,217,235,255,272,287,306,324],{"id":6,"raw":7,"subject":14,"body_html":15,"body_text":16,"firm_name":17,"letter_id":18,"created_at":19,"fei_number":20,"letter_url":21,"updated_at":22,"action_type":23,"case_status":24,"posted_date":25,"marcs_cms_no":26,"product_type":27,"closeout_date":20,"issuing_office":11,"recipient_name":28,"body_fetched_at":29,"delivery_method":30,"recipient_title":20,"reference_number":31,"action_taken_date":32,"medical_device_id":20,"response_letter_date":20},1223,[8,9,10,11,12,13,13,13],"\u003Ctime datetime=\"2024-10-08T13:20:00Z\">10\u002F08\u002F2024\u003C\u002Ftime>\n","\u003Ctime datetime=\"2024-09-24T04:00:00Z\">09\u002F24\u002F2024\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fmmc-healthcare-ltd-684644-09242024\">MMC Healthcare Ltd.\u003C\u002Fa>","Center for Drug Evaluation and Research (CDER)","CGMP\u002FFinished Pharmaceuticals\u002FAdulterated\u003Cbr \u002F>\r\n","","CGMP\u002FFinished Pharmaceuticals\u002FAdulterated","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Email\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>320-24-62\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Nageswara Rao Gupta Manepalli\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Managing Director\u002FCEO\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>MMC Healthcare Ltd.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>34-B Sidco Industrial Estate\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Thirumazhisai, Chennai\u003C\u002Fspan> \u003Cspan>600124\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Tamil Nadu\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>India\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:ceo@mmchealthcareltd.com\"> ceo@mmchealthcareltd.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>Warning Letter\u003C\u002Fstrong> 320-24-62\u003C\u002Fp>\n\n\u003Cp>September 24, 2024\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Manepalli:\u003C\u002Fp>\n\n\u003Cp>The U.S. Food and Drug Administration (FDA) inspected your drug manufacturing facility, MMC Healthcare Ltd., FEI 3014773352, at 34-B Sidco Industrial Estate, Thirumazhisai, Chennai, Tamil Nadu, from March 25 to 30, 2024.\u003C\u002Fp>\n\n\u003Cp>This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\u003C\u002Fp>\n\n\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\n\n\u003Cp>We reviewed your April 18, 2024 response to our Form FDA 483 in detail.\u003C\u002Fp>\n\n\u003Cp>During our inspection, our investigator observed specific violations including, but not limited to, the following.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>1. Your firm failed to establish an adequate quality control unit with the responsibility and authority to approve or reject all components, drug product containers, closures, in-process materials, packaging materials, labeling, and drug products (21 CFR 211.22(a)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>During the inspection of your facility our Investigator observed that your 2021 \u003Cstrong>(b)(4)\u003C\u002Fstrong> Tablets “PROCESS VALIDATION” report had data added, backdated signatures, and replaced pages. Your Quality Assurance Manager, Quality Control Manager, Formulation Research &amp; Development Manager, and Production Manager admitted to participating in these practices.\u003C\u002Fp>\n\n\u003Cp>Review of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> Capsules \u003Cstrong>(b)(4)\u003C\u002Fstrong> mg “PROCESS VALIDATION” report collected during the inspection also found a backdated approval stamp and signatures.\u003C\u002Fp>\n\n\u003Cp>In your response, you state that “due to pressure and tensions the concerned team mentioned the back date instead of current date unintentionally.” Additionally, you provide evidence of training conducted with your validation team to prevent such issues from recurring.\u003C\u002Fp>\n\n\u003Cp>Your response is inadequate because you fail to fully review the extent of your practice of backdating CGMP documents. You did not provide adequate evidence to demonstrate that you have conducted a comprehensive assessment of all systems and adequately remediated the deficiencies related to your documentation practices. There is also no indication that you have implemented appropriate and effective corrective actions and preventive actions (CAPAs) throughout your drug manufacturing operations to ensure your manufacturing operation is under control and that your quality unit (QU) is adequately exercising its responsibilities.\u003C\u002Fp>\n\n\u003Cp>Data integrity is critical throughout the CGMP data life cycle, including in the creation, modification, processing, maintenance, archival, retrieval, transmission, and disposition of date after the record’s retention period ends.\u003C\u002Fp>\n\n\u003Cp>In your response to this letter, provide:\u003C\u002Fp>\n\n\u003Cp>• A comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\u003Cbr>\n&nbsp; o A determination of whether procedures used by your firm are robust and appropriate.\u003Cbr>\n&nbsp; o Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices.\u003Cbr>\n&nbsp; o A complete and final review of each batch and its related information before the QU disposition decision.\u003Cbr>\n&nbsp; o Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products.\u003C\u002Fp>\n\n\u003Cp>Also describe the plan to ensure your senior and executive management supports quality assurance and reliable operations, including but not limited to, timely provision of resources to proactively address emerging manufacturing\u002Fquality issues and to assure a continuing state of control.\u003Cbr>\n• A comprehensive, independent assessment of your overall system for investigating deviations, discrepancies, complaints, out-of-specification (OOS) results, and failures. Provide a detailed action plan to remediate this system. Your action plan should include, but not be limited to, significant improvements in investigation competencies, scope determination, root cause evaluation, CAPA effectiveness, QU oversight, and written procedures. Address how your firm will ensure all phases of investigations are appropriately conducted.\u003Cbr>\n• A comprehensive, independent assessment of documentation systems used throughout your manufacturing and laboratory operations to determine where documentation practices are insufficient. Include a detailed CAPA plan that comprehensively remediates your firm’s documentation practices to ensure you retain attributable, legible, complete, original, accurate, contemporaneous records throughout your operation.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>2. Your firm failed to exercise appropriate controls over computer or related systems to assure that only authorized personnel institute changes in master production and control records, or other records (21 CFR 211.68(b)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your ultraviolet-visible (UV-Vis) spectrophotometer computer system lacked appropriate controls to assure the integrity of electronic test data, such as an audit trail and defined user access levels. This UV-Vis system was used for release testing of drug product batches.\u003C\u002Fp>\n\n\u003Cp>In your response, you state that you “would like to update the UV\u002FVis [sic] software” to be compliant and provide a quote for new software.\u003C\u002Fp>\n\n\u003Cp>Your response is inadequate because it does not provide sufficient details describing:\u003C\u002Fp>\n\n\u003Cp>• Timeframe for your corrective action.\u003Cbr>\n• Security features of your updated UV-Vis computer system.\u003Cbr>\n• User access levels, access privileges, or authorized users to perform the analyses, collect data, review data, or perform other functions.\u003Cbr>\n• Integrity of data generated by your computerized systems in the interim and any other interim measures, prior to the full implementation of your corrective actions.\u003Cbr>\n• Extent of this practice and how you will fully secure other CGMP computer systems in your facility.\u003C\u002Fp>\n\n\u003Cp>It is essential that your firm keeps track of all changes made to your electronic data. The use of audit trails for computerized analytical instrumentation helps to ensure all additions, deletions, or modifications of information in your electronic records are authorized. It also allows you to verify the quality and integrity of the electronic data your laboratory generates.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide:\u003C\u002Fp>\n\n\u003Cp>• A comprehensive, independent assessment and CAPA plan for computer system security and integrity. Include a report that identifies design and control vulnerabilities, and appropriate remediations for each of your laboratory and manufacturing computer systems. This should include, but not be limited to:\u003Cbr>\n&nbsp; o An evaluation of the impact of this violation.\u003Cbr>\n&nbsp; o A list of all hardware that includes all equipment, both standalone and network, in your laboratory and manufacturing.\u003Cbr>\n&nbsp; o Identification of vulnerabilities in hardware and software, encompassing both networked and non-networked systems.\u003Cbr>\n&nbsp; o A list of all software configurations (both equipment software and Laboratory Information Management System) and versions, details of all user privileges, and oversight responsibilities for your computerized systems. Regarding user privileges, specify user roles and associated user privileges (including the specific permissions allowed for anyone who has administrative rights) for all staff who have access to the laboratory and manufacturing computer systems, and their organizational affiliation and title. Also describe how you will ensure staff are not given administrative rights, or other permissions that compromise data retention or reliability.\u003Cbr>\n&nbsp; o System security provisions, including but not limited to, whether unique usernames\u002Fpasswords are always used, and their confidentiality safeguarded.\u003Cbr>\n&nbsp; o Detailed procedures for robust use and review of audit trail data, and current status of audit trail implementation for each of your systems.\u003Cbr>\n&nbsp; o Timeline for the implementation and qualification of your updated UV-Vis software.\u003Cbr>\n&nbsp; o Interim control measures and procedural changes for the control, review, and full retention of laboratory data.\u003Cbr>\n&nbsp; o Comprehensive and sustainable CAPA for retention of all CGMP data including interim data. This includes provisions that address not only the need to retain batch-related data for appropriate periods, but also the long-term retention of all source data from development studies that support design, qualification, validation, and application.\u003Cbr>\n&nbsp; o A detailed summary of your procedural updates and associated training, including but not limited to, system security control to prevent unauthorized access, and ensure appropriate user role assignments, secondary review of all analyses, and other system controls.\u003Cbr>\n&nbsp; o Your remediated program for ensuring strict ongoing control over electronic and paper-based data to ensure that all additions, deletions, or modifications of information in your records are authorized, and all data is retained. Provide your full CAPA plan and any improvements made to date.\u003Cbr>\n&nbsp; o Provisions for oversight from Quality Assurance managers, executives, and internal auditors with appropriate IT expertise (e.g., understanding of infrastructure, configuration, network requirements, strict segregation of administrative rights).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>3. Your firm failed to establish the accuracy, sensitivity, specificity, and reproducibility of its test methods (21 CFR 211.165(e)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>You did not use a United States Pharmacopeia (USP) method to test multiple drug products nor did you show equivalency or superiority for your alternate methods. For example, your \u003Cem>E. coli\u003C\u002Fem> test method for \u003Cstrong>(b)(4)\u003C\u002Fstrong> Solution and \u003Cstrong>(b)(4)\u003C\u002Fstrong> Tablets drug products only required sub-culturing if turbidity was observed. This differs from the USP method which proceeds with sub-culturing regardless of visual observation of turbidity. Additionally, you could not provide method validation data that established the adequacy of the test methods you use.\u003C\u002Fp>\n\n\u003Cp>Test methods must be validated to show they are suitable for their intended use, and equivalent or better than applicable USP compendial methods. The reproducibility of your test methods is essential to determine if your drug products meet established specifications for microbial attributes.\u003C\u002Fp>\n\n\u003Cp>In your response, you state that you revised your test method to align with the USP and retrained your microbiologists. You also state that you retested most batches of \u003Cstrong>(b)(4)\u003C\u002Fstrong> Solution within expiry using the revised method, all of which passed.\u003C\u002Fp>\n\n\u003Cp>Your response is inadequate. You do not commit to retest all products and batches within expiry with the revised method. In addition, there is no indication that your method is equivalent or superior to the USP. There is also no information to evaluate all your test methods to ensure they are aligned with the USP.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide:\u003C\u002Fp>\n\n\u003Cp>• A comprehensive, independent assessment of your laboratory practices, procedures, methods, equipment, documentation, and analyst competencies. Based on this review, provide a detailed plan to remediate and evaluate the effectiveness of your laboratory system.\u003Cbr>\n• A summary of results from testing reserve samples of all drug product batches within expiry. You should test microbiological quality (total counts and identification of bioburden to detect any objectionable microbes) of each batch. If testing yields an OOS result, indicate the corrective actions you will take, including notifying customers and initiating recalls.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Data Integrity Remediation\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your quality system does not adequately ensure the accuracy and integrity of data to support the safety, effectiveness, and quality of the drugs you manufacture. See FDA’s guidance document \u003Cem>Data Integrity and Compliance With Drug CGMP\u003C\u002Fem> for guidance on establishing and following CGMP compliant data integrity practices at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F119267\u002Fdownload.\u003C\u002Fp>\n\n\u003Cp>We strongly recommend that you retain an independent third-party, qualified consultant to assist in your remediation. In response to this letter, provide:\u003C\u002Fp>\n\n\u003Cp>• A comprehensive investigation into the extent of the inaccuracies in data records and reporting. Your investigation should include:\u003Cbr>\n&nbsp; o A detailed investigation protocol and methodology; a summary of all laboratories, manufacturing operations, and systems to be covered by the assessment; and a justification for any part of your operation that you propose to exclude.\u003Cbr>\n&nbsp; o Interviews of current and former employees to identify the nature, scope, and root cause of data inaccuracies. We recommend that these interviews be conducted by a qualified third party.\u003Cbr>\n&nbsp; o An assessment of the extent of data integrity deficiencies at your facility. Identify omissions, alterations, deletions, record destruction, non-contemporaneous record completion, and other deficiencies. Describe all parts of your facility’s operations in which you discovered data integrity lapses.\u003Cbr>\n&nbsp; o A comprehensive retrospective evaluation of the nature of the testing and manufacturing data integrity deficiencies. We recommend that a qualified third party with specific expertise in the area where potential breaches were identified should evaluate all data integrity lapses.\u003C\u002Fp>\n\n\u003Cp>• A current risk assessment of the potential effects of the observed failures on the quality of your drugs. Your assessment should include analyses of the risks to patients caused by the release of drugs affected by a lapse of data integrity and analyses of the risks posed by ongoing operations.\u003C\u002Fp>\n\n\u003Cp>• A management strategy for your firm that includes the details of your global CAPA plan. Your strategy should include:\u003Cbr>\n&nbsp; o A detailed corrective action plan that describes how you intend to ensure the reliability and completeness of all the data you generate including analytical data, manufacturing records, and all data submitted to FDA.\u003Cbr>\n&nbsp; o A comprehensive description of the root causes of your data integrity lapses including evidence that the scope and depth of the current action plan is commensurate with the findings of the investigation and risk assessment. Indicate whether individuals responsible for data integrity lapses remain able to influence CGMP-related or drug application data at your firm.\u003Cbr>\n&nbsp; o Interim measures describing the actions you have taken or will take to protect patients and to ensure the quality of your drugs, such as notifying your customers, recalling product, conducting additional testing, adding lots to your stability programs to assure stability, drug application actions, and enhanced complaint monitoring.\u003Cbr>\n&nbsp; o Long-term measures describing any remediation efforts and enhancements to procedures, processes, methods, controls, systems, management oversight, and human resources (e.g., training, staffing improvements) designed to ensure the integrity of your company’s data.\u003Cbr>\n&nbsp; o A commitment to have a qualified consultant conduct extensive annual audits, for at least 2 years, to assist in evaluating CAPA effectiveness after you have executed your data integrity remediation protocol.\u003Cbr>\n&nbsp; o Inform FDA if you will be hiring a Chief Integrity Officer who is fully empowered to receive anonymous complaints from employees reporting data integrity concerns and with the authority to ensure any potential breach is promptly investigated (by independent quality assurance function, along with expertise from outside entities whenever needed).\u003Cbr>\n&nbsp; o A status report for any of the above activities already underway or completed.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\u003C\u002Fp>\n\n\u003Cp>FDA placed your firm on Import Alert 66-40 on September 6, 2024.\u003C\u002Fp>\n\n\u003Cp>Correct any violations promptly. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to any violations.\u003C\u002Fp>\n\n\u003Cp>Failure to address any violations may also result in the FDA continuing to refuse admission of articles manufactured at MMC Healthcare Ltd., 34-B Sidco Industrial Estate, Thirumazhisai, Chennai into the United States under section 801(a)(3) of the FD&amp;C Act, 21 U.S.C. 381(a)(3).\u003C\u002Fp>\n\n\u003Cp>Articles under this authority that appear to be adulterated may be detained or refused admission, in that the methods and controls used in their manufacture do not appear to conform to CGMP within the meaning of section 501(a)(2)(B) of the FD&amp;C Act, 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\n\n\u003Cp>Send your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3014773352 and ATTN: Russell Riley.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Francis Godwin\u003Cbr>\nDirector\u003Cbr>\nOffice of Manufacturing Quality\u003Cbr>\nOffice of Compliance\u003Cbr>\nCenter for Drug Evaluation and Research\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Email\n\nReference #:\n\n320-24-62\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMr. Nageswara Rao Gupta Manepalli\n\nRecipient Title\n\nManaging Director\u002FCEO\n\nMMC Healthcare Ltd.\n\n34-B Sidco Industrial Estate\n\nThirumazhisai, Chennai 600124\n\nTamil Nadu\n\nIndia\n\nceo@mmchealthcareltd.com\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nWarning Letter 320-24-62\n\nSeptember 24, 2024\n\nDear Mr. Manepalli:\n\nThe U.S. Food and Drug Administration (FDA) inspected your drug manufacturing facility, MMC Healthcare Ltd., FEI 3014773352, at 34-B Sidco Industrial Estate, Thirumazhisai, Chennai, Tamil Nadu, from March 25 to 30, 2024.\n\nThis warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\n\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B).\n\nWe reviewed your April 18, 2024 response to our Form FDA 483 in detail.\n\nDuring our inspection, our investigator observed specific violations including, but not limited to, the following.\n\n1. Your firm failed to establish an adequate quality control unit with the responsibility and authority to approve or reject all components, drug product containers, closures, in-process materials, packaging materials, labeling, and drug products (21 CFR 211.22(a)).\n\nDuring the inspection of your facility our Investigator observed that your 2021 (b)(4) Tablets “PROCESS VALIDATION” report had data added, backdated signatures, and replaced pages. Your Quality Assurance Manager, Quality Control Manager, Formulation Research & Development Manager, and Production Manager admitted to participating in these practices.\n\nReview of the (b)(4) Capsules (b)(4) mg “PROCESS VALIDATION” report collected during the inspection also found a backdated approval stamp and signatures.\n\nIn your response, you state that “due to pressure and tensions the concerned team mentioned the back date instead of current date unintentionally.” Additionally, you provide evidence of training conducted with your validation team to prevent such issues from recurring.\n\nYour response is inadequate because you fail to fully review the extent of your practice of backdating CGMP documents. You did not provide adequate evidence to demonstrate that you have conducted a comprehensive assessment of all systems and adequately remediated the deficiencies related to your documentation practices. There is also no indication that you have implemented appropriate and effective corrective actions and preventive actions (CAPAs) throughout your drug manufacturing operations to ensure your manufacturing operation is under control and that your quality unit (QU) is adequately exercising its responsibilities.\n\nData integrity is critical throughout the CGMP data life cycle, including in the creation, modification, processing, maintenance, archival, retrieval, transmission, and disposition of date after the record’s retention period ends.\n\nIn your response to this letter, provide:\n\n• A comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\n\no A determination of whether procedures used by your firm are robust and appropriate.\n\no Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices.\n\no A complete and final review of each batch and its related information before the QU disposition decision.\n\no Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products.\n\nAlso describe the plan to ensure your senior and executive management supports quality assurance and reliable operations, including but not limited to, timely provision of resources to proactively address emerging manufacturing\u002Fquality issues and to assure a continuing state of control.\n\n• A comprehensive, independent assessment of your overall system for investigating deviations, discrepancies, complaints, out-of-specification (OOS) results, and failures. Provide a detailed action plan to remediate this system. Your action plan should include, but not be limited to, significant improvements in investigation competencies, scope determination, root cause evaluation, CAPA effectiveness, QU oversight, and written procedures. Address how your firm will ensure all phases of investigations are appropriately conducted.\n\n• A comprehensive, independent assessment of documentation systems used throughout your manufacturing and laboratory operations to determine where documentation practices are insufficient. Include a detailed CAPA plan that comprehensively remediates your firm’s documentation practices to ensure you retain attributable, legible, complete, original, accurate, contemporaneous records throughout your operation.\n\n2. Your firm failed to exercise appropriate controls over computer or related systems to assure that only authorized personnel institute changes in master production and control records, or other records (21 CFR 211.68(b)).\n\nYour ultraviolet-visible (UV-Vis) spectrophotometer computer system lacked appropriate controls to assure the integrity of electronic test data, such as an audit trail and defined user access levels. This UV-Vis system was used for release testing of drug product batches.\n\nIn your response, you state that you “would like to update the UV\u002FVis [sic] software” to be compliant and provide a quote for new software.\n\nYour response is inadequate because it does not provide sufficient details describing:\n\n• Timeframe for your corrective action.\n\n• Security features of your updated UV-Vis computer system.\n\n• User access levels, access privileges, or authorized users to perform the analyses, collect data, review data, or perform other functions.\n\n• Integrity of data generated by your computerized systems in the interim and any other interim measures, prior to the full implementation of your corrective actions.\n\n• Extent of this practice and how you will fully secure other CGMP computer systems in your facility.\n\nIt is essential that your firm keeps track of all changes made to your electronic data. The use of audit trails for computerized analytical instrumentation helps to ensure all additions, deletions, or modifications of information in your electronic records are authorized. It also allows you to verify the quality and integrity of the electronic data your laboratory generates.\n\nIn response to this letter, provide:\n\n• A comprehensive, independent assessment and CAPA plan for computer system security and integrity. Include a report that identifies design and control vulnerabilities, and appropriate remediations for each of your laboratory and manufacturing computer systems. This should include, but not be limited to:\n\no An evaluation of the impact of this violation.\n\no A list of all hardware that includes all equipment, both standalone and network, in your laboratory and manufacturing.\n\no Identification of vulnerabilities in hardware and software, encompassing both networked and non-networked systems.\n\no A list of all software configurations (both equipment software and Laboratory Information Management System) and versions, details of all user privileges, and oversight responsibilities for your computerized systems. Regarding user privileges, specify user roles and associated user privileges (including the specific permissions allowed for anyone who has administrative rights) for all staff who have access to the laboratory and manufacturing computer systems, and their organizational affiliation and title. Also describe how you will ensure staff are not given administrative rights, or other permissions that compromise data retention or reliability.\n\no System security provisions, including but not limited to, whether unique usernames\u002Fpasswords are always used, and their confidentiality safeguarded.\n\no Detailed procedures for robust use and review of audit trail data, and current status of audit trail implementation for each of your systems.\n\no Timeline for the implementation and qualification of your updated UV-Vis software.\n\no Interim control measures and procedural changes for the control, review, and full retention of laboratory data.\n\no Comprehensive and sustainable CAPA for retention of all CGMP data including interim data. This includes provisions that address not only the need to retain batch-related data for appropriate periods, but also the long-term retention of all source data from development studies that support design, qualification, validation, and application.\n\no A detailed summary of your procedural updates and associated training, including but not limited to, system security control to prevent unauthorized access, and ensure appropriate user role assignments, secondary review of all analyses, and other system controls.\n\no Your remediated program for ensuring strict ongoing control over electronic and paper-based data to ensure that all additions, deletions, or modifications of information in your records are authorized, and all data is retained. Provide your full CAPA plan and any improvements made to date.\n\no Provisions for oversight from Quality Assurance managers, executives, and internal auditors with appropriate IT expertise (e.g., understanding of infrastructure, configuration, network requirements, strict segregation of administrative rights).\n\n3. Your firm failed to establish the accuracy, sensitivity, specificity, and reproducibility of its test methods (21 CFR 211.165(e)).\n\nYou did not use a United States Pharmacopeia (USP) method to test multiple drug products nor did you show equivalency or superiority for your alternate methods. For example, your E. coli test method for (b)(4) Solution and (b)(4) Tablets drug products only required sub-culturing if turbidity was observed. This differs from the USP method which proceeds with sub-culturing regardless of visual observation of turbidity. Additionally, you could not provide method validation data that established the adequacy of the test methods you use.\n\nTest methods must be validated to show they are suitable for their intended use, and equivalent or better than applicable USP compendial methods. The reproducibility of your test methods is essential to determine if your drug products meet established specifications for microbial attributes.\n\nIn your response, you state that you revised your test method to align with the USP and retrained your microbiologists. You also state that you retested most batches of (b)(4) Solution within expiry using the revised method, all of which passed.\n\nYour response is inadequate. You do not commit to retest all products and batches within expiry with the revised method. In addition, there is no indication that your method is equivalent or superior to the USP. There is also no information to evaluate all your test methods to ensure they are aligned with the USP.\n\nIn response to this letter, provide:\n\n• A comprehensive, independent assessment of your laboratory practices, procedures, methods, equipment, documentation, and analyst competencies. Based on this review, provide a detailed plan to remediate and evaluate the effectiveness of your laboratory system.\n\n• A summary of results from testing reserve samples of all drug product batches within expiry. You should test microbiological quality (total counts and identification of bioburden to detect any objectionable microbes) of each batch. If testing yields an OOS result, indicate the corrective actions you will take, including notifying customers and initiating recalls.\n\nData Integrity Remediation\n\nYour quality system does not adequately ensure the accuracy and integrity of data to support the safety, effectiveness, and quality of the drugs you manufacture. See FDA’s guidance document Data Integrity and Compliance With Drug CGMP for guidance on establishing and following CGMP compliant data integrity practices at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F119267\u002Fdownload.\n\nWe strongly recommend that you retain an independent third-party, qualified consultant to assist in your remediation. In response to this letter, provide:\n\n• A comprehensive investigation into the extent of the inaccuracies in data records and reporting. Your investigation should include:\n\no A detailed investigation protocol and methodology; a summary of all laboratories, manufacturing operations, and systems to be covered by the assessment; and a justification for any part of your operation that you propose to exclude.\n\no Interviews of current and former employees to identify the nature, scope, and root cause of data inaccuracies. We recommend that these interviews be conducted by a qualified third party.\n\no An assessment of the extent of data integrity deficiencies at your facility. Identify omissions, alterations, deletions, record destruction, non-contemporaneous record completion, and other deficiencies. Describe all parts of your facility’s operations in which you discovered data integrity lapses.\n\no A comprehensive retrospective evaluation of the nature of the testing and manufacturing data integrity deficiencies. We recommend that a qualified third party with specific expertise in the area where potential breaches were identified should evaluate all data integrity lapses.\n\n• A current risk assessment of the potential effects of the observed failures on the quality of your drugs. Your assessment should include analyses of the risks to patients caused by the release of drugs affected by a lapse of data integrity and analyses of the risks posed by ongoing operations.\n\n• A management strategy for your firm that includes the details of your global CAPA plan. Your strategy should include:\n\no A detailed corrective action plan that describes how you intend to ensure the reliability and completeness of all the data you generate including analytical data, manufacturing records, and all data submitted to FDA.\n\no A comprehensive description of the root causes of your data integrity lapses including evidence that the scope and depth of the current action plan is commensurate with the findings of the investigation and risk assessment. Indicate whether individuals responsible for data integrity lapses remain able to influence CGMP-related or drug application data at your firm.\n\no Interim measures describing the actions you have taken or will take to protect patients and to ensure the quality of your drugs, such as notifying your customers, recalling product, conducting additional testing, adding lots to your stability programs to assure stability, drug application actions, and enhanced complaint monitoring.\n\no Long-term measures describing any remediation efforts and enhancements to procedures, processes, methods, controls, systems, management oversight, and human resources (e.g., training, staffing improvements) designed to ensure the integrity of your company’s data.\n\no A commitment to have a qualified consultant conduct extensive annual audits, for at least 2 years, to assist in evaluating CAPA effectiveness after you have executed your data integrity remediation protocol.\n\no Inform FDA if you will be hiring a Chief Integrity Officer who is fully empowered to receive anonymous complaints from employees reporting data integrity concerns and with the authority to ensure any potential breach is promptly investigated (by independent quality assurance function, along with expertise from outside entities whenever needed).\n\no A status report for any of the above activities already underway or completed.\n\nConclusion\n\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\n\nFDA placed your firm on Import Alert 66-40 on September 6, 2024.\n\nCorrect any violations promptly. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to any violations.\n\nFailure to address any violations may also result in the FDA continuing to refuse admission of articles manufactured at MMC Healthcare Ltd., 34-B Sidco Industrial Estate, Thirumazhisai, Chennai into the United States under section 801(a)(3) of the FD&C Act, 21 U.S.C. 381(a)(3).\n\nArticles under this authority that appear to be adulterated may be detained or refused admission, in that the methods and controls used in their manufacture do not appear to conform to CGMP within the meaning of section 501(a)(2)(B) of the FD&C Act, 21 U.S.C. 351(a)(2)(B).\n\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\n\nSend your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3014773352 and ATTN: Russell Riley.\n\nSincerely,\n\n\u002FS\u002F\n\nFrancis Godwin\n\nDirector\n\nOffice of Manufacturing Quality\n\nOffice of Compliance\n\nCenter for Drug Evaluation and Research","MMC Healthcare Ltd.","mmc-healthcare-ltd-684644-09242024","2026-08-18T06:42:28.856152+00:00",null,"https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fmmc-healthcare-ltd-684644-09242024","2026-10-26T08:09:26.775337+00:00","Warning Letter","Issued","2024-10-08","684644","Drugs","Mr. Nageswara Rao Gupta Manepalli","2026-08-19T22:31:41.964+00:00","Via Email","320-24-62","2024-09-24",{"id":34,"raw":35,"subject":40,"body_html":42,"body_text":43,"firm_name":44,"letter_id":45,"created_at":46,"fei_number":20,"letter_url":47,"updated_at":48,"action_type":23,"case_status":49,"posted_date":50,"marcs_cms_no":51,"product_type":52,"closeout_date":53,"issuing_office":39,"recipient_name":54,"body_fetched_at":55,"delivery_method":56,"recipient_title":20,"reference_number":20,"action_taken_date":57,"medical_device_id":20,"response_letter_date":20},2978,[36,37,38,39,40,13,41,13],"\u003Ctime datetime=\"2021-12-14T14:20:00Z\">12\u002F14\u002F2021\u003C\u002Ftime>\n","\u003Ctime datetime=\"2021-11-23T05:00:00Z\">11\u002F23\u002F2021\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fdevilbiss-healthcare-llc-619182-11232021\">DeVilbiss Healthcare LLC\u003C\u002Fa>","Office of Medical Device and Radiological Health Operations (Division 1)","Medical Device Reporting\u002FMisbranded","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fdrive-devilbiss-healthcare-llc-619182-10232024\">\u003Ctime datetime=\"2024-10-30T04:00:00Z\">10\u002F30\u002F2024\u003C\u002Ftime>\n\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>UNITED PARCEL SERVICE OVERNIGHT DELIVERY and EMAIL\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Derek Lampert\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Chief Executive Officer\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>DeVilbiss Healthcare LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>99 Seaview Blvd, Suite 210\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Port Washington\u003C\u002Fspan>, \u003Cspan>NY\u003C\u002Fspan> \u003Cspan>11050\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Office of Medical Device and Radiological Health Operations (Division 1)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>Dear Mr. Lampert:\u003C\u002Fp>\n\n\u003Cp>The United States Food and Drug Administration (FDA) conducted an inspection of your firm’s medical device operations at 100 DeVilbiss Dr, Somerset, PA, from 7\u002F28\u002F21 – 8\u002F25\u002F21. &nbsp;During the inspection, an FDA investigator determined that your firm is a manufacturer of oxygen concentrators, nebulizers, suction units, non-continuous ventilators and related accessories. &nbsp;Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\u003C\u002Fp>\n\n\u003Cp>This inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820. We received responses on September 16, 2021 and November 12, 2021 from Tony Sapp, Director, Regulatory Affairs and Audits, concerning our investigator’s observations noted on the Form FDA 483, List of Inspectional Observations (FDA-483) that was issued on August 25, 2021. &nbsp;We address the responses below, in relation to each of the noted violations. &nbsp;These violations include, but are not limited to, the following:\u003C\u002Fp>\n\n\u003Cp>1.&nbsp;&nbsp; &nbsp;Failure to confirm that design outputs meet design input requirements during design verification testing, as required by 21 CFR 820.30(f). &nbsp;Specifically,\u003C\u002Fp>\n\n\u003Cp>The model 525 oxygen concentrator is designed using the ZW280D2 compressor, which is specified by the manufacturer for an operating ambient temperature range of 40°F-\u003Cstrong>(b)(4)\u003C\u002Fstrong>°F (5°C-\u003Cstrong>(b)(4)\u003C\u002Fstrong>°C). &nbsp;Design verification test report for IEC 60601-01, Medical Electrical Equipment, report no. 31691761.005, 2018, Table 11-1-1, page 149, states that thermocouple measurements taken in the interior of the finished device showed an interior temperature above the temperature specifications of the compressor in \u003Cstrong>(b)(4)\u003C\u002Fstrong> of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> measurement sites at an environmental temperature of 22.9°C. At 40˚C, the interior temperature was above the temperature specifications of the compressor at all ten measurement sites. &nbsp;\u003C\u002Fp>\n\n\u003Cp>We reviewed your responses for this matter and conclude that they are not adequate. &nbsp;In your initial response you provided test reports that showed device interior temperatures ambient to the compressor to be frequently above the stated specification of \u003Cstrong>(b)(4)\u003C\u002Fstrong>°C. &nbsp;You based your response on a statement in the manufacturer’s specification, “It is the responsibility of the user to determine the suitability of the product for their intended use.” &nbsp;Your response maintains that this statement allows you to use a compressor for a use above its specified temperature range as long as you perform testing that shows the compressor is able to function above its recommended range. &nbsp;This testing does not address all aspects of the product’s intended use, including the long-term effects on a compressor that operates for many hours above its specified range, including overheating, worn cup seals, fan failures, and shortened life span.\u003C\u002Fp>\n\n\u003Cp>Included in your initial response is your “GSE Compressor Life Test Report,” which you maintain, demonstrates that the compressor is capable of operating for a normal lifetime at \u003Cstrong>(b)(4)\u003C\u002Fstrong>°C. This document, however, is of a study done to establish the expected lifespan of the compressor through accelerated aging. &nbsp;The \u003Cstrong>(b)(4)\u003C\u002Fstrong>°C ambient temperature is one of the stress factors used in the study. &nbsp;This would demonstrate not that \u003Cstrong>(b)(4)\u003C\u002Fstrong>°C is acceptable for long term operation, but instead shows that it is a high temperature that stresses the compressor for purposes of accelerated aging.&nbsp;\u003C\u002Fp>\n\n\u003Cp>In your response of 11\u002F12\u002F21 you provided two test reports, “Compressor Temperature Test Protocol and Report,” and “\u003Cstrong>(b)(4)\u003C\u002Fstrong> Test Protocol and Report.” &nbsp;The test of compressor temperatures ran for a duration of \u003Cstrong>(b)(4)\u003C\u002Fstrong> and used visual acceptance criteria of “no damage or deformation.” Ambient temperatures were recorded within the \u003Cstrong>(b)(4)\u003C\u002Fstrong> period that were higher than the manufacturer’s specified temperature for the compressors. &nbsp;The 525 Oxygen Concentrator is typically run for much longer periods of time than only \u003Cstrong>(b)(4)\u003C\u002Fstrong>, resulting in possible temperature \u003Cstrong>(b)(4)\u003C\u002Fstrong> that could result in much higher ambient temperatures over time. &nbsp;The test of \u003Cstrong>(b)(4)\u003C\u002Fstrong> did not include any definition of a time element in the test method or results. &nbsp;It cannot be determined the duration of the test, or how often data readings were taken.&nbsp;\u003C\u002Fp>\n\n\u003Cp>Please provide documentation that describes how you will address the fact that you are commercially marketing a device that is designed and built with a major component that has been shown by testing to be operating in ambient temperatures above its specified temperature range. &nbsp;\u003C\u002Fp>\n\n\u003Cp>2.&nbsp;&nbsp; &nbsp;Failure to maintain complaint files and establish and maintain procedures for receiving, reviewing, and evaluating complaints by a formally designated unit, as required by 21 CFR 820.198(a). &nbsp;Specifically,&nbsp;\u003C\u002Fp>\n\n\u003Cp>Your Complaint Handling Procedure, DVHC-SOP-0020, rev. 2, states in section 6.0 that Regulatory Affairs will ensure that complaints are reviewed and evaluated “in a timely and uniform fashion.” &nbsp;The procedure further provides in section 7.3, that a determination is made whether serious injury or death was reported and whether medical intervention was required. You are not following your procedure in that complaints are not documented in a timely manner and you are not documenting the determination of whether or not the complaint is reportable under 21 CFR Part 803 – Medical Device Reporting. &nbsp;Examples include, but are not limited to:\u003C\u002Fp>\n\n\u003Cp>•&nbsp;&nbsp; &nbsp;Complaint RO_0320803 was reported to an employee in customer service on 01\u002F19\u002F2021 and described a patient who was in distress from receiving low oxygen; however, the complaint was documented on 04\u002F02\u002F2021, 73 days later, simply as “defective alarm.”&nbsp;\u003C\u002Fp>\n\n\u003Cp>•&nbsp;&nbsp; &nbsp;Complaints were not reviewed for MDR reportability as prescribed in DVHC-SOP-0020, Complaint Handling Procedure, section 7.4, that requires each complaint to be evaluated for reportability according to Adverse Event Reporting procedure DVHC-SOP-0021, including documentation on the applicable form, Adverse Event Determination Form (DVHC-FORM-0105), which requires providing all information necessary to make a reportability determination. &nbsp;Examples include:&nbsp;\u003C\u002Fp>\n\n\u003Cp>&nbsp;RO_0264829, received on 04\u002F02\u002F2020\u003Cbr>\n­ RO_0252308, received on 1\u002F28\u002F2020\u003Cbr>\n­ RO_0208546, received on 04\u002F05\u002F2019\u003Cbr>\n­ RO_0180765, received on 08\u002F23\u002F2018\u003C\u002Fp>\n\n\u003Cp>•&nbsp;&nbsp; &nbsp;Complaint #RO_0208546, recorded on 04\u002F05\u002F2019, alleges a possible malfunction with a DeVilbiss 525DS Oxygen Concentrator, serial number \u003Cstrong>(b)(4)\u003C\u002Fstrong>, in which the complaint documented “extremely hot in the patient’s home to the point where they were smoking and too hot to touch. The one that happened today happened during a set up and the machine was only running for about 20 minutes while my tech was doing his instruction. The wife commented that she smelled something burning and the tech noticed the concentrator smoking and unplugged it. The machine never alarmed or turned off. The machine stayed hot to the touch for about 40 minutes. When it got back to the warehouse, I noticed that it had just been serviced by DeVilbiss on 3\u002F21\u002F19.” &nbsp;No information regarding the patient was included in the complaint report; there was no record of attempt to obtain patient information; and no record of follow-up with complainant to gather information relevant to determination of reportability.\u003C\u002Fp>\n\n\u003Cp>•&nbsp;&nbsp; &nbsp;Complaint #RO_0252308, recorded on 1\u002F28\u002F2020, alleges a possible malfunction with a DeVilbiss 525DS Oxygen Concentrator, serial number \u003Cstrong>(b)(4)\u003C\u002Fstrong>, in which the complaint documented the unit had clearly overheated as the case interior was melting and deforming as well as a portion of the back cover, and gross particle filter housing. The outlet air tubing from the compressor was so hot that it began melting the foam insulation of the back cover. The cooling fan below the compressor was not running at all. The complaint further documented it was self-evident that was a failure of the thermal cutoff for this unit as it should have shut down well before it ever got hot enough to begin to melt itself. &nbsp;No documentation of complainant or record of attempt to contact complainant to gather information relevant to reportability.\u003C\u002Fp>\n\n\u003Cp>We have reviewed your responses dated 9\u002F16\u002F21 and 11\u002F12\u002F21 and concluded that the adequacy of your responses cannot be determined at this time. Your responses state that you are revising complaint handling procedures to create more guidance with complaint detail record keeping. Your response also describes an ongoing effort to review complaints received between March 26, 2018 and July 27, 2021.&nbsp;\u003C\u002Fp>\n\n\u003Cp>Please provide documentation demonstrating that you have established the applicable procedures for receiving, reviewing and evaluating complaints by a formally designated unit, ensuring that all complaints are processed in a uniform and timely manner, oral complaints are documented on receipt; and complaints are evaluated to determine whether the complaint represents a reportable event. &nbsp;\u003C\u002Fp>\n\n\u003Cp>\u003Cbr>\n3.&nbsp;&nbsp; &nbsp;Failure to adequately establish procedures for corrective and preventive action, as required by 21 CFR 820.100(a). &nbsp;Specifically,&nbsp;\u003C\u002Fp>\n\n\u003Cp>Your CAPA procedure, DVHC-SOP-0029, Rev 03, section 7.2.5, states that a CAPA will be created when “a review of quality data suggests that \u003Cstrong>(b)(4)\u003C\u002Fstrong> is trending in a direction that could lead to a potential undesirable event.” &nbsp;No provision in your CAPA procedure requires opening a CAPA for a quality issue that presents a high risk to patients, and not necessarily based only on a \u003Cstrong>(b)(4)\u003C\u002Fstrong> “trending in a direction that could lead to a potential undesirable event.”\u003C\u002Fp>\n\n\u003Cp>We have reviewed your responses dated 9\u002F16\u002F21 and 11\u002F12\u002F21 and concluded that the adequacy of your responses cannot be determined at this time. &nbsp;Your initial response maintains that the rate of occurrence should not be calculated based on total complaints but based on total devices in the field. &nbsp;Your response does not address defining “trending in a direction that could lead to a potential undesirable event,” or what types of quality data are to be considered more significant indicators of possible quality issues than others. &nbsp;It does not address opening CAPAs commensurate with the significance and risk of the nonconformity. &nbsp;Your response of 11\u002F12\u002F21 describes your efforts to review complaints and establish a new risk-based alert limit for complaint reporting, and a timely and recurring complaint risk review.&nbsp;\u003C\u002Fp>\n\n\u003Cp>Please provide examples of how you are documenting and analyzing these quality data, and how your procedure assures that your investigations of events are commensurate with the significance and risk of nonconformities and events.\u003C\u002Fp>\n\n\u003Cp>4.&nbsp;&nbsp; &nbsp;Failure to evaluate and investigate any complaint involving the possible failure of a device, labeling, or packaging to meet any of its specifications, unless such investigation has already been performed for a similar complaint and another investigation is not necessary, as required by 21 CFR 820.198(c). &nbsp;Specifically,&nbsp;\u003C\u002Fp>\n\n\u003Cp>Your Complaint Handling Procedure, DVHC-SOP-0020, rev. 2, states in section 7.1.4 that any complaint involving the possible failure of a device, labeling, or packaging to meet any of its specifications shall be reviewed, evaluated and investigated unless an investigation has already been performed for a similar complaint and another investigation is not necessary. &nbsp;The following is an example of a complaint record that included documentation that parts were replaced or serviced, but did not document failure investigations:\u003C\u002Fp>\n\n\u003Cp>•&nbsp;&nbsp; &nbsp;Complaint #RO_0331417. The firm documented “FAIL” as the only information with the complaint and in the additional notes, documented “Na Nean” referring to a slang term “Na Mean”. The record notes state that the sieve beds were replaced due to low O2, and the compressor was replaced due to low pressure. The investigation does not document why the compressor, which was under warranty, failed.\u003C\u002Fp>\n\n\u003Cp>We have reviewed your responses dated 9\u002F16\u002F21 and 11\u002F12\u002F21 and concluded that the adequacy of your responses cannot be determined at this time. Your responses state that you are revising complaint handling procedures to create more guidance with complaint detail record keeping. Additionally, you are currently reviewing complaints received between March 26, 2018 and July 27, 2021. &nbsp;\u003C\u002Fp>\n\n\u003Cp>Please provide documentation demonstrating that you have established the applicable procedures to evaluate and investigate any complaint involving the possible failure of a device, labeling, or packaging to meet any of its specifications and the outcome of your retrospective review.\u003C\u002Fp>\n\n\u003Cp>5.&nbsp;&nbsp; &nbsp;Failure to establish procedures for rework of nonconforming products, including retesting and reevaluation of the nonconforming product after rework, to ensure that the product meets its current approved specifications; as well as documentation of the rework and reevaluation activities in the DHR, including a determination of any adverse effect from the rework upon the product, as required by 21 CFR 820.90(b)(2). &nbsp;Specifically, you do not have a written procedure that governs rework for in-process products. &nbsp;\u003C\u002Fp>\n\n\u003Cp>We have reviewed your responses dated 9\u002F16\u002F21 and 11\u002F12\u002F21 and concluded that they are inadequate. &nbsp;Your response of 11\u002F12\u002F21 provided your new in-process rework procedure, which does not require that a record of testing after rework must be included in that unit’s device history record (DHR). &nbsp;\u003C\u002Fp>\n\n\u003Cp>Please provide documentation that demonstrates you have established and implemented your procedure governing rework of in-process products, and that all rework activities and testing are recorded in the device history record (DHR).\u003C\u002Fp>\n\n\u003Cp>Our inspection also revealed that these devices are misbranded within the meaning of Section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that your firm failed or refused to furnish material or information regarding the device that is required by or under Section 519 of the Act, 21 U.S.C. § 360i, and 21 CFR Part 803 – Medical Device Reporting. Violation includes, but is not limited to:\u003C\u002Fp>\n\n\u003Cp>6.&nbsp;&nbsp; &nbsp;Failure to establish an internal system which provides for timely and effective identification, communication and evaluation of events that may be subject to medical device reporting requirements, as required by 21 CFR 803.17(a)(1). &nbsp;Specifically, Complaints were not reviewed and recorded as unreportable for over 200 days after receipt of the complaint. &nbsp;Examples include but are not limited to, complaint numbers RO_0174581, RO_0171904, RO_0188624, and RO_0198227. &nbsp;\u003C\u002Fp>\n\n\u003Cp>We have reviewed your responses dated 9\u002F16\u002F21 and 11\u002F12\u002F21 and concluded that the adequacy of your responses cannot be determined at this time. &nbsp;Your responses state that you are reviewing and updating your procedures and processes for complaint handling and MDR reporting regarding intake, review, evaluation, and reporting of complaints. &nbsp;\u003C\u002Fp>\n\n\u003Cp>Please provide documentation that demonstrates you have established and implemented a procedure which provides for timely and effective identification, communication and evaluation of events that may be subject to medical device reporting requirements. &nbsp;\u003C\u002Fp>\n\n\u003Cp>7.&nbsp;&nbsp; &nbsp;Failure to submit an MDR report within 30 days of receiving or otherwise becoming aware of information that reasonably suggests that a marketed device may have malfunctioned or caused or contributed to a death or serious injury, as required by 21 CFR 803.50(a)(1). &nbsp;Specifically,&nbsp;\u003C\u002Fp>\n\n\u003Cp>On 01\u002F19\u002F2021, you were contacted regarding an injury event in which the patient suffered dyspnea, anxiety, low oxygen saturation and shaking\u002Ftremors, alleging a malfunction with a DeVilbiss 525DS Oxygen Concentrator, serial number \u003Cstrong>(b)(4)\u003C\u002Fstrong>. &nbsp;An MDR was not submitted to FDA until 04\u002F06\u002F2021. You did not report an adverse event within 30 days.\u003C\u002Fp>\n\n\u003Cp>We have reviewed your responses dated 9\u002F16\u002F21 and 11\u002F12\u002F21 and concluded that the adequacy of your responses cannot be determined at this time. &nbsp;Your responses state that you are revising the applicable procedures and conducting training to ensure clarification on the specific information that should be collected as part of the complaint intake process, including robust incident details to ensure prompt and compliant escalation to Regulatory Affairs for evaluation in regard to MDR filing. &nbsp;\u003C\u002Fp>\n\n\u003Cp>You also state that, based on your review of complaints thus far, you have identified several events where MDRs should have been reported, and are in the process of identifying additional events for reporting. &nbsp;These corrective actions are ongoing at this time.\u003C\u002Fp>\n\n\u003Cp>Please provide documentation that demonstrates that you have submitted MDRs for all applicable complaints that reasonably suggest that a marketed device may have caused or contributed to a death or serious injury, and that reportable events received since the time of the inspection have been reported within the required 30-day timeframe.\u003C\u002Fp>\n\n\u003Cp>Your firm should take prompt action to correct the violations addressed in this letter. &nbsp;Failure to promptly correct these violations may result in regulatory action being initiated by the FDA without further notice. &nbsp;These actions include, but are not limited to, seizure, injunction, and civil money penalties. &nbsp;Also, federal agencies may be advised of the issuance of Warning Letters about devices so that they may take this information into account when considering the award of contracts. &nbsp;\u003C\u002Fp>\n\n\u003Cp>Additionally, should FDA determine that you have Quality System Regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been corrected. &nbsp;Also, should FDA determine that your devices do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted. If you believe that your products are not in violation of the Act, please respond to FDA with your reasoning and any supporting information for our consideration. &nbsp;\u003C\u002Fp>\n\n\u003Cp>Please notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to correct the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. &nbsp;Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. &nbsp;If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. &nbsp;If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. &nbsp;Your firm’s response should be comprehensive and address all violations included in this Warning Letter.&nbsp;\u003C\u002Fp>\n\n\u003Cp>If you have questions regarding any issues in this letter, please contact Compliance Officer Richard Cherry at (215) 717-3075 or at richard.cherry@fda.hhs.gov. &nbsp;Please send your reply electronically to Gina Brackett, Director of Compliance Branch, at gina.brackett@fda.hhs.gov.&nbsp;\u003C\u002Fp>\n\n\u003Cp>Finally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. &nbsp;It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. &nbsp;The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. &nbsp;Your firm should investigate and determine the causes of the violations and take prompt actions to correct the violations and bring the products into compliance.&nbsp;\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002Fs\u002F\u003Cbr>\nJoseph Matrisciano, Jr.\u003Cbr>\nProgram Division Director\u003Cbr>\nOffice of Medical Device and Radiological Health\u003Cbr>\nDivision 1\u003C\u002Fp>\n\n\u003Cp>cc: &nbsp;&nbsp; &nbsp;Joseph Lewarski, Senior Vice President, Clinical Affairs\u003Cbr>\n&nbsp;&nbsp; &nbsp;Tony Sapp, Director, Regulatory Affairs and Audits\u003Cbr>\n&nbsp;\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nUNITED PARCEL SERVICE OVERNIGHT DELIVERY and EMAIL\n\nProduct:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nDerek Lampert\n\nRecipient Title\n\nChief Executive Officer\n\nDeVilbiss Healthcare LLC\n\n99 Seaview Blvd, Suite 210\n\nPort Washington, NY 11050\n\nUnited States\n\nIssuing Office:\n\nOffice of Medical Device and Radiological Health Operations (Division 1)\n\nUnited States\n\nDear Mr. Lampert:\n\nThe United States Food and Drug Administration (FDA) conducted an inspection of your firm’s medical device operations at 100 DeVilbiss Dr, Somerset, PA, from 7\u002F28\u002F21 – 8\u002F25\u002F21. During the inspection, an FDA investigator determined that your firm is a manufacturer of oxygen concentrators, nebulizers, suction units, non-continuous ventilators and related accessories. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\n\nThis inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820. We received responses on September 16, 2021 and November 12, 2021 from Tony Sapp, Director, Regulatory Affairs and Audits, concerning our investigator’s observations noted on the Form FDA 483, List of Inspectional Observations (FDA-483) that was issued on August 25, 2021. We address the responses below, in relation to each of the noted violations. These violations include, but are not limited to, the following:\n\n1. Failure to confirm that design outputs meet design input requirements during design verification testing, as required by 21 CFR 820.30(f). Specifically,\n\nThe model 525 oxygen concentrator is designed using the ZW280D2 compressor, which is specified by the manufacturer for an operating ambient temperature range of 40°F-(b)(4)°F (5°C-(b)(4)°C). Design verification test report for IEC 60601-01, Medical Electrical Equipment, report no. 31691761.005, 2018, Table 11-1-1, page 149, states that thermocouple measurements taken in the interior of the finished device showed an interior temperature above the temperature specifications of the compressor in (b)(4) of the (b)(4) measurement sites at an environmental temperature of 22.9°C. At 40˚C, the interior temperature was above the temperature specifications of the compressor at all ten measurement sites.\n\nWe reviewed your responses for this matter and conclude that they are not adequate. In your initial response you provided test reports that showed device interior temperatures ambient to the compressor to be frequently above the stated specification of (b)(4)°C. You based your response on a statement in the manufacturer’s specification, “It is the responsibility of the user to determine the suitability of the product for their intended use.” Your response maintains that this statement allows you to use a compressor for a use above its specified temperature range as long as you perform testing that shows the compressor is able to function above its recommended range. This testing does not address all aspects of the product’s intended use, including the long-term effects on a compressor that operates for many hours above its specified range, including overheating, worn cup seals, fan failures, and shortened life span.\n\nIncluded in your initial response is your “GSE Compressor Life Test Report,” which you maintain, demonstrates that the compressor is capable of operating for a normal lifetime at (b)(4)°C. This document, however, is of a study done to establish the expected lifespan of the compressor through accelerated aging. The (b)(4)°C ambient temperature is one of the stress factors used in the study. This would demonstrate not that (b)(4)°C is acceptable for long term operation, but instead shows that it is a high temperature that stresses the compressor for purposes of accelerated aging.\n\nIn your response of 11\u002F12\u002F21 you provided two test reports, “Compressor Temperature Test Protocol and Report,” and “(b)(4) Test Protocol and Report.” The test of compressor temperatures ran for a duration of (b)(4) and used visual acceptance criteria of “no damage or deformation.” Ambient temperatures were recorded within the (b)(4) period that were higher than the manufacturer’s specified temperature for the compressors. The 525 Oxygen Concentrator is typically run for much longer periods of time than only (b)(4), resulting in possible temperature (b)(4) that could result in much higher ambient temperatures over time. The test of (b)(4) did not include any definition of a time element in the test method or results. It cannot be determined the duration of the test, or how often data readings were taken.\n\nPlease provide documentation that describes how you will address the fact that you are commercially marketing a device that is designed and built with a major component that has been shown by testing to be operating in ambient temperatures above its specified temperature range.\n\n2. Failure to maintain complaint files and establish and maintain procedures for receiving, reviewing, and evaluating complaints by a formally designated unit, as required by 21 CFR 820.198(a). Specifically,\n\nYour Complaint Handling Procedure, DVHC-SOP-0020, rev. 2, states in section 6.0 that Regulatory Affairs will ensure that complaints are reviewed and evaluated “in a timely and uniform fashion.” The procedure further provides in section 7.3, that a determination is made whether serious injury or death was reported and whether medical intervention was required. You are not following your procedure in that complaints are not documented in a timely manner and you are not documenting the determination of whether or not the complaint is reportable under 21 CFR Part 803 – Medical Device Reporting. Examples include, but are not limited to:\n\n• Complaint RO_0320803 was reported to an employee in customer service on 01\u002F19\u002F2021 and described a patient who was in distress from receiving low oxygen; however, the complaint was documented on 04\u002F02\u002F2021, 73 days later, simply as “defective alarm.”\n\n• Complaints were not reviewed for MDR reportability as prescribed in DVHC-SOP-0020, Complaint Handling Procedure, section 7.4, that requires each complaint to be evaluated for reportability according to Adverse Event Reporting procedure DVHC-SOP-0021, including documentation on the applicable form, Adverse Event Determination Form (DVHC-FORM-0105), which requires providing all information necessary to make a reportability determination. Examples include:\n\nRO_0264829, received on 04\u002F02\u002F2020\n\n­ RO_0252308, received on 1\u002F28\u002F2020\n\n­ RO_0208546, received on 04\u002F05\u002F2019\n\n­ RO_0180765, received on 08\u002F23\u002F2018\n\n• Complaint #RO_0208546, recorded on 04\u002F05\u002F2019, alleges a possible malfunction with a DeVilbiss 525DS Oxygen Concentrator, serial number (b)(4), in which the complaint documented “extremely hot in the patient’s home to the point where they were smoking and too hot to touch. The one that happened today happened during a set up and the machine was only running for about 20 minutes while my tech was doing his instruction. The wife commented that she smelled something burning and the tech noticed the concentrator smoking and unplugged it. The machine never alarmed or turned off. The machine stayed hot to the touch for about 40 minutes. When it got back to the warehouse, I noticed that it had just been serviced by DeVilbiss on 3\u002F21\u002F19.” No information regarding the patient was included in the complaint report; there was no record of attempt to obtain patient information; and no record of follow-up with complainant to gather information relevant to determination of reportability.\n\n• Complaint #RO_0252308, recorded on 1\u002F28\u002F2020, alleges a possible malfunction with a DeVilbiss 525DS Oxygen Concentrator, serial number (b)(4), in which the complaint documented the unit had clearly overheated as the case interior was melting and deforming as well as a portion of the back cover, and gross particle filter housing. The outlet air tubing from the compressor was so hot that it began melting the foam insulation of the back cover. The cooling fan below the compressor was not running at all. The complaint further documented it was self-evident that was a failure of the thermal cutoff for this unit as it should have shut down well before it ever got hot enough to begin to melt itself. No documentation of complainant or record of attempt to contact complainant to gather information relevant to reportability.\n\nWe have reviewed your responses dated 9\u002F16\u002F21 and 11\u002F12\u002F21 and concluded that the adequacy of your responses cannot be determined at this time. Your responses state that you are revising complaint handling procedures to create more guidance with complaint detail record keeping. Your response also describes an ongoing effort to review complaints received between March 26, 2018 and July 27, 2021.\n\nPlease provide documentation demonstrating that you have established the applicable procedures for receiving, reviewing and evaluating complaints by a formally designated unit, ensuring that all complaints are processed in a uniform and timely manner, oral complaints are documented on receipt; and complaints are evaluated to determine whether the complaint represents a reportable event.\n\n3. Failure to adequately establish procedures for corrective and preventive action, as required by 21 CFR 820.100(a). Specifically,\n\nYour CAPA procedure, DVHC-SOP-0029, Rev 03, section 7.2.5, states that a CAPA will be created when “a review of quality data suggests that (b)(4) is trending in a direction that could lead to a potential undesirable event.” No provision in your CAPA procedure requires opening a CAPA for a quality issue that presents a high risk to patients, and not necessarily based only on a (b)(4) “trending in a direction that could lead to a potential undesirable event.”\n\nWe have reviewed your responses dated 9\u002F16\u002F21 and 11\u002F12\u002F21 and concluded that the adequacy of your responses cannot be determined at this time. Your initial response maintains that the rate of occurrence should not be calculated based on total complaints but based on total devices in the field. Your response does not address defining “trending in a direction that could lead to a potential undesirable event,” or what types of quality data are to be considered more significant indicators of possible quality issues than others. It does not address opening CAPAs commensurate with the significance and risk of the nonconformity. Your response of 11\u002F12\u002F21 describes your efforts to review complaints and establish a new risk-based alert limit for complaint reporting, and a timely and recurring complaint risk review.\n\nPlease provide examples of how you are documenting and analyzing these quality data, and how your procedure assures that your investigations of events are commensurate with the significance and risk of nonconformities and events.\n\n4. Failure to evaluate and investigate any complaint involving the possible failure of a device, labeling, or packaging to meet any of its specifications, unless such investigation has already been performed for a similar complaint and another investigation is not necessary, as required by 21 CFR 820.198(c). Specifically,\n\nYour Complaint Handling Procedure, DVHC-SOP-0020, rev. 2, states in section 7.1.4 that any complaint involving the possible failure of a device, labeling, or packaging to meet any of its specifications shall be reviewed, evaluated and investigated unless an investigation has already been performed for a similar complaint and another investigation is not necessary. The following is an example of a complaint record that included documentation that parts were replaced or serviced, but did not document failure investigations:\n\n• Complaint #RO_0331417. The firm documented “FAIL” as the only information with the complaint and in the additional notes, documented “Na Nean” referring to a slang term “Na Mean”. The record notes state that the sieve beds were replaced due to low O2, and the compressor was replaced due to low pressure. The investigation does not document why the compressor, which was under warranty, failed.\n\nWe have reviewed your responses dated 9\u002F16\u002F21 and 11\u002F12\u002F21 and concluded that the adequacy of your responses cannot be determined at this time. Your responses state that you are revising complaint handling procedures to create more guidance with complaint detail record keeping. Additionally, you are currently reviewing complaints received between March 26, 2018 and July 27, 2021.\n\nPlease provide documentation demonstrating that you have established the applicable procedures to evaluate and investigate any complaint involving the possible failure of a device, labeling, or packaging to meet any of its specifications and the outcome of your retrospective review.\n\n5. Failure to establish procedures for rework of nonconforming products, including retesting and reevaluation of the nonconforming product after rework, to ensure that the product meets its current approved specifications; as well as documentation of the rework and reevaluation activities in the DHR, including a determination of any adverse effect from the rework upon the product, as required by 21 CFR 820.90(b)(2). Specifically, you do not have a written procedure that governs rework for in-process products.\n\nWe have reviewed your responses dated 9\u002F16\u002F21 and 11\u002F12\u002F21 and concluded that they are inadequate. Your response of 11\u002F12\u002F21 provided your new in-process rework procedure, which does not require that a record of testing after rework must be included in that unit’s device history record (DHR).\n\nPlease provide documentation that demonstrates you have established and implemented your procedure governing rework of in-process products, and that all rework activities and testing are recorded in the device history record (DHR).\n\nOur inspection also revealed that these devices are misbranded within the meaning of Section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that your firm failed or refused to furnish material or information regarding the device that is required by or under Section 519 of the Act, 21 U.S.C. § 360i, and 21 CFR Part 803 – Medical Device Reporting. Violation includes, but is not limited to:\n\n6. Failure to establish an internal system which provides for timely and effective identification, communication and evaluation of events that may be subject to medical device reporting requirements, as required by 21 CFR 803.17(a)(1). Specifically, Complaints were not reviewed and recorded as unreportable for over 200 days after receipt of the complaint. Examples include but are not limited to, complaint numbers RO_0174581, RO_0171904, RO_0188624, and RO_0198227.\n\nWe have reviewed your responses dated 9\u002F16\u002F21 and 11\u002F12\u002F21 and concluded that the adequacy of your responses cannot be determined at this time. Your responses state that you are reviewing and updating your procedures and processes for complaint handling and MDR reporting regarding intake, review, evaluation, and reporting of complaints.\n\nPlease provide documentation that demonstrates you have established and implemented a procedure which provides for timely and effective identification, communication and evaluation of events that may be subject to medical device reporting requirements.\n\n7. Failure to submit an MDR report within 30 days of receiving or otherwise becoming aware of information that reasonably suggests that a marketed device may have malfunctioned or caused or contributed to a death or serious injury, as required by 21 CFR 803.50(a)(1). Specifically,\n\nOn 01\u002F19\u002F2021, you were contacted regarding an injury event in which the patient suffered dyspnea, anxiety, low oxygen saturation and shaking\u002Ftremors, alleging a malfunction with a DeVilbiss 525DS Oxygen Concentrator, serial number (b)(4). An MDR was not submitted to FDA until 04\u002F06\u002F2021. You did not report an adverse event within 30 days.\n\nWe have reviewed your responses dated 9\u002F16\u002F21 and 11\u002F12\u002F21 and concluded that the adequacy of your responses cannot be determined at this time. Your responses state that you are revising the applicable procedures and conducting training to ensure clarification on the specific information that should be collected as part of the complaint intake process, including robust incident details to ensure prompt and compliant escalation to Regulatory Affairs for evaluation in regard to MDR filing.\n\nYou also state that, based on your review of complaints thus far, you have identified several events where MDRs should have been reported, and are in the process of identifying additional events for reporting. These corrective actions are ongoing at this time.\n\nPlease provide documentation that demonstrates that you have submitted MDRs for all applicable complaints that reasonably suggest that a marketed device may have caused or contributed to a death or serious injury, and that reportable events received since the time of the inspection have been reported within the required 30-day timeframe.\n\nYour firm should take prompt action to correct the violations addressed in this letter. Failure to promptly correct these violations may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties. Also, federal agencies may be advised of the issuance of Warning Letters about devices so that they may take this information into account when considering the award of contracts.\n\nAdditionally, should FDA determine that you have Quality System Regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been corrected. Also, should FDA determine that your devices do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted. If you believe that your products are not in violation of the Act, please respond to FDA with your reasoning and any supporting information for our consideration.\n\nPlease notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to correct the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address all violations included in this Warning Letter.\n\nIf you have questions regarding any issues in this letter, please contact Compliance Officer Richard Cherry at (215) 717-3075 or at richard.cherry@fda.hhs.gov. Please send your reply electronically to Gina Brackett, Director of Compliance Branch, at gina.brackett@fda.hhs.gov.\n\nFinally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of the violations and take prompt actions to correct the violations and bring the products into compliance.\n\nSincerely,\n\n\u002Fs\u002F\n\nJoseph Matrisciano, Jr.\n\nProgram Division Director\n\nOffice of Medical Device and Radiological Health\n\nDivision 1\n\ncc: Joseph Lewarski, Senior Vice President, Clinical Affairs\n\nTony Sapp, Director, Regulatory Affairs and Audits","DeVilbiss Healthcare LLC","devilbiss-healthcare-llc-619182-11232021","2026-08-18T06:42:29.262718+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fdevilbiss-healthcare-llc-619182-11232021","2026-10-26T08:08:23.773628+00:00","Closed Out","2021-12-14","619182","Medical Devices","2024-10-30","Derek Lampert","2026-08-20T02:20:42.968+00:00","UNITED PARCEL SERVICE OVERNIGHT DELIVERY and EMAIL","2021-11-23",{"id":59,"raw":60,"subject":14,"body_html":65,"body_text":66,"firm_name":67,"letter_id":68,"created_at":69,"fei_number":20,"letter_url":70,"updated_at":71,"action_type":23,"case_status":24,"posted_date":72,"marcs_cms_no":73,"product_type":27,"closeout_date":20,"issuing_office":64,"recipient_name":74,"body_fetched_at":75,"delivery_method":30,"recipient_title":20,"reference_number":20,"action_taken_date":76,"medical_device_id":20,"response_letter_date":20},1966,[61,62,63,64,14,13,13,13],"\u003Ctime datetime=\"2023-08-01T13:20:00Z\">08\u002F01\u002F2023\u003C\u002Ftime>\n","\u003Ctime datetime=\"2023-07-25T04:00:00Z\">07\u002F25\u002F2023\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fbaxter-healthcare-corporation-654136-07252023\">Baxter Healthcare Corporation\u003C\u002Fa>","Center for Drug Evaluation and Research | CDER","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Email\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. José E. Almeida\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Chairman, CEO and President\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Baxter Healthcare Corporation\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>1 Baxter Parkway\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Deerfield\u003C\u002Fspan>, \u003Cspan>IL\u003C\u002Fspan> \u003Cspan>60015\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research | CDER\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>Warning Letter\u003C\u002Fstrong> 320-23-18\u003C\u002Fp>\n\n\u003Cp>July 25, 2023\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Almeida:\u003C\u002Fp>\n\n\u003Cp>The U.S. Food and Drug Administration (FDA) inspected your drug manufacturing facility, Baxter Pharmaceuticals India Pvt. Ltd., 3004610460, at Village Vasana Chacharwadi, Taluka Sanand, Ahmedabad, India, from January 19 to January 27, 2023.\u003C\u002Fp>\n\n\u003Cp>This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\u003C\u002Fp>\n\n\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\n\n\u003Cp>We reviewed your February 17, 2023 response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\u003C\u002Fp>\n\n\u003Cp>During our inspection, our investigators observed specific violations including, but not limited to, the following.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>1. Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>You failed to conduct adequate investigations into endotoxin testing and your 100% automated visual inspection system. You conducted investigations that were not thorough, expanded to an appropriate scope, or based on scientifically supported root cause(s). You did not identify and implement appropriate corrective actions and preventive actions (CAPA). Specifically,\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>Your firm invalidated multiple endotoxin tests for finished products upon discovery of particulate matter in one or more wells used to perform the kinetic-turbidimetric assay (KTA) method. You failed to characterize the particulate matter and attributed the particulates to environmental and laboratory conditions, such as air ducts and activities being performed by personnel in the immediate vicinity of the analysis. You did not definitively identify the source or sources of the particulate matter, define the scope of potentially impacted operations (including potential manufacturing causes), and implement scientifically justified CAPA in a timely manner.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>In a previous inspection (May 2022), FDA cited your firm for inadequate investigations into these and other similar out-of-specification (OOS) endotoxin testing that you invalidated due to uncharacterized particulate contamination in one or more wells during KTA analyses. Prior to and during an October 5, 2022 regulatory meeting with your firm, we requested you perform a retrospective assessment of investigations associated with OOS endotoxin results or endotoxin testing deviations. During the current inspection, your personnel explained that these investigations were not reopened or otherwise reassessed. Although you retained a third-party consultant to perform a retrospective assessment of endotoxin investigations associated with OOS endotoxin result investigations, you did not provide the third-party consultant with an investigation cited during the May 2022 inspection. You also did not ensure the assessment included approximately 20 invalidated laboratory tests generated in 2021 and 2022 (including multiple investigations since the May 2022 inspection).\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>Your firm did not adequately investigate failures of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> automatic inspection machine to detect known defects, including particulate matter in injectable drug products. Despite the data indicating significant deficiencies in the machine’s ability to detect known defects during its use, you continued to employ the \u003Cstrong>(b)(4)\u003C\u002Fstrong> automatic inspection machine to inspect commercially distributed products (e.g., several batches of \u003Cstrong>(b)(4)\u003C\u002Fstrong> injection \u003Cstrong>(b)(4)\u003C\u002Fstrong> mg\u002FmL USP). Notably, you fully relied on this automated visual inspection system to detect various defects including particulate contamination for an extended period and did not perform a 100% manual visual inspection for all defects.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>Challenges with defect kits indicated failing rejection rates or other deficiencies. For example, an October 2022 challenge excluded the use of \u003Cstrong>(b)(4)\u003C\u002Fstrong> particles despite their lower detectability than other “dark” particles in \u003Cstrong>(b)(4)\u003C\u002Fstrong> mL amber glass vials. The challenge also used a highly detectable particle range of \u003Cstrong>(b)(4)\u003C\u002Fstrong> μm, but still indicated detection and capability issues. Similar challenges to the \u003Cstrong>(b)(4)\u003C\u002Fstrong> automatic inspection machine utilized commercial inspection parameters. You did not initiate adequate investigations into these detection issues. You lacked adequate assurance that sterile injectable drug batches visually inspected with the \u003Cstrong>(b)(4)\u003C\u002Fstrong> automatic inspection machine were free from visible particulates.\u003C\u002Fp>\n\n\u003Cp>Your response is inadequate. Your firm previously committed to evaluate and implement improvements to your procedures and practices associated with the conduct of investigations following the conclusion of the July 27 to August 4, 2017, inspection of this facility and in response to the warning letter sent to your firm on July 5, 2018. You also reported significant CAPA activities to address the frequency of endotoxin testing OOS results and deviations following the October 5, 2022, regulatory meeting.\u003C\u002Fp>\n\n\u003Cp>In your February 17, 2023, response to the Form FDA 483 issued at the conclusion of the most recent inspection, you commit to further revisions of your investigation procedures.\u003C\u002Fp>\n\n\u003Cp>However, you do not adequately address your failure to conduct timely investigations into recurring and persistent issues. Your response did not adequately address the use of insufficiently qualified \u003Cstrong>(b)(4)\u003C\u002Fstrong> equipment for 100% visual inspection of injectable drug products for approximately five years (until October 2022) and the excessive number of samples contaminated with endotoxins or particles in your laboratory.\u003C\u002Fp>\n\n\u003Cp>We encourage the use of automated visual inspection for particulates to augment the 100% manual visual inspection program. Automated methods should be rigorously studied for their capability and robustness under various conditions, machine settings, container-closure sizes, defect types, and other variables. In addition, any use of automated particulate inspection does not supplant the need for 100% manual visual inspection for various other attributes (e.g., cracks).\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A written commitment to have all lots of finished products manufactured at your facility analyzed for endotoxins by a qualified laboratory until you have thoroughly investigated each endotoxin test invalidation event since January 1, 2018, and implemented all necessary CAPA to prevent recurrence of endotoxin result invalidations. This should include but not be limited to assuring CAPA effectiveness for your particulate and pipetting issues.\u003C\u002Fli>\n\t\u003Cli>A comprehensive, independent assessment and remediation plan of your systems for the visual inspection of sterile injectable drugs for defects, including the presence of particulate matter, used for products distributed in the United States that remain within expiry. The assessment should include acceptance and rejection criteria, personnel training, supervision, equipment and personnel qualification, equipment maintenance, and process validation and the procedures governing them. Provide your detailed remediation action plan that includes dates by which each remediation activity will be completed and a periodic independent reassessment of the plan’s effectiveness.\u003C\u002Fli>\n\t\u003Cli>An independent third-party assessment and remediation plan for your CAPA program. Provide a report that evaluates whether the program includes effective root cause analysis, ensures CAPA effectiveness, analyzes investigation trends, improves the CAPA program when needed, implements final quality unit decisions, and is fully supported by executive management.\u003C\u002Fli>\n\t\u003Cli>A third-party protocol and the executed protocol final report for the retrospective review of particulate matter investigations associated with distributed in the United States that remain within expiry, irrespective of whether the original investigation resulted in the invalidation of the original result. The protocol should include an evaluation of the investigation’s thoroughness; assignment and scientific justification for root cause(s); documentation of CAPA implementation, and documented effectiveness of CAPA.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cstrong>2. Your firm failed to establish and follow adequate written procedures for cleaning and maintenance of equipment (21 CFR 211.67(b)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>An FDA investigator observed white spots at the bottom of a \u003Cstrong>(b)(4)\u003C\u002Fstrong> L bulk solution holding tank used to supply a non-dedicated filling machine despite the vessel being documented as clean. You subsequently analyzed and identified the white spots as \u003Cstrong>(b)(4)\u003C\u002Fstrong> (the product previously processed on this equipment) at levels of up to \u003Cstrong>(b)(4)\u003C\u002Fstrong> parts per million (ppm). Your limit for post-cleaning residues is not more than \u003Cstrong>(b)(4)\u003C\u002Fstrong> ppm.\u003C\u002Fp>\n\n\u003Cp>Your response is inadequate. Although you revised your cleaning procedure to require vessels to be dry before conducting the visual inspection for cleanliness and implemented visual verification of the vessel interior via a sight glass following the cleaning and \u003Cstrong>(b)(4)\u003C\u002Fstrong> activities, you did not provide scientific justification for your use of visual inspection to verify the removal of residues to levels as low as \u003Cstrong>(b)(4)\u003C\u002Fstrong> ppm. Your response noted \u003Cstrong>(b)(4)\u003C\u002Fstrong> injection, not \u003Cstrong>(b)(4)\u003C\u002Fstrong> injection, is the “worst-case product” processed in this vessel, but you did not provide a comprehensive investigation to assess the impact of this cleaning deviation on products previously manufactured on this and other non-dedicated equipment. You also did not propose a systemic assessment of your equipment cleaning program.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A comprehensive, independent retrospective assessment of your cleaning effectiveness to evaluate the scope of cross-contamination hazards. Include the identity of residues, other manufacturing equipment that may have been improperly cleaned, and an assessment whether cross-contaminated products may have been released for distribution. The assessment should identify any inadequacies of cleaning procedures and practices, and encompass each piece of manufacturing equipment used to manufacture more than one product.\u003C\u002Fli>\n\t\u003Cli>A CAPA plan, based on the retrospective assessment of your cleaning program, that includes appropriate remediations to your cleaning processes and practices, and timelines for completion. Provide a detailed summary of vulnerabilities in your process for lifecycle management of equipment cleaning. Describe improvements to your cleaning program, including enhancements to cleaning effectiveness; improved ongoing verification of proper cleaning execution for all products and equipment; and all other needed remediations.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cstrong>3. Your firm failed to establish adequate written procedures for production and process control designed to assure that drug products you manufacture have the identity, strength, quality, and purity they purport or are represented to possess, and to follow all of your written production and process control procedures (21 CFR 211.100(a) and (b)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your program for the visual inspection of sterile injectable drug products does not provide adequate assurance that finished products manufactured at your facility possess their purported quality attributes, including that they are free from particulate matter. For example,\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>Personnel performed 100% manual visual inspection of sterile injectable units for less than the minimum amount of time required by your written procedures.\u003C\u002Fli>\n\t\u003Cli>You lacked scientific justification for removing vials containing \u003Cstrong>(b)(4)\u003C\u002Fstrong> particles from the defect kits used to qualify visual inspection processes. For example, although \u003Cstrong>(b)(4)\u003C\u002Fstrong> particles were more difficult to reproducibly detect than \u003Cstrong>(b)(4)\u003C\u002Fstrong> stopper particles in the \u003Cstrong>(b)(4)\u003C\u002Fstrong> mL amber vials, you elected to only use the \u003Cstrong>(b)(4)\u003C\u002Fstrong> stopper particles in the defect kits.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>Your response is inadequate. You commit to using a “pacing device” during the 100% manual visual inspections and requiring a supervisor to periodically verify the inspection times. You did not provide a description of the pacing device or commit to requalify operators following implementation of the pacing device. Additionally, you did not commit to evaluate operator performance throughout a \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\n\n\u003Cp>You also state a successful qualification program does not evaluate “… an inspector’s ability to differentiate and identify various types and morphologies of particles.” However, it is critical to be able to reproducibly detect particulate defects of different types, morphologies, and sizes.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide a comprehensive, independent assessment of each lot of sterile injectable drugs distributed from your facility to the United States that remains within expiry to meet the requirement of being essentially free of visible particles. The assessment should also include consideration of gaps and other deficiencies identified in the independent assessment of your systems for visual inspection of sterile injectable drugs.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>4. Your firm failed to use equipment in the manufacture, processing, packing, or holding of drug products that is of appropriate design, adequate size, and suitably located to facilitate operations for its intended use and for its cleaning and maintenance (21 CFR 211.63).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Equipment used in the manufacture of terminally sterilized drugs at your facility is not designed or maintained appropriately. Our inspection revealed instances of damaged metal and plastic parts, open vials exposed to worn bolt threading, and process flow that required employees to duck underneath the sterile processing line conveyer in order to perform interventions near open vials (e.g., stopper addition on the \u003Cstrong>(b)(4)\u003C\u002Fstrong> filling line).\u003C\u002Fp>\n\n\u003Cp>Your response is inadequate. Although you commit to replacing the threaded bolt \u003Cstrong>(b)(4)\u003C\u002Fstrong> on the \u003Cstrong>(b)(4)\u003C\u002Fstrong> filling line with a different part that will not expose a threading over open vials, you did not commit to evaluate production rooms and production equipment for wear, damage, or poor design that may lead to the generation of particulate matter in the vicinity of open vials. You also plan to install a \u003Cstrong>(b)(4)\u003C\u002Fstrong> conveyor at the capping machine outfeed, and merge filling and capping areas, for two filling lines (\u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong>), but you did not commit to perform a comprehensive assessment of your facility’s production lines to ensure they are appropriately designed and controlled.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A comprehensive, independent assessment of the design of each sterile drug production line, including facility layout, equipment placement and ergonomics, and personnel and material flow. Provide your detailed remediation plan with timelines to address the findings of the assessment. Describe specific tangible improvements to be made to the sterile processing operation design and control. Include a plan to assess the effectiveness of the improvements.\u003C\u002Fli>\n\t\u003Cli>A comprehensive, independent assessment of the condition of equipment including change parts, and the procedures and practices associated with equipment maintenance. Provide your detailed remediation action plan that includes dates by which each remediation activity will be completed and periodic assessment of the plan’s effectiveness.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cstrong>Ineffective Quality System\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Significant findings in this letter demonstrate that your firm does not operate an effective quality system in accord with CGMP. In addition to the lack of effective production oversight, we found your quality unit is not enabled to exercise proper authority and\u002For has insufficiently implemented its responsibilities. Executive management should immediately and comprehensively assess your company’s global manufacturing operations to ensure that your systems, processes, and products conform to FDA requirements.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Process Controls\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your firm does not have an adequate ongoing program for monitoring process control to ensure stable manufacturing operations and consistent drug quality.\u003C\u002Fp>\n\n\u003Cp>See FDA’s guidance document \u003Cem>Process Validation: General Principles and Practices\u003C\u002Fem> for general principles and approaches that FDA considers appropriate elements of process validation at https:\u002F\u002Fwww.fda.gov\u002Ffiles\u002Fdrugs\u002Fpublished\u002FProcess-Validation--General-Principles-and-Practices.pdf.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>CGMP Consultant Recommended\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Based upon the nature of the violations we identified at your firm and because you failed to correct repeat violations, we strongly recommend engaging a consultant qualified as set forth in 21 CFR 211.34 and independent of your firm to assist your firm in meeting CGMP requirements. Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\u003C\u002Fp>\n\n\u003Cp>If you are considering an action that is likely to lead to a disruption in the supply of drugs produced at your facility, FDA requests that you contact CDER’s Drug Shortages Staff immediately, at drugshortages@fda.hhs.gov, so that FDA can work with you on the most effective way to bring your operations into compliance with the law. Contacting the Drug Shortages Staff also allows you to meet any obligations you may have to report discontinuances or interruptions in your drug manufacture under 21 U.S.C. 356C(b). This also allows FDA to consider, as soon as possible, what actions, if any, may be needed to avoid shortages and protect the health of patients who depend on your products.\u003C\u002Fp>\n\n\u003Cp>Correct any violations promptly. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to any violations.\u003C\u002Fp>\n\n\u003Cp>Failure to address any violations may also result in the FDA refusing admission of articles manufactured at Baxter Pharmaceuticals India Pvt. Ltd., 3004610460, at Village Vasana Chacharwadi, Taluka Sanand, Ahmedabad, Gujarat, India into the United States under section 801(a)(3) of the FD&amp;C Act, 21 U.S.C. 381(a)(3). Articles under this authority that appear to be adulterated may be detained or refused admission, in that the methods and controls used in their manufacture do not appear to conform to CGMP within the meaning of section 501(a)(2)(B) of the FD&amp;C Act, 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\n\n\u003Cp>We request you email Temeka Moore, Temeka.Moore@fda.hhs.gov, within five days of receipt of this letter to schedule a regulatory meeting.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup>. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\n\n\u003Cp>Send your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3004610460 and ATTN: Jason F. Chancey.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Francis Godwin\u003Cbr>\nDirector\u003Cbr>\nOffice of Manufacturing Quality\u003Cbr>\nOffice of Compliance\u003Cbr>\nCenter for Drug Evaluation and Research\u003C\u002Fp>\n\n\u003Cp>Cc: Rishikesh Jaiwant, Senior Director Manufacturing and Operations- Ahmedabad\u003Cbr>\n(rishikesh_jaiwant@baxter.com)\u003C\u002Fp>\n\n\u003Cp>_________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> Under program enhancements for the Generic Drug User Fee Amendments (GDUFA) reauthorization for fiscal years (FYs) 2023-2027, also known as the GDUFA III Commitment Letter, your facility may be eligible for a Post-Warning Letter Meeting to obtain preliminary feedback from FDA on the adequacy and completeness of your corrective action plans.\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Email\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMr. José E. Almeida\n\nRecipient Title\n\nChairman, CEO and President\n\nBaxter Healthcare Corporation\n\n1 Baxter Parkway\n\nDeerfield, IL 60015\n\nUnited States\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research | CDER\n\nUnited States\n\nWarning Letter 320-23-18\n\nJuly 25, 2023\n\nDear Mr. Almeida:\n\nThe U.S. Food and Drug Administration (FDA) inspected your drug manufacturing facility, Baxter Pharmaceuticals India Pvt. Ltd., 3004610460, at Village Vasana Chacharwadi, Taluka Sanand, Ahmedabad, India, from January 19 to January 27, 2023.\n\nThis warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\n\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B).\n\nWe reviewed your February 17, 2023 response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\n\nDuring our inspection, our investigators observed specific violations including, but not limited to, the following.\n\n1. Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).\n\nYou failed to conduct adequate investigations into endotoxin testing and your 100% automated visual inspection system. You conducted investigations that were not thorough, expanded to an appropriate scope, or based on scientifically supported root cause(s). You did not identify and implement appropriate corrective actions and preventive actions (CAPA). Specifically,\n\nYour firm invalidated multiple endotoxin tests for finished products upon discovery of particulate matter in one or more wells used to perform the kinetic-turbidimetric assay (KTA) method. You failed to characterize the particulate matter and attributed the particulates to environmental and laboratory conditions, such as air ducts and activities being performed by personnel in the immediate vicinity of the analysis. You did not definitively identify the source or sources of the particulate matter, define the scope of potentially impacted operations (including potential manufacturing causes), and implement scientifically justified CAPA in a timely manner.\n\nIn a previous inspection (May 2022), FDA cited your firm for inadequate investigations into these and other similar out-of-specification (OOS) endotoxin testing that you invalidated due to uncharacterized particulate contamination in one or more wells during KTA analyses. Prior to and during an October 5, 2022 regulatory meeting with your firm, we requested you perform a retrospective assessment of investigations associated with OOS endotoxin results or endotoxin testing deviations. During the current inspection, your personnel explained that these investigations were not reopened or otherwise reassessed. Although you retained a third-party consultant to perform a retrospective assessment of endotoxin investigations associated with OOS endotoxin result investigations, you did not provide the third-party consultant with an investigation cited during the May 2022 inspection. You also did not ensure the assessment included approximately 20 invalidated laboratory tests generated in 2021 and 2022 (including multiple investigations since the May 2022 inspection).\n\nYour firm did not adequately investigate failures of the (b)(4) automatic inspection machine to detect known defects, including particulate matter in injectable drug products. Despite the data indicating significant deficiencies in the machine’s ability to detect known defects during its use, you continued to employ the (b)(4) automatic inspection machine to inspect commercially distributed products (e.g., several batches of (b)(4) injection (b)(4) mg\u002FmL USP). Notably, you fully relied on this automated visual inspection system to detect various defects including particulate contamination for an extended period and did not perform a 100% manual visual inspection for all defects.\n\nChallenges with defect kits indicated failing rejection rates or other deficiencies. For example, an October 2022 challenge excluded the use of (b)(4) particles despite their lower detectability than other “dark” particles in (b)(4) mL amber glass vials. The challenge also used a highly detectable particle range of (b)(4) μm, but still indicated detection and capability issues. Similar challenges to the (b)(4) automatic inspection machine utilized commercial inspection parameters. You did not initiate adequate investigations into these detection issues. You lacked adequate assurance that sterile injectable drug batches visually inspected with the (b)(4) automatic inspection machine were free from visible particulates.\n\nYour response is inadequate. Your firm previously committed to evaluate and implement improvements to your procedures and practices associated with the conduct of investigations following the conclusion of the July 27 to August 4, 2017, inspection of this facility and in response to the warning letter sent to your firm on July 5, 2018. You also reported significant CAPA activities to address the frequency of endotoxin testing OOS results and deviations following the October 5, 2022, regulatory meeting.\n\nIn your February 17, 2023, response to the Form FDA 483 issued at the conclusion of the most recent inspection, you commit to further revisions of your investigation procedures.\n\nHowever, you do not adequately address your failure to conduct timely investigations into recurring and persistent issues. Your response did not adequately address the use of insufficiently qualified (b)(4) equipment for 100% visual inspection of injectable drug products for approximately five years (until October 2022) and the excessive number of samples contaminated with endotoxins or particles in your laboratory.\n\nWe encourage the use of automated visual inspection for particulates to augment the 100% manual visual inspection program. Automated methods should be rigorously studied for their capability and robustness under various conditions, machine settings, container-closure sizes, defect types, and other variables. In addition, any use of automated particulate inspection does not supplant the need for 100% manual visual inspection for various other attributes (e.g., cracks).\n\nIn response to this letter, provide:\n\nA written commitment to have all lots of finished products manufactured at your facility analyzed for endotoxins by a qualified laboratory until you have thoroughly investigated each endotoxin test invalidation event since January 1, 2018, and implemented all necessary CAPA to prevent recurrence of endotoxin result invalidations. This should include but not be limited to assuring CAPA effectiveness for your particulate and pipetting issues.\n\nA comprehensive, independent assessment and remediation plan of your systems for the visual inspection of sterile injectable drugs for defects, including the presence of particulate matter, used for products distributed in the United States that remain within expiry. The assessment should include acceptance and rejection criteria, personnel training, supervision, equipment and personnel qualification, equipment maintenance, and process validation and the procedures governing them. Provide your detailed remediation action plan that includes dates by which each remediation activity will be completed and a periodic independent reassessment of the plan’s effectiveness.\n\nAn independent third-party assessment and remediation plan for your CAPA program. Provide a report that evaluates whether the program includes effective root cause analysis, ensures CAPA effectiveness, analyzes investigation trends, improves the CAPA program when needed, implements final quality unit decisions, and is fully supported by executive management.\n\nA third-party protocol and the executed protocol final report for the retrospective review of particulate matter investigations associated with distributed in the United States that remain within expiry, irrespective of whether the original investigation resulted in the invalidation of the original result. The protocol should include an evaluation of the investigation’s thoroughness; assignment and scientific justification for root cause(s); documentation of CAPA implementation, and documented effectiveness of CAPA.\n\n2. Your firm failed to establish and follow adequate written procedures for cleaning and maintenance of equipment (21 CFR 211.67(b)).\n\nAn FDA investigator observed white spots at the bottom of a (b)(4) L bulk solution holding tank used to supply a non-dedicated filling machine despite the vessel being documented as clean. You subsequently analyzed and identified the white spots as (b)(4) (the product previously processed on this equipment) at levels of up to (b)(4) parts per million (ppm). Your limit for post-cleaning residues is not more than (b)(4) ppm.\n\nYour response is inadequate. Although you revised your cleaning procedure to require vessels to be dry before conducting the visual inspection for cleanliness and implemented visual verification of the vessel interior via a sight glass following the cleaning and (b)(4) activities, you did not provide scientific justification for your use of visual inspection to verify the removal of residues to levels as low as (b)(4) ppm. Your response noted (b)(4) injection, not (b)(4) injection, is the “worst-case product” processed in this vessel, but you did not provide a comprehensive investigation to assess the impact of this cleaning deviation on products previously manufactured on this and other non-dedicated equipment. You also did not propose a systemic assessment of your equipment cleaning program.\n\nIn response to this letter, provide:\n\nA comprehensive, independent retrospective assessment of your cleaning effectiveness to evaluate the scope of cross-contamination hazards. Include the identity of residues, other manufacturing equipment that may have been improperly cleaned, and an assessment whether cross-contaminated products may have been released for distribution. The assessment should identify any inadequacies of cleaning procedures and practices, and encompass each piece of manufacturing equipment used to manufacture more than one product.\n\nA CAPA plan, based on the retrospective assessment of your cleaning program, that includes appropriate remediations to your cleaning processes and practices, and timelines for completion. Provide a detailed summary of vulnerabilities in your process for lifecycle management of equipment cleaning. Describe improvements to your cleaning program, including enhancements to cleaning effectiveness; improved ongoing verification of proper cleaning execution for all products and equipment; and all other needed remediations.\n\n3. Your firm failed to establish adequate written procedures for production and process control designed to assure that drug products you manufacture have the identity, strength, quality, and purity they purport or are represented to possess, and to follow all of your written production and process control procedures (21 CFR 211.100(a) and (b)).\n\nYour program for the visual inspection of sterile injectable drug products does not provide adequate assurance that finished products manufactured at your facility possess their purported quality attributes, including that they are free from particulate matter. For example,\n\nPersonnel performed 100% manual visual inspection of sterile injectable units for less than the minimum amount of time required by your written procedures.\n\nYou lacked scientific justification for removing vials containing (b)(4) particles from the defect kits used to qualify visual inspection processes. For example, although (b)(4) particles were more difficult to reproducibly detect than (b)(4) stopper particles in the (b)(4) mL amber vials, you elected to only use the (b)(4) stopper particles in the defect kits.\n\nYour response is inadequate. You commit to using a “pacing device” during the 100% manual visual inspections and requiring a supervisor to periodically verify the inspection times. You did not provide a description of the pacing device or commit to requalify operators following implementation of the pacing device. Additionally, you did not commit to evaluate operator performance throughout a (b)(4).\n\nYou also state a successful qualification program does not evaluate “… an inspector’s ability to differentiate and identify various types and morphologies of particles.” However, it is critical to be able to reproducibly detect particulate defects of different types, morphologies, and sizes.\n\nIn response to this letter, provide a comprehensive, independent assessment of each lot of sterile injectable drugs distributed from your facility to the United States that remains within expiry to meet the requirement of being essentially free of visible particles. The assessment should also include consideration of gaps and other deficiencies identified in the independent assessment of your systems for visual inspection of sterile injectable drugs.\n\n4. Your firm failed to use equipment in the manufacture, processing, packing, or holding of drug products that is of appropriate design, adequate size, and suitably located to facilitate operations for its intended use and for its cleaning and maintenance (21 CFR 211.63).\n\nEquipment used in the manufacture of terminally sterilized drugs at your facility is not designed or maintained appropriately. Our inspection revealed instances of damaged metal and plastic parts, open vials exposed to worn bolt threading, and process flow that required employees to duck underneath the sterile processing line conveyer in order to perform interventions near open vials (e.g., stopper addition on the (b)(4) filling line).\n\nYour response is inadequate. Although you commit to replacing the threaded bolt (b)(4) on the (b)(4) filling line with a different part that will not expose a threading over open vials, you did not commit to evaluate production rooms and production equipment for wear, damage, or poor design that may lead to the generation of particulate matter in the vicinity of open vials. You also plan to install a (b)(4) conveyor at the capping machine outfeed, and merge filling and capping areas, for two filling lines ((b)(4) and (b)(4)), but you did not commit to perform a comprehensive assessment of your facility’s production lines to ensure they are appropriately designed and controlled.\n\nIn response to this letter, provide:\n\nA comprehensive, independent assessment of the design of each sterile drug production line, including facility layout, equipment placement and ergonomics, and personnel and material flow. Provide your detailed remediation plan with timelines to address the findings of the assessment. Describe specific tangible improvements to be made to the sterile processing operation design and control. Include a plan to assess the effectiveness of the improvements.\n\nA comprehensive, independent assessment of the condition of equipment including change parts, and the procedures and practices associated with equipment maintenance. Provide your detailed remediation action plan that includes dates by which each remediation activity will be completed and periodic assessment of the plan’s effectiveness.\n\nIneffective Quality System\n\nSignificant findings in this letter demonstrate that your firm does not operate an effective quality system in accord with CGMP. In addition to the lack of effective production oversight, we found your quality unit is not enabled to exercise proper authority and\u002For has insufficiently implemented its responsibilities. Executive management should immediately and comprehensively assess your company’s global manufacturing operations to ensure that your systems, processes, and products conform to FDA requirements.\n\nProcess Controls\n\nYour firm does not have an adequate ongoing program for monitoring process control to ensure stable manufacturing operations and consistent drug quality.\n\nSee FDA’s guidance document Process Validation: General Principles and Practices for general principles and approaches that FDA considers appropriate elements of process validation at https:\u002F\u002Fwww.fda.gov\u002Ffiles\u002Fdrugs\u002Fpublished\u002FProcess-Validation--General-Principles-and-Practices.pdf.\n\nCGMP Consultant Recommended\n\nBased upon the nature of the violations we identified at your firm and because you failed to correct repeat violations, we strongly recommend engaging a consultant qualified as set forth in 21 CFR 211.34 and independent of your firm to assist your firm in meeting CGMP requirements. Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\n\nConclusion\n\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\n\nIf you are considering an action that is likely to lead to a disruption in the supply of drugs produced at your facility, FDA requests that you contact CDER’s Drug Shortages Staff immediately, at drugshortages@fda.hhs.gov, so that FDA can work with you on the most effective way to bring your operations into compliance with the law. Contacting the Drug Shortages Staff also allows you to meet any obligations you may have to report discontinuances or interruptions in your drug manufacture under 21 U.S.C. 356C(b). This also allows FDA to consider, as soon as possible, what actions, if any, may be needed to avoid shortages and protect the health of patients who depend on your products.\n\nCorrect any violations promptly. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to any violations.\n\nFailure to address any violations may also result in the FDA refusing admission of articles manufactured at Baxter Pharmaceuticals India Pvt. Ltd., 3004610460, at Village Vasana Chacharwadi, Taluka Sanand, Ahmedabad, Gujarat, India into the United States under section 801(a)(3) of the FD&C Act, 21 U.S.C. 381(a)(3). Articles under this authority that appear to be adulterated may be detained or refused admission, in that the methods and controls used in their manufacture do not appear to conform to CGMP within the meaning of section 501(a)(2)(B) of the FD&C Act, 21 U.S.C. 351(a)(2)(B).\n\nWe request you email Temeka Moore, Temeka.Moore@fda.hhs.gov, within five days of receipt of this letter to schedule a regulatory meeting.\n\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days1. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\n\nSend your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3004610460 and ATTN: Jason F. Chancey.\n\nSincerely,\n\n\u002FS\u002F\n\nFrancis Godwin\n\nDirector\n\nOffice of Manufacturing Quality\n\nOffice of Compliance\n\nCenter for Drug Evaluation and Research\n\nCc: Rishikesh Jaiwant, Senior Director Manufacturing and Operations- Ahmedabad\n\n(rishikesh_jaiwant@baxter.com)\n\n_________________\n\n1 Under program enhancements for the Generic Drug User Fee Amendments (GDUFA) reauthorization for fiscal years (FYs) 2023-2027, also known as the GDUFA III Commitment Letter, your facility may be eligible for a Post-Warning Letter Meeting to obtain preliminary feedback from FDA on the adequacy and completeness of your corrective action plans.","Baxter Healthcare Corporation","baxter-healthcare-corporation-654136-07252023","2026-08-18T06:42:28.994808+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fbaxter-healthcare-corporation-654136-07252023","2026-10-26T08:08:01.800292+00:00","2023-08-01","654136","Mr. José E. Almeida","2026-08-20T00:49:44.234+00:00","2023-07-25",{"id":78,"raw":79,"subject":83,"body_html":84,"body_text":85,"firm_name":86,"letter_id":87,"created_at":88,"fei_number":20,"letter_url":89,"updated_at":90,"action_type":23,"case_status":24,"posted_date":91,"marcs_cms_no":92,"product_type":27,"closeout_date":20,"issuing_office":11,"recipient_name":93,"body_fetched_at":94,"delivery_method":95,"recipient_title":20,"reference_number":96,"action_taken_date":97,"medical_device_id":20,"response_letter_date":20},18,[80,81,82,11,83,13,13,13],"\u003Ctime datetime=\"2026-07-21T04:00:00Z\">07\u002F21\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2026-07-13T04:00:00Z\">07\u002F13\u002F2026\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Falmon-healthcare-private-limited-729291-07132026\">Almon Healthcare Private Limited\u003C\u002Fa>","CGMP\u002FActive Pharmaceutical Ingredient (API)\u002FAdulterated","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Email Return Receipt Requested\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>320-26-102\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Rajesh Gandhi\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Chairman\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Almon Healthcare Private Limited\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>Plot No 4, Sankalp Industrial Estate, Behind Kerala GIDC, Bavala\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Ahmedabad\u003C\u002Fspan> \u003Cspan>382240\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Gujarat\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>India\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>Warning Letter\u003C\u002Fstrong> 320-26-102\u003C\u002Fp>\u003Cp>July 13, 2026\u003C\u002Fp>\u003Cp>Dear Mr. Gandhi:\u003C\u002Fp>\u003Cp>The United States Food and Drug Administration (FDA) inspected your drug manufacturing facility, Almon Healthcare Private Limited, FEI 3030509366, at Plot No 4, Sankalp Industrial Estate, Behind Kerala GIDC, Bavala, Ahmedabad, from February 9 to 13, 2026.\u003C\u002Fp>\u003Cp>This warning letter summarizes significant deviations from Current Good Manufacturing Practice (CGMP) for active pharmaceutical ingredients (APIs).\u003C\u002Fp>\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your APIs are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\u003Cp>We reviewed your March 6, 2026, response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\u003C\u002Fp>\u003Cp>During our inspection, our investigator observed specific deviations including, but not limited to, the following.\u003C\u002Fp>\u003Cp>\u003Cstrong>1. Failure of your quality unit to exercise its responsibility to ensure the API and intermediates manufactured at your facility are in compliance with CGMP.\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your quality unit (QU) failed to perform identity testing on incoming raw materials used in the manufacture of APIs \u003Cstrong>(b)(4)\u003C\u002Fstrong>, which are intended for use in pharmacy compounding.\u003C\u002Fp>\u003Cp>Specifically, your firm intentionally accepted lots of \u003Cstrong>(b)(4)\u003C\u002Fstrong> that were deliberately mislabeled by your supplier as \u003Cstrong>(b)(4)\u003C\u002Fstrong>. During the inspection, your QU admitted that this was a deliberate and ongoing practice since 2024 to circumvent your firm’s lack of a required \u003Cstrong>(b)(4)\u003C\u002Fstrong> license. You subsequently used this mislabeled and untested material to manufacture multiple batches of \u003Cstrong>(b)(4)\u003C\u002Fstrong> that you ultimately shipped to the United States. Furthermore, your QU relied on your supplier’s certificate of analysis without conducting supplier qualification as your standard operating procedure requires.\u003C\u002Fp>\u003Cp>In your response, you acknowledge the mislabeling practice, state you have since obtained the required \u003Cstrong>(b)(4)\u003C\u002Fstrong> license, and commit to performing identity testing of all future lots of \u003Cstrong>(b)(4)\u003C\u002Fstrong>. You also state that a retrospective reevaluation of residual solvent chromatographic data confirms that peaks previously observed in the affected \u003Cstrong>(b)(4)\u003C\u002Fstrong> batches are attributable to \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\u003Cp>Your response is inadequate. Your analytical conclusions are unsubstantiated because your response does not provide the supporting chromatograms or results from your identity tests. Furthermore, you do not provide a risk assessment for batches already distributed to the United States. Your response also does not address the systemic quality failure that allowed your firm to knowingly accept and recode mislabeled materials without performing identity testing. Finally, you fail to propose any substantive corrective actions to remediate your supplier qualification program to prevent a recurrence of this critical failure.\u003C\u002Fp>\u003Cp>Without adequate testing, you do not have scientific evidence that incoming materials conform to appropriate specifications prior to use in the manufacture of your drugs. As a manufacturer, you have a responsibility to sample, test, and examine incoming materials before use in production to assure adequate quality. Executive management should immediately and comprehensively assess your company’s global manufacturing operations to ensure that your systems, processes, and products conform to FDA requirements.\u003C\u002Fp>\u003Cp>Your practice of receiving \u003Cstrong>(b)(4)\u003C\u002Fstrong> mislabeled as \u003Cstrong>(b)(4)\u003C\u002Fstrong> poses a significant safety risk to personnel who may handle the material without knowing its true identity. Due to lack of awareness, workers may fail to take the precautions necessary to prevent exposure. \u003Cstrong>(b)(4)\u003C\u002Fstrong> is acutely toxic to humans and has caused fatal poisoning incidents worldwide.\u003C\u002Fp>\u003Cp>Furthermore, an adequate QU overseeing all elements of CGMP is necessary to consistently ensure drug quality. FDA considers the expectations outlined in ICH Q7 when determining whether API are manufactured in conformance with CGMP, including the sections on quality oversight. See FDA’s guidance document Q7 Good Manufacturing Practice Guidance for Active Pharmaceutical Ingredients for guidance regarding CGMP for the manufacture of API at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71518\u002Fdownload.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\u003Cbr>o A determination of whether procedures used by your firm are robust and appropriate\u003Cbr>o Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices\u003Cbr>o A complete and final review of each batch and its related information before the QU disposition decision\u003Cbr>o Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products\u003Cbr>o Also describe how top management supports quality assurance and reliable operations including, but not limited to timely provision of resources to proactively address emerging manufacturing\u002Fquality issues and to assure a continuing state of control.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>2. Failure to ensure that all test procedures are scientifically sound and appropriate to ensure that your intermediate and API conform to established standards of quality and purity.\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your firm failed to validate or adequately verify multiple test methods used for testing key starting materials and finished APIs. Specifically, you did not validate the in-house analytical methods, including the stability-indicating methods, used to support the \u003Cstrong>(b)(4)\u003C\u002Fstrong> retest dates for your products shipped to the United States. Furthermore, your firm failed to adequately implement and verify an analytical method transferred from your contract testing laboratory CTL) used for routine testing and stability studies of \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Your implemented method was unable to detect multiple unknown impurities that your CTL’s validated method identified.\u003C\u002Fp>\u003Cp>In your response, you commit to executing forced degradation studies to demonstrate your methods are stability-indicating and to reassessing the validity of the assigned \u003Cstrong>(b)(4)\u003C\u002Fstrong> retest dates for the APIs shipped to the United States. You also commit to executing validation and verification protocols for compendial and in-house methods. You attribute the discrepancy in impurity detection in \u003Cstrong>(b)(4)\u003C\u002Fstrong> to an incorrectly set processing threshold and provide reprocessed data to suggest your results are now comparable.\u003C\u002Fp>\u003Cp>Your response is inadequate because it fails to comprehensively assess your laboratory systems to ensure that all test methods are appropriately validated or verified. You have not established any interim controls for ongoing production while you conduct your retrospective review of batches tested with unvalidated methods. Additionally, while you attempt to explain the threshold differences between the CTL and the in-house verification study for \u003Cstrong>(b)(4)\u003C\u002Fstrong>, you fail to address whether the methods are truly equivalent.\u003C\u002Fp>\u003Cp>Without an appropriate laboratory and stability-indicating methods, you lack adequate scientific evidence to support whether your drug products meet established specifications and retain their quality attributes through their labeled expiry.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A comprehensive independent assessment of your laboratory practices, procedures, methods, equipment, documentation, and analyst competencies. Based on this review, provide a detailed plan to remediate and evaluate the effectiveness of your laboratory system.\u003C\u002Fli>\u003Cli>A list of validated\u002Fverified chemical specifications, including test methods, used to analyze each batch of your drug products before a lot disposition decision.\u003Cbr>o An action plan and timelines for conducting full chemical testing of retain samples to determine the quality of all batches of drug product distributed to the United States that are within expiry as of the date of this letter.\u003Cbr>o A summary of all results obtained from testing retain samples from each batch. If such testing reveals substandard quality drug products, take rapid corrective actions, such as notifying customers and product recalls.\u003C\u002Fli>\u003Cli>A comprehensive assessment and corrective action and preventive action plan to ensure the adequacy of your stability program. Your remediated program should include, but not be limited to:\u003Cbr>o Stability-indicating methods\u003Cbr>o Stability studies for each drug product in its marketed container-closure system before distribution is permitted\u003Cbr>o An ongoing program in which representative batches of each product are added each year to the program to determine the shelf-life claim remains valid\u003Cbr>o Detailed definition of the specific attributes to be tested at each station (timepoint)\u003Cbr>o All procedures that describe these and other elements of your remediated stability program\u003C\u002Fli>\u003Cli>Confirm the retest dates for \u003Cstrong>(b)(4)\u003C\u002Fstrong> using the revalidated stability-indicating method. This reassessment should ensure that all previously assigned retest dates are accurate.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>3. Failure to clean equipment to prevent contamination or carry-over of a material that would alter the quality of the intermediates and API beyond the official or other established specifications.\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your firm failed to adequately clean and maintain non-dedicated API manufacturing equipment used to manufacture as many as \u003Cstrong>(b)(4)\u003C\u002Fstrong> different APIs. For example, our investigator observed \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong> particles on product contact surfaces, including the lid and \u003Cstrong>(b)(4)\u003C\u002Fstrong> of \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and \u003Cstrong>(b)(4)\u003C\u002Fstrong> liquid draining from the \u003Cstrong>(b)(4)\u003C\u002Fstrong> even though the \u003Cstrong>(b)(4)\u003C\u002Fstrong> was documented as “empty and cleaned.” Additionally, your firm failed to maintain cleaning records for a non-dedicated \u003Cstrong>(b)(4)\u003C\u002Fstrong> product transfer pipe.\u003C\u002Fp>\u003Cp>Your cleaning verification report for \u003Cstrong>(b)(4)\u003C\u002Fstrong> addressed only batch-to-batch cleaning. It did not address product changeover. It also lacked scientific justification for product selection and residue limit calculations based on solubility, difficulty of cleaning, and toxicity, as required by your cleaning validation procedure. Your firm affirmed to our investigator that no formal cleaning validation has been performed and that you have not established a maximum allowable carryover limit as required by your procedure.\u003C\u002Fp>\u003Cp>In your response, you attribute the observed residues on the \u003Cstrong>(b)(4)\u003C\u002Fstrong> to the previous batch of the same non-U.S. API, explaining that only a “gross cleaning” is performed between batches during a \u003Cstrong>(b)(4)\u003C\u002Fstrong>. You conclude there was no risk of carryover. You assert that the \u003Cstrong>(b)(4)\u003C\u002Fstrong> transfer pipe is dedicated to a \u003Cstrong>(b)(4)\u003C\u002Fstrong> and also conclude there is no cross-contamination risk and confirm you do not use cleaning logs.\u003C\u002Fp>\u003Cp>Furthermore, you state that you “executed cleaning validation\u002Fverification activities for selected products” manufactured on shared equipment.\u003C\u002Fp>\u003Cp>Your response is inadequate because it does not provide assurance that your cleaning processes are adequate to prevent cross-contamination and carryover risks. It addresses only the \u003Cstrong>(b)(4)\u003C\u002Fstrong> particles observed in the \u003Cstrong>(b)(4)\u003C\u002Fstrong>, attributing them to a non-U.S. API campaign, while failing to test the observed \u003Cstrong>(b)(4)\u003C\u002Fstrong> liquid and other particle deposits. You did not expand your investigation to other equipment or conduct a retrospective review of released batches to assess product impact.\u003C\u002Fp>\u003Cp>Your claim that the \u003Cstrong>(b)(4)\u003C\u002Fstrong> transfer pipe is dedicated to a \u003Cstrong>(b)(4)\u003C\u002Fstrong> is unsubstantiated and contradicts information provided during the inspection. Further, you do not explain why cleaning validation was limited to selected products, nor do you provide supporting documentation to support or demonstrate that your cleaning practices adequately remove product residues.\u003C\u002Fp>\u003Cp>Inadequately cleaned and maintained manufacturing equipment can lead to potential cross-contamination that could compromise your API’s quality and safety.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A comprehensive, independent retrospective assessment of your cleaning effectiveness to evaluate the scope of cross-contamination hazards. Include the identity of residues, other manufacturing equipment that may have been improperly cleaned, and an assessment of whether cross-contaminated products may have been released for distribution. The assessment should identify any inadequacies of cleaning procedures and practices and encompass each piece of manufacturing equipment used to manufacture intermediates and API products.\u003C\u002Fli>\u003Cli>Appropriate improvements to your cleaning validation program with special emphasis on incorporating conditions identified as worst case in your API manufacturing operations. This should include but not be limited to identification and evaluation of all worst-case:\u003Cbr>o Drugs with higher toxicities\u003Cbr>o Drugs with higher potencies\u003Cbr>o Drugs with lower solubility in their cleaning solvents\u003Cbr>o Drugs with characteristics that make them difficult to clean\u003Cbr>o Swabbing locations for areas that are most difficult to clean\u003Cbr>o Maximum hold times before cleaning\u003C\u002Fli>\u003Cli>A summary of updated standard operating procedures that ensure an appropriate program is in place for verification and validation of cleaning procedures for products, processes, and equipment.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>CGMP Consultant Recommended\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Based upon the nature of the deviations we identified at your firm, you should engage a consultant qualified to evaluate your operations and to assist your firm in meeting CGMP requirements. The qualified consultant should also perform a comprehensive six-system audit of your entire operation for CGMP compliance and evaluate the completion and efficacy of your corrective actions and preventive actions before you pursue resolution of your firm’s compliance status with FDA.\u003C\u002Fp>\u003Cp>Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The deviations cited in this letter are not intended to be an all-inclusive list of deviations that exist at your facility. You are responsible for investigating and determining the causes of any deviations and for preventing their recurrence or the occurrence of other deviations.\u003C\u002Fp>\u003Cp>FDA placed all drugs and drug products offered for import into the United States from your firm on Import Alert 66-40 on June 9, 2026.\u003C\u002Fp>\u003Cp>Correct any deviations promptly. FDA may withhold approval of new applications or supplements listing your firm as a manufacturer until any deviations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to any deviations.\u003C\u002Fp>\u003Cp>Failure to address any deviations may also result in the FDA continuing to refuse admission of articles manufactured at Almon Healthcare Private Limited located at Plot No 4, Sankalp Industrial Estate, Behind Kerala GIDC, Bavala, Ahmedabad, into the United States under section 801(a)(3) of the FD&amp;C Act, 21 U.S.C. 381(a)(3). Articles under this authority that appear to be adulterated may be detained or refused admission, in that the methods and controls used in their manufacture do not appear to conform to CGMP within the meaning of section 501(a)(2)(B) of the FD&amp;C Act, 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any deviations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\u003Cp>Send your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3030509366 and ATTN: Jamie Dion.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Francis Godwin\u003Cbr>Director\u003Cbr>Office of Manufacturing Quality\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Email Return Receipt Requested\n\nReference #:\n\n320-26-102\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMr. Rajesh Gandhi\n\nRecipient Title\n\nChairman\n\nAlmon Healthcare Private Limited\n\nPlot No 4, Sankalp Industrial Estate, Behind Kerala GIDC, Bavala\n\nAhmedabad 382240\n\nGujarat\n\nIndia\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nWarning Letter 320-26-102\nJuly 13, 2026\nDear Mr. Gandhi:\nThe United States Food and Drug Administration (FDA) inspected your drug manufacturing facility, Almon Healthcare Private Limited, FEI 3030509366, at Plot No 4, Sankalp Industrial Estate, Behind Kerala GIDC, Bavala, Ahmedabad, from February 9 to 13, 2026.\nThis warning letter summarizes significant deviations from Current Good Manufacturing Practice (CGMP) for active pharmaceutical ingredients (APIs).\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your APIs are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B).\nWe reviewed your March 6, 2026, response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\nDuring our inspection, our investigator observed specific deviations including, but not limited to, the following.\n1. Failure of your quality unit to exercise its responsibility to ensure the API and intermediates manufactured at your facility are in compliance with CGMP.\nYour quality unit (QU) failed to perform identity testing on incoming raw materials used in the manufacture of APIs (b)(4), which are intended for use in pharmacy compounding.\nSpecifically, your firm intentionally accepted lots of (b)(4) that were deliberately mislabeled by your supplier as (b)(4). During the inspection, your QU admitted that this was a deliberate and ongoing practice since 2024 to circumvent your firm’s lack of a required (b)(4) license. You subsequently used this mislabeled and untested material to manufacture multiple batches of (b)(4) that you ultimately shipped to the United States. Furthermore, your QU relied on your supplier’s certificate of analysis without conducting supplier qualification as your standard operating procedure requires.\nIn your response, you acknowledge the mislabeling practice, state you have since obtained the required (b)(4) license, and commit to performing identity testing of all future lots of (b)(4). You also state that a retrospective reevaluation of residual solvent chromatographic data confirms that peaks previously observed in the affected (b)(4) batches are attributable to (b)(4).\nYour response is inadequate. Your analytical conclusions are unsubstantiated because your response does not provide the supporting chromatograms or results from your identity tests. Furthermore, you do not provide a risk assessment for batches already distributed to the United States. Your response also does not address the systemic quality failure that allowed your firm to knowingly accept and recode mislabeled materials without performing identity testing. Finally, you fail to propose any substantive corrective actions to remediate your supplier qualification program to prevent a recurrence of this critical failure.\nWithout adequate testing, you do not have scientific evidence that incoming materials conform to appropriate specifications prior to use in the manufacture of your drugs. As a manufacturer, you have a responsibility to sample, test, and examine incoming materials before use in production to assure adequate quality. Executive management should immediately and comprehensively assess your company’s global manufacturing operations to ensure that your systems, processes, and products conform to FDA requirements.\nYour practice of receiving (b)(4) mislabeled as (b)(4) poses a significant safety risk to personnel who may handle the material without knowing its true identity. Due to lack of awareness, workers may fail to take the precautions necessary to prevent exposure. (b)(4) is acutely toxic to humans and has caused fatal poisoning incidents worldwide.\nFurthermore, an adequate QU overseeing all elements of CGMP is necessary to consistently ensure drug quality. FDA considers the expectations outlined in ICH Q7 when determining whether API are manufactured in conformance with CGMP, including the sections on quality oversight. See FDA’s guidance document Q7 Good Manufacturing Practice Guidance for Active Pharmaceutical Ingredients for guidance regarding CGMP for the manufacture of API at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71518\u002Fdownload.\nIn response to this letter, provide:\nA comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\no A determination of whether procedures used by your firm are robust and appropriate\no Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices\no A complete and final review of each batch and its related information before the QU disposition decision\no Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products\no Also describe how top management supports quality assurance and reliable operations including, but not limited to timely provision of resources to proactively address emerging manufacturing\u002Fquality issues and to assure a continuing state of control.\n2. Failure to ensure that all test procedures are scientifically sound and appropriate to ensure that your intermediate and API conform to established standards of quality and purity.\nYour firm failed to validate or adequately verify multiple test methods used for testing key starting materials and finished APIs. Specifically, you did not validate the in-house analytical methods, including the stability-indicating methods, used to support the (b)(4) retest dates for your products shipped to the United States. Furthermore, your firm failed to adequately implement and verify an analytical method transferred from your contract testing laboratory CTL) used for routine testing and stability studies of (b)(4). Your implemented method was unable to detect multiple unknown impurities that your CTL’s validated method identified.\nIn your response, you commit to executing forced degradation studies to demonstrate your methods are stability-indicating and to reassessing the validity of the assigned (b)(4) retest dates for the APIs shipped to the United States. You also commit to executing validation and verification protocols for compendial and in-house methods. You attribute the discrepancy in impurity detection in (b)(4) to an incorrectly set processing threshold and provide reprocessed data to suggest your results are now comparable.\nYour response is inadequate because it fails to comprehensively assess your laboratory systems to ensure that all test methods are appropriately validated or verified. You have not established any interim controls for ongoing production while you conduct your retrospective review of batches tested with unvalidated methods. Additionally, while you attempt to explain the threshold differences between the CTL and the in-house verification study for (b)(4), you fail to address whether the methods are truly equivalent.\nWithout an appropriate laboratory and stability-indicating methods, you lack adequate scientific evidence to support whether your drug products meet established specifications and retain their quality attributes through their labeled expiry.\nIn response to this letter, provide:\nA comprehensive independent assessment of your laboratory practices, procedures, methods, equipment, documentation, and analyst competencies. Based on this review, provide a detailed plan to remediate and evaluate the effectiveness of your laboratory system.\nA list of validated\u002Fverified chemical specifications, including test methods, used to analyze each batch of your drug products before a lot disposition decision.\no An action plan and timelines for conducting full chemical testing of retain samples to determine the quality of all batches of drug product distributed to the United States that are within expiry as of the date of this letter.\no A summary of all results obtained from testing retain samples from each batch. If such testing reveals substandard quality drug products, take rapid corrective actions, such as notifying customers and product recalls.\nA comprehensive assessment and corrective action and preventive action plan to ensure the adequacy of your stability program. Your remediated program should include, but not be limited to:\no Stability-indicating methods\no Stability studies for each drug product in its marketed container-closure system before distribution is permitted\no An ongoing program in which representative batches of each product are added each year to the program to determine the shelf-life claim remains valid\no Detailed definition of the specific attributes to be tested at each station (timepoint)\no All procedures that describe these and other elements of your remediated stability program\nConfirm the retest dates for (b)(4) using the revalidated stability-indicating method. This reassessment should ensure that all previously assigned retest dates are accurate.\n3. Failure to clean equipment to prevent contamination or carry-over of a material that would alter the quality of the intermediates and API beyond the official or other established specifications.\nYour firm failed to adequately clean and maintain non-dedicated API manufacturing equipment used to manufacture as many as (b)(4) different APIs. For example, our investigator observed (b)(4) and (b)(4) particles on product contact surfaces, including the lid and (b)(4) of (b)(4), and (b)(4) liquid draining from the (b)(4) even though the (b)(4) was documented as “empty and cleaned.” Additionally, your firm failed to maintain cleaning records for a non-dedicated (b)(4) product transfer pipe.\nYour cleaning verification report for (b)(4) addressed only batch-to-batch cleaning. It did not address product changeover. It also lacked scientific justification for product selection and residue limit calculations based on solubility, difficulty of cleaning, and toxicity, as required by your cleaning validation procedure. Your firm affirmed to our investigator that no formal cleaning validation has been performed and that you have not established a maximum allowable carryover limit as required by your procedure.\nIn your response, you attribute the observed residues on the (b)(4) to the previous batch of the same non-U.S. API, explaining that only a “gross cleaning” is performed between batches during a (b)(4). You conclude there was no risk of carryover. You assert that the (b)(4) transfer pipe is dedicated to a (b)(4) and also conclude there is no cross-contamination risk and confirm you do not use cleaning logs.\nFurthermore, you state that you “executed cleaning validation\u002Fverification activities for selected products” manufactured on shared equipment.\nYour response is inadequate because it does not provide assurance that your cleaning processes are adequate to prevent cross-contamination and carryover risks. It addresses only the (b)(4) particles observed in the (b)(4), attributing them to a non-U.S. API campaign, while failing to test the observed (b)(4) liquid and other particle deposits. You did not expand your investigation to other equipment or conduct a retrospective review of released batches to assess product impact.\nYour claim that the (b)(4) transfer pipe is dedicated to a (b)(4) is unsubstantiated and contradicts information provided during the inspection. Further, you do not explain why cleaning validation was limited to selected products, nor do you provide supporting documentation to support or demonstrate that your cleaning practices adequately remove product residues.\nInadequately cleaned and maintained manufacturing equipment can lead to potential cross-contamination that could compromise your API’s quality and safety.\nIn response to this letter, provide:\nA comprehensive, independent retrospective assessment of your cleaning effectiveness to evaluate the scope of cross-contamination hazards. Include the identity of residues, other manufacturing equipment that may have been improperly cleaned, and an assessment of whether cross-contaminated products may have been released for distribution. The assessment should identify any inadequacies of cleaning procedures and practices and encompass each piece of manufacturing equipment used to manufacture intermediates and API products.\nAppropriate improvements to your cleaning validation program with special emphasis on incorporating conditions identified as worst case in your API manufacturing operations. This should include but not be limited to identification and evaluation of all worst-case:\no Drugs with higher toxicities\no Drugs with higher potencies\no Drugs with lower solubility in their cleaning solvents\no Drugs with characteristics that make them difficult to clean\no Swabbing locations for areas that are most difficult to clean\no Maximum hold times before cleaning\nA summary of updated standard operating procedures that ensure an appropriate program is in place for verification and validation of cleaning procedures for products, processes, and equipment.\nCGMP Consultant Recommended\nBased upon the nature of the deviations we identified at your firm, you should engage a consultant qualified to evaluate your operations and to assist your firm in meeting CGMP requirements. The qualified consultant should also perform a comprehensive six-system audit of your entire operation for CGMP compliance and evaluate the completion and efficacy of your corrective actions and preventive actions before you pursue resolution of your firm’s compliance status with FDA.\nYour use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\nConclusion\nThe deviations cited in this letter are not intended to be an all-inclusive list of deviations that exist at your facility. You are responsible for investigating and determining the causes of any deviations and for preventing their recurrence or the occurrence of other deviations.\nFDA placed all drugs and drug products offered for import into the United States from your firm on Import Alert 66-40 on June 9, 2026.\nCorrect any deviations promptly. FDA may withhold approval of new applications or supplements listing your firm as a manufacturer until any deviations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to any deviations.\nFailure to address any deviations may also result in the FDA continuing to refuse admission of articles manufactured at Almon Healthcare Private Limited located at Plot No 4, Sankalp Industrial Estate, Behind Kerala GIDC, Bavala, Ahmedabad, into the United States under section 801(a)(3) of the FD&C Act, 21 U.S.C. 381(a)(3). Articles under this authority that appear to be adulterated may be detained or refused admission, in that the methods and controls used in their manufacture do not appear to conform to CGMP within the meaning of section 501(a)(2)(B) of the FD&C Act, 21 U.S.C. 351(a)(2)(B).\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any deviations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\nSend your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3030509366 and ATTN: Jamie Dion.\nSincerely,\n\u002FS\u002F\nFrancis Godwin\nDirector\nOffice of Manufacturing Quality\nOffice of Compliance\nCenter for Drug Evaluation and Research","Almon Healthcare Private Limited","almon-healthcare-private-limited-729291-07132026","2026-08-18T06:42:28.498414+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Falmon-healthcare-private-limited-729291-07132026","2026-10-26T08:07:52.860413+00:00","2026-07-21","729291","Mr. Rajesh Gandhi","2026-08-19T04:28:21.954+00:00","Via Email Return Receipt Requested","320-26-102","2026-07-13",{"id":99,"raw":100,"subject":106,"body_html":107,"body_text":108,"firm_name":109,"letter_id":110,"created_at":111,"fei_number":20,"letter_url":112,"updated_at":113,"action_type":23,"case_status":24,"posted_date":114,"marcs_cms_no":115,"product_type":116,"closeout_date":20,"issuing_office":104,"recipient_name":117,"body_fetched_at":118,"delivery_method":119,"recipient_title":20,"reference_number":120,"action_taken_date":121,"medical_device_id":20,"response_letter_date":20},697,[101,102,103,104,105,13,13,13],"\u003Ctime datetime=\"2025-08-26T04:00:00Z\">08\u002F26\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-08-15T04:00:00Z\">08\u002F15\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Finnate-healthcare-institute-695592-08152025\">Innate Healthcare Institute\u003C\u002Fa>","Center for Biologics Evaluation and Research (CBER)","Deviations\u002FCFR\u002FRegulations for Human Cells, Tissues &amp; Cellular Products (HCT\u002FPs)","Deviations\u002FCFR\u002FRegulations for Human Cells, Tissues & Cellular Products (HCT\u002FPs)","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS and Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>CBER 25-695592\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Biologics                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Travis Whitney, NMD, DAASCP, MSc, MSAc \u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Founder and Chief Medical Officer\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Innate Healthcare Institute\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>4835 East Cactus Road, Suite 140\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Scottsdale\u003C\u002Fspan>, \u003Cspan>AZ\u003C\u002Fspan> \u003Cspan>85254\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:info@innatehealthcare.org\"> info@innatehealthcare.org \u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Biologics Evaluation and Research (CBER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>August 15, 202\u003C\u002Fp>\u003Cp>CBER 25-695592\u003C\u002Fp>\u003Cp>Dear Dr. Whitney:&nbsp;\u003C\u002Fp>\u003Cp>The United States Food and Drug Administration (FDA) reviewed your company’s website at https:\u002F\u002Finnatehealthcare.org (last visited August 2025), through which your company markets “umbilical cord mesenchymal stem cells (UC-MSCs),” which you also describe as “UC-MSC therapy” (hereinafter, “your product”) for allogeneic use. This letter is to advise you that your misbranding of your product while held for sale after shipment in interstate commerce violates section 301(k) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. § 331(k).&nbsp;\u003C\u002Fp>\u003Cp>\u003Cstrong>Violations&nbsp;\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Based on information and records reviewed by FDA, https:\u002F\u002Finnatehealthcare.org (last visited August 2025), your product is intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease or conditions in humans and\u002For are intended to affect the structure or function of the body. For example,&nbsp;\u003C\u002Fp>\u003Cp>On your website, https:\u002F\u002Finnatehealthcare.org, you provide the following statements:\u003C\u002Fp>\u003Cul>\u003Cli>“At Innate Healthcare Institute, we combine an effective blend of integrative medicine and regenerative stem cell medicine, treating Autism at its root.”\u003C\u002Fli>\u003Cli>“Stem cell therapy has really helped our son with his autism”\u003C\u002Fli>\u003Cli>“Stem cell therapy with human umbilical cord tissue derived mesenchymal stem cells (UC-MSCs) corrects the inflammatory process by modulating the immune system from a pro-inflammatory attacking state to an anti-inflammatory healthy state. They also have the ability to regenerate damage done from the autoimmune attack. Stem cells do this by secreting healing activators such as growth factors, cytokines, and exosomes to the surrounding environment.”\u003C\u002Fli>\u003Cli>“Stem cell therapy for autism can lead to improvement in cognitive ability, behaviors, and sociability.”\u003C\u002Fli>\u003Cli>“Regenerative cell medicine has the potential to help with many conditions such as pain due to osteoarthritis, tendinopathy\u002Ftendonitis, degenerative disc disease, herniated discs, neuropathy, fractures, muscle injuries, ligament and tendon injuries, COPD, peripheral neuropathy, sexual dysfunction, autoimmune conditions, heart disease, and many more.”\u003C\u002Fli>\u003C\u002Ful>\u003Cp>Therefore, your product is a drug as defined in section 201(g)(1) of the FD&amp;C Act, 21 U.S.C. § 321(g)(1), and a biological product as defined in section 351(i) of the Public Health Service Act (PHS Act), 42 U.S.C. § 262(i).&nbsp;\u003C\u002Fp>\u003Cp>Your UC-MSCs product is also a human cell, tissue, or cellular or tissue-based product (HCT\u002FP) as defined in 21 CFR 1271.3(d) and is subject to regulation under 21 CFR part 1271, issued under the authority of section 361 of the PHS Act, 42 U.S.C. § 264. HCT\u002FPs that do not meet all the criteria in 21 CFR 1271.10(a) are not regulated solely under section 361 of the PHS Act and the regulations in 21 CFR part 1271. Unless an exception in 21 CFR 1271.15 applies, such products are regulated as drugs, devices, and\u002For biological products under the FD&amp;C Act and\u002For the PHS Act and are subject to additional regulation, including applicable premarket review. Based on a review of relevant materials, Innate Healthcare Institute does not qualify for any exception in 21 CFR 1271.15, and your product fails to meet all criteria in 21 CFR 1271.10(a).&nbsp;\u003C\u002Fp>\u003Cp>For example, your UC-MSCs product fails to meet the minimal manipulation criterion set forth in 21 CFR 1271.10(a)(1) and defined for structural tissue in 21 CFR 1271.3(f)(1), because your processing alters the original relevant characteristics of the umbilical cord related to its utility for reconstruction, repair, or replacement. The processing of the umbilical cord from the form of a conduit into an injectable form, significantly alters the physical state of the HCT\u002FP. The umbilical cord is more than minimally manipulated because such processing alters the original relevant characteristics of the HCT\u002FP relating to its utility to serve as a conduit by effectively altering or eliminating its physical integrity and tubular form.&nbsp;\u003C\u002Fp>\u003Cp>In addition, your UC-MSCs product fails to meet the criterion that the HCT\u002FPs be “intended for homologous use only,” which means that the “labeling, advertising, or other indications of the manufacturer’s objective intent” demonstrate that the HCT\u002FP is intended to perform “the same basic function or functions in the recipient as in the donor.” 21 CFR 1271.3(c) and 1271.10(a)(2). Your product is not intended solely to perform the same basic function or functions of the HCT\u002FP in the recipient as in the donor (e.g., serving as a conduit). Rather, your product is intended for use in the treatment of autism as well as other diseases or conditions, which is not a basic function of the umbilical cord in the donor.\u003C\u002Fp>\u003Cp>Therefore, this HCT\u002FP is not regulated solely under section 361 of the PHS Act, 42 U.S.C. § 264, and the regulations in 21 CFR part 1271.\u003Cem>\u003Cstrong>\u003Csup>1\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> See 21 CFR 1271.20. In addition to being regulated under section 361 of the PHS Act and 21 CFR part 1271, your product is regulated as a drug as defined in section 201(g)(1) of the FD&amp;C Act, 21 U.S.C. § 321(g)(1), and a biological product as defined in section 351(i) of the PHS Act, 42 U.S.C. § 262(i), as stated above.\u003C\u002Fp>\u003Cp>Subject to certain exceptions not applicable here, to lawfully introduce or deliver for introduction into interstate commerce a drug that is a biological product, a valid BLA must be in effect under section 351(a)(1) of the PHS Act, 42 U.S.C. § 262(a)(1). Such licenses are issued only after showing that the product is safe, pure, and potent. Your product is not the subject of an approved BLA.\u003C\u002Fp>\u003Cp>Furthermore, your product is a misbranded drug under section 502(f)(1) of the FD&amp;C Act, 21 U.S.C. § 352(f)(1). A drug is misbranded under section 502(f)(1) if the drug fails to bear adequate directions for its intended use(s). “Adequate directions for use” means directions under which a layperson can use a drug safely and for the purposes for which it is intended. 21 CFR 201.5. Prescription drugs, as defined in section 503(b)(1)(A) of the FD&amp;C Act, 21 U.S.C. § 353(b)(1)(A), can only be used safely at the direction, and under the supervision, of a licensed practitioner.\u003C\u002Fp>\u003Cp>Your product is intended for use in the treatment of one or more diseases that are not amenable to self-diagnosis or treatment without the supervision of a licensed practitioner. Therefore, it is impossible to write adequate directions for a layperson to use your product safely for its intended purposes. Accordingly, your product fails to bear adequate directions for its intended uses and, therefore, is misbranded under section 502(f)(1) of the FD&amp;C Act, 21 U.S.C. § 352(f)(1). Misbranding your product while it is held for sale after shipment of the drug or one or more of its components in interstate commerce is prohibited under section 301(k) of the FD&amp;C Act, 21 U.S.C. § 331(k).\u003C\u002Fp>\u003Cp>\u003Cstrong>Additional Concerns\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>FDA’s review of your website also found that you market exosomes. As a general matter, exosomes intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease or conditions in humans and\u002For are intended to affect the structure or function of the body are regulated as drugs as defined in section 201(g)(1) of the FD&amp;C Act and biological products under section 351 of the PHS Act and and are subject to premarket review and approval requirements. We also direct your attention to FDA’s Public Safety Notification on Exosome Products, available at https:\u002F\u002Fwww.fda.gov\u002Fvaccines-blood-biologics\u002Fsafety-availability-biologics\u002Fpublic-safety-notification-exosome-products. FDA issued this public safety notification following multiple reports of serious adverse events experienced by patients who were treated with exosome products.\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>This letter is not intended to be an all-inclusive list of deficiencies that may exist in connection with your product. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure full compliance with all applicable requirements in the FD&amp;C Act, PHS Act, and all applicable regulations.\u003C\u002Fp>\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address these matters may result in action without further notice including, without limitation, seizure and\u002For injunction.\u003C\u002Fp>\u003Cp>Please submit your response in writing within fifteen (15) working days from your receipt of this letter, outlining the specific steps you have taken or plan to take to address any violations and prevent their recurrence. Include any documentation necessary to show that the matters have been addressed. If you cannot address these matters within fifteen (15) working days, please explain the reason for your delay and the timeframe for completion. If you do not believe your product is in violation of the FD&amp;C Act, PHS Act, or applicable regulations, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\u003Cp>Send your electronic response to CBERDCMRecommendations@fda.hhs.gov. If you have questions regarding this letter, contact the Division of Case Management, CBER at CBERDCMRecommendations@fda.hhs.gov.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Melissa J. Mendoza\u003Cbr>Director\u003Cbr>Office of Compliance and Biologics Quality\u003Cbr>Center for Biologics Evaluation and Research\u003C\u002Fp>\u003Cp>CC:\u003C\u002Fp>\u003Cp>Innate Healthcare, LLC\u003Cbr>4840 East Indian School Road\u003Cbr>Suite 104\u003Cbr>Phoenix, AZ 85018\u003C\u002Fp>\u003Cp>____________________\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> Because your product fails to meet at least one criterion in 21 CFR 1271.10(a), this letter does not evaluate all other criteria in 21 CFR 1271.10(a).\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS and Electronic Mail\n\nReference #:\n\nCBER 25-695592\n\nProduct:\n\nBiologics\n\nRecipient:\n\nRecipient Name\n\nTravis Whitney, NMD, DAASCP, MSc, MSAc\n\nRecipient Title\n\nFounder and Chief Medical Officer\n\nInnate Healthcare Institute\n\n4835 East Cactus Road, Suite 140\n\nScottsdale, AZ 85254\n\nUnited States\n\ninfo@innatehealthcare.org\n\nIssuing Office:\n\nCenter for Biologics Evaluation and Research (CBER)\n\nUnited States\n\nWARNING LETTER\nAugust 15, 202\nCBER 25-695592\nDear Dr. Whitney:\nThe United States Food and Drug Administration (FDA) reviewed your company’s website at https:\u002F\u002Finnatehealthcare.org (last visited August 2025), through which your company markets “umbilical cord mesenchymal stem cells (UC-MSCs),” which you also describe as “UC-MSC therapy” (hereinafter, “your product”) for allogeneic use. This letter is to advise you that your misbranding of your product while held for sale after shipment in interstate commerce violates section 301(k) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. § 331(k).\nViolations\nBased on information and records reviewed by FDA, https:\u002F\u002Finnatehealthcare.org (last visited August 2025), your product is intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease or conditions in humans and\u002For are intended to affect the structure or function of the body. For example,\nOn your website, https:\u002F\u002Finnatehealthcare.org, you provide the following statements:\n“At Innate Healthcare Institute, we combine an effective blend of integrative medicine and regenerative stem cell medicine, treating Autism at its root.”\n“Stem cell therapy has really helped our son with his autism”\n“Stem cell therapy with human umbilical cord tissue derived mesenchymal stem cells (UC-MSCs) corrects the inflammatory process by modulating the immune system from a pro-inflammatory attacking state to an anti-inflammatory healthy state. They also have the ability to regenerate damage done from the autoimmune attack. Stem cells do this by secreting healing activators such as growth factors, cytokines, and exosomes to the surrounding environment.”\n“Stem cell therapy for autism can lead to improvement in cognitive ability, behaviors, and sociability.”\n“Regenerative cell medicine has the potential to help with many conditions such as pain due to osteoarthritis, tendinopathy\u002Ftendonitis, degenerative disc disease, herniated discs, neuropathy, fractures, muscle injuries, ligament and tendon injuries, COPD, peripheral neuropathy, sexual dysfunction, autoimmune conditions, heart disease, and many more.”\nTherefore, your product is a drug as defined in section 201(g)(1) of the FD&C Act, 21 U.S.C. § 321(g)(1), and a biological product as defined in section 351(i) of the Public Health Service Act (PHS Act), 42 U.S.C. § 262(i).\nYour UC-MSCs product is also a human cell, tissue, or cellular or tissue-based product (HCT\u002FP) as defined in 21 CFR 1271.3(d) and is subject to regulation under 21 CFR part 1271, issued under the authority of section 361 of the PHS Act, 42 U.S.C. § 264. HCT\u002FPs that do not meet all the criteria in 21 CFR 1271.10(a) are not regulated solely under section 361 of the PHS Act and the regulations in 21 CFR part 1271. Unless an exception in 21 CFR 1271.15 applies, such products are regulated as drugs, devices, and\u002For biological products under the FD&C Act and\u002For the PHS Act and are subject to additional regulation, including applicable premarket review. Based on a review of relevant materials, Innate Healthcare Institute does not qualify for any exception in 21 CFR 1271.15, and your product fails to meet all criteria in 21 CFR 1271.10(a).\nFor example, your UC-MSCs product fails to meet the minimal manipulation criterion set forth in 21 CFR 1271.10(a)(1) and defined for structural tissue in 21 CFR 1271.3(f)(1), because your processing alters the original relevant characteristics of the umbilical cord related to its utility for reconstruction, repair, or replacement. The processing of the umbilical cord from the form of a conduit into an injectable form, significantly alters the physical state of the HCT\u002FP. The umbilical cord is more than minimally manipulated because such processing alters the original relevant characteristics of the HCT\u002FP relating to its utility to serve as a conduit by effectively altering or eliminating its physical integrity and tubular form.\nIn addition, your UC-MSCs product fails to meet the criterion that the HCT\u002FPs be “intended for homologous use only,” which means that the “labeling, advertising, or other indications of the manufacturer’s objective intent” demonstrate that the HCT\u002FP is intended to perform “the same basic function or functions in the recipient as in the donor.” 21 CFR 1271.3(c) and 1271.10(a)(2). Your product is not intended solely to perform the same basic function or functions of the HCT\u002FP in the recipient as in the donor (e.g., serving as a conduit). Rather, your product is intended for use in the treatment of autism as well as other diseases or conditions, which is not a basic function of the umbilical cord in the donor.\nTherefore, this HCT\u002FP is not regulated solely under section 361 of the PHS Act, 42 U.S.C. § 264, and the regulations in 21 CFR part 1271.1 See 21 CFR 1271.20. In addition to being regulated under section 361 of the PHS Act and 21 CFR part 1271, your product is regulated as a drug as defined in section 201(g)(1) of the FD&C Act, 21 U.S.C. § 321(g)(1), and a biological product as defined in section 351(i) of the PHS Act, 42 U.S.C. § 262(i), as stated above.\nSubject to certain exceptions not applicable here, to lawfully introduce or deliver for introduction into interstate commerce a drug that is a biological product, a valid BLA must be in effect under section 351(a)(1) of the PHS Act, 42 U.S.C. § 262(a)(1). Such licenses are issued only after showing that the product is safe, pure, and potent. Your product is not the subject of an approved BLA.\nFurthermore, your product is a misbranded drug under section 502(f)(1) of the FD&C Act, 21 U.S.C. § 352(f)(1). A drug is misbranded under section 502(f)(1) if the drug fails to bear adequate directions for its intended use(s). “Adequate directions for use” means directions under which a layperson can use a drug safely and for the purposes for which it is intended. 21 CFR 201.5. Prescription drugs, as defined in section 503(b)(1)(A) of the FD&C Act, 21 U.S.C. § 353(b)(1)(A), can only be used safely at the direction, and under the supervision, of a licensed practitioner.\nYour product is intended for use in the treatment of one or more diseases that are not amenable to self-diagnosis or treatment without the supervision of a licensed practitioner. Therefore, it is impossible to write adequate directions for a layperson to use your product safely for its intended purposes. Accordingly, your product fails to bear adequate directions for its intended uses and, therefore, is misbranded under section 502(f)(1) of the FD&C Act, 21 U.S.C. § 352(f)(1). Misbranding your product while it is held for sale after shipment of the drug or one or more of its components in interstate commerce is prohibited under section 301(k) of the FD&C Act, 21 U.S.C. § 331(k).\nAdditional Concerns\nFDA’s review of your website also found that you market exosomes. As a general matter, exosomes intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease or conditions in humans and\u002For are intended to affect the structure or function of the body are regulated as drugs as defined in section 201(g)(1) of the FD&C Act and biological products under section 351 of the PHS Act and and are subject to premarket review and approval requirements. We also direct your attention to FDA’s Public Safety Notification on Exosome Products, available at https:\u002F\u002Fwww.fda.gov\u002Fvaccines-blood-biologics\u002Fsafety-availability-biologics\u002Fpublic-safety-notification-exosome-products. FDA issued this public safety notification following multiple reports of serious adverse events experienced by patients who were treated with exosome products.\nConclusion\nThis letter is not intended to be an all-inclusive list of deficiencies that may exist in connection with your product. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure full compliance with all applicable requirements in the FD&C Act, PHS Act, and all applicable regulations.\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address these matters may result in action without further notice including, without limitation, seizure and\u002For injunction.\nPlease submit your response in writing within fifteen (15) working days from your receipt of this letter, outlining the specific steps you have taken or plan to take to address any violations and prevent their recurrence. Include any documentation necessary to show that the matters have been addressed. If you cannot address these matters within fifteen (15) working days, please explain the reason for your delay and the timeframe for completion. If you do not believe your product is in violation of the FD&C Act, PHS Act, or applicable regulations, include your reasoning and any supporting information for our consideration.\nSend your electronic response to CBERDCMRecommendations@fda.hhs.gov. If you have questions regarding this letter, contact the Division of Case Management, CBER at CBERDCMRecommendations@fda.hhs.gov.\nSincerely,\n\u002FS\u002F\nMelissa J. Mendoza\nDirector\nOffice of Compliance and Biologics Quality\nCenter for Biologics Evaluation and Research\nCC:\nInnate Healthcare, LLC\n4840 East Indian School Road\nSuite 104\nPhoenix, AZ 85018\n____________________\n1 Because your product fails to meet at least one criterion in 21 CFR 1271.10(a), this letter does not evaluate all other criteria in 21 CFR 1271.10(a).","Innate Healthcare Institute","innate-healthcare-institute-695592-08152025","2026-08-18T06:42:28.676509+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Finnate-healthcare-institute-695592-08152025","2026-10-26T08:08:58.9915+00:00","2025-08-26","695592","Biologics","Travis Whitney, NMD, DAASCP, MSc, MSAc","2026-08-19T16:28:46.246+00:00","VIA UPS and Electronic Mail","CBER 25-695592","2025-08-15",{"id":123,"raw":124,"subject":14,"body_html":128,"body_text":129,"firm_name":130,"letter_id":131,"created_at":111,"fei_number":20,"letter_url":132,"updated_at":133,"action_type":23,"case_status":24,"posted_date":134,"marcs_cms_no":135,"product_type":27,"closeout_date":20,"issuing_office":11,"recipient_name":136,"body_fetched_at":137,"delivery_method":138,"recipient_title":20,"reference_number":139,"action_taken_date":140,"medical_device_id":20,"response_letter_date":20},821,[125,126,127,11,12,13,13,13],"\u003Ctime datetime=\"2025-06-17T04:00:00Z\">06\u002F17\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-06-12T04:00:00Z\">06\u002F12\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fkenil-healthcare-private-limited-704786-06122025\">Kenil Healthcare Private Limited\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>320-25-81\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Anil Patel\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Owner and Director\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Kenil Healthcare Private Limited\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>Plot No. 319, Village Acharasan, Ankhol-Vamaj Road\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Tal-Kadi, District Mehsana\u003C\u002Fspan> \u003Cspan>382715\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Gujarat\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>India\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>Warning Letter\u003C\u002Fstrong> 320-25-81\u003C\u002Fp>\u003Cp>June 12, 2025\u003C\u002Fp>\u003Cp>Dear Mr. Patel:\u003C\u002Fp>\u003Cp>The United States Food and Drug Administration (FDA) inspected your drug manufacturing facility, Kenil Healthcare Private Limited, FEI 3022380309, at Plot No. 319, Village Acharasan, Ankhol-Vamaj Road, Tal-Kadi, District Mehsana, Gujarat, from December 5 to 11, 2024.\u003C\u002Fp>\u003Cp>This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\u003C\u002Fp>\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 351(a)(2)(B). We reviewed your December 30, 2024 response and subsequent correspondences to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\u003C\u002Fp>\u003Cp>During our inspection, our investigators observed specific violations including, but not limited to, the following.\u003C\u002Fp>\u003Cp>\u003Cstrong>1. Your firm failed to clean, maintain, and, as appropriate for the nature of the drug, sanitize and\u002For sterilize equipment and utensils at appropriate intervals to prevent malfunctions or contamination that would alter the safety, identity, strength, quality, or purity of the drug product beyond the official or other established requirements (21 CFR 211.67(a)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>You failed to adequately clean and maintain your filling rooms and tube filling equipment used to manufacture your \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong> over-the-counter (OTC) drug products. For example, our investigators observed the following:\u003C\u002Fp>\u003Cul>\u003Cli>The presence of mold and dirt on the walls in your filling and sealing rooms.\u003C\u002Fli>\u003Cli>Soiled and stained air handling units.\u003C\u002Fli>\u003Cli>Unidentified product buildup inside your \u003Cstrong>(b)(4)\u003C\u002Fstrong> manufacturing vessel and tube filling equipment.\u003C\u002Fli>\u003Cli>More than one drug product was found on the packaging line.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>In addition, your firm did not have validated cleaning procedures, including written equipment usage and cleaning logs to demonstrate that your drug product manufacturing equipment was adequately cleaned and maintained.\u003C\u002Fp>\u003Cp>In your response, you state that you revised your cleaning procedures and logbooks and commit to retrain your staff on cleaning practices and procedures. You also state that cleaning and sanitization of the filling and sealing rooms was conducted and building maintenance will be performed. Your response is inadequate because you failed to provide supporting data to demonstrate that your cleaning practices are sufficient to remove contaminants from the product surfaces of your drug product manufacturing equipment. You also failed to provide any documentation that the above-mentioned activities occurred. Furthermore, you failed to assess the impact of your inadequate cleaning processes on products that are currently on the market and within expiry.\u003C\u002Fp>\u003Cp>It is essential that your facility and equipment are cleaned, and sanitary conditions are maintained, to ensure ongoing suitability for drug manufacturing, and to protect drug products from contamination.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A comprehensive, independent retrospective assessment of your cleaning effectiveness to evaluate the scope of cross-contamination hazards. Include the identity of residues, other manufacturing equipment that may have been improperly cleaned, and an assessment whether cross-contaminated products may have been released for distribution. The assessment should identify any inadequacies of cleaning procedures and practices and encompass each piece of manufacturing equipment used to manufacture more than one product.\u003C\u002Fli>\u003Cli>Your corrective action and preventive action (CAPA) plan to implement routine, vigilant operations management oversight of facilities and equipment. This plan should ensure, among other things, prompt detection of equipment\u002Ffacilities performance issues, effective execution of repairs, adherence to appropriate preventive maintenance schedules, timely technological upgrades to the equipment\u002Ffacility infrastructure, and improved systems for ongoing management review.\u003C\u002Fli>\u003Cli>A CAPA plan, based on the retrospective assessment of your cleaning program, that includes appropriate remediations to your cleaning processes and practices, and timelines for completion. Provide a detailed summary of vulnerabilities in your process for lifecycle management of equipment cleaning. Describe improvements to your cleaning program, including enhancements to cleaning effectiveness; improved ongoing verification of proper cleaning execution for all products and equipment; and all other needed remediations.\u003C\u002Fli>\u003Cli>Appropriate improvements to your cleaning validation program, with special emphasis on incorporating conditions identified as worst case in your drug manufacturing operation. This should include, but not be limited to, identification and evaluation of all worst-case:\u003Cbr>o Drugs with higher toxicities\u003Cbr>o Drugs with higher drug potencies\u003Cbr>o Drugs of lower solubility in their cleaning solvents\u003Cbr>o Drugs with characteristics that make them difficult to clean\u003Cbr>o Swabbing locations for areas that are most difficult to clean\u003Cbr>o Maximum hold times before cleaning\u003C\u002Fli>\u003Cli>In addition, describe the steps that must be taken in your change management system before introduction of new manufacturing equipment or a new product.\u003C\u002Fli>\u003Cli>A summary of updated standard operating procedures that ensure an appropriate program is in place for verification and validation of cleaning procedures for products, processes, and equipment.\u003C\u002Fli>\u003Cli>Additional photographic evidence that demonstrates thorough cleaning of your filling and sealing areas, including but not limited to Rooms \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and the completion of all necessary building maintenance in those areas.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>2. Your firm failed to have buildings used in the manufacture, processing, packing, or holding of drug products with adequate space for the orderly placement of equipment and materials to prevent mix-ups and contamination (21 CFR 211.42(b)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your firm’s packaging and labeling operations are performed without adequate controls to prevent mix-ups and cross-contamination. For example, our investigators observed employees performing manual packaging and labeling operations on the floor of the manufacturing room. Investigators also noted that multiple drug products were packaged simultaneously without adequate separation and spacing. The drug products were also packaged without the use of batch records.\u003C\u002Fp>\u003Cp>Our investigators also observed that your reserve samples were improperly stored, commingled with expired products, and lacked routine monitoring.\u003C\u002Fp>\u003Cp>In your response, you state that you implemented procedures for dispensing and issuing packaging materials. Your response also includes plans to expand your warehouse. Your response is inadequate because you failed to address the interim plans to prevent labeling mixups in your current packaging area while you remediate your lack of adequate facility spacing. You also do not describe how you intend to ensure that the procedural updates are effective.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>Your CAPA plan to improve packaging and labeling operations, including equipment and facility upgrades, effective preventive and corrective maintenance, enhanced performance monitoring, improved operations management oversight, and any other needed actions. Your CAPA plan should also assure the proper segregation and sufficient space for the orderly storage of samples.\u003C\u002Fli>\u003Cli>An action plan and timeline for conducting retrospective assessment of all your reserve samples in your sample storage area. Include supporting documentation to ensure that no product or package mix-ups have occurred, and any corrective actions, such as notifying customers of identified product mix-ups.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>3. Your firm’s quality control unit failed to exercise its responsibility to ensure drug products manufactured are in compliance with CGMP, and meet established specifications for identity, strength, quality, and purity (21 CFR 211.22).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your quality unit (QU) did not provide adequate oversight for the manufacture of your drug products. For example, your QU failed to ensure the following:\u003C\u002Fp>\u003Cul>\u003Cli>Review and approval of written procedures for production and process controls that are designed to assure the quality of your drug products, i.e., process validation (21 CFR 211.100(a)).\u003C\u002Fli>\u003Cli>Establishment of an adequate, ongoing stability program (21 CFR 211.166(a)).\u003C\u002Fli>\u003Cli>Adequate batch production and control records that include complete documentation of the accomplishment of each significant step in the manufacture, processing, packing, or holding of the batch, for each batch of drug product (21 CFR 211.188).\u003C\u002Fli>\u003Cli>Adequate review and approval of production and control records before a batch is released or distributed (21 CFR 211.192)\u003C\u002Fli>\u003Cli>Production and process control activities, such as equipment qualification, are documented at the time of performance (21 CFR 211.100(b)). Specifically, investigators observed your quality assurance manager generating and completing equipment qualification documents investigators previously requested. This practice raises concerns about the integrity and reliability of your firm’s data and documentation.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>Your firm’s quality systems are inadequate. See FDA’s guidance document \u003Cem>Quality Systems Approach to Pharmaceutical CGMP Regulations\u003C\u002Fem> for help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR, parts 210 and 211 at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload.\u003C\u002Fp>\u003Cp>Your quality system does not adequately ensure the accuracy and integrity of data to support the safety, effectiveness, and quality of the drugs you manufacture. See FDA’s guidance document \u003Cem>Data Integrity and Compliance With Drug CGMP\u003C\u002Fem> for guidance on establishing and following CGMP compliant data integrity practices at \u003Cem>Data Integrity and Compliance With Drug CGMP:\u003C\u002Fem>\u003Cbr>\u003Cem>Questions and Answers | FDA\u003C\u002Fem>\u003C\u002Fp>\u003Cp>We acknowledge that you are using an independent third-party consultant to audit your operation and assist in meeting FDA requirements.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A comprehensive investigation into the extent of the inaccuracies in data records and reporting. Your investigation should include:\u003Cbr>o A detailed investigation protocol and methodology; a summary of all laboratories, manufacturing operations, and systems to be covered by the assessment; and a justification for any part of your operation that you propose to exclude.\u003Cbr>o Interviews of current and former employees to identify the nature, scope, and root cause of data inaccuracies. We recommend that these interviews be conducted by a qualified third party.\u003Cbr>o An assessment of the extent of data integrity deficiencies at your facility. Identify omissions, alterations, deletions, record destruction, non-contemporaneous record completion, and other deficiencies. Describe all parts of your facility’s operations in which you discovered data integrity lapses.\u003C\u002Fli>\u003Cli>A current risk assessment of the potential effects of the observed failures on the quality of your drugs. Your assessment should include analyses of the risks to patients caused by the release of drugs affected by a lapse of data integrity and analyses of the risks posed by ongoing operations.\u003C\u002Fli>\u003Cli>A management strategy for your firm that includes the details of your global CAPA plan.\u003C\u002Fli>\u003Cli>Your strategy should include:\u003Cbr>o A detailed corrective action plan that describes how you intend to ensure the reliability and completeness of all the data you generate, including analytical data, manufacturing records, and all data submitted to FDA.\u003Cbr>o A comprehensive description of the root causes of your data integrity lapses, including evidence that the scope and depth of the current action plan is commensurate with the findings of the investigation and risk assessment. Indicate whether individuals responsible for data integrity lapses remain able to influence CGMP-related or drug application data at your firm.\u003Cbr>o Interim measures describing the actions you have taken or will take to protect patients and to ensure the quality of your drugs, such as notifying your customers, recalling product, conducting additional testing, adding batches to your stability programs to assure stability, drug application actions, and enhanced complaint monitoring.\u003Cbr>o Long-term measures describing any remediation efforts and enhancements to procedures, processes, methods, controls, systems, management oversight, and human resources (e.g., training, staffing improvements) designed to ensure the integrity of your company’s data.\u003Cbr>o A commitment to have a qualified consultant conduct extensive annual audits, for at least two years, to assist in evaluating CAPA effectiveness after you have executed your data integrity remediation protocol.\u003Cbr>o Inform FDA if you will be hiring a Chief Integrity Officer who is fully empowered to receive anonymous complaints from employees reporting data integrity concerns and with the authority to ensure any potential breach is promptly investigated (by independent quality assurance function, along with expertise from outside entities whenever needed).\u003Cbr>o A status report for any of the above activities already underway or completed.\u003C\u002Fli>\u003Cli>A comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\u003Cbr>o A determination of whether procedures used by your firm are robust and appropriate.\u003Cbr>o Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices.\u003Cbr>o A complete and final review of each batch and its related information before the QU disposition decision.\u003Cbr>o Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products.\u003C\u002Fli>\u003Cli>A comprehensive, independent assessment of your overall system for investigating deviations, discrepancies, complaints, out-of-specification results, and failures. Provide a detailed action plan to remediate this system. Your action plan should include, but not be limited to, significant improvements in investigation competencies, scope determination, root cause evaluation, CAPA effectiveness, QU oversight, and written procedures. Address how your firm will ensure all phases of investigations are appropriately conducted.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>Drug Recall\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>On March 26, 2025, FDA held a teleconference with you and your U.S. Agent, JMM Services LLC. We recommended that you recall all your drug products within expiry currently in distribution to the U.S. market. On April 9, 2025, your firm committed to recall the products within expiry. After several subsequent attempts were made to contact you and your registered U.S. Agent regarding the recall, you initiated the recall of all your drug products on April 24, 2025.\u003C\u002Fp>\u003Cp>\u003Cstrong>CGMP Consultant Recommended\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Based upon the nature of the violations we identified at your firm, you should engage a consultant qualified as set forth in 21 CFR 211.34 to evaluate your operations and to assist your firm in meeting CGMP requirements. The qualified consultant should also perform a comprehensive six-system audit of your entire operation for CGMP compliance and evaluate the completion and efficacy of your CAPAs before you pursue resolution of your firm’s compliance status with FDA.\u003C\u002Fp>\u003Cp>Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\u003C\u002Fp>\u003Cp>\u003Cstrong>Cosmetics Manufactured for Distribution in the United States\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>In addition, some of the products you manufacture may be regulated as cosmetics, as defined in section 201(i) of the FD&amp;C Act (21 U.S.C. 321(i)). Any cosmetics you manufacture must comply with applicable statutory and regulatory requirements, including the FD&amp;C Act. A cosmetic is deemed adulterated under section 601(c) of the FD&amp;C Act (21 U.S.C. 361(c)) if it has been prepared, packed, or held under insanitary conditions whereby it may have become contaminated with filth or whereby it may have been rendered injurious to health. Some conditions that cause the drug products you manufacture to be adulterated may also cause any cosmetics you manufacture to be adulterated. We note that under section 301(a) of the FD&amp;C Act (21 U.S.C. 331(a)), it is a prohibited act to introduce or deliver for introduction into interstate commerce a cosmetic that is adulterated. Further, your facility may be subject to requirements under the Modernization of Cosmetics Regulation Act of 2022 (MoCRA). You may find the FD&amp;C Act, MoCRA, and FDA’s regulations through links on FDA’s website at www.fda.gov.\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\u003C\u002Fp>\u003Cp>FDA placed all drugs and drug products offered for import into the United States from your firm on Import Alert 66-40 on April 4, 2025.\u003C\u002Fp>\u003Cp>Correct any violations promptly. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to any violations.\u003C\u002Fp>\u003Cp>Failure to address any violations may also result in the FDA continuing to refuse admission of articles manufactured at Kenil Healthcare Private Limited, located at Plot No. 319, Village Acharasan, Ankhol-Vamaj Road Ta-Kadi, District Mehsana, Gujarat, 382715, India, into the United States under section 801(a)(3) of the FD&amp;C Act, 21 U.S.C. 381(a)(3). Articles under this authority that appear to be adulterated may be detained or refused admission, in that the methods and controls used in their manufacture do not appear to conform to CGMP within the meaning of section 501(a)(2)(B) of the FD&amp;C Act, 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\u003Cp>Send your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3022380309 and ATTN: Yvette Johnson.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Francis Godwin\u003Cbr>Director\u003Cbr>Office of Manufacturing Quality\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003C\u002Fp>\u003Cp>Cc: Registered U.S. Agent\u003Cbr>Ms. Julia Moffitt, JMM Services\u003Cbr>Email: julia@jmm.one; Info@jmm.one\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA Electronic Mail\n\nReference #:\n\n320-25-81\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMr. Anil Patel\n\nRecipient Title\n\nOwner and Director\n\nKenil Healthcare Private Limited\n\nPlot No. 319, Village Acharasan, Ankhol-Vamaj Road\n\nTal-Kadi, District Mehsana 382715\n\nGujarat\n\nIndia\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nWarning Letter 320-25-81\nJune 12, 2025\nDear Mr. Patel:\nThe United States Food and Drug Administration (FDA) inspected your drug manufacturing facility, Kenil Healthcare Private Limited, FEI 3022380309, at Plot No. 319, Village Acharasan, Ankhol-Vamaj Road, Tal-Kadi, District Mehsana, Gujarat, from December 5 to 11, 2024.\nThis warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B). We reviewed your December 30, 2024 response and subsequent correspondences to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\nDuring our inspection, our investigators observed specific violations including, but not limited to, the following.\n1. Your firm failed to clean, maintain, and, as appropriate for the nature of the drug, sanitize and\u002For sterilize equipment and utensils at appropriate intervals to prevent malfunctions or contamination that would alter the safety, identity, strength, quality, or purity of the drug product beyond the official or other established requirements (21 CFR 211.67(a)).\nYou failed to adequately clean and maintain your filling rooms and tube filling equipment used to manufacture your (b)(4) and (b)(4) over-the-counter (OTC) drug products. For example, our investigators observed the following:\nThe presence of mold and dirt on the walls in your filling and sealing rooms.\nSoiled and stained air handling units.\nUnidentified product buildup inside your (b)(4) manufacturing vessel and tube filling equipment.\nMore than one drug product was found on the packaging line.\nIn addition, your firm did not have validated cleaning procedures, including written equipment usage and cleaning logs to demonstrate that your drug product manufacturing equipment was adequately cleaned and maintained.\nIn your response, you state that you revised your cleaning procedures and logbooks and commit to retrain your staff on cleaning practices and procedures. You also state that cleaning and sanitization of the filling and sealing rooms was conducted and building maintenance will be performed. Your response is inadequate because you failed to provide supporting data to demonstrate that your cleaning practices are sufficient to remove contaminants from the product surfaces of your drug product manufacturing equipment. You also failed to provide any documentation that the above-mentioned activities occurred. Furthermore, you failed to assess the impact of your inadequate cleaning processes on products that are currently on the market and within expiry.\nIt is essential that your facility and equipment are cleaned, and sanitary conditions are maintained, to ensure ongoing suitability for drug manufacturing, and to protect drug products from contamination.\nIn response to this letter, provide:\nA comprehensive, independent retrospective assessment of your cleaning effectiveness to evaluate the scope of cross-contamination hazards. Include the identity of residues, other manufacturing equipment that may have been improperly cleaned, and an assessment whether cross-contaminated products may have been released for distribution. The assessment should identify any inadequacies of cleaning procedures and practices and encompass each piece of manufacturing equipment used to manufacture more than one product.\nYour corrective action and preventive action (CAPA) plan to implement routine, vigilant operations management oversight of facilities and equipment. This plan should ensure, among other things, prompt detection of equipment\u002Ffacilities performance issues, effective execution of repairs, adherence to appropriate preventive maintenance schedules, timely technological upgrades to the equipment\u002Ffacility infrastructure, and improved systems for ongoing management review.\nA CAPA plan, based on the retrospective assessment of your cleaning program, that includes appropriate remediations to your cleaning processes and practices, and timelines for completion. Provide a detailed summary of vulnerabilities in your process for lifecycle management of equipment cleaning. Describe improvements to your cleaning program, including enhancements to cleaning effectiveness; improved ongoing verification of proper cleaning execution for all products and equipment; and all other needed remediations.\nAppropriate improvements to your cleaning validation program, with special emphasis on incorporating conditions identified as worst case in your drug manufacturing operation. This should include, but not be limited to, identification and evaluation of all worst-case:\no Drugs with higher toxicities\no Drugs with higher drug potencies\no Drugs of lower solubility in their cleaning solvents\no Drugs with characteristics that make them difficult to clean\no Swabbing locations for areas that are most difficult to clean\no Maximum hold times before cleaning\nIn addition, describe the steps that must be taken in your change management system before introduction of new manufacturing equipment or a new product.\nA summary of updated standard operating procedures that ensure an appropriate program is in place for verification and validation of cleaning procedures for products, processes, and equipment.\nAdditional photographic evidence that demonstrates thorough cleaning of your filling and sealing areas, including but not limited to Rooms (b)(4) and (b)(4), and the completion of all necessary building maintenance in those areas.\n2. Your firm failed to have buildings used in the manufacture, processing, packing, or holding of drug products with adequate space for the orderly placement of equipment and materials to prevent mix-ups and contamination (21 CFR 211.42(b)).\nYour firm’s packaging and labeling operations are performed without adequate controls to prevent mix-ups and cross-contamination. For example, our investigators observed employees performing manual packaging and labeling operations on the floor of the manufacturing room. Investigators also noted that multiple drug products were packaged simultaneously without adequate separation and spacing. The drug products were also packaged without the use of batch records.\nOur investigators also observed that your reserve samples were improperly stored, commingled with expired products, and lacked routine monitoring.\nIn your response, you state that you implemented procedures for dispensing and issuing packaging materials. Your response also includes plans to expand your warehouse. Your response is inadequate because you failed to address the interim plans to prevent labeling mixups in your current packaging area while you remediate your lack of adequate facility spacing. You also do not describe how you intend to ensure that the procedural updates are effective.\nIn response to this letter, provide:\nYour CAPA plan to improve packaging and labeling operations, including equipment and facility upgrades, effective preventive and corrective maintenance, enhanced performance monitoring, improved operations management oversight, and any other needed actions. Your CAPA plan should also assure the proper segregation and sufficient space for the orderly storage of samples.\nAn action plan and timeline for conducting retrospective assessment of all your reserve samples in your sample storage area. Include supporting documentation to ensure that no product or package mix-ups have occurred, and any corrective actions, such as notifying customers of identified product mix-ups.\n3. Your firm’s quality control unit failed to exercise its responsibility to ensure drug products manufactured are in compliance with CGMP, and meet established specifications for identity, strength, quality, and purity (21 CFR 211.22).\nYour quality unit (QU) did not provide adequate oversight for the manufacture of your drug products. For example, your QU failed to ensure the following:\nReview and approval of written procedures for production and process controls that are designed to assure the quality of your drug products, i.e., process validation (21 CFR 211.100(a)).\nEstablishment of an adequate, ongoing stability program (21 CFR 211.166(a)).\nAdequate batch production and control records that include complete documentation of the accomplishment of each significant step in the manufacture, processing, packing, or holding of the batch, for each batch of drug product (21 CFR 211.188).\nAdequate review and approval of production and control records before a batch is released or distributed (21 CFR 211.192)\nProduction and process control activities, such as equipment qualification, are documented at the time of performance (21 CFR 211.100(b)). Specifically, investigators observed your quality assurance manager generating and completing equipment qualification documents investigators previously requested. This practice raises concerns about the integrity and reliability of your firm’s data and documentation.\nYour firm’s quality systems are inadequate. See FDA’s guidance document Quality Systems Approach to Pharmaceutical CGMP Regulations for help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR, parts 210 and 211 at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload.\nYour quality system does not adequately ensure the accuracy and integrity of data to support the safety, effectiveness, and quality of the drugs you manufacture. See FDA’s guidance document Data Integrity and Compliance With Drug CGMP for guidance on establishing and following CGMP compliant data integrity practices at Data Integrity and Compliance With Drug CGMP:\nQuestions and Answers | FDA\nWe acknowledge that you are using an independent third-party consultant to audit your operation and assist in meeting FDA requirements.\nIn response to this letter, provide:\nA comprehensive investigation into the extent of the inaccuracies in data records and reporting. Your investigation should include:\no A detailed investigation protocol and methodology; a summary of all laboratories, manufacturing operations, and systems to be covered by the assessment; and a justification for any part of your operation that you propose to exclude.\no Interviews of current and former employees to identify the nature, scope, and root cause of data inaccuracies. We recommend that these interviews be conducted by a qualified third party.\no An assessment of the extent of data integrity deficiencies at your facility. Identify omissions, alterations, deletions, record destruction, non-contemporaneous record completion, and other deficiencies. Describe all parts of your facility’s operations in which you discovered data integrity lapses.\nA current risk assessment of the potential effects of the observed failures on the quality of your drugs. Your assessment should include analyses of the risks to patients caused by the release of drugs affected by a lapse of data integrity and analyses of the risks posed by ongoing operations.\nA management strategy for your firm that includes the details of your global CAPA plan.\nYour strategy should include:\no A detailed corrective action plan that describes how you intend to ensure the reliability and completeness of all the data you generate, including analytical data, manufacturing records, and all data submitted to FDA.\no A comprehensive description of the root causes of your data integrity lapses, including evidence that the scope and depth of the current action plan is commensurate with the findings of the investigation and risk assessment. Indicate whether individuals responsible for data integrity lapses remain able to influence CGMP-related or drug application data at your firm.\no Interim measures describing the actions you have taken or will take to protect patients and to ensure the quality of your drugs, such as notifying your customers, recalling product, conducting additional testing, adding batches to your stability programs to assure stability, drug application actions, and enhanced complaint monitoring.\no Long-term measures describing any remediation efforts and enhancements to procedures, processes, methods, controls, systems, management oversight, and human resources (e.g., training, staffing improvements) designed to ensure the integrity of your company’s data.\no A commitment to have a qualified consultant conduct extensive annual audits, for at least two years, to assist in evaluating CAPA effectiveness after you have executed your data integrity remediation protocol.\no Inform FDA if you will be hiring a Chief Integrity Officer who is fully empowered to receive anonymous complaints from employees reporting data integrity concerns and with the authority to ensure any potential breach is promptly investigated (by independent quality assurance function, along with expertise from outside entities whenever needed).\no A status report for any of the above activities already underway or completed.\nA comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\no A determination of whether procedures used by your firm are robust and appropriate.\no Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices.\no A complete and final review of each batch and its related information before the QU disposition decision.\no Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products.\nA comprehensive, independent assessment of your overall system for investigating deviations, discrepancies, complaints, out-of-specification results, and failures. Provide a detailed action plan to remediate this system. Your action plan should include, but not be limited to, significant improvements in investigation competencies, scope determination, root cause evaluation, CAPA effectiveness, QU oversight, and written procedures. Address how your firm will ensure all phases of investigations are appropriately conducted.\nDrug Recall\nOn March 26, 2025, FDA held a teleconference with you and your U.S. Agent, JMM Services LLC. We recommended that you recall all your drug products within expiry currently in distribution to the U.S. market. On April 9, 2025, your firm committed to recall the products within expiry. After several subsequent attempts were made to contact you and your registered U.S. Agent regarding the recall, you initiated the recall of all your drug products on April 24, 2025.\nCGMP Consultant Recommended\nBased upon the nature of the violations we identified at your firm, you should engage a consultant qualified as set forth in 21 CFR 211.34 to evaluate your operations and to assist your firm in meeting CGMP requirements. The qualified consultant should also perform a comprehensive six-system audit of your entire operation for CGMP compliance and evaluate the completion and efficacy of your CAPAs before you pursue resolution of your firm’s compliance status with FDA.\nYour use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\nCosmetics Manufactured for Distribution in the United States\nIn addition, some of the products you manufacture may be regulated as cosmetics, as defined in section 201(i) of the FD&C Act (21 U.S.C. 321(i)). Any cosmetics you manufacture must comply with applicable statutory and regulatory requirements, including the FD&C Act. A cosmetic is deemed adulterated under section 601(c) of the FD&C Act (21 U.S.C. 361(c)) if it has been prepared, packed, or held under insanitary conditions whereby it may have become contaminated with filth or whereby it may have been rendered injurious to health. Some conditions that cause the drug products you manufacture to be adulterated may also cause any cosmetics you manufacture to be adulterated. We note that under section 301(a) of the FD&C Act (21 U.S.C. 331(a)), it is a prohibited act to introduce or deliver for introduction into interstate commerce a cosmetic that is adulterated. Further, your facility may be subject to requirements under the Modernization of Cosmetics Regulation Act of 2022 (MoCRA). You may find the FD&C Act, MoCRA, and FDA’s regulations through links on FDA’s website at www.fda.gov.\nConclusion\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\nFDA placed all drugs and drug products offered for import into the United States from your firm on Import Alert 66-40 on April 4, 2025.\nCorrect any violations promptly. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to any violations.\nFailure to address any violations may also result in the FDA continuing to refuse admission of articles manufactured at Kenil Healthcare Private Limited, located at Plot No. 319, Village Acharasan, Ankhol-Vamaj Road Ta-Kadi, District Mehsana, Gujarat, 382715, India, into the United States under section 801(a)(3) of the FD&C Act, 21 U.S.C. 381(a)(3). Articles under this authority that appear to be adulterated may be detained or refused admission, in that the methods and controls used in their manufacture do not appear to conform to CGMP within the meaning of section 501(a)(2)(B) of the FD&C Act, 21 U.S.C. 351(a)(2)(B).\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\nSend your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3022380309 and ATTN: Yvette Johnson.\nSincerely,\n\u002FS\u002F\nFrancis Godwin\nDirector\nOffice of Manufacturing Quality\nOffice of Compliance\nCenter for Drug Evaluation and Research\nCc: Registered U.S. Agent\nMs. Julia Moffitt, JMM Services\nEmail: julia@jmm.one; Info@jmm.one","Kenil Healthcare Private Limited","kenil-healthcare-private-limited-704786-06122025","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fkenil-healthcare-private-limited-704786-06122025","2026-10-26T08:09:08.479043+00:00","2025-06-17","704786","Mr. Anil Patel","2026-08-19T16:39:44.873+00:00","VIA Electronic Mail","320-25-81","2025-06-12",{"id":142,"raw":143,"subject":14,"body_html":147,"body_text":148,"firm_name":149,"letter_id":150,"created_at":88,"fei_number":20,"letter_url":151,"updated_at":152,"action_type":23,"case_status":24,"posted_date":153,"marcs_cms_no":154,"product_type":27,"closeout_date":20,"issuing_office":11,"recipient_name":155,"body_fetched_at":156,"delivery_method":157,"recipient_title":20,"reference_number":158,"action_taken_date":159,"medical_device_id":20,"response_letter_date":20},324,[144,145,146,11,14,13,13,13],"\u003Ctime datetime=\"2026-02-24T05:00:00Z\">02\u002F24\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2026-02-12T05:00:00Z\">02\u002F12\u002F2026\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Faq-usa-inc-dba-ross-healthcare-inc-719517-02122026\">AQ USA Inc., d.b.a Ross Healthcare Inc. \u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>320-26-45\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Marc N. Ross\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Quality Manager\u002FCo-Owner\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>AQ USA Inc., d.b.a Ross Healthcare Inc. \u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>210 S Duffner Dr., Suite A\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Lynden\u003C\u002Fspan>, \u003Cspan>WA\u003C\u002Fspan> \u003Cspan>98264\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>Warning Letter\u003C\u002Fstrong> 320-26-45\u003C\u002Fp>\u003Cp>February 12, 2026\u003C\u002Fp>\u003Cp>Dear Mr. Ross:\u003C\u002Fp>\u003Cp>The United States Food and Drug Administration (FDA) inspected your drug manufacturing facility, AQ USA Inc., d.b.a Ross Healthcare Inc., FEI 3015167023, at 210 S Duffner Dr., Suite A, Lynden, from July 30 to August 12, 2025. We note that Ross Healthcare Inc. (FEI #3010166452) operates a manufacturing facility in Delta, B.C., Canada that was placed on Import Alert 66-40 on November 30, 2017, due to significant CGMP violations. Evidence obtained during the inspection demonstrates that you are manufacturing the same product line at your Lynden, Washington facility that was previously produced at the Canadian facility.\u003C\u002Fp>\u003Cp>This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\u003C\u002Fp>\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\u003Cp>We reviewed your August 21, 2025, response to our Form FDA 483 in detail.\u003C\u002Fp>\u003Cp>During our inspection, our investigators observed specific violations including, but not limited to, the following.\u003C\u002Fp>\u003Cp>\u003Cstrong>1. Your firm failed to conduct, for each batch of drug product, appropriate laboratory testing, as necessary, required to be free of objectionable microorganisms. Your firm also failed to establish laboratory controls that include scientifically sound and appropriate specifications, standards, sampling plans, and test procedures designed to assure that components, drug product containers, closures, in-process materials, labeling, and drug products conform to appropriate standards of identity, strength, quality, and purity ((21 CFR 211.165(b) &amp; 21 CFR 211.160(b)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your firm manufactures drug products such as \u003Cstrong>(b)(4)\u003C\u002Fstrong>, intended for \u003Cstrong>(b)(4)\u003C\u002Fstrong>. You failed to conduct adequate finished product testing for each batch of your drug product. For example, you released your finished drug product \u003Cstrong>(b)(4)\u003C\u002Fstrong> without testing for critical microbial attributes (e.g., total count, absence of objectionable microorganisms).\u003C\u002Fp>\u003Cp>Furthermore, you failed to establish scientifically sound and adequate specifications for microbial limits for your drug products. For example, we reviewed your established microbiological limits for total aerobic plate count and note that they are set \u003Cstrong>(b)(4)\u003C\u002Fstrong> times greater than the United States Pharmacopeia (USP) &lt;61&gt; \u003Cem>Microbiological Examination Of Nonsterile Products: Microbial Enumeration Tests\u003C\u002Fem> limit of 10² cfu.\u003C\u002Fp>\u003Cp>In your response, you state that you will conduct the microbial rapid test system validation accordance with USP &lt;1223&gt; \u003Cem>Validation of Alternative Microbiological Methods\u003C\u002Fem> requirements and the manufacturer’s specifications. You also note that you will verify system suitability for the specific product type and that you will maintain comprehensive raw data documentation for all tested batches.\u003C\u002Fp>\u003Cp>Your response is inadequate because it lacks sufficient detail regarding tests for each finished drug batch and fails to include a risk assessment or retrospective review of products released without appropriate testing.\u003C\u002Fp>\u003Cp>Adequate microbial specifications and testing methods to detect objectionable microorganisms in the presence of each drug product must be established. Without testing each batch prior to release, you did not have scientific evidence that all \u003Cstrong>(b)(4) \u003C\u002Fstrong>drug product batches were free of objectionable microbial contamination.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A list of chemical and microbial specifications including test methods used to analyze each batch of your drug products before a batch disposition decision.\u003Cbr>o An action plan and timelines for conducting full chemical and microbiological testing of retain samples to determine the quality of all batches of drug product distributed to the United States that are within expiry as of the date of this letter.\u003Cbr>o A summary of all results obtained from testing retain samples from each batch. If such testing reveals substandard quality drug products, take rapid corrective actions such as notifying customers and product recalls.\u003C\u002Fli>\u003Cli>A comprehensive independent assessment of your laboratory practices, procedures, methods, equipment, documentation, and analyst competencies. Based on this review, provide a detailed plan to remediate and evaluate the effectiveness of your laboratory system.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>2. Your firm failed to establish and follow written procedures describing in sufficient detail the receipt, identification, storage, handling, sampling, testing, and approval or rejection of components and drug product containers and closures (21 CFR 211.80(a)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your firm approved “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” for use as a component in your drug products. For example, “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” is approximately \u003Cstrong>(b)(4)\u003C\u002Fstrong>% of your \u003Cstrong>(b)(4)\u003C\u002Fstrong> drug product. At a minimum, you must use \u003Cstrong>(b)(4)\u003C\u002Fstrong> (refer to USP \u003Cstrong>(b)(4)\u003C\u002Fstrong>) to manufacture your non-sterile drug products. \u003Cstrong>(b)(4)\u003C\u002Fstrong> must be suitable for its intended use and routinely tested to ensure ongoing conformance with appropriate chemical and microbiological attributes.\u003C\u002Fp>\u003Cp>In your response, you indicate that you will discontinue the use of “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” and procure and use only \u003Cstrong>(b)(4)\u003C\u002Fstrong> that meets USP \u003Cstrong>(b)(4)\u003C\u002Fstrong> specifications. You also state that you will initiate contract testing of your current \u003Cstrong>(b)(4)\u003C\u002Fstrong> supply for microbiological and chemical quality. Your response is inadequate because you failed to address drug products currently on the market that were manufactured using “\u003Cstrong>(b)(4)\u003C\u002Fstrong>”.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A comprehensive, independent review of your material system including, but not limited to:\u003Cbr>o Evaluating all suppliers of materials (components, containers, and closures) to determine if they are reliable and appropriately qualified.\u003Cbr>o An assessment of all materials to determine whether they are consistently of acceptable quality.\u003Cbr>o A review to ensure assigned expiration or retest dates are appropriate (supported by data).\u003Cbr>o Adequacy of the supplier qualification program, and its selection, qualification, and disqualification provisions.\u003Cbr>o Based on a thorough review, provide a summary of your systemic corrective action and preventive action (CAPA) plan to remediate the vendor qualification program and prevent use of unsuitable components, containers, and closures.\u003C\u002Fli>\u003Cli>A detailed risk assessment for drug products currently in U.S. distribution, or within expiry, manufactured using inappropriate \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Specify actions that you will take in response to the risk assessment, such as customer notifications and product recalls.\u003C\u002Fli>\u003Cli>A procedure for your \u003Cstrong>(b)(4)\u003C\u002Fstrong> monitoring that specifies routine microbial testing of \u003Cstrong>(b)(4)\u003C\u002Fstrong> to ensure its acceptability for use in each batch of drug products produced by your firm.\u003C\u002Fli>\u003Cli>The microbiological quality control specifications you use to test and release each incoming lot of component for use in manufacturing.\u003C\u002Fli>\u003Cli>A summary of results from testing retain samples of all drug product batches within expiry. You should test microbiological quality (total counts and identification of bioburden to detect any objectionable microbes) of each batch. If testing yields an out-of-specification (OOS) result, indicate the corrective actions you will take, including notifying customers and initiating recalls.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>3. Your firm failed to conduct at least one test to verify the identity of each component of a drug product. Your firm also failed to validate and establish the reliability of your component supplier’s test analyses at appropriate intervals (21 CFR 211.84(d)(1) and 211.84(d)(2)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your firm failed to test incoming raw materials including active pharmaceutical ingredients (e.g., \u003Cstrong>(b)(4)\u003C\u002Fstrong>) used to manufacture your drug products to determine their identity, purity, strength, and other appropriate quality attributes. You released \u003Cstrong>(b)(4)\u003C\u002Fstrong> USP lots into production without performing adequate acceptance testing, including identity. In addition, you relied on your suppliers’ certificate of analysis (COA) without establishing the reliability of each of your component suppliers’ test analyses at appropriate intervals.\u003C\u002Fp>\u003Cp>In your response, you state that you will immediately withhold all incoming lots of \u003Cstrong>(b)(4)\u003C\u002Fstrong> USP and other raw ingredients pending sampling, testing, and approval by the quality control unit. Your response is inadequate because you do not provide details to demonstrate that your components meet all compendial requirements (e.g., specific tests to be performed). Additionally, you do not propose testing retain samples or otherwise conducting an analysis of previously used \u003Cstrong>(b)(4)\u003C\u002Fstrong> USP lots as well as other drug product components to ensure that all quality attributes are met.\u003C\u002Fp>\u003Cp>Without adequate testing, you do not have scientific evidence that the components conform to appropriate specifications before their use in the manufacture of your drug products. You are responsible for sampling, testing, and examining drug components before use in production to ensure that acceptable quality parameters are met.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>The chemical and microbiological quality control specifications you use to test and release each incoming lot of components for use in manufacturing.\u003C\u002Fli>\u003Cli>A description of how you will test each component lot for conformity with all appropriate specifications for identity, strength, quality, and purity. If you intend to accept any results from your supplier’s COA instead of testing each component lot for strength, quality, and purity, specify how you will robustly establish the reliability of your supplier’s results through initial validation as well as periodic re-validation. In addition, include a commitment to always conduct at least one specific identity test for each incoming component lot.\u003C\u002Fli>\u003Cli>A summary of results obtained from testing all components to evaluate the reliability of the COA from each component manufacturer. Include your SOP that describes this COA validation program.\u003C\u002Fli>\u003Cli>A summary of your program for qualifying and overseeing contract facilities that test the drug products you manufacture.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>4. Your firm failed to establish and follow an adequate written testing program designed to assess the stability characteristics of drug products and to use results of stability testing to determine appropriate storage conditions and expiration dates (21 CFR 211.166(a)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your firm does not have adequate stability testing data to demonstrate that the microbiological properties of your drug products meet established specifications and that they remain acceptable for the duration of their labeled shelf lives of \u003Cstrong>(b)(4)\u003C\u002Fstrong>. During the inspection you were unable to provide raw data for any microbiological testing conducted. In addition, your firm lacked adequate stability chambers to ensure appropriate storage conditions (e.g., temperature and humidity) for your stability samples.\u003C\u002Fp>\u003Cp>In your response you state that you will draft written testing program protocols to identify all marketed products for immediate stability testing, retrieve representative samples for testing initiation, and assign interim expiry dates pending preliminary data generation.\u003C\u002Fp>\u003Cp>Your response is inadequate because it fails to include sufficient details on your stability program, including how you will ensure adequate sampling and appropriate specifications. Additionally, it does not include a retrospective risk assessment for your distributed drug products that are currently on the U.S. market and within expiry. Without appropriate stability studies, you do not have scientific evidence to support whether your drug products meet established specifications and retain their quality attributes throughout their assigned shelf life.\u003C\u002Fp>\u003Cp>In your response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A comprehensive, independent assessment and corrective action and preventive action plan to ensure the adequacy of your stability program. Your remediated program should include, but not be limited to:\u003Cbr>o Stability-indicating methods\u003Cbr>o Stability studies for each drug product in its marketed container-closure system before distribution is permitted\u003Cbr>o An ongoing program in which representative batches of each product are added each year to the program to determine if the shelf-life claim remains valid\u003Cbr>o Detailed definition of the specific attributes to be tested at each station (timepoint).\u003C\u002Fli>\u003Cli>All procedures that describe these and other elements of your remediated stability program.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>5. Your firm’s quality control unit failed to exercise its responsibility to ensure drug products manufactured are in compliance with CGMP, and meet established specifications for identity, strength, quality, and purity (21 CFR 211.22)\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>You lacked adequate quality unit (QU) oversight for the manufacture of your drug products. For example, your QU failed to ensure the following:\u003C\u002Fp>\u003Cul>\u003Cli>Establishment of adequate production procedures and process control to assure your drug products have the identity, strength, quality, and purity they purport or are represented to possess (21 CFR 211.100(a)).\u003C\u002Fli>\u003Cli>Establishment of adequate batch production and control records that contain the accomplishment of each significant step in the manufacture, processing, packing, or holding of the batch, for each batch of drug product (21 CFR 211.188(b)).\u003C\u002Fli>\u003Cli>Validation of test methods to verify their accuracy, sensitivity, specificity, and reproducibility (21 CFR 211.165(e)).\u003C\u002Fli>\u003C\u002Ful>\u003Cp>In your response, you commit to drafting and approving procedures and retraining personnel. Additionally, you commit to performing process validation, updating batch records, and validating test methods.\u003C\u002Fp>\u003Cp>Your response is inadequate because you do not address how you plan to ensure that your quality unit has sufficient resources to carry out its responsibilities and consistently ensure drug quality.\u003C\u002Fp>\u003Cp>You did not provide details about how you will conduct process validation. Furthermore, you did not provide revised batch production records. Complete and accurate batch production and control records are necessary to ensure that manufacturing processes are consistently followed and reproducible. In addition, you did not provide sufficient evidence to demonstrate in-house methods are equivalent or superior to the USP methods.\u003C\u002Fp>\u003Cp>Significant findings in this letter demonstrate that your firm does not operate an effective quality system in accordance with CGMP. See FDA’s guidance document \u003Cem>Quality Systems Approach to Pharmaceutical CGMP Regulations\u003C\u002Fem> for help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR, parts 210 and 211 at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\u003Cbr>o A determination of whether procedures used by your firm are robust and appropriate\u003Cbr>o Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices\u003Cbr>o A complete and final review of each batch and its related information before the QU disposition decision\u003Cbr>o Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products. Also describe how top management supports quality assurance and reliable operations, including but not limited to timely provision of resources to proactively address emerging manufacturing\u002Fquality issues and to assure a continuing state of control.\u003C\u002Fli>\u003Cli>A timeline for performing process validation for each of your marketed drug products. Also provide a risk assessment and any follow up actions to be taken for the distributed drug products produced without performing any process validation studies.\u003C\u002Fli>\u003Cli>A comprehensive independent assessment of your laboratory practices, procedures, and methods. Based on this review, provide a detailed plan to remediate and evaluate the effectiveness of your laboratory system.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>CGMP Consultant Recommended\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Based upon the nature of the violations we identified at your firm, you should engage a consultant qualified as set forth in 21 CFR 211.34 to assist your firm in meeting CGMP requirements.\u003C\u002Fp>\u003Cp>Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\u003C\u002Fp>\u003Cp>Correct any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\u003C\u002Fp>\u003Cp>Failure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\u003C\u002Fp>\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\u003Cp>Send your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3015167023 and ATTN: Niketa Patel.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Francis Godwin\u003Cbr>Director\u003Cbr>Office of Manufacturing Quality\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS\n\nReference #:\n\n320-26-45\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMr. Marc N. Ross\n\nRecipient Title\n\nQuality Manager\u002FCo-Owner\n\nAQ USA Inc., d.b.a Ross Healthcare Inc.\n\n210 S Duffner Dr., Suite A\n\nLynden, WA 98264\n\nUnited States\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nWarning Letter 320-26-45\nFebruary 12, 2026\nDear Mr. Ross:\nThe United States Food and Drug Administration (FDA) inspected your drug manufacturing facility, AQ USA Inc., d.b.a Ross Healthcare Inc., FEI 3015167023, at 210 S Duffner Dr., Suite A, Lynden, from July 30 to August 12, 2025. We note that Ross Healthcare Inc. (FEI #3010166452) operates a manufacturing facility in Delta, B.C., Canada that was placed on Import Alert 66-40 on November 30, 2017, due to significant CGMP violations. Evidence obtained during the inspection demonstrates that you are manufacturing the same product line at your Lynden, Washington facility that was previously produced at the Canadian facility.\nThis warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B).\nWe reviewed your August 21, 2025, response to our Form FDA 483 in detail.\nDuring our inspection, our investigators observed specific violations including, but not limited to, the following.\n1. Your firm failed to conduct, for each batch of drug product, appropriate laboratory testing, as necessary, required to be free of objectionable microorganisms. Your firm also failed to establish laboratory controls that include scientifically sound and appropriate specifications, standards, sampling plans, and test procedures designed to assure that components, drug product containers, closures, in-process materials, labeling, and drug products conform to appropriate standards of identity, strength, quality, and purity ((21 CFR 211.165(b) & 21 CFR 211.160(b)).\nYour firm manufactures drug products such as (b)(4), intended for (b)(4). You failed to conduct adequate finished product testing for each batch of your drug product. For example, you released your finished drug product (b)(4) without testing for critical microbial attributes (e.g., total count, absence of objectionable microorganisms).\nFurthermore, you failed to establish scientifically sound and adequate specifications for microbial limits for your drug products. For example, we reviewed your established microbiological limits for total aerobic plate count and note that they are set (b)(4) times greater than the United States Pharmacopeia (USP) \u003C61> Microbiological Examination Of Nonsterile Products: Microbial Enumeration Tests limit of 10² cfu.\nIn your response, you state that you will conduct the microbial rapid test system validation accordance with USP \u003C1223> Validation of Alternative Microbiological Methods requirements and the manufacturer’s specifications. You also note that you will verify system suitability for the specific product type and that you will maintain comprehensive raw data documentation for all tested batches.\nYour response is inadequate because it lacks sufficient detail regarding tests for each finished drug batch and fails to include a risk assessment or retrospective review of products released without appropriate testing.\nAdequate microbial specifications and testing methods to detect objectionable microorganisms in the presence of each drug product must be established. Without testing each batch prior to release, you did not have scientific evidence that all (b)(4) drug product batches were free of objectionable microbial contamination.\nIn response to this letter, provide:\nA list of chemical and microbial specifications including test methods used to analyze each batch of your drug products before a batch disposition decision.\no An action plan and timelines for conducting full chemical and microbiological testing of retain samples to determine the quality of all batches of drug product distributed to the United States that are within expiry as of the date of this letter.\no A summary of all results obtained from testing retain samples from each batch. If such testing reveals substandard quality drug products, take rapid corrective actions such as notifying customers and product recalls.\nA comprehensive independent assessment of your laboratory practices, procedures, methods, equipment, documentation, and analyst competencies. Based on this review, provide a detailed plan to remediate and evaluate the effectiveness of your laboratory system.\n2. Your firm failed to establish and follow written procedures describing in sufficient detail the receipt, identification, storage, handling, sampling, testing, and approval or rejection of components and drug product containers and closures (21 CFR 211.80(a)).\nYour firm approved “(b)(4)” for use as a component in your drug products. For example, “(b)(4)” is approximately (b)(4)% of your (b)(4) drug product. At a minimum, you must use (b)(4) (refer to USP (b)(4)) to manufacture your non-sterile drug products. (b)(4) must be suitable for its intended use and routinely tested to ensure ongoing conformance with appropriate chemical and microbiological attributes.\nIn your response, you indicate that you will discontinue the use of “(b)(4)” and procure and use only (b)(4) that meets USP (b)(4) specifications. You also state that you will initiate contract testing of your current (b)(4) supply for microbiological and chemical quality. Your response is inadequate because you failed to address drug products currently on the market that were manufactured using “(b)(4)”.\nIn response to this letter, provide:\nA comprehensive, independent review of your material system including, but not limited to:\no Evaluating all suppliers of materials (components, containers, and closures) to determine if they are reliable and appropriately qualified.\no An assessment of all materials to determine whether they are consistently of acceptable quality.\no A review to ensure assigned expiration or retest dates are appropriate (supported by data).\no Adequacy of the supplier qualification program, and its selection, qualification, and disqualification provisions.\no Based on a thorough review, provide a summary of your systemic corrective action and preventive action (CAPA) plan to remediate the vendor qualification program and prevent use of unsuitable components, containers, and closures.\nA detailed risk assessment for drug products currently in U.S. distribution, or within expiry, manufactured using inappropriate (b)(4). Specify actions that you will take in response to the risk assessment, such as customer notifications and product recalls.\nA procedure for your (b)(4) monitoring that specifies routine microbial testing of (b)(4) to ensure its acceptability for use in each batch of drug products produced by your firm.\nThe microbiological quality control specifications you use to test and release each incoming lot of component for use in manufacturing.\nA summary of results from testing retain samples of all drug product batches within expiry. You should test microbiological quality (total counts and identification of bioburden to detect any objectionable microbes) of each batch. If testing yields an out-of-specification (OOS) result, indicate the corrective actions you will take, including notifying customers and initiating recalls.\n3. Your firm failed to conduct at least one test to verify the identity of each component of a drug product. Your firm also failed to validate and establish the reliability of your component supplier’s test analyses at appropriate intervals (21 CFR 211.84(d)(1) and 211.84(d)(2)).\nYour firm failed to test incoming raw materials including active pharmaceutical ingredients (e.g., (b)(4)) used to manufacture your drug products to determine their identity, purity, strength, and other appropriate quality attributes. You released (b)(4) USP lots into production without performing adequate acceptance testing, including identity. In addition, you relied on your suppliers’ certificate of analysis (COA) without establishing the reliability of each of your component suppliers’ test analyses at appropriate intervals.\nIn your response, you state that you will immediately withhold all incoming lots of (b)(4) USP and other raw ingredients pending sampling, testing, and approval by the quality control unit. Your response is inadequate because you do not provide details to demonstrate that your components meet all compendial requirements (e.g., specific tests to be performed). Additionally, you do not propose testing retain samples or otherwise conducting an analysis of previously used (b)(4) USP lots as well as other drug product components to ensure that all quality attributes are met.\nWithout adequate testing, you do not have scientific evidence that the components conform to appropriate specifications before their use in the manufacture of your drug products. You are responsible for sampling, testing, and examining drug components before use in production to ensure that acceptable quality parameters are met.\nIn response to this letter, provide:\nThe chemical and microbiological quality control specifications you use to test and release each incoming lot of components for use in manufacturing.\nA description of how you will test each component lot for conformity with all appropriate specifications for identity, strength, quality, and purity. If you intend to accept any results from your supplier’s COA instead of testing each component lot for strength, quality, and purity, specify how you will robustly establish the reliability of your supplier’s results through initial validation as well as periodic re-validation. In addition, include a commitment to always conduct at least one specific identity test for each incoming component lot.\nA summary of results obtained from testing all components to evaluate the reliability of the COA from each component manufacturer. Include your SOP that describes this COA validation program.\nA summary of your program for qualifying and overseeing contract facilities that test the drug products you manufacture.\n4. Your firm failed to establish and follow an adequate written testing program designed to assess the stability characteristics of drug products and to use results of stability testing to determine appropriate storage conditions and expiration dates (21 CFR 211.166(a)).\nYour firm does not have adequate stability testing data to demonstrate that the microbiological properties of your drug products meet established specifications and that they remain acceptable for the duration of their labeled shelf lives of (b)(4). During the inspection you were unable to provide raw data for any microbiological testing conducted. In addition, your firm lacked adequate stability chambers to ensure appropriate storage conditions (e.g., temperature and humidity) for your stability samples.\nIn your response you state that you will draft written testing program protocols to identify all marketed products for immediate stability testing, retrieve representative samples for testing initiation, and assign interim expiry dates pending preliminary data generation.\nYour response is inadequate because it fails to include sufficient details on your stability program, including how you will ensure adequate sampling and appropriate specifications. Additionally, it does not include a retrospective risk assessment for your distributed drug products that are currently on the U.S. market and within expiry. Without appropriate stability studies, you do not have scientific evidence to support whether your drug products meet established specifications and retain their quality attributes throughout their assigned shelf life.\nIn your response to this letter, provide:\nA comprehensive, independent assessment and corrective action and preventive action plan to ensure the adequacy of your stability program. Your remediated program should include, but not be limited to:\no Stability-indicating methods\no Stability studies for each drug product in its marketed container-closure system before distribution is permitted\no An ongoing program in which representative batches of each product are added each year to the program to determine if the shelf-life claim remains valid\no Detailed definition of the specific attributes to be tested at each station (timepoint).\nAll procedures that describe these and other elements of your remediated stability program.\n5. Your firm’s quality control unit failed to exercise its responsibility to ensure drug products manufactured are in compliance with CGMP, and meet established specifications for identity, strength, quality, and purity (21 CFR 211.22)\nYou lacked adequate quality unit (QU) oversight for the manufacture of your drug products. For example, your QU failed to ensure the following:\nEstablishment of adequate production procedures and process control to assure your drug products have the identity, strength, quality, and purity they purport or are represented to possess (21 CFR 211.100(a)).\nEstablishment of adequate batch production and control records that contain the accomplishment of each significant step in the manufacture, processing, packing, or holding of the batch, for each batch of drug product (21 CFR 211.188(b)).\nValidation of test methods to verify their accuracy, sensitivity, specificity, and reproducibility (21 CFR 211.165(e)).\nIn your response, you commit to drafting and approving procedures and retraining personnel. Additionally, you commit to performing process validation, updating batch records, and validating test methods.\nYour response is inadequate because you do not address how you plan to ensure that your quality unit has sufficient resources to carry out its responsibilities and consistently ensure drug quality.\nYou did not provide details about how you will conduct process validation. Furthermore, you did not provide revised batch production records. Complete and accurate batch production and control records are necessary to ensure that manufacturing processes are consistently followed and reproducible. In addition, you did not provide sufficient evidence to demonstrate in-house methods are equivalent or superior to the USP methods.\nSignificant findings in this letter demonstrate that your firm does not operate an effective quality system in accordance with CGMP. See FDA’s guidance document Quality Systems Approach to Pharmaceutical CGMP Regulations for help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR, parts 210 and 211 at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload.\nIn response to this letter, provide:\nA comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\no A determination of whether procedures used by your firm are robust and appropriate\no Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices\no A complete and final review of each batch and its related information before the QU disposition decision\no Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products. Also describe how top management supports quality assurance and reliable operations, including but not limited to timely provision of resources to proactively address emerging manufacturing\u002Fquality issues and to assure a continuing state of control.\nA timeline for performing process validation for each of your marketed drug products. Also provide a risk assessment and any follow up actions to be taken for the distributed drug products produced without performing any process validation studies.\nA comprehensive independent assessment of your laboratory practices, procedures, and methods. Based on this review, provide a detailed plan to remediate and evaluate the effectiveness of your laboratory system.\nCGMP Consultant Recommended\nBased upon the nature of the violations we identified at your firm, you should engage a consultant qualified as set forth in 21 CFR 211.34 to assist your firm in meeting CGMP requirements.\nYour use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\nConclusion\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\nCorrect any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\nFailure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\nSend your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3015167023 and ATTN: Niketa Patel.\nSincerely,\n\u002FS\u002F\nFrancis Godwin\nDirector\nOffice of Manufacturing Quality\nOffice of Compliance\nCenter for Drug Evaluation and Research","AQ USA Inc., d.b.a Ross Healthcare Inc.","aq-usa-inc-dba-ross-healthcare-inc-719517-02122026","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Faq-usa-inc-dba-ross-healthcare-inc-719517-02122026","2026-10-26T08:07:56.968886+00:00","2026-02-24","719517","Mr. Marc N. Ross","2026-08-19T04:56:40.433+00:00","VIA UPS","320-26-45","2026-02-12",{"id":161,"raw":162,"subject":166,"body_html":167,"body_text":168,"firm_name":169,"letter_id":170,"created_at":171,"fei_number":20,"letter_url":172,"updated_at":173,"action_type":23,"case_status":24,"posted_date":174,"marcs_cms_no":175,"product_type":176,"closeout_date":20,"issuing_office":11,"recipient_name":177,"body_fetched_at":178,"delivery_method":179,"recipient_title":20,"reference_number":20,"action_taken_date":180,"medical_device_id":20,"response_letter_date":20},21685,[163,164,165,11,166,13,13,13],"\u003Ctime datetime=\"2026-10-06T04:00:00Z\">10\u002F06\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2026-10-01T04:00:00Z\">10\u002F01\u002F2026\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fplatinum-healthcare-llc-735147-10012026\">The Platinum Healthcare LLC\u003C\u002Fa>","Unapproved New Drugs","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA ELECTRONIC MAIL READ\u002FDELIVERY RECEIPT REQUESTED\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n                          \u003Cbr>Over-the-Counter Drugs\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Jamey Hagan\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>CEO\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>The Platinum Healthcare LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>1019 N 1st Street\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Pulaski\u003C\u002Fspan>, \u003Cspan>TN\u003C\u002Fspan> \u003Cspan>38478\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:office@platinumwellnesscenter.org\"> office@platinumwellnesscenter.org\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>October 1, 2026\u003C\u002Fp>\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003Cbr>Reference Number: 735147\u003C\u002Fp>\u003Cp>To Jamey Hagan:\u003C\u002Fp>\u003Cp>This warning letter advises you of significant violations observed during a U.S. Food and Drug Administration (FDA) review of your website, https:\u002F\u002Fplatinumwellnesscenter.org\u002F, and provides you an opportunity to address them. Promptly address any violations described herein without delay, including ensuring that appropriate resources are allocated to fully address them and prevent their recurrence. This is not intended to be an all-inclusive list of the violations that may exist in connection with your products or operations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations. Failure to adequately address any violations may result in regulatory or legal action without further notice including, without limitation, seizure and injunction.\u003C\u002Fp>\u003Cp>As discussed below, the “Sycosis” and “Syphillinum” products available for purchase on your website are unapproved new drugs. Unapproved drug products marketed for the treatment of sexually transmitted infections (STIs) and\u002For their symptoms and sold directly to consumers present a serious public health concern. Individuals who rely on these products may forgo timely, appropriate medical care, increasing their risk of severe complications such as infertility, sepsis, and death. Further, a false sense of having been adequately treated may lead individuals to unknowingly transmit infections to their partners. FDA has not approved any over-the-counter (OTC) drug product for the treatment, cure, mitigation, or prevention of any STI. Effective treatment requires diagnosis and supervision by a licensed healthcare professional.\u003C\u002Fp>\u003Cp>\u003Cstrong>FDA Review\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Violations were identified and documented during a review of your website https:\u002F\u002Fplatinumwellnesscenter.org\u002F in July 2026. Based on our review, “Sycosis” and “Syphillinum” are unapproved new drugs under section 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 355(a). As explained further below, introducing or delivering these products for introduction into interstate commerce violates sections 301(d) and 505(a) of the FD&amp;C Act, 21 U.S.C. 331(d) and 355(a).\u003C\u002Fp>\u003Cp>This review was conducted as part of FDA’s public health responsibility to protect the public from unsafe, ineffective, and poor-quality drugs.\u003C\u002Fp>\u003Cp>\u003Cstrong>Violations of the Federal Food, Drug, and Cosmetic Act\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The following are violations identified during our review. As a reminder, this is not an all-inclusive list of violations that may exist in connection with your products or operations.\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>Unapproved New Drug Violations\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fp>\u003Cp>Based on a review of your website, “Sycosis” and “Syphillinum” are drugs under section 201(g)(1) of the FD&amp;C Act, 21 U.S.C. 321(g)(1), because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and\u002For intended to affect the structure or any function of the body. Examples from your product labeling, including on your website, that provide evidence of the intended use (as defined in 21 CFR 201.128) of these products as drugs include, but may not be limited to, the following:\u003C\u002Fp>\u003Cp>\u003Cu>Sycosis\u003C\u002Fu>\u003Cbr>On the webpage https:\u002F\u002Fplatinumwellnesscenter.org\u002Fstore\u002Fsycosis\u002F:\u003C\u002Fp>\u003Cul>\u003Cli>“Oral antigen for desensitizing and stimulating the body’s immune defense mechanism against problems caused by the Gonorrhea miasm.”\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cu>Syphillinum\u003C\u002Fu>\u003Cbr>On the webpage https:\u002F\u002Fplatinumwellnesscenter.org\u002Fstore\u002Fsyphilinum\u002F:\u003C\u002Fp>\u003Cul>\u003Cli>“Oral antigen for desensitizing and stimulating the body’s immune defense mechanism against problems caused by the Syphilis miasm.”\u003C\u002Fli>\u003C\u002Ful>\u003Cp>“Sycosis” and “Syphillinum” are “new drugs” under section 201(p) of the FD&amp;C Act, 21 U.S.C. 321(p), because they are not generally recognized as safe and effective (GRASE) for use under the conditions prescribed, recommended, or suggested in their labeling. With certain exceptions not applicable here, a new drug may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in section 505(a) of the FD&amp;C Act, 21 U.S.C. 355(a). No approved applications pursuant to section 505 of the FD&amp;C Act, 21 U.S.C. 355, are in effect for these products. Accordingly, these products are unapproved new drugs. The introduction or delivery for introduction into interstate commerce of these unapproved new drug products violates sections 301(d) and 505(a) of the FD&amp;C Act, 21 U.S.C. 331(d) and 355(a).\u003C\u002Fp>\u003Cp>We recognize that your “Sycosis” and “Syphillinum” products are labeled as homeopathic drugs with active ingredient(s) measured in homeopathic strengths. Under section 201(g)(1) of the FD&amp;C Act, 21 U.S.C. 321(g)(1), the term “drug” includes articles recognized in the official Homeopathic Pharmacopeia of the United States (HPUS), or any supplement to it. Homeopathic drug products are subject to the same statutory requirements as other drugs; nothing in the FD&amp;C Act exempts homeopathic drugs from any of the requirements related to adulteration, misbranding, or FDA approval.\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>As previously stated, you are responsible for investigating and determining the root causes of any violations and implementing corrective and preventative measures to ensure future and sustained compliance so that these violations and any others do not occur.\u003C\u002Fp>\u003Cp>Send your written response to FDAAdvisory@fda.hhs.gov within fifteen (15) business days of receipt of this letter. Include the specific steps you have taken to correct any violations, an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you have information that you believe demonstrates that your products are not in violation of the FD&amp;C Act and FDA regulations, include that information for our consideration. Identify your response with reference number “735147” in the subject line of the email.\u003C\u002Fp>\u003Cp>Please note FDA posts warning letters on www.fda.gov.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Tina Smith, M.S.\u003Cbr>Captain, U.S. Public Health Service\u003Cbr>Director\u003Cbr>Office of Unapproved Drugs and Labeling Compliance\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003Cbr>U.S. Food and Drug Administration\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA ELECTRONIC MAIL READ\u002FDELIVERY RECEIPT REQUESTED\n\nProduct:\n\nDrugs\n\nOver-the-Counter Drugs\n\nRecipient:\n\nRecipient Name\n\nJamey Hagan\n\nRecipient Title\n\nCEO\n\nThe Platinum Healthcare LLC\n\n1019 N 1st Street\n\nPulaski, TN 38478\n\nUnited States\n\noffice@platinumwellnesscenter.org\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nOctober 1, 2026\nWARNING LETTER\nReference Number: 735147\nTo Jamey Hagan:\nThis warning letter advises you of significant violations observed during a U.S. Food and Drug Administration (FDA) review of your website, https:\u002F\u002Fplatinumwellnesscenter.org\u002F, and provides you an opportunity to address them. Promptly address any violations described herein without delay, including ensuring that appropriate resources are allocated to fully address them and prevent their recurrence. This is not intended to be an all-inclusive list of the violations that may exist in connection with your products or operations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations. Failure to adequately address any violations may result in regulatory or legal action without further notice including, without limitation, seizure and injunction.\nAs discussed below, the “Sycosis” and “Syphillinum” products available for purchase on your website are unapproved new drugs. Unapproved drug products marketed for the treatment of sexually transmitted infections (STIs) and\u002For their symptoms and sold directly to consumers present a serious public health concern. Individuals who rely on these products may forgo timely, appropriate medical care, increasing their risk of severe complications such as infertility, sepsis, and death. Further, a false sense of having been adequately treated may lead individuals to unknowingly transmit infections to their partners. FDA has not approved any over-the-counter (OTC) drug product for the treatment, cure, mitigation, or prevention of any STI. Effective treatment requires diagnosis and supervision by a licensed healthcare professional.\nFDA Review\nViolations were identified and documented during a review of your website https:\u002F\u002Fplatinumwellnesscenter.org\u002F in July 2026. Based on our review, “Sycosis” and “Syphillinum” are unapproved new drugs under section 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 355(a). As explained further below, introducing or delivering these products for introduction into interstate commerce violates sections 301(d) and 505(a) of the FD&C Act, 21 U.S.C. 331(d) and 355(a).\nThis review was conducted as part of FDA’s public health responsibility to protect the public from unsafe, ineffective, and poor-quality drugs.\nViolations of the Federal Food, Drug, and Cosmetic Act\nThe following are violations identified during our review. As a reminder, this is not an all-inclusive list of violations that may exist in connection with your products or operations.\nUnapproved New Drug Violations\nBased on a review of your website, “Sycosis” and “Syphillinum” are drugs under section 201(g)(1) of the FD&C Act, 21 U.S.C. 321(g)(1), because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and\u002For intended to affect the structure or any function of the body. Examples from your product labeling, including on your website, that provide evidence of the intended use (as defined in 21 CFR 201.128) of these products as drugs include, but may not be limited to, the following:\nSycosis\nOn the webpage https:\u002F\u002Fplatinumwellnesscenter.org\u002Fstore\u002Fsycosis\u002F:\n“Oral antigen for desensitizing and stimulating the body’s immune defense mechanism against problems caused by the Gonorrhea miasm.”\nSyphillinum\nOn the webpage https:\u002F\u002Fplatinumwellnesscenter.org\u002Fstore\u002Fsyphilinum\u002F:\n“Oral antigen for desensitizing and stimulating the body’s immune defense mechanism against problems caused by the Syphilis miasm.”\n“Sycosis” and “Syphillinum” are “new drugs” under section 201(p) of the FD&C Act, 21 U.S.C. 321(p), because they are not generally recognized as safe and effective (GRASE) for use under the conditions prescribed, recommended, or suggested in their labeling. With certain exceptions not applicable here, a new drug may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in section 505(a) of the FD&C Act, 21 U.S.C. 355(a). No approved applications pursuant to section 505 of the FD&C Act, 21 U.S.C. 355, are in effect for these products. Accordingly, these products are unapproved new drugs. The introduction or delivery for introduction into interstate commerce of these unapproved new drug products violates sections 301(d) and 505(a) of the FD&C Act, 21 U.S.C. 331(d) and 355(a).\nWe recognize that your “Sycosis” and “Syphillinum” products are labeled as homeopathic drugs with active ingredient(s) measured in homeopathic strengths. Under section 201(g)(1) of the FD&C Act, 21 U.S.C. 321(g)(1), the term “drug” includes articles recognized in the official Homeopathic Pharmacopeia of the United States (HPUS), or any supplement to it. Homeopathic drug products are subject to the same statutory requirements as other drugs; nothing in the FD&C Act exempts homeopathic drugs from any of the requirements related to adulteration, misbranding, or FDA approval.\nConclusion\nAs previously stated, you are responsible for investigating and determining the root causes of any violations and implementing corrective and preventative measures to ensure future and sustained compliance so that these violations and any others do not occur.\nSend your written response to FDAAdvisory@fda.hhs.gov within fifteen (15) business days of receipt of this letter. Include the specific steps you have taken to correct any violations, an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you have information that you believe demonstrates that your products are not in violation of the FD&C Act and FDA regulations, include that information for our consideration. Identify your response with reference number “735147” in the subject line of the email.\nPlease note FDA posts warning letters on www.fda.gov.\nSincerely,\n\u002FS\u002F\nTina Smith, M.S.\nCaptain, U.S. Public Health Service\nDirector\nOffice of Unapproved Drugs and Labeling Compliance\nOffice of Compliance\nCenter for Drug Evaluation and Research\nU.S. Food and Drug Administration","The Platinum Healthcare LLC","platinum-healthcare-llc-735147-10012026","2026-10-14T12:31:16.41489+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fplatinum-healthcare-llc-735147-10012026","2026-11-17T01:02:03.701861+00:00","2026-10-06","735147","Drugs Over-the-Counter Drugs","Jamey Hagan","2026-10-14T12:33:33.251+00:00","VIA ELECTRONIC MAIL READ\u002FDELIVERY RECEIPT REQUESTED","2026-10-01",{"id":182,"raw":183,"subject":187,"body_html":188,"body_text":189,"firm_name":190,"letter_id":191,"created_at":69,"fei_number":20,"letter_url":192,"updated_at":193,"action_type":23,"case_status":24,"posted_date":194,"marcs_cms_no":195,"product_type":27,"closeout_date":20,"issuing_office":64,"recipient_name":196,"body_fetched_at":197,"delivery_method":138,"recipient_title":20,"reference_number":20,"action_taken_date":198,"medical_device_id":20,"response_letter_date":20},1526,[184,185,186,64,187,13,13,13],"\u003Ctime datetime=\"2024-04-09T13:20:00Z\">04\u002F09\u002F2024\u003C\u002Ftime>\n","\u003Ctime datetime=\"2024-03-28T04:00:00Z\">03\u002F28\u002F2024\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fkilitch-healthcare-india-limited-672956-03282024\">Kilitch Healthcare India Limited\u003C\u002Fa>","CGMP\u002FFinished Pharmaceutical\u002FAdulterated","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Paresh Mehta\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Managing Director\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Kilitch Healthcare India Limited\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>902-B, Godrej Coliseum, Behind Everard Nagar\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Off. Eastern Express Highway, Nr. Priyadarshani Circle\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Sion (E.), Mumbai\u003C\u002Fspan> \u003Cspan>400022\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>India\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research | CDER\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>Warning Letter\u003C\u002Fstrong> 320-24-29\u003C\u002Fp>\n\n\u003Cp>March 28, 2024\u003Cbr>\n\u003Cbr>\nDear Mr. Mehta:\u003C\u002Fp>\n\n\u003Cp>The U.S. Food and Drug Administration (FDA) inspected your drug manufacturing facility, Kilitch Healthcare India Limited, FEI 3011853060, at R - 904 905 T T C Industrial Road,\u003Cbr>\nNavi Mumbai from October 12 to October 20, 2023.\u003C\u002Fp>\n\n\u003Cp>This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\u003C\u002Fp>\n\n\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\n\n\u003Cp>Because your drug products were prepared, packed, or held under insanitary conditions, whereby they may have become contaminated with filth or rendered injurious to health, your drug products are also adulterated within the meaning of section 501(a)(2)(A) of the FD&amp;C Act, 21 U.S.C. 351(a)(2)(A).\u003C\u002Fp>\n\n\u003Cp>We reviewed your November 10, 2023 response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\u003C\u002Fp>\n\n\u003Cp>During our inspection, our investigators observed specific violations including, but not limited to, the following.\u003C\u002Fp>\n\n\u003Cp>\u003Cu>\u003Cstrong>Insanitary Conditions\u003C\u002Fstrong>\u003C\u002Fu>\u003C\u002Fp>\n\n\u003Cp>Your drug products are adulterated under section 501(a)(2)(A) of the FD&amp;C Act because they were prepared, packed, or held under insanitary conditions. FDA investigators observed your facility to be in a state of disrepair, poorly cleaned and maintained as evidenced by:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>\u003Cstrong>(b)(4)\u003C\u002Fstrong> residue on the \u003Cstrong>(b)(4)\u003C\u002Fstrong> adjacent to the HEPA filters in the ISO 5 area.\u003C\u002Fli>\n\t\u003Cli>Multiple barefoot employees in an ISO 8 area, without required gowning, including gloves, while handling materials being transferred into the ISO 7 manufacturing area.\u003C\u002Fli>\n\t\u003Cli>Operators used visibly dirty restricted access barrier system (RABS) \u003Cstrong>(b)(4)\u003C\u002Fstrong> for interventions on the filling line.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>Your response is not adequate. While you commit to replacing the \u003Cstrong>(b)(4)\u003C\u002Fstrong> that surround the HEPA filtration system, your response does not include an evaluation of the residue on the \u003Cstrong>(b)(4)\u003C\u002Fstrong> to determine its identity or investigate the source. You also commit to perform re-training of personnel for gowning requirements and implement a procedure for sterilization of RABS \u003Cstrong>(b)(4)\u003C\u002Fstrong>, however, you do not evaluate the microbiological impact that lack of proper gowning and unclean RABS \u003Cstrong>(b)(4)\u003C\u002Fstrong> has on your classified areas, such as ISO 5, ISO 7, and ISO 8. The potential impact to sterile drug products produced under these insanitary conditions is also not addressed.\u003C\u002Fp>\n\n\u003Cp>\u003Cu>\u003Cstrong>CGMP Violations\u003C\u002Fstrong>\u003C\u002Fu>\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>1. Your firm failed to establish and follow appropriate written procedures that are designed to prevent microbiological contamination of drug products purporting to be sterile, and that include validation of all aseptic and sterilization processes (21 CFR 211.113(b)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>\u003Cem>Poor Practices in the Aseptic Processing Areas\u003C\u002Fem>\u003C\u002Fp>\n\n\u003Cp>In addition to the insanitary conditions described above, during the inspection of your facility, we observed poor practices and behaviors in ISO 5 areas during the manufacturing of sterile drug products. These poor practices included, but are not limited to:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>Operators performing interventions on the filling line in ISO 5 areas using a cloth to wipe the \u003Cstrong>(b)(4)\u003C\u002Fstrong> of the filling \u003Cstrong>(b)(4)\u003C\u002Fstrong> and the conveyor.\u003C\u002Fli>\n\t\u003Cli>Operators leaning over the filling line, including open and filled eye drop bottles, blocking unidirectional airflow.\u003C\u002Fli>\n\t\u003Cli>Operators in the ISO 5 area not wearing goggles and therefore had exposed skin during line set-up and aseptic processing.\u003C\u002Fli>\n\t\u003Cli>Operators observed placing bags of components that made contact with the walls in the ISO 7 area into the ISO 5 area without the bags being disinfected.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>Your response is inadequate because it does not address the lack of oversight for the operators’ aseptic behaviors and if the initial training received was sufficient. Further, these poor aseptic practices were not investigated to determine the impact to sterile drug products and aseptic processing areas.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>Inadequate Media Fill Program\u003C\u002Fem>\u003C\u002Fp>\n\n\u003Cp>Your media fills failed to accurately simulate commercial operations. Our inspection found the aseptic operations simulated during your media fills were not sufficiently representative of commercial aseptic manufacturing operations. It is your routine practice not to document interventions of the filling line in the manufacturing batch record during production. Because of this, your program lacks reliable data to determine the quantity and duration of interventions to simulate during media fills. In addition, during the inspection there were numerous interventions performed during routine manufacturing that were either not simulated as part of a media fill, or lacking in quantity and duration in the media fills compared to what was observed during production.\u003C\u002Fp>\n\n\u003Cp>Your response is inadequate. While you commit to document routine interventions during manufacturing, you fail to evaluate the interventions used in your media fill program and whether they represent routine production. Your operators performed numerous, manually intensive interventions during aseptic operations. As such, the quantity and duration of process simulation interventions should closely resemble the actual manufacturing process. If a media fill program fails to incorporate contamination risk factors and closely simulate actual drug product exposure, the state of process control and sterility assurance cannot be accurately assessed.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>Inadequate Smoke Studies\u003C\u002Fem>\u003C\u002Fp>\n\n\u003Cp>Smoke studies performed by your firm are not adequate to show unidirectional airflow in the aseptic processing areas. Multiple instances of turbulent airflow in critical areas of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> filling line were noted, including above the filling \u003Cstrong>(b)(4)\u003C\u002Fstrong>. In addition, smoke study videos did not include set-up of the aseptic processing line or interventions of the filling line that simulate actual manufacturing.\u003C\u002Fp>\n\n\u003Cp>In your response you commit to repeat smoke studies with defined set-up and interventions. This is not adequate as you do not provide details such as who is performing and evaluating the smoke studies, how you will determine what interventions are included, and how you will address potential deficiencies.\u003C\u002Fp>\n\n\u003Cp>See FDA’s guidance document \u003Cem>Sterile Drug Products Produced by Aseptic Processing—Current Good Manufacturing Practice\u003C\u002Fem> to help you meet the CGMP requirements when manufacturing sterile drugs using aseptic processing at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71026\u002Fdownload.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide the following:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>Your plan to ensure appropriate aseptic practices and cleanroom behavior during production. Include steps to ensure routine and effective supervisory oversight for all production batches.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>Also describe the frequency of quality unit (QU) oversight (e.g., audit) during aseptic processing and its support operations.\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A thorough retrospective review and risk assessment that evaluates how poor aseptic technique and cleanroom behavior may have affected the quality and sterility of your drugs.\u003C\u002Fli>\n\t\u003Cli>A comprehensive, independent assessment of the design and control of your firm’s manufacturing operations, with a detailed and thorough review of all microbiological hazards.\u003C\u002Fli>\n\t\u003Cli>A detailed risk assessment addressing the hazards posed by distributing drug products with potentially objectionable contamination. Specify actions you will take in response to the risk assessment, such as customer notifications and product recalls.\u003C\u002Fli>\n\t\u003Cli>Complete investigations into all batches with potential objectionable microbial contamination or an out-of-specification (OOS) microbiological result (whether or not later invalidated). The investigations should detail your findings regarding the root causes of the contamination.\u003C\u002Fli>\n\t\u003Cli>Comprehensive risk assessment of all contamination hazards with respect to your aseptic processes, equipment, and facilities, including an independent assessment that includes, but is not limited to:\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>&nbsp; &nbsp; o All human interactions within the ISO 5 area\u003Cbr>\n&nbsp; &nbsp; o Equipment placement and suitability, including ergonomics for each human interaction.\u003Cbr>\n&nbsp; &nbsp; o Air quality in the ISO 5 area, and surrounding room including, but not limited to, air volume, air flow, and microbial\u002Fparticulate levels\u003Cbr>\n&nbsp; &nbsp; o Reduction or elimination of aseptic manipulations and connections (e.g., replacing \u003Cstrong>(b)(4)\u003C\u002Fstrong> aseptic connections with \u003Cstrong>(b)(4)\u003C\u002Fstrong> system)\u003Cbr>\n&nbsp; &nbsp; o Facility layout\u003Cbr>\n&nbsp; &nbsp; o Personnel Flows and Material Flows (throughout all rooms used to conduct and support sterile operations)\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A detailed remediation plan with timelines to address the findings of the contamination hazards risk assessment. Describe specific tangible improvements to be made to aseptic processing operation design and control.\u003C\u002Fli>\n\t\u003Cli>A plan to implement systemic remediations that address a pattern of recurring contamination events and ensure sustainable control of your aseptic processing operations.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cstrong>2. Your firm failed to ensure that laboratory records included complete data derived from all tests necessary to ensure compliance with established specifications and standards (21 CFR 211.194(a)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your firm failed to collect the required amount of environmental and personnel monitoring samples required by your procedures to support the manufacture of sterile drug products. During the inspection, a reconciliation of samples that should have been taken during manufacturing activities and those that were actually taken did not match. Interviews with microbiology laboratory staff and management confirmed that it is your routine practice to fabricate results for samples that were never taken or to alter results for samples that would otherwise fail to meet established specifications.\u003C\u002Fp>\n\n\u003Cp>Batch record information for environmental monitoring (EM) is not recorded at the time of completion. For example, a batch record was being filled out in the microbiology laboratory on October 12, 2023, for batch \u003Cstrong>(b)(4)\u003C\u002Fstrong> that was manufactured in March 2023, approximately six months prior to the recorded date. Data for the microbiological activity in the filtration\u002Ffilling area in the batch record was blank on October 12, 2023. This includes the air sample and non-viable particulate counting start and end times, activity done by signatures and dates, and the checked by signatures and dates. When the record was later provided on October 19, 2023, the record was filled out with times, signatures, and dates in March 2023.\u003C\u002Fp>\n\n\u003Cp>During our inspection, investigators observed multiple sample collections in the ISO 5 and ISO 7 areas, and on personnel that resulted in plate readings with numerous colony forming units (CFUs). Your firm stated that prior to the start of the inspection, where you admitted routine fabrication of environmental monitoring results, no single action limit excursion had been documented, however, FDA investigators observed the following during the inspection:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>15 action level excursions for ISO 5 area environmental monitoring samples\u003C\u002Fli>\n\t\u003Cli>13 action level excursions for personnel monitoring samples\u003C\u002Fli>\n\t\u003Cli>5 action level excursions for ISO 7 area environmental monitoring samples\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>Laboratory technicians falsified this data which is critical to maintaining an ongoing state of control in your aseptic processing facility. Data integrity is critical throughout the CGMP data life cycle, including in the creation, modification, processing, maintenance, archival, retrieval, transmission, and disposition of date after the record’s retention period ends.\u003C\u002Fp>\n\n\u003Cp>Your response states that a new checklist and procedure for oversight will be implemented. This response is not adequate as it does not address the data integrity issues that were identified by FDA. In addition, your response does not include a holistic review of data recording practices at your facility. Further, your corrective action and preventive action (CAPA) of adding a laboratory quality unit (QU) checklist for microbiologist tasks is not adequate to ensure contemporaneous completion of laboratory records.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide the following:\u003C\u002Fp>\n\n\u003Cp>A comprehensive, independent assessment of your laboratory practices, procedures, methods, equipment, documentation, and analyst competencies. Based on this review, provide a detailed plan to remediate and evaluate the effectiveness of your laboratory system.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Data Integrity Remediation\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your quality system does not adequately ensure the accuracy and integrity of data to support the safety, effectiveness, and quality of the drugs you manufacture. See FDA’s guidance document\u003Cbr>\n\u003Cbr>\n\u003Cem>Data Integrity and Compliance With Drug CGMP\u003C\u002Fem> for guidance on establishing and following CGMP compliant data integrity practices at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F119267\u002Fdownload.\u003C\u002Fp>\n\n\u003Cp>We acknowledge that you are using an independent third-party consultant to audit your operation and assist in meeting FDA requirements. In response to this letter, provide:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A comprehensive investigation into the extent of the inaccuracies in data records and reporting. Your investigation should include:\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>&nbsp; &nbsp; o A detailed investigation protocol and methodology; a summary of all laboratories, manufacturing operations, and systems to be covered by the assessment; and a justification for any part of your operation that you propose to exclude.\u003Cbr>\n&nbsp; &nbsp; o Interviews of current and former employees to identify the nature, scope, and root cause of data inaccuracies. We recommend that these interviews be conducted by a qualified third party.\u003Cbr>\n&nbsp; &nbsp; o An assessment of the extent of data integrity deficiencies at your facility. Identify omissions, alterations, deletions, record destruction, non-contemporaneous record completion, and other deficiencies. Describe all parts of your facility’s operations in which you discovered data integrity lapses.\u003Cbr>\n&nbsp; &nbsp; o A comprehensive retrospective evaluation of the nature of the testing data integrity deficiencies. We recommend that a qualified third party with specific expertise in the area where potential breaches were identified should evaluate all data integrity lapses.\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A current risk assessment of the potential effects of the observed failures on the quality of your drugs. Your assessment should include analyses of the risks to patients caused by the release of drugs affected by a lapse of data integrity and analyses of the risks posed by ongoing operations.\u003C\u002Fli>\n\t\u003Cli>A management strategy for your firm that includes the details of your global CAPA plan. Your strategy should include:\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>&nbsp; &nbsp; o A detailed corrective action plan that describes how you intend to ensure the reliability and completeness of all the data you generate including analytical data, manufacturing records, and all data submitted to FDA.\u003Cbr>\n&nbsp; &nbsp; o A comprehensive description of the root causes of your data integrity lapses including evidence that the scope and depth of the current action plan is commensurate with the findings of the investigation and risk assessment. Indicate whether individuals responsible for data integrity lapses remain able to influence CGMP-related or drug application data at your firm.\u003Cbr>\n&nbsp; &nbsp; o Interim measures describing the actions you have taken or will take to protect patients and to ensure the quality of your drugs, such as notifying your customers, recalling product, conducting additional testing, adding lots to your stability programs to assure stability, drug application actions, and enhanced complaint monitoring.\u003Cbr>\n&nbsp; &nbsp; o Long-term measures describing any remediation efforts and enhancements to procedures, processes, methods, controls, systems, management oversight, and human resources (e.g., training, staffing improvements) designed to ensure the integrity of your company’s data.\u003Cbr>\n&nbsp; &nbsp; o A commitment to have a qualified consultant conduct extensive annual audits, for at least two years, to assist in evaluating CAPA effectiveness after you have executed your data integrity remediation protocol.\u003Cbr>\n&nbsp; &nbsp; o Inform FDA if you will be hiring a Chief Integrity Officer who is fully empowered to receive anonymous complaints from employees reporting data integrity concerns and with the authority to ensure any potential breach is promptly investigated (by independent quality assurance function, along with expertise from outside entities whenever needed).\u003Cbr>\n&nbsp; &nbsp; o A status report for any of the above activities already underway or completed.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>3. Your firm failed to perform operations within specifically defined areas of adequate size and to have separate or defined areas or such other control systems necessary to prevent contamination or mix-ups in aseptic processing areas (21 CFR 211.42(c)(10)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>\u003Cem>Environmental Monitoring Deficiencies\u003C\u002Fem>\u003C\u002Fp>\n\n\u003Cp>Your environmental monitoring (EM) program is deficient. Locations selected for EM in critical areas such as the ISO 5 aseptic processing line, do not have scientific justification to support the chosen locations. For example, standard operating procedure (SOP) KHIL\u002FRB\u002FQC\u002F036 “Swab Testing” describes locations such as “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” without providing details to ensure samples are taken from the same location each time. When asked to provide justification for sampling locations, no documentation was provided.\u003C\u002Fp>\n\n\u003Cp>Additionally, the materials used to perform environmental and personnel monitoring are inadequate. The media used does not contain a neutralizing agent and operators were observed spraying \u003Cstrong>(b)(4)\u003C\u002Fstrong> near open plates. The plates themselves were observed numerous times to have desiccated media pulling away from the sides of the plates and cracking.\u003C\u002Fp>\n\n\u003Cp>Your response is inadequate as you do not include a risk based, scientific study to determine sampling locations for your environmental monitoring. In addition, you failed to evaluate how the growth media and plate deficiencies potentially impact your drug products and facility’s state of control for microbial contamination.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>Facility Maintenance Deficiencies\u003C\u002Fem>\u003C\u002Fp>\n\n\u003Cp>During the inspection, numerous instances of your facility being in a state of disrepair or unclean were noted. This includes but is not limited to:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>\u003Cstrong>(b)(4)\u003C\u002Fstrong> surrounding the HEPA filters in the ISO 5 area were detached, creating gaps where air from the ISO 7 area could flow into the ISO 5 area.\u003C\u002Fli>\n\t\u003Cli>Hose connected to a leaking purified water use point was submerged in a bucket of stagnant water.\u003C\u002Fli>\n\t\u003Cli>Peeling paint, stains, and residue on the ceiling of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> room.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>Your response is inadequate as you failed to consider that persistently deficient environmental controls (e.g., poor design of processing lines, lack of data integrity, and insufficient environmental monitoring) provide a fundamental lack of meaningful retrospective data to support sterility assurance.\u003Cbr>\n\u003Cbr>\nA vigilant ongoing EM program, and supporting laboratory, are essential to detect and respond to potential product contamination hazards in your manufacturing environment in a timely manner. Loss of environmental control in an aseptic manufacturing facility can ultimately pose a serious hazard to patients.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>An independent assessment of your EM program including, but not limited to, establishing appropriate limits, sampling frequencies, investigating deviations, and trend analysis. Also ensure the implementation of a comprehensive CAPA plan.\u003C\u002Fli>\n\t\u003Cli>Your CAPA plan to implement routine, vigilant operations management oversight of facilities and equipment. This plan should ensure, among other things, prompt detection of equipment\u002Ffacilities performance issues, effective execution of repairs, adherence to appropriate preventive maintenance schedules, timely technological upgrades to the equipment\u002Ffacility infrastructure, and improved systems for ongoing management review.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cstrong>4. Your firm’s quality control unit failed to exercise its responsibility to ensure drug products manufactured are in compliance with CGMP, and meet established specifications for identity, strength, quality, and purity (21 CFR 211.22).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your firm’s QU failed to adequately execute its responsibilities. For example:\u003C\u002Fp>\n\n\u003Cp>A. Your QU failed to follow approved, written production and process controls. Your firm was manufacturing Multi Action Relief Drops, Polyvinyl Alcohol 0.5%, Povidone 0.6%, and Tetrahydrozoline HCl 0.05% using non-pharmaceutical grade \u003Cstrong>(b)(4)\u003C\u002Fstrong> as a preservative. When your customer requested a switch to pharmaceutical grade \u003Cstrong>(b)(4)\u003C\u002Fstrong>, you proceeded to repeat process validation without opening a change control per SOP KHIL\u002FRB\u002FQA\u002F016\u002F-R07, “Change Control.” You also failed to conduct a risk assessment of product that was in the U.S. market with non-pharmaceutical grade \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\n\n\u003Cp>B. Your QU released drug product batches of Equate Hydration Polyethylene Glycol 400 and Propylene Glycol Eye Drops \u003Cstrong>(b)(4)\u003C\u002Fstrong> before the process validation was completed, as required in your SOP KHIL\u002FRB\u002FQA\u002F081 “Process Validation.” Your QU stated that due to a customer request they released the product for distribution before the studies were completed (21 CFR 100(a)).\u003C\u002Fp>\n\n\u003Cp>C. Your QU failed to ensure that adequate stability data supported your drug expiration dates. Equate Hydration Polyethylene Glycol 400 and Propylene Glycol Eye Drops \u003Cstrong>(b)(4)\u003C\u002Fstrong> was released with a \u003Cstrong>(b)(4)\u003C\u002Fstrong> expiration date based on only three months of accelerated stability data. (21 CFR 211.166(b)).\u003C\u002Fp>\n\n\u003Cp>D. Your sampling plan to test for diethylene glycol (DEG) and ethylene glycol (EG) in polyethylene glycol is not representative. For example, when receiving the same vendor lot of polyethylene glycol multiple times, only the first shipment of the lot is sampled and tested for DEG and EG. Subsequent shipments with the same vendor lot are not sampled and tested for DEG and EG (21 CFR 211.84).\u003C\u002Fp>\n\n\u003Cp>Your response is inadequate for the following:\u003C\u002Fp>\n\n\u003Cp>A. You failed to review all formulations to ensure that when required, United States Pharmacopeia (USP) grade materials are used to manufacture drug products for the U.S. market and that change controls are opened when required by your procedure.\u003C\u002Fp>\n\n\u003Cp>B. Procedural updates are not sufficient to address the QU disregarding what was written in the previous version of the SOP to release product without completed process validation.\u003C\u002Fp>\n\n\u003Cp>C. A review of expiration dates and the stability data that support them was not included as part of your response.\u003C\u002Fp>\n\n\u003Cp>D. A plan for testing to verify that DEG and EG was at acceptable levels in all lots of raw materials and finished drug products was not included as part of your corrective action plan.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide the following:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>&nbsp; &nbsp; o A determination of whether procedures used by your firm are robust and appropriate.\u003Cbr>\n&nbsp; &nbsp; o Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices.\u003Cbr>\n&nbsp; &nbsp; o A complete and final review of each batch and its related information before the QU disposition decision.\u003Cbr>\n&nbsp; &nbsp; o Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products.\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A comprehensive, independent assessment of your change management system. This assessment should include, but not be limited to, your procedure(s) to ensure changes are justified, reviewed, and approved by your quality unit. Your change management program should also include provisions for determining change effectiveness.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>The use of ingredients contaminated with DEG or EG has resulted in various lethal poisoning incidents in humans worldwide. See FDA’s guidance document \u003Cem>Testing of Glycerin, Propylene Glycol, Maltitol Solution, Hydrogenated Starch Hydrolysate, Sorbitol Solution, and Other High-Risk Drug Components for Diethylene Glycol and Ethylene Glycol\u003C\u002Fem> to help you meet the CGMP requirements when manufacturing drugs containing ingredients at high-risk for DEG or EG contamination at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F167974\u002Fdownload.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A commitment to provide DEG and EG test results, no later than 30 calendar days from the date of this letter, from testing retains for all lots of high-risk drug components used in the manufacture of drug products. Alternatively, if a retain of a component lot is unavailable, perform retain sample testing of all implicated finished drug product batches for the presence of DEG and EG.\u003C\u002Fli>\n\t\u003Cli>A full risk assessment for drug products that are within expiry which contain any ingredient at risk for DEG or EG contamination (including, but not limited to, glycerin). Take prompt and appropriate actions to determine the safety of all lots of the component(s) and any related drug product that could contain DEG or EG, including customer notifications and product recalls for any contaminated lots. Identify additional appropriate CAPA that secure supply chains in the future, including, but not limited to, ensuring that all incoming raw material lots are from fully qualified manufacturers and free from unsafe impurities. Detail these actions in your response to this letter.\u003C\u002Fli>\n\t\u003Cli>A description of how you will test each component lot for conformity with all appropriate specifications for identity, strength, quality, and purity. If you intend to accept any results from your supplier’s certificate of analysis (COA) instead of testing each component lot for strength, quality, and purity, specify how you will robustly establish the reliability of your supplier’s results through initial validation as well as periodic revalidation. In addition, include a commitment to always conduct at least one specific identity test for each incoming component lot. In the case of glycerin, propylene glycol, and certain additional high-risk components we note that this includes the performance of parts A, B, and C of the USP monograph.\u003C\u002Fli>\n\t\u003Cli>The chemical quality control specifications you use to test each incoming lot of high-risk drug components to determine acceptability for use in manufacturing.\u003C\u002Fli>\n\t\u003Cli>A comprehensive, independent review of your material system to determine whether all suppliers of components, containers, and closures, are each qualified and the materials are assigned appropriate expiration or retest dates. The review should also determine whether incoming material controls are adequate to prevent use of unsuitable components, containers, and closures.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cstrong>Ineffective Quality System\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Significant findings in this letter demonstrate that your firm does not operate an effective quality system in accord with CGMP. In addition to the lack of effective management oversight of your production and laboratory operations, we found your quality unit is not enabled to exercise proper authority and\u002For has insufficiently implemented its responsibilities. Executive management should immediately and comprehensively assess your company’s global manufacturing operations to ensure that your systems, processes, and products conform to FDA requirements.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Delay in Drug Product Recall\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>FDA held a teleconference with your firm and your U.S. Agent on October 25, 2023, to discuss our concerns regarding your sterile ophthalmic drug products. During this call, we recommended that you recall all drug products within expiry due to the insanitary conditions at your facility and other egregious violations, as described in this letter.\u003C\u002Fp>\n\n\u003Cp>Due to the potential public health risks associated with the situation at your facility, the Agency released their own announcement on October 27, 2023 (https:\u002F\u002Fwww.fda.gov\u002Fdrugs\u002Fdrug-safety-and-availability\u002Ffda-warns-consumers-not-purchase-or-use-certain-eye-drops-several-major-brands-due-risk-eye). Despite numerous attempts by the Agency to obtain your recall decision, your firm did not initiate a recall until November 15, 2023 (https:\u002F\u002Fwww.fda.gov\u002Fsafety\u002Frecalls-market-withdrawals-safety-alerts\u002Fkilitch-healthcare-india-limited-issues-voluntary-nationwide-recall-various-eye-drops-potential), approximately three weeks after the initial discussion.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Drug Production Suspended\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>We acknowledge your commitment to suspend production of all drugs for the U.S. market. In response to this letter, clarify whether you intend to resume manufacturing drugs for the U.S. market at this facility in the future.\u003C\u002Fp>\n\n\u003Cp>If you plan to resume any manufacturing operations regulated under the FD&amp;C Act, notify this office before resuming your drug manufacturing operations. You are responsible for resolving all deficiencies and systemic flaws to ensure your firm is capable of ongoing CGMP compliance. In your notification to the Agency, provide a summary of your remediations to demonstrate that you have appropriately completed all corrective action and preventive actions (CAPAs).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>CGMP Consultant Recommended\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Based upon the nature of the violations we identified at your firm, you should engage a consultant qualified as set forth in 21 CFR 211.34 to evaluate your operations and to assist your firm in meeting CGMP requirements if your firm intends to resume manufacturing drugs for the U.S. market. The qualified consultant should also perform a comprehensive six-system audit\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> of your entire operation for CGMP compliance and evaluate the completion and efficacy of your corrective actions and preventive actions before you pursue resolution of your firm’s compliance status with FDA. Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\u003C\u002Fp>\n\n\u003Cp>FDA placed your firm on Import Alert 66-40 on October 23, 2023.\u003C\u002Fp>\n\n\u003Cp>Correct any violations promptly. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to any violations.\u003C\u002Fp>\n\n\u003Cp>Failure to address any violations may also result in the FDA continuing to refuse admission of articles manufactured at Kilitch Healthcare India Limited, T T C Industrial Road, Navi Mumbai into the United States under section 801(a)(3) of the FD&amp;C Act, 21 U.S.C. 381(a)(3). Articles under this authority that appear to be adulterated may be detained or refused admission, in that the methods and controls used in their manufacture do not appear to conform to CGMP within the meaning of section 501(a)(2)(B) of the FD&amp;C Act, 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\n\n\u003Cp>Send your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3011853060 and ATTN: Sarah Rhoades.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Francis Godwin\u003Cbr>\nDirector\u003Cbr>\nOffice of Manufacturing Quality\u003Cbr>\nOffice of Compliance\u003Cbr>\nCenter for Drug Evaluation and Research\u003C\u002Fp>\n\n\u003Cp>___________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> i.e., Quality System, Facilities &amp; Equipment System, Materials System, Production System, Packaging &amp; Labeling System, and Laboratory Control System per FDA’s guidance document Quality Systems Approach to Pharmaceutical CGMP Regulations.\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA Electronic Mail\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMr. Paresh Mehta\n\nRecipient Title\n\nManaging Director\n\nKilitch Healthcare India Limited\n\n902-B, Godrej Coliseum, Behind Everard Nagar\n\nOff. Eastern Express Highway, Nr. Priyadarshani Circle\n\nSion (E.), Mumbai 400022\n\nIndia\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research | CDER\n\nUnited States\n\nWarning Letter 320-24-29\n\nMarch 28, 2024\n\nDear Mr. Mehta:\n\nThe U.S. Food and Drug Administration (FDA) inspected your drug manufacturing facility, Kilitch Healthcare India Limited, FEI 3011853060, at R - 904 905 T T C Industrial Road,\n\nNavi Mumbai from October 12 to October 20, 2023.\n\nThis warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\n\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B).\n\nBecause your drug products were prepared, packed, or held under insanitary conditions, whereby they may have become contaminated with filth or rendered injurious to health, your drug products are also adulterated within the meaning of section 501(a)(2)(A) of the FD&C Act, 21 U.S.C. 351(a)(2)(A).\n\nWe reviewed your November 10, 2023 response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\n\nDuring our inspection, our investigators observed specific violations including, but not limited to, the following.\n\nInsanitary Conditions\n\nYour drug products are adulterated under section 501(a)(2)(A) of the FD&C Act because they were prepared, packed, or held under insanitary conditions. FDA investigators observed your facility to be in a state of disrepair, poorly cleaned and maintained as evidenced by:\n\n(b)(4) residue on the (b)(4) adjacent to the HEPA filters in the ISO 5 area.\n\nMultiple barefoot employees in an ISO 8 area, without required gowning, including gloves, while handling materials being transferred into the ISO 7 manufacturing area.\n\nOperators used visibly dirty restricted access barrier system (RABS) (b)(4) for interventions on the filling line.\n\nYour response is not adequate. While you commit to replacing the (b)(4) that surround the HEPA filtration system, your response does not include an evaluation of the residue on the (b)(4) to determine its identity or investigate the source. You also commit to perform re-training of personnel for gowning requirements and implement a procedure for sterilization of RABS (b)(4), however, you do not evaluate the microbiological impact that lack of proper gowning and unclean RABS (b)(4) has on your classified areas, such as ISO 5, ISO 7, and ISO 8. The potential impact to sterile drug products produced under these insanitary conditions is also not addressed.\n\nCGMP Violations\n\n1. Your firm failed to establish and follow appropriate written procedures that are designed to prevent microbiological contamination of drug products purporting to be sterile, and that include validation of all aseptic and sterilization processes (21 CFR 211.113(b)).\n\nPoor Practices in the Aseptic Processing Areas\n\nIn addition to the insanitary conditions described above, during the inspection of your facility, we observed poor practices and behaviors in ISO 5 areas during the manufacturing of sterile drug products. These poor practices included, but are not limited to:\n\nOperators performing interventions on the filling line in ISO 5 areas using a cloth to wipe the (b)(4) of the filling (b)(4) and the conveyor.\n\nOperators leaning over the filling line, including open and filled eye drop bottles, blocking unidirectional airflow.\n\nOperators in the ISO 5 area not wearing goggles and therefore had exposed skin during line set-up and aseptic processing.\n\nOperators observed placing bags of components that made contact with the walls in the ISO 7 area into the ISO 5 area without the bags being disinfected.\n\nYour response is inadequate because it does not address the lack of oversight for the operators’ aseptic behaviors and if the initial training received was sufficient. Further, these poor aseptic practices were not investigated to determine the impact to sterile drug products and aseptic processing areas.\n\nInadequate Media Fill Program\n\nYour media fills failed to accurately simulate commercial operations. Our inspection found the aseptic operations simulated during your media fills were not sufficiently representative of commercial aseptic manufacturing operations. It is your routine practice not to document interventions of the filling line in the manufacturing batch record during production. Because of this, your program lacks reliable data to determine the quantity and duration of interventions to simulate during media fills. In addition, during the inspection there were numerous interventions performed during routine manufacturing that were either not simulated as part of a media fill, or lacking in quantity and duration in the media fills compared to what was observed during production.\n\nYour response is inadequate. While you commit to document routine interventions during manufacturing, you fail to evaluate the interventions used in your media fill program and whether they represent routine production. Your operators performed numerous, manually intensive interventions during aseptic operations. As such, the quantity and duration of process simulation interventions should closely resemble the actual manufacturing process. If a media fill program fails to incorporate contamination risk factors and closely simulate actual drug product exposure, the state of process control and sterility assurance cannot be accurately assessed.\n\nInadequate Smoke Studies\n\nSmoke studies performed by your firm are not adequate to show unidirectional airflow in the aseptic processing areas. Multiple instances of turbulent airflow in critical areas of the (b)(4) filling line were noted, including above the filling (b)(4). In addition, smoke study videos did not include set-up of the aseptic processing line or interventions of the filling line that simulate actual manufacturing.\n\nIn your response you commit to repeat smoke studies with defined set-up and interventions. This is not adequate as you do not provide details such as who is performing and evaluating the smoke studies, how you will determine what interventions are included, and how you will address potential deficiencies.\n\nSee FDA’s guidance document Sterile Drug Products Produced by Aseptic Processing—Current Good Manufacturing Practice to help you meet the CGMP requirements when manufacturing sterile drugs using aseptic processing at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71026\u002Fdownload.\n\nIn response to this letter, provide the following:\n\nYour plan to ensure appropriate aseptic practices and cleanroom behavior during production. Include steps to ensure routine and effective supervisory oversight for all production batches.\n\nAlso describe the frequency of quality unit (QU) oversight (e.g., audit) during aseptic processing and its support operations.\n\nA thorough retrospective review and risk assessment that evaluates how poor aseptic technique and cleanroom behavior may have affected the quality and sterility of your drugs.\n\nA comprehensive, independent assessment of the design and control of your firm’s manufacturing operations, with a detailed and thorough review of all microbiological hazards.\n\nA detailed risk assessment addressing the hazards posed by distributing drug products with potentially objectionable contamination. Specify actions you will take in response to the risk assessment, such as customer notifications and product recalls.\n\nComplete investigations into all batches with potential objectionable microbial contamination or an out-of-specification (OOS) microbiological result (whether or not later invalidated). The investigations should detail your findings regarding the root causes of the contamination.\n\nComprehensive risk assessment of all contamination hazards with respect to your aseptic processes, equipment, and facilities, including an independent assessment that includes, but is not limited to:\n\no All human interactions within the ISO 5 area\n\no Equipment placement and suitability, including ergonomics for each human interaction.\n\no Air quality in the ISO 5 area, and surrounding room including, but not limited to, air volume, air flow, and microbial\u002Fparticulate levels\n\no Reduction or elimination of aseptic manipulations and connections (e.g., replacing (b)(4) aseptic connections with (b)(4) system)\n\no Facility layout\n\no Personnel Flows and Material Flows (throughout all rooms used to conduct and support sterile operations)\n\nA detailed remediation plan with timelines to address the findings of the contamination hazards risk assessment. Describe specific tangible improvements to be made to aseptic processing operation design and control.\n\nA plan to implement systemic remediations that address a pattern of recurring contamination events and ensure sustainable control of your aseptic processing operations.\n\n2. Your firm failed to ensure that laboratory records included complete data derived from all tests necessary to ensure compliance with established specifications and standards (21 CFR 211.194(a)).\n\nYour firm failed to collect the required amount of environmental and personnel monitoring samples required by your procedures to support the manufacture of sterile drug products. During the inspection, a reconciliation of samples that should have been taken during manufacturing activities and those that were actually taken did not match. Interviews with microbiology laboratory staff and management confirmed that it is your routine practice to fabricate results for samples that were never taken or to alter results for samples that would otherwise fail to meet established specifications.\n\nBatch record information for environmental monitoring (EM) is not recorded at the time of completion. For example, a batch record was being filled out in the microbiology laboratory on October 12, 2023, for batch (b)(4) that was manufactured in March 2023, approximately six months prior to the recorded date. Data for the microbiological activity in the filtration\u002Ffilling area in the batch record was blank on October 12, 2023. This includes the air sample and non-viable particulate counting start and end times, activity done by signatures and dates, and the checked by signatures and dates. When the record was later provided on October 19, 2023, the record was filled out with times, signatures, and dates in March 2023.\n\nDuring our inspection, investigators observed multiple sample collections in the ISO 5 and ISO 7 areas, and on personnel that resulted in plate readings with numerous colony forming units (CFUs). Your firm stated that prior to the start of the inspection, where you admitted routine fabrication of environmental monitoring results, no single action limit excursion had been documented, however, FDA investigators observed the following during the inspection:\n\n15 action level excursions for ISO 5 area environmental monitoring samples\n\n13 action level excursions for personnel monitoring samples\n\n5 action level excursions for ISO 7 area environmental monitoring samples\n\nLaboratory technicians falsified this data which is critical to maintaining an ongoing state of control in your aseptic processing facility. Data integrity is critical throughout the CGMP data life cycle, including in the creation, modification, processing, maintenance, archival, retrieval, transmission, and disposition of date after the record’s retention period ends.\n\nYour response states that a new checklist and procedure for oversight will be implemented. This response is not adequate as it does not address the data integrity issues that were identified by FDA. In addition, your response does not include a holistic review of data recording practices at your facility. Further, your corrective action and preventive action (CAPA) of adding a laboratory quality unit (QU) checklist for microbiologist tasks is not adequate to ensure contemporaneous completion of laboratory records.\n\nIn response to this letter, provide the following:\n\nA comprehensive, independent assessment of your laboratory practices, procedures, methods, equipment, documentation, and analyst competencies. Based on this review, provide a detailed plan to remediate and evaluate the effectiveness of your laboratory system.\n\nData Integrity Remediation\n\nYour quality system does not adequately ensure the accuracy and integrity of data to support the safety, effectiveness, and quality of the drugs you manufacture. See FDA’s guidance document\n\nData Integrity and Compliance With Drug CGMP for guidance on establishing and following CGMP compliant data integrity practices at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F119267\u002Fdownload.\n\nWe acknowledge that you are using an independent third-party consultant to audit your operation and assist in meeting FDA requirements. In response to this letter, provide:\n\nA comprehensive investigation into the extent of the inaccuracies in data records and reporting. Your investigation should include:\n\no A detailed investigation protocol and methodology; a summary of all laboratories, manufacturing operations, and systems to be covered by the assessment; and a justification for any part of your operation that you propose to exclude.\n\no Interviews of current and former employees to identify the nature, scope, and root cause of data inaccuracies. We recommend that these interviews be conducted by a qualified third party.\n\no An assessment of the extent of data integrity deficiencies at your facility. Identify omissions, alterations, deletions, record destruction, non-contemporaneous record completion, and other deficiencies. Describe all parts of your facility’s operations in which you discovered data integrity lapses.\n\no A comprehensive retrospective evaluation of the nature of the testing data integrity deficiencies. We recommend that a qualified third party with specific expertise in the area where potential breaches were identified should evaluate all data integrity lapses.\n\nA current risk assessment of the potential effects of the observed failures on the quality of your drugs. Your assessment should include analyses of the risks to patients caused by the release of drugs affected by a lapse of data integrity and analyses of the risks posed by ongoing operations.\n\nA management strategy for your firm that includes the details of your global CAPA plan. Your strategy should include:\n\no A detailed corrective action plan that describes how you intend to ensure the reliability and completeness of all the data you generate including analytical data, manufacturing records, and all data submitted to FDA.\n\no A comprehensive description of the root causes of your data integrity lapses including evidence that the scope and depth of the current action plan is commensurate with the findings of the investigation and risk assessment. Indicate whether individuals responsible for data integrity lapses remain able to influence CGMP-related or drug application data at your firm.\n\no Interim measures describing the actions you have taken or will take to protect patients and to ensure the quality of your drugs, such as notifying your customers, recalling product, conducting additional testing, adding lots to your stability programs to assure stability, drug application actions, and enhanced complaint monitoring.\n\no Long-term measures describing any remediation efforts and enhancements to procedures, processes, methods, controls, systems, management oversight, and human resources (e.g., training, staffing improvements) designed to ensure the integrity of your company’s data.\n\no A commitment to have a qualified consultant conduct extensive annual audits, for at least two years, to assist in evaluating CAPA effectiveness after you have executed your data integrity remediation protocol.\n\no Inform FDA if you will be hiring a Chief Integrity Officer who is fully empowered to receive anonymous complaints from employees reporting data integrity concerns and with the authority to ensure any potential breach is promptly investigated (by independent quality assurance function, along with expertise from outside entities whenever needed).\n\no A status report for any of the above activities already underway or completed.\n\n3. Your firm failed to perform operations within specifically defined areas of adequate size and to have separate or defined areas or such other control systems necessary to prevent contamination or mix-ups in aseptic processing areas (21 CFR 211.42(c)(10)).\n\nEnvironmental Monitoring Deficiencies\n\nYour environmental monitoring (EM) program is deficient. Locations selected for EM in critical areas such as the ISO 5 aseptic processing line, do not have scientific justification to support the chosen locations. For example, standard operating procedure (SOP) KHIL\u002FRB\u002FQC\u002F036 “Swab Testing” describes locations such as “(b)(4)” without providing details to ensure samples are taken from the same location each time. When asked to provide justification for sampling locations, no documentation was provided.\n\nAdditionally, the materials used to perform environmental and personnel monitoring are inadequate. The media used does not contain a neutralizing agent and operators were observed spraying (b)(4) near open plates. The plates themselves were observed numerous times to have desiccated media pulling away from the sides of the plates and cracking.\n\nYour response is inadequate as you do not include a risk based, scientific study to determine sampling locations for your environmental monitoring. In addition, you failed to evaluate how the growth media and plate deficiencies potentially impact your drug products and facility’s state of control for microbial contamination.\n\nFacility Maintenance Deficiencies\n\nDuring the inspection, numerous instances of your facility being in a state of disrepair or unclean were noted. This includes but is not limited to:\n\n(b)(4) surrounding the HEPA filters in the ISO 5 area were detached, creating gaps where air from the ISO 7 area could flow into the ISO 5 area.\n\nHose connected to a leaking purified water use point was submerged in a bucket of stagnant water.\n\nPeeling paint, stains, and residue on the ceiling of the (b)(4) room.\n\nYour response is inadequate as you failed to consider that persistently deficient environmental controls (e.g., poor design of processing lines, lack of data integrity, and insufficient environmental monitoring) provide a fundamental lack of meaningful retrospective data to support sterility assurance.\n\nA vigilant ongoing EM program, and supporting laboratory, are essential to detect and respond to potential product contamination hazards in your manufacturing environment in a timely manner. Loss of environmental control in an aseptic manufacturing facility can ultimately pose a serious hazard to patients.\n\nIn response to this letter, provide:\n\nAn independent assessment of your EM program including, but not limited to, establishing appropriate limits, sampling frequencies, investigating deviations, and trend analysis. Also ensure the implementation of a comprehensive CAPA plan.\n\nYour CAPA plan to implement routine, vigilant operations management oversight of facilities and equipment. This plan should ensure, among other things, prompt detection of equipment\u002Ffacilities performance issues, effective execution of repairs, adherence to appropriate preventive maintenance schedules, timely technological upgrades to the equipment\u002Ffacility infrastructure, and improved systems for ongoing management review.\n\n4. Your firm’s quality control unit failed to exercise its responsibility to ensure drug products manufactured are in compliance with CGMP, and meet established specifications for identity, strength, quality, and purity (21 CFR 211.22).\n\nYour firm’s QU failed to adequately execute its responsibilities. For example:\n\nA. Your QU failed to follow approved, written production and process controls. Your firm was manufacturing Multi Action Relief Drops, Polyvinyl Alcohol 0.5%, Povidone 0.6%, and Tetrahydrozoline HCl 0.05% using non-pharmaceutical grade (b)(4) as a preservative. When your customer requested a switch to pharmaceutical grade (b)(4), you proceeded to repeat process validation without opening a change control per SOP KHIL\u002FRB\u002FQA\u002F016\u002F-R07, “Change Control.” You also failed to conduct a risk assessment of product that was in the U.S. market with non-pharmaceutical grade (b)(4).\n\nB. Your QU released drug product batches of Equate Hydration Polyethylene Glycol 400 and Propylene Glycol Eye Drops (b)(4) before the process validation was completed, as required in your SOP KHIL\u002FRB\u002FQA\u002F081 “Process Validation.” Your QU stated that due to a customer request they released the product for distribution before the studies were completed (21 CFR 100(a)).\n\nC. Your QU failed to ensure that adequate stability data supported your drug expiration dates. Equate Hydration Polyethylene Glycol 400 and Propylene Glycol Eye Drops (b)(4) was released with a (b)(4) expiration date based on only three months of accelerated stability data. (21 CFR 211.166(b)).\n\nD. Your sampling plan to test for diethylene glycol (DEG) and ethylene glycol (EG) in polyethylene glycol is not representative. For example, when receiving the same vendor lot of polyethylene glycol multiple times, only the first shipment of the lot is sampled and tested for DEG and EG. Subsequent shipments with the same vendor lot are not sampled and tested for DEG and EG (21 CFR 211.84).\n\nYour response is inadequate for the following:\n\nA. You failed to review all formulations to ensure that when required, United States Pharmacopeia (USP) grade materials are used to manufacture drug products for the U.S. market and that change controls are opened when required by your procedure.\n\nB. Procedural updates are not sufficient to address the QU disregarding what was written in the previous version of the SOP to release product without completed process validation.\n\nC. A review of expiration dates and the stability data that support them was not included as part of your response.\n\nD. A plan for testing to verify that DEG and EG was at acceptable levels in all lots of raw materials and finished drug products was not included as part of your corrective action plan.\n\nIn response to this letter, provide the following:\n\nA comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\n\no A determination of whether procedures used by your firm are robust and appropriate.\n\no Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices.\n\no A complete and final review of each batch and its related information before the QU disposition decision.\n\no Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products.\n\nA comprehensive, independent assessment of your change management system. This assessment should include, but not be limited to, your procedure(s) to ensure changes are justified, reviewed, and approved by your quality unit. Your change management program should also include provisions for determining change effectiveness.\n\nThe use of ingredients contaminated with DEG or EG has resulted in various lethal poisoning incidents in humans worldwide. See FDA’s guidance document Testing of Glycerin, Propylene Glycol, Maltitol Solution, Hydrogenated Starch Hydrolysate, Sorbitol Solution, and Other High-Risk Drug Components for Diethylene Glycol and Ethylene Glycol to help you meet the CGMP requirements when manufacturing drugs containing ingredients at high-risk for DEG or EG contamination at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F167974\u002Fdownload.\n\nIn response to this letter, provide:\n\nA commitment to provide DEG and EG test results, no later than 30 calendar days from the date of this letter, from testing retains for all lots of high-risk drug components used in the manufacture of drug products. Alternatively, if a retain of a component lot is unavailable, perform retain sample testing of all implicated finished drug product batches for the presence of DEG and EG.\n\nA full risk assessment for drug products that are within expiry which contain any ingredient at risk for DEG or EG contamination (including, but not limited to, glycerin). Take prompt and appropriate actions to determine the safety of all lots of the component(s) and any related drug product that could contain DEG or EG, including customer notifications and product recalls for any contaminated lots. Identify additional appropriate CAPA that secure supply chains in the future, including, but not limited to, ensuring that all incoming raw material lots are from fully qualified manufacturers and free from unsafe impurities. Detail these actions in your response to this letter.\n\nA description of how you will test each component lot for conformity with all appropriate specifications for identity, strength, quality, and purity. If you intend to accept any results from your supplier’s certificate of analysis (COA) instead of testing each component lot for strength, quality, and purity, specify how you will robustly establish the reliability of your supplier’s results through initial validation as well as periodic revalidation. In addition, include a commitment to always conduct at least one specific identity test for each incoming component lot. In the case of glycerin, propylene glycol, and certain additional high-risk components we note that this includes the performance of parts A, B, and C of the USP monograph.\n\nThe chemical quality control specifications you use to test each incoming lot of high-risk drug components to determine acceptability for use in manufacturing.\n\nA comprehensive, independent review of your material system to determine whether all suppliers of components, containers, and closures, are each qualified and the materials are assigned appropriate expiration or retest dates. The review should also determine whether incoming material controls are adequate to prevent use of unsuitable components, containers, and closures.\n\nIneffective Quality System\n\nSignificant findings in this letter demonstrate that your firm does not operate an effective quality system in accord with CGMP. In addition to the lack of effective management oversight of your production and laboratory operations, we found your quality unit is not enabled to exercise proper authority and\u002For has insufficiently implemented its responsibilities. Executive management should immediately and comprehensively assess your company’s global manufacturing operations to ensure that your systems, processes, and products conform to FDA requirements.\n\nDelay in Drug Product Recall\n\nFDA held a teleconference with your firm and your U.S. Agent on October 25, 2023, to discuss our concerns regarding your sterile ophthalmic drug products. During this call, we recommended that you recall all drug products within expiry due to the insanitary conditions at your facility and other egregious violations, as described in this letter.\n\nDue to the potential public health risks associated with the situation at your facility, the Agency released their own announcement on October 27, 2023 (https:\u002F\u002Fwww.fda.gov\u002Fdrugs\u002Fdrug-safety-and-availability\u002Ffda-warns-consumers-not-purchase-or-use-certain-eye-drops-several-major-brands-due-risk-eye). Despite numerous attempts by the Agency to obtain your recall decision, your firm did not initiate a recall until November 15, 2023 (https:\u002F\u002Fwww.fda.gov\u002Fsafety\u002Frecalls-market-withdrawals-safety-alerts\u002Fkilitch-healthcare-india-limited-issues-voluntary-nationwide-recall-various-eye-drops-potential), approximately three weeks after the initial discussion.\n\nDrug Production Suspended\n\nWe acknowledge your commitment to suspend production of all drugs for the U.S. market. In response to this letter, clarify whether you intend to resume manufacturing drugs for the U.S. market at this facility in the future.\n\nIf you plan to resume any manufacturing operations regulated under the FD&C Act, notify this office before resuming your drug manufacturing operations. You are responsible for resolving all deficiencies and systemic flaws to ensure your firm is capable of ongoing CGMP compliance. In your notification to the Agency, provide a summary of your remediations to demonstrate that you have appropriately completed all corrective action and preventive actions (CAPAs).\n\nCGMP Consultant Recommended\n\nBased upon the nature of the violations we identified at your firm, you should engage a consultant qualified as set forth in 21 CFR 211.34 to evaluate your operations and to assist your firm in meeting CGMP requirements if your firm intends to resume manufacturing drugs for the U.S. market. The qualified consultant should also perform a comprehensive six-system audit1 of your entire operation for CGMP compliance and evaluate the completion and efficacy of your corrective actions and preventive actions before you pursue resolution of your firm’s compliance status with FDA. Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\n\nConclusion\n\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\n\nFDA placed your firm on Import Alert 66-40 on October 23, 2023.\n\nCorrect any violations promptly. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to any violations.\n\nFailure to address any violations may also result in the FDA continuing to refuse admission of articles manufactured at Kilitch Healthcare India Limited, T T C Industrial Road, Navi Mumbai into the United States under section 801(a)(3) of the FD&C Act, 21 U.S.C. 381(a)(3). Articles under this authority that appear to be adulterated may be detained or refused admission, in that the methods and controls used in their manufacture do not appear to conform to CGMP within the meaning of section 501(a)(2)(B) of the FD&C Act, 21 U.S.C. 351(a)(2)(B).\n\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\n\nSend your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3011853060 and ATTN: Sarah Rhoades.\n\nSincerely,\n\n\u002FS\u002F\n\nFrancis Godwin\n\nDirector\n\nOffice of Manufacturing Quality\n\nOffice of Compliance\n\nCenter for Drug Evaluation and Research\n\n___________________\n\n1 i.e., Quality System, Facilities & Equipment System, Materials System, Production System, Packaging & Labeling System, and Laboratory Control System per FDA’s guidance document Quality Systems Approach to Pharmaceutical CGMP Regulations.","Kilitch Healthcare India Limited","kilitch-healthcare-india-limited-672956-03282024","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fkilitch-healthcare-india-limited-672956-03282024","2026-10-26T08:09:08.906666+00:00","2024-04-09","672956","Mr. Paresh Mehta","2026-08-20T00:11:39.349+00:00","2024-03-28",{"id":200,"raw":201,"subject":205,"body_html":206,"body_text":207,"firm_name":208,"letter_id":209,"created_at":69,"fei_number":20,"letter_url":210,"updated_at":211,"action_type":23,"case_status":24,"posted_date":212,"marcs_cms_no":213,"product_type":27,"closeout_date":20,"issuing_office":64,"recipient_name":214,"body_fetched_at":215,"delivery_method":138,"recipient_title":20,"reference_number":20,"action_taken_date":216,"medical_device_id":20,"response_letter_date":20},1748,[202,203,204,64,205,13,13,13],"\u003Ctime datetime=\"2023-11-14T14:20:00Z\">11\u002F14\u002F2023\u003C\u002Ftime>\n","\u003Ctime datetime=\"2023-10-20T04:00:00Z\">10\u002F20\u002F2023\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fglobal-pharma-healthcare-private-limited-657325-10202023\">Global Pharma Healthcare Private Limited\u003C\u002Fa>","CGMP\u002FFinished Pharmaceuticals\u002FAdulterated\u002FMisbranded","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Dr. A.R. Venkatesh\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Chief Executive Officer\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Global Pharma Healthcare Private Limited\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>A-9 SIDCO Pharmaceutical Complex\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Thiruporur\u003C\u002Fspan> \u003Cspan>603110\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Tamil Nadu\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>India\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research | CDER\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>Warning Letter \u003C\u002Fstrong>320-24-03\u003C\u002Fp>\n\n\u003Cp>October 20, 2023\u003C\u002Fp>\n\n\u003Cp>Dear Dr. Venkatesh:\u003C\u002Fp>\n\n\u003Cp>The U.S. Food and Drug Administration (FDA) inspected your drug manufacturing facility, Global Pharma Healthcare Private Limited, FEI 3012323885, at A-9 SIDCO Pharmaceutical Complex, Thiruporur, from February 20 to March 2, 2023.\u003C\u002Fp>\n\n\u003Cp>This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\u003C\u002Fp>\n\n\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\n\n\u003Cp>Because your drug products were prepared, packed, or held under insanitary conditions, whereby they may have become contaminated with filth or rendered injurious to health, your drug products are also adulterated within the meaning of section 501(a)(2)(A) of the FD&amp;C Act, 21 U.S.C. 351(a)(2)(A)\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup>.\u003C\u002Fp>\n\n\u003Cp>In addition, EZRICARE Artificial Tears, Delsam Pharma’s ARTIFICIAL TEARS, and Delsam Pharma’s ARTIFICIAL EYE OINTMENT are misbranded under section 502(j) of the FD&amp;C Act, 21 U.S.C. 352(j), and Delsam Pharma’s ARTIFICIAL EYE OINTMENT is further misbranded under section 502(a) of the FD&amp;C Act, 21 U.S.C. 352(a). Introduction or delivery for introduction of misbranded products into interstate commerce is prohibited under section 301(a) of the FD&amp;C Act, 21 U.S.C. 331(a). These violations are described in more detail below.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>\u003Cem>Pseudomonas aeruginosa\u003C\u002Fem> Outbreak and FDA Testing of Samples\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>In December 2022, FDA began collaborating with the Center for Disease Control and Prevention (CDC) on an investigation into the multistate outbreak of antibiotic-resistant \u003Cem>Pseudomonas aeruginosa\u003C\u002Fem> infections that ultimately affected more than 80 patients and led to 4 patient deaths and at least 14 cases of vision loss. As part of this investigation, FDA collected finished product samples of Artificial Tears and Artificial Eye Ointment batches that were manufactured by your facility, and we sent the samples for sterility testing at FDA laboratories. Our analysis of intact (unopened) units found that 18 batches of Artificial Tears were non-sterile. In addition, we also sampled a batch of your Artificial Eye Ointment product, and this batch was also found to be non-sterile. The testing of these intact units revealed that your ophthalmic drug products were intrinsically contaminated with microorganisms. Microbiological isolates from the non-sterile samples were further characterized using whole genome sequencing and compared to isolates in a national database.\u003Csup>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> \u003Cem>Pseudomonas aeruginosa\u003C\u002Fem> isolates from three different batches of intact Artificial Tears samples collected by FDA were found to be close genetic matches to more than 85 clinical isolates associated with this outbreak. These test results demonstrate that these lots are adulterated under section 501(a)(1) of the FD&amp;C Act, in that they have been contaminated with filth, and rendered injurious to health.\u003C\u002Fp>\n\n\u003Cp>Significantly, the pervasive contamination of your drug products, as indicated by FDA sample results, also demonstrates that all drugs made at your facility are adulterated under section 501(a)(2)(A) of the FD&amp;C Act as they have been manufactured under insanitary conditions.\u003C\u002Fp>\n\n\u003Cp>In addition, two intact samples of Artificial Tears from different batches were found to contain visible, foreign particles.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>CGMP Violations\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>We reviewed your March 22, 2023, response to our Form FDA 483 in detail. During our inspection, our investigators observed specific violations including, but not limited to, the following.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>1. Your firm failed to establish and follow appropriate written procedures that are designed to prevent microbiological contamination of drug products purporting to be sterile, and that include validation of all aseptic and sterilization processes (21 CFR 211.113(b)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>\u003Cem>Inadequate Equipment and Processes\u003C\u002Fem>\u003C\u002Fp>\n\n\u003Cp>A. You lacked adequate scientific evidence that the aseptic filling machine used for manufacture of Artificial Tears was suitable for its intended use. Your qualification report was inadequate, including a lack of data on any batches filled as part of the qualification study. Further, all batches of Artificial Tears distributed to the U.S. market were manufactured using filling machine parameters that were outside the design specifications of the equipment.\u003C\u002Fp>\n\n\u003Cp>B. You lacked validation of the processes used to manufacture your aseptically filled Artificial Tears, for example:\u003C\u002Fp>\n\n\u003Cp>• You failed to validate methods that were intended to render your ophthalmic drug products sterile. Specifically, you lacked a study to show the \u003Cstrong>(b)(4)\u003C\u002Fstrong> performed on your Artificial Tears product using a \u003Cstrong>(b)(4)\u003C\u002Fstrong> can reliably achieve sterilization.\u003C\u002Fp>\n\n\u003Cp>• Your media fill program lacked assurance that aseptic processing operations are appropriately performed to prevent microbial contamination. Our inspection found that you failed to perform appropriate and sufficient media fills studies, for example:\u003Cbr>\n&nbsp; &nbsp; o Your media fills failed to adequately simulate the commercial aseptic manufacturing operation. Interventions were not simulated sufficiently or accurately. In addition, you have a manually intensive line with minimal barrier protection where the possibility of contamination is greater. Despite this, you filled \u003Cstrong>(b)(4)\u003C\u002Fstrong>-\u003Cstrong>(b)(4)\u003C\u002Fstrong>% of the production batch size during media fills.\u003Cbr>\n&nbsp; &nbsp; o Manufacturing lines used to produce the Artificial Tears and Artificial Eye Ointment products were not qualified by three successful media fills.\u003Cbr>\n&nbsp; &nbsp; o You removed integral units (i.e., units with intact container-closure systems) from media fills without adequate justification and failed to incubate all integral units for the full \u003Cstrong>(b)(4)\u003C\u002Fstrong> period.\u003Cbr>\n&nbsp; &nbsp; o The personnel responsible for visual inspection of media-filled units lacked appropriate training and qualification.\u003C\u002Fp>\n\n\u003Cp>C. You lacked meaningful airflow pattern studies for your aseptic processing lines. The studies were not performed under dynamic conditions and lacked simulation of interventions and other routine activities that occur during aseptic manufacturing operations.\u003C\u002Fp>\n\n\u003Cp>D. Your firm also shipped an ointment product to the United States that was manufactured using a \u003Cstrong>(b)(4)\u003C\u002Fstrong> sterilization process. You failed to ensure the \u003Cstrong>(b)(4)\u003C\u002Fstrong> process employed by your contractor to sterilize your Artificial Eye Ointment was validated.\u003C\u002Fp>\n\n\u003Cp>Your response is inadequate, including the following:\u003C\u002Fp>\n\n\u003Cp>• You lack details of your internal investigation into the product contamination. Your investigation is not comprehensive, including but not limited to, a lack of descriptions of the activities performed and root cause analysis. You also lack details on sampling and laboratory methods used for environmental and other tests.\u003C\u002Fp>\n\n\u003Cp>• There is a lack of detail relating to future dynamic airflow pattern studies; heating, ventilation, and air conditioning (HVAC) system qualification; or media fill procedural revisions.\u003C\u002Fp>\n\n\u003Cp>• You also fail to include a commitment to validate the \u003Cstrong>(b)(4)\u003C\u002Fstrong> sterilization process and sterility test methods for the Artificial Eye Ointment products.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>Lack of Container Closure Integrity\u003C\u002Fem>\u003C\u002Fp>\n\n\u003Cp>You lacked evidence of reliable container closure integrity for your multi-use ophthalmic products that purport to be sterile. While visual inspections revealed leakers during batch manufacture, there was no assurance that your visual inspection procedure was adequate.\u003C\u002Fp>\n\n\u003Cp>Your product distributors received complaints of leaking Artificial Tears and Artificial Eye Ointment units. FDA’s laboratory performed container closure integrity testing of Artificial Eye Ointment, batch H29, manufactured at your facility. FDA tested 20 units, and 1 unit was found to allow microbiological ingress, which further confirmed that your container-closure system lacks integrity and is insufficient for maintaining sterility. Notably, batch H29 was also found to be non-sterile through FDA testing.\u003C\u002Fp>\n\n\u003Cp>All sterile drugs must be packaged using a container-closure system that protects product integrity for the duration of its shelf-life. Maintenance of product integrity throughout stresses of its manufacture, storage, distribution, and consumer use is critical to product quality and safety. Loss of container-closure integrity is a direct cause of non-sterility of medicines.\u003C\u002Fp>\n\n\u003Cp>In your response, you state you will perform container-closure integrity testing using a dye ingress method for your Artificial Tears product and a comprehensive sterility assessment. Your response is inadequate because your container-closure integrity testing protocol does not extend to Artificial Eye Ointment. In addition, you do not sufficiently address the sensitivity of your dye ingress method. The sensitivity of the method to be employed for your study is unclear, and you do not indicate whether it is capable of correlating with detection of bacteria comparable in size to\u003Cem> Pseudomonas aeruginosa\u003C\u002Fem>. Furthermore, your response does not include details on the comprehensive sterility assessment.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>Inadequate Formulation for Artificial Tears and Artificial Eye Ointment\u003C\u002Fem>\u003C\u002Fp>\n\n\u003Cp>You manufactured multi-dose, over-the-counter (OTC) ophthalmic drug products for the product owners, EzriCare LLC, and Delsam Pharma LLC. These products lacked antimicrobial properties to preserve the formulation. Significantly, your firm also marketed this multi-dose product without performing antimicrobial effectiveness studies. It is essential that multi-dose ophthalmic drug products contain one or more suitable substances that will preserve the product and minimize the hazard of injury resulting from incidental contamination during use.\u003C\u002Fp>\n\n\u003Cp>In your response, you state that antimicrobial effectiveness testing (AET) will be initiated for your Artificial Tears product, and you will use these studies to determine if a suitable preservative will be added to the formulation. Your response is inadequate because you do not explain why you failed to perform AET studies prior to launch of your drug product, and how you will correct such fundamental flaws in your product development program. You also make no commitment to conduct AET for the Artificial Eye Ointment formulation. In addition, although your protocol indicates that you follow the United States Pharmacopeia (USP), the acceptance criteria in the Artificial Tears protocol is less stringent and not in alignment with USP &lt;51&gt; \u003Cem>Antimicrobial Effectiveness Testing\u003C\u002Fem>.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>Inadequate Gowning Practices &amp; Operator Qualification\u003C\u002Fem>\u003C\u002Fp>\n\n\u003Cp>Cleanroom operators lacked adequate gowning and qualification for performing aseptic operations. Your deficient practices and procedures placed products at high risk for contamination, for example:\u003C\u002Fp>\n\n\u003Cp>A. A gowning demonstration revealed that cleanroom operators do not don sterile goggles and therefore have exposed skin around their eyes during aseptic operations.\u003C\u002Fp>\n\n\u003Cp>B. Cleanroom garments were not suitable for their intended use. For example, garments indicated to be clean were observed to be stained, worn out, and stored improperly. In addition, your firm re-used cleanroom garments for an unspecified number of times without tracking or validation.\u003C\u002Fp>\n\n\u003Cp>C. You lacked written procedures and a training program on proper aseptic behavior and gowning for cleanroom operators. You also lacked evidence that all cleanroom operators are qualified through participation in a media fill, and the microbiological limit set in your gowning validation procedure is unsuitable for aseptic operations.\u003C\u002Fp>\n\n\u003Cp>D. You lacked written procedures and a training program on proper aseptic behavior and gowning for cleanroom operators. You also lacked evidence that all cleanroom operators were qualified through participation in a media fill and justification for the microbiological limits used in your aseptic processing operator gowning qualification procedure (i.e., no more than (NMT) \u003Cstrong>(b)(4)\u003C\u002Fstrong> colony forming units (cfu) for each gowning location). You also lacked a commitment to systematically review staff qualifications and competencies throughout your operation, including but not limited to, ensuring an effective CGMP training program.\u003C\u002Fp>\n\n\u003Cp>In your response, you state that gowning qualification will be performed through media fills, and an in-house study will evaluate the impact of repeated sterilization cycles on cleanroom garments to establish an acceptable number of sterilization cycles. Your response is inadequate. You lack a comprehensive review of all aspects of personnel gowning, the qualification program, aseptic technique, cleanroom behavior, and an examination of the role of people as a contamination hazard in your processes. To further illustrate, you continue to lack substantive actions to implement sterile goggles, enhance practices to prevent sterile gown contamination, gowning qualification criteria (e.g., sampling requirements, location descriptions, acceptance limits with justifications), and many other basic elements of a compliant sterile facility. Your response also fails to address how your inadequate gowning practices impacted your sterile drug products.\u003Cbr>\nSee FDA’s guidance document \u003Cem>Sterile Drug Products Produced by Aseptic Processing—Current Good Manufacturing Practice\u003C\u002Fem> to help you meet the CGMP requirements when manufacturing sterile drugs using aseptic processing at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71026\u002Fdownload.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide the following:\u003C\u002Fp>\n\n\u003Cp>• Comprehensive risk assessment of all contamination hazards with respect to your aseptic processes, equipment, and facilities, including an independent assessment that includes, but is not limited to:\u003Cbr>\n&nbsp; &nbsp; o All human interactions within the ISO 5 area\u003Cbr>\n&nbsp; &nbsp; o Equipment placement and ergonomics\u003Cbr>\n&nbsp; &nbsp; o Air quality in the ISO 5 area and surrounding room\u003Cbr>\n&nbsp; &nbsp; o Facility layout\u003Cbr>\n&nbsp; &nbsp; o Personnel Flows and Material Flows (throughout all rooms used to conduct and support sterile operations)\u003C\u002Fp>\n\n\u003Cp>• A detailed remediation plan with timelines to address the findings of the independent contamination hazards risk assessment. Describe specific tangible improvements to be made to aseptic processing operation design and control at your facility. Explain how your corrective action and preventive action (CAPA) will robustly remediate your deficient sterile manufacturing operation. Also describe your plans for qualification and validation of your comprehensively remediated facility, processes and equipment.\u003C\u002Fp>\n\n\u003Cp>• A remediation plan that better assures ongoing management oversight throughout the manufacturing lifecycle of all drug products. Provide a more data-driven and scientifically sound program that identifies sources of process variability and assures that manufacturing (including both production and packaging) operations meet appropriate parameters and quality standards. This includes, but is not limited to, evaluating suitability of equipment for its intended use, ensuring quality of input materials, determining the capability and reliability of each manufacturing process step and its controls, and vigilant ongoing monitoring of process performance and product quality.\u003C\u002Fp>\n\n\u003Cp>• Your CAPA plan to implement routine, vigilant operations management oversight of facilities and equipment. This plan should ensure, among other things, prompt detection of equipment\u002Ffacilities performance issues, effective execution of repairs, adherence to appropriate preventive maintenance schedules, timely technological upgrades to the equipment\u002Ffacility infrastructure, and improved systems for ongoing management review.\u003C\u002Fp>\n\n\u003Cp>• Your plan to ensure that inspection and other quality control methods for container-closure systems, including but not limited to opaque bottles and ointment tubes, can robustly detect integrity breaches.\u003C\u002Fp>\n\n\u003Cp>• A comprehensive, independent assessment of the qualifications and competencies of staff to conduct their job duties throughout your operations, including:\u003Cbr>\n&nbsp; &nbsp; o a system that ensures each staff member receives training to enable them to properly perform each of their job duties in advance of performing job tasks\u003Cbr>\n&nbsp; &nbsp; o a review of your training curriculum, including courses, timing, frequency, and training effectiveness\u003Cbr>\n&nbsp; &nbsp; o supervision to determine ongoing adherence of staff to procedures and proper practices\u003Cbr>\n&nbsp; &nbsp; o provisions for retraining in response to deficient performance or, when appropriate, re-evaluating whether the individual has the appropriate qualifications and expertise (training, education, skills) for the type and complexity of their assigned work\u003Cbr>\n&nbsp; &nbsp; o training of supervisors and managers in CGMPs\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>2. Your firm failed to test samples of each component for identity and conformity with all appropriate written specifications for purity, strength, and quality. Your firm also failed to validate and establish the reliability of your component supplier’s test analyses at appropriate intervals (21 CFR 211.84(d)(1) and 211.84(d)(2)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>You did not ensure that incoming lots of active pharmaceutical ingredient (API) and packaging materials were suitable for use in manufacturing.\u003C\u002Fp>\n\n\u003Cp>Your firm released API for use in drug manufacturing based on a component supplier’s certificate of analysis (COA), although you neither established the reliability of the analysis through appropriate validation nor performed identity testing. Notably, examples included two lots of carboxy methyl cellulose sodium API used to manufacture Artificial Tears batches distributed to the U.S. market.\u003C\u002Fp>\n\n\u003Cp>You also failed to adequately test primary packaging materials, including caps and plugs, used in the Artificial Tears container-closure system. For example, between 2019 and 2022, you received \u003Cstrong>(b)(4)\u003C\u002Fstrong> shipments of caps and plugs supplied as sterile from a vendor and released them for use based on the supplier’s COA without adequate testing.\u003C\u002Fp>\n\n\u003Cp>Identity testing for each component lot used in drug product manufacturing is required, and you may only rely on COA for other component attributes if you validate the supplier’s test results to ensure their reliability at appropriate intervals.\u003C\u002Fp>\n\n\u003Cp>A drug product produced by aseptic processing can become contaminated not only by unacceptable practices in the manufacturing operation, but also due to the use of one or more defective components, containers, or closures.\u003C\u002Fp>\n\n\u003Cp>Your response is inadequate for reasons that include, but are not limited to, the following:\u003C\u002Fp>\n\n\u003Cp>• You fail to indicate that all existing and new suppliers will be qualified.\u003C\u002Fp>\n\n\u003Cp>• It lacks details on procedural revisions to be made, including how you intend to establish and maintain assurance of the reliability of your supplier’s COA.\u003C\u002Fp>\n\n\u003Cp>• It also lacks details on your retrospective testing, including the scope of materials to be tested, sampling and testing methods, and how you intend to ensure that incoming materials are suitable for their intended use.\u003C\u002Fp>\n\n\u003Cp>We also note that you listed drug products with FDA as being manufactured at your facility and intended for distribution in the United States, including paracetamol syrup, clotrimazole 1%, and Diaprene Children Maximum Topical Creams, that contain components with a high risk of diethylene glycol (DEG) or ethylene glycol (EG) contamination, such as glycerin and propylene glycol. The use of ingredients contaminated with DEG or EG has resulted in various lethal poisoning incidents in humans worldwide. See FDA’s guidance document \u003Cem>Testing of Glycerin, Propylene Glycol, Maltitol Solution, Hydrogenated Starch Hydrolysate, Sorbitol Solution, and Other High-Risk Drug Components for Diethylene Glycol and Ethylene Glycol \u003C\u002Fem>to help you meet the CGMP requirements when manufacturing drugs containing ingredients at high-risk for DEG or EG contamination (“high-risk drug components”), at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F167974\u002Fdownload.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide the following:\u003Cbr>\n\u003Cbr>\n• A comprehensive, independent review of your material system to determine whether all suppliers of components, containers, and closures, are each qualified and the materials are assigned appropriate expiration or retest dates. The review should also determine whether incoming material controls are adequate to prevent use of unsuitable components, containers, and closures.\u003C\u002Fp>\n\n\u003Cp>• The chemical and microbiological quality control specifications you use to test and release each incoming lot of components for use in manufacturing.\u003C\u002Fp>\n\n\u003Cp>• A summary of results obtained from testing all components to evaluate the reliability of the COA from each component manufacturer. Include your standard operating procedure (SOP) that describes this COA validation program.\u003C\u002Fp>\n\n\u003Cp>• A summary of your program for qualifying and overseeing contract facilities that test the drug products you manufacture.\u003C\u002Fp>\n\n\u003Cp>• A commitment to provide DEG and EG test results, no later than 30 calendar days from the date of this letter, from testing retains for all lots of high-risk drug components used in the manufacture of drug products. Alternatively, if a retain of a component lot is unavailable, perform retain sample testing of all potentially affected finished drug product batches for the presence of DEG and EG.\u003C\u002Fp>\n\n\u003Cp>• A full risk assessment for drug products that are within expiry which contain any ingredient at risk for DEG or EG contamination (including but not limited to glycerin). Take prompt and appropriate actions to determine the safety of all lots of the component(s) and any related drug product that could contain DEG or EG, including customer notifications and product recalls for any contaminated lots. Identify additional appropriate corrective actions and preventive actions that secure supply chains in the future, including but not limited to ensuring that all incoming raw material lots are from fully qualified manufacturers and free from unsafe impurities. Detail these actions in your response to this letter.\u003C\u002Fp>\n\n\u003Cp>• A description of how you will test each component lot for conformity with all appropriate specifications for identity, strength, quality, and purity. If you intend to accept any results from your supplier’s COA instead of testing each component lot for strength, quality, and purity, specify how you will robustly establish the reliability of your supplier’s results through initial validation as well as periodic revalidation. In addition, include a commitment to always conduct at least one specific identity test for each incoming component lot. In the case of glycerin, propylene glycol, and certain additional high-risk components we note that this includes the performance of parts A, B, and C of the United States Pharmacopeia (USP) monograph.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>3. Your firm failed to establish a system for monitoring environmental conditions in aseptic processing areas and an adequate system for cleaning and disinfecting the room to produce aseptic conditions (21 CFR 211.42(c)(10)(iv) and 211.42(c)(10)(v)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>\u003Cem>Sterilization and Cleaning\u003C\u002Fem>\u003Cbr>\n\u003Cbr>\nYou failed to adequately sterilize and clean your equipment used for drug product manufacturing, for example:\u003C\u002Fp>\n\n\u003Cp>A. You failed to ensure that all equipment with direct product contact was sterilized. During the inspection, you were not able to provide records showing sterilization of product contact equipment on the “\u003Cstrong>(b)(4)\u003C\u002Fstrong> Line,” including the filling \u003Cstrong>(b)(4)\u003C\u002Fstrong>, \u003Cstrong>(b)(4)\u003C\u002Fstrong> tubing, and \u003Cstrong>(b)(4)\u003C\u002Fstrong> bowls. Review of sterilization records revealed that you only documented that garments and tools were sterilized. You also lacked written procedures describing sterilization of the manufacturing equipment.\u003C\u002Fp>\n\n\u003Cp>B. You failed to adequately clean the equipment used to aseptically produce Artificial Tears. Significantly, our investigators observed visible grease-like residue on product contact surfaces of your filling machine after they had been cleaned.\u003C\u002Fp>\n\n\u003Cp>You also lacked written procedures and other documentation describing cleaning of the manufacturing equipment.\u003C\u002Fp>\n\n\u003Cp>C. You lacked cleaning validation studies for the shared manufacturing equipment on the “\u003Cstrong>(b)(4)\u003C\u002Fstrong> Line.”\u003C\u002Fp>\n\n\u003Cp>Inadequately cleaned and maintained equipment can lead to cross-contamination and poor quality drug products.\u003C\u002Fp>\n\n\u003Cp>Your response is inadequate for reasons that include, but are not limited to, the following:\u003C\u002Fp>\n\n\u003Cp>• You fail to provide cleaning procedures or cleaning validation protocols. In addition, no commitment is made to comprehensively evaluate the suitability of your filling machine and other equipment for the manufacture of sterile drug products.\u003C\u002Fp>\n\n\u003Cp>• You fail to provide details of your proposed testing of retain samples.\u003C\u002Fp>\n\n\u003Cp>• You fail to provide explanations for the conflicting information provided to FDA investigators during the inspection. For example, investigators were initially told that \u003Cstrong>(b)(4)\u003C\u002Fstrong> bowls on the filling line were not cleaned or sterilized. These statements were later retracted; however, you were unable to provide sufficient information to support claims that \u003Cstrong>(b)(4)\u003C\u002Fstrong> bowls were cleaned and sterilized.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>Monitoring Environmental Conditions\u003C\u002Fem>\u003C\u002Fp>\n\n\u003Cp>Your environmental monitoring (EM) program (including personnel monitoring (PM)) was inadequate for classified areas used to produce sterile ophthalmic drug products. For example, non-viable air samples were not collected inside the Grade A filling zone or the Grade B surrounding areas during active filling, you lacked studies to demonstrate that residual disinfectant would not interfere with the swabs used for viable surface monitoring, and you lacked identification data on isolates recovered from EM and PM sampling.\u003Cbr>\n\u003Cbr>\nVigilant and responsive environmental and personnel monitoring programs should be designed to provide meaningful information on the state of control of your aseptic processing environment. Operations that include highly manually intensive aseptic activities warrant a more extensive environmental and personnel monitoring program, including but not limited to, heightened emphasis on well-timed sampling to appropriately monitor batch manufacturing conditions.\u003C\u002Fp>\n\n\u003Cp>In your response, you mention a limited number of environmental samples taken in January 2023 were sent to a third-party laboratory and these samples did not reveal Pseudomonas aeruginosa in your environment. This response is inadequate. The last batches of Artificial Tears shipped to the United States had been manufactured many months before (in April 2022) your limited sampling was conducted, according to records provided by your firm. Environmental sampling that occurs several months after batch manufacture is of little temporal significance. There is also minimal scientific value in testing sterile drug manufacturing areas solely for the presence of a single microbial species. You also had batch retain samples tested by a third-party laboratory and you reported in your response that these samples did not fail sterility testing. However, it is not unexpected that sterility testing of retains of otherwise contaminated batches may pass sterility testing because of the non-uniform nature of microbiological contamination. As noted above, many of your firm’s batches were found to be non-sterile upon FDA testing and were associated with grave adverse events.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide the following:\u003C\u002Fp>\n\n\u003Cp>• A comprehensive, independent assessment of the design and control of your firm’s manufacturing operations, with a detailed and thorough review of all microbiological hazards.\u003C\u002Fp>\n\n\u003Cp>• A comprehensive, independent retrospective assessment of your cleaning effectiveness to evaluate the scope of cross-contamination hazards. Include the identity of residues, other manufacturing equipment that may have been improperly cleaned, and an assessment whether cross-contaminated products may have been released for distribution. The assessment should identify any inadequacies of cleaning procedures and practices and encompass each piece of manufacturing equipment used to manufacture more than one product.\u003C\u002Fp>\n\n\u003Cp>• A CAPA plan, based on the retrospective assessment of your cleaning and disinfection program, that includes appropriate remediations to your cleaning and disinfection processes and practices, and timelines for completion. Provide a detailed summary of vulnerabilities in your process for lifecycle management of equipment cleaning and disinfection. Describe improvements to your cleaning and disinfection program, including enhancements to cleaning effectiveness; improved ongoing verification of proper cleaning and disinfection execution for all products and equipment; and all other needed remediations.\u003C\u002Fp>\n\n\u003Cp>• Appropriate improvements to your cleaning validation program, with special emphasis on incorporating conditions identified as worst case in your drug manufacturing operation. This should include but not be limited to identification and evaluation of all worst-case:\u003Cbr>\n&nbsp; &nbsp; o Drugs with higher toxicities\u003Cbr>\n&nbsp; &nbsp; o Drugs with higher drug potencies\u003Cbr>\n&nbsp; &nbsp; o Drugs of lower solubility in their cleaning solvents\u003Cbr>\n&nbsp; &nbsp; o Drugs with characteristics that make them difficult to clean\u003Cbr>\n&nbsp; &nbsp; o Swabbing locations for areas that are most difficult to clean\u003Cbr>\n&nbsp; &nbsp; o Maximum hold times before cleaning\u003C\u002Fp>\n\n\u003Cp>In addition, describe the steps that must be taken in your change management system before introduction of new manufacturing equipment or a new product.\u003C\u002Fp>\n\n\u003Cp>• A summary of updated SOPs that ensure an appropriate program is in place for verification and validation of cleaning procedures for products, processes, and equipment.\u003C\u002Fp>\n\n\u003Cp>• A comprehensive, independent review of your personnel and environmental monitoring programs, including but not limited to, a plan to fully remediate these programs. For example, describe changes to equipment, procedures, and practices that will ensure meaningful ongoing data is collected to promptly detect and respond to emerging risks in your classified areas. Provide an updated timeline for implementation of your program, including a summary of the CAPA steps you will be undertaking to ensure effective remediation.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>4. Your firm failed to establish the accuracy, sensitivity, specificity, and reproducibility of its test methods, and you also failed to conduct appropriate laboratory testing to determine whether each batch of drug product purporting to be sterile conforms to such requirements (21 CFR 211.165(e) and 211.167(a)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your firm lacked adequate sterility testing, for example:\u003C\u002Fp>\n\n\u003Cp>A. You failed to show that your sterility test method was suitable to detect microorganisms in your ophthalmic drug products.\u003C\u002Fp>\n\n\u003Cp>Method suitability testing ensures the method can reliably determine the presence of microbial growth in the product. Method validation and verification is necessary to support reliable determinations of identity, strength, quality, purity, and potency of drugs. Without evaluating the validity of methods, you lack the basic assurance that the data provided to customers was an accurate reflection of pharmaceutical product quality and safety.\u003C\u002Fp>\n\n\u003Cp>B. You lacked growth promotion tests of the media used for media fills and personnel monitoring.\u003C\u002Fp>\n\n\u003Cp>The validity of your microbiological testing cannot be ensured without appropriate testing of media.\u003C\u002Fp>\n\n\u003Cp>In your response, you make commitments to review your sterility testing and other analytical method validations, initiate sterility method verification, and revise your media preparation procedures. Your response is inadequate because you fail to provide revised procedures and you do not address your failure to perform adequate sterility testing on your distributed finished drug products.\u003Cbr>\n\u003Cbr>\nIn response to this letter, provide the following:\u003C\u002Fp>\n\n\u003Cp>• A comprehensive, independent assessment of your laboratory practices, procedures, methods, equipment, documentation, and analyst competencies. Based on this review, provide a detailed plan to remediate and evaluate the effectiveness of your laboratory system.\u003C\u002Fp>\n\n\u003Cp>• A detailed risk assessment addressing the hazards posed by distributing contaminated drug products.\u003C\u002Fp>\n\n\u003Cp>• Complete investigations into all batches with confirmed and potential microbial contamination. The investigations should detail your findings regarding the root causes of the contamination.\u003C\u002Fp>\n\n\u003Cp>• All chemical and microbial test methods used to analyze each of your drug products.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>5. Your firm’s quality control unit failed to exercise its responsibility to ensure drug products manufactured are in compliance with CGMP, and meet established specifications for identity, strength, quality, and purity (21 CFR 211.22).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your firm failed to establish an adequate quality unit (QU) with the responsibilities and authority to oversee the manufacture of your drug products. For example:\u003C\u002Fp>\n\n\u003Cp>A. You failed to perform adequate batch release to ensure the acceptability of all batches of Artificial Tears, prior to release for the U.S. market.\u003C\u002Fp>\n\n\u003Cp>B. Your quality system does not adequately ensure the accuracy and integrity of data to support the quality of the drugs you manufacture. For example, your firm permitted the unacceptable practice of using pre-filled batch release documents.\u003C\u002Fp>\n\n\u003Cp>C. You failed to follow your change management procedure. The impact of the change to the specification for the inner cap (plug) used as part of your Artificial Tears container-closure system to a plug “with prehole” was not evaluated.\u003C\u002Fp>\n\n\u003Cp>In your response, you state you will perform an impact assessment for all change controls initiated. Your response is inadequate for reasons that include, but are not limited to, the following:\u003C\u002Fp>\n\n\u003Cp>• You do not assess all records potentially affected by lapses in data integrity. You also do not assess how poor documentation practices affected distributed drug product nor how you could strengthen QU oversight. You also do not provide copies of the missing batch release documents you indicated that you have now recovered.\u003C\u002Fp>\n\n\u003Cp>• You do not perform a review and impact assessment for changes made outside of your change management system and not previously evaluated.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide the following:\u003C\u002Fp>\n\n\u003Cp>• A comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\u003Cbr>\n&nbsp; &nbsp; o A determination of whether procedures used by your firm are robust and appropriate\u003Cbr>\n&nbsp; &nbsp; o Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices\u003Cbr>\n&nbsp; &nbsp; o A complete and final review of each batch and its related information before the QU disposition decision\u003Cbr>\n&nbsp; &nbsp; o Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products\u003C\u002Fp>\n\n\u003Cp>Also describe how top management supports quality assurance and reliable operations, including but not limited to, timely provision of resources to proactively address emerging manufacturing\u002Fquality issues and to assure a continuing state of control.\u003C\u002Fp>\n\n\u003Cp>• A comprehensive, independent assessment of your change management system. This assessment should include, but not be limited to, your procedure(s) to ensure changes are justified, reviewed, and approved by your quality unit. Your change management program should also include provisions for determining change effectiveness.\u003C\u002Fp>\n\n\u003Cp>• A complete assessment of documentation systems used throughout your manufacturing and laboratory operations to determine where documentation practices are insufficient. Include a detailed CAPA plan that comprehensively remediates your firm’s documentation practices to ensure you retain attributable, legible, complete, original, accurate, contemporaneous records throughout your operation.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Data Integrity Remediation\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your quality system does not adequately ensure the accuracy and integrity of data to support the safety, effectiveness, and quality of the drugs you manufacture. See FDA’s guidance document \u003Cem>Data Integrity and Compliance With Drug CGMP: Questions and Answers\u003C\u002Fem> for guidance on establishing and following CGMP-compliant data integrity practices at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F119267\u002Fdownload.\u003C\u002Fp>\n\n\u003Cp>Your firm should retain a qualified consultant to assist in your remediation. In response to this letter, provide:\u003C\u002Fp>\n\n\u003Cp>A. A comprehensive investigation into the extent of the inaccuracies in data records and reporting including results of the data review for drugs distributed to the United States. Include a detailed description of the scope and root causes of your data integrity lapses.\u003C\u002Fp>\n\n\u003Cp>B. A current risk assessment of the potential effects of the observed failures on the quality of your drugs. Your assessment should include analyses of the risks to patients caused by the release of drugs affected by a lapse of data integrity and analyses of the risks posed by ongoing operations.\u003C\u002Fp>\n\n\u003Cp>C. A management strategy for your firm that includes the details of your global CAPA plan. The detailed corrective action plan should describe how you intend to ensure the reliability and completeness of all data generated by your firm including microbiological and analytical data, manufacturing records, and all data submitted to FDA.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Misbranded Drug Violations\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>EZRICARE Artificial Tears, Delsam Pharma’s ARTIFICIAL TEARS, and Delsam Pharma’s ARTIFICIAL EYE OINTMENT are “drugs” as defined by section 201(g)(1)(B) of the FD&amp;C Act, 21 U.S.C. 321(g)(1)(B), because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and\u002For under section 201(g)(1)(C) of the FD&amp;C Act, 21 U.S.C. 321(g)(1)(C), because they are intended to affect the structure or any function of the body. Specifically, EZRICARE Artificial Tears and Delsam Pharma’s ARTIFICIAL TEARS are intended for use as ophthalmic demulcents, and Delsam Pharma’s ARTIFICIAL EYE OINTMENT is intended for use as an ophthalmic emollient.\u003C\u002Fp>\n\n\u003Cp>Examples of claims from your product labeling that provide evidence of the intended uses (as defined by 21 CFR 201.128) of your products as drugs include, but may not be limited to, the following:\u003C\u002Fp>\n\n\u003Cp>EZRICARE Artificial Tears\u003Cbr>\n“Drug Facts . . . Uses . . . ■ for use as a protectant against further irritation or to relieve dryness of the eye ■ for the temporary relief of discomfort due to minor irritations of the eye, or to exposure to wind or sun” [from your product’s label]\u003C\u002Fp>\n\n\u003Cp>Delsam Pharma’s ARTIFICIAL TEARS\u003Cbr>\n“Drug Facts . . . Uses . . . ■ for use as a protectant against further irritation or to relieve dryness of the eye ■ for the temporary relief of discomfort due to minor irritations of the eye, or to exposure to wind or sun” [from your product’s label]\u003C\u002Fp>\n\n\u003Cp>Delsam Pharma’s ARTIFICIAL EYE OINTMENT\u003Cbr>\n“Drug Facts . . . Uses . . . For use as a lubricant to prevent further irritation or to relieve dryness of the eyes.” [from your product’s label]\u003C\u002Fp>\n\n\u003Cp>EZRICARE Artificial Tears, Delsam Pharma’s ARTIFICIAL TEARS, and Delsam Pharma’s ARTIFICIAL EYE OINTMENT are misbranded under section 502(j) of the FD&amp;C Act, 21 U.S.C. 352(j), because they are not sterile. 21 CFR 200.50 states that all preparations offered or intended for ophthalmic use should be sterile, and if not are deemed misbranded under section 502(j) of the FD&amp;C Act.\u003Csup>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> However, FDA analysis of samples of EZRICARE Artificial Tears, Delsam Pharma’s ARTIFICIAL TEARS, and Delsam Pharma’s ARTIFICIAL EYE OINTMENT determined that these products were contaminated with microorganisms. For example, microorganisms in your products included but were not limited to the following: EZRICARE Artificial Tears contained \u003Cem>Pseudomonas\u003C\u002Fem> species, Delsam Pharma’s ARTIFICIAL TEARS contained \u003Cem>Bacillus\u003C\u002Fem> species, and Delsam Pharma’s ARTIFICIAL EYE OINTMENT contained \u003Cem>Burkholderia cepacia\u003C\u002Fem> complex. There is a reasonable probability that instillation of a bacterially contaminated eye product into the eye may cause a range of ocular infections, from minor to serious, vision-threatening infections which could progress in some cases to life-threatening systemic bacterial infection. Therefore, EZRICARE Artificial Tears, Delsam Pharma’s ARTIFICIAL TEARS, and Delsam Pharma’s ARTIFICIAL EYE OINTMENT are misbranded under section 502(j) of the FD&amp;C Act, 21 U.S.C. 352(j).\u003C\u002Fp>\n\n\u003Cp>In addition, Delsam Pharma’s ARTIFICIAL EYE OINTMENT is further misbranded under section 502(a) of the FD&amp;C Act, 21 U.S.C 352(a), because its labeling is false or misleading. Specifically, the principal display panel (PDP) of the product label purports the product to be “sterile.” However, FDA analysis of samples of Delsam Pharma’s ARTIFICIAL EYE OINTMENT determined that it was contaminated with microorganisms including \u003Cem>Burkholderia cepacia\u003C\u002Fem> complex. Therefore, the labeling for Delsam Pharma’s ARTIFICIAL EYE OINTMENT is false or misleading, because the product is not in fact sterile for its intended use as an ophthalmic emollient drug product, and thus the product is misbranded under section 502(a) of the FD&amp;C Act, 21 U.S.C. 352(a).\u003C\u002Fp>\n\n\u003Cp>The introduction or delivery for introduction of a misbranded drug into interstate commerce is prohibited under section 301(a) of the FD&amp;C Act, 21 U.S.C. 331(a).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Drug Recalls\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>On January 30, 2023, FDA held a teleconference with you. We recommended you consider removing all batches of EzriCare Artificial Tears and Delsam Pharma’s Artificial Tears in distribution from the U.S. market. On February 2, 2023, you initiated a voluntary recall of EzriCare Artificial Tears and Delsam Pharma’s Artificial Tears based on bacterial contamination and CGMP concerns discussed with your firm. The company announcement was posted to the FDA website: https:\u002F\u002Fwww.fda.gov\u002Fsafety\u002Frecalls-market-withdrawals-safety-alerts\u002Fglobal-pharma-healthcare-issues-voluntary-nationwide-recall-artificial-tears-lubricant-eye-drops-due.\u003C\u002Fp>\n\n\u003Cp>On February 22, 2023, FDA held another teleconference with you. We recommended you remove batch H29 of Delsam Pharma’s Artificial Eye Ointment in U.S. distribution. On February 24, 2023, you initiated a voluntary recall of Delsam Pharma’s Artificial Eye Ointment due to non-sterility. The company announcement was posted to the FDA website: https:\u002F\u002Fwww.fda.gov\u002Fsafety\u002Frecalls-market-withdrawals-safety-alerts\u002Fglobal-pharma-healthcare-issues-voluntary-nationwide-recall-delsam-pharma-artificial-eye-ointment.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Drug Production Suspended\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>We acknowledge your commitment to suspend production of drugs for the U.S. market.\u003C\u002Fp>\n\n\u003Cp>Given the egregious violations of CGMP at your facility, if you plan to resume drug manufacturing operations for the U.S. market, decide to transfer your ownership, contract out any processes, or move to a new location, notify this office.\u003C\u002Fp>\n\n\u003Cp>Based upon the nature of the violations we identified at your firm, you should engage a consultant qualified as set forth in 21 CFR 211.34, to assist your firm in meeting drug CGMP requirements, if your firm intends to resume manufacturing drugs for the U.S. market. The qualified consultant should also perform a comprehensive six-system audit\u003Csup>\u003Cem>\u003Cstrong>4\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> of your entire operation for CGMP compliance and evaluate the completion and efficacy of all corrective actions and preventive actions before you pursue resolution of your firm’s compliance status with FDA.\u003C\u002Fp>\n\n\u003Cp>Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Responsibilities as a Contractor\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Drugs must be manufactured in conformance with CGMP. FDA is aware that many drug manufacturers use independent contractors such as production facilities, testing laboratories, packagers, and labelers. FDA regards contractors as extensions of the manufacturer.\u003C\u002Fp>\n\n\u003Cp>You are responsible for the quality of drugs you produce as a contract facility regardless of agreements in place with product owners. You are required to ensure that drugs are made in accordance with section 501(a)(2)(B) of the FD&amp;C Act for safety, identity, strength, quality, and purity. See FDA’s guidance document \u003Cem>Contract Manufacturing Arrangements for Drugs: Quality Agreements\u003C\u002Fem> at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F86193\u002Fdownload.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Ineffective Quality System\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Significant findings in this letter demonstrate that your firm does not operate an effective quality system in accord with CGMP. In addition to a severe lack of effective production oversight of facilities and equipment, we found your quality unit is not enabled to exercise proper authority and has insufficiently implemented its responsibilities. You should immediately and comprehensively assess your company’s global manufacturing operations to ensure that systems, processes, and the products manufactured conform to FDA requirements.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\u003C\u002Fp>\n\n\u003Cp>FDA placed your firm on Import Alert 66-40 on January 3, 2023, after your response to our 704(a)(4) Request for Records sent to you on November 15, 2022, demonstrated CGMP violations related to controls for DEG\u002FEG in high-risk components used in your drugs.\u003C\u002Fp>\n\n\u003Cp>The inspectional findings and sample results detailed above further demonstrate your firm’s noncompliance.\u003C\u002Fp>\n\n\u003Cp>Your firm remains on Import Alert 66-40.\u003C\u002Fp>\n\n\u003Cp>Correct any violations promptly. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to any violations.\u003C\u002Fp>\n\n\u003Cp>Failure to address any violations may also result in the FDA continuing to refuse admission of articles manufactured at Global Pharma Healthcare Private Limited, A-9 SIDCO Pharmaceutical Complex, Thiruporur, into the United States under section 801(a)(3) of the FD&amp;C Act, 21 U.S.C. 381(a)(3). Articles under this authority that appear to be adulterated or misbranded may be detained or refused admission, in that the methods and controls used in their manufacture do not appear to conform to CGMP within the meaning of section 501(a)(2)(B) of the FD&amp;C Act, 21 U.S.C. 351(a)(2)(B) and are misbranded under section 502 of the FD&amp;C Act, respectively.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion\u003C\u002Fp>\n\n\u003Cp>Send your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3012323885 and ATTN: Carrie Ann Plucinski.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Francis Godwin\u003Cbr>\nDirector\u003Cbr>\nOffice of Manufacturing Quality\u003Cbr>\nOffice of Compliance\u003Cbr>\nCenter for Drug Evaluation and Research\u003C\u002Fp>\n\n\u003Cp>____________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> 21 CFR 200.50(a)(2) states, in relevant part, “…liquid preparations offered or intended for ophthalmic use that are not sterile may be regarded as adulterated…”\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> National Center for Biotechnology Information (NCBI)\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem> 21 CFR 200.50(a)(2) states, in relevant part, “liquid preparations offered or intended for ophthalmic use that are not sterile…may be deemed misbranded within the meaning of section 502(j) of the FD&amp;C Act. This ruling is extended to affect all preparations for ophthalmic use. By this regulation, this ruling is applicable to ophthalmic preparations that are regulated as drugs.”\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>4\u003C\u002Fstrong>\u003C\u002Fem> i.e., Quality System, Facilities &amp; Equipment System, Materials System, Production System, Packaging &amp; Labeling System, and Laboratory Control System per FDA’s guidance document Quality Systems Approach to Pharmaceutical CGMP Regulations.\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA Electronic Mail\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nDr. A.R. Venkatesh\n\nRecipient Title\n\nChief Executive Officer\n\nGlobal Pharma Healthcare Private Limited\n\nA-9 SIDCO Pharmaceutical Complex\n\nThiruporur 603110\n\nTamil Nadu\n\nIndia\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research | CDER\n\nUnited States\n\nWarning Letter 320-24-03\n\nOctober 20, 2023\n\nDear Dr. Venkatesh:\n\nThe U.S. Food and Drug Administration (FDA) inspected your drug manufacturing facility, Global Pharma Healthcare Private Limited, FEI 3012323885, at A-9 SIDCO Pharmaceutical Complex, Thiruporur, from February 20 to March 2, 2023.\n\nThis warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\n\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B).\n\nBecause your drug products were prepared, packed, or held under insanitary conditions, whereby they may have become contaminated with filth or rendered injurious to health, your drug products are also adulterated within the meaning of section 501(a)(2)(A) of the FD&C Act, 21 U.S.C. 351(a)(2)(A)1.\n\nIn addition, EZRICARE Artificial Tears, Delsam Pharma’s ARTIFICIAL TEARS, and Delsam Pharma’s ARTIFICIAL EYE OINTMENT are misbranded under section 502(j) of the FD&C Act, 21 U.S.C. 352(j), and Delsam Pharma’s ARTIFICIAL EYE OINTMENT is further misbranded under section 502(a) of the FD&C Act, 21 U.S.C. 352(a). Introduction or delivery for introduction of misbranded products into interstate commerce is prohibited under section 301(a) of the FD&C Act, 21 U.S.C. 331(a). These violations are described in more detail below.\n\nPseudomonas aeruginosa Outbreak and FDA Testing of Samples\n\nIn December 2022, FDA began collaborating with the Center for Disease Control and Prevention (CDC) on an investigation into the multistate outbreak of antibiotic-resistant Pseudomonas aeruginosa infections that ultimately affected more than 80 patients and led to 4 patient deaths and at least 14 cases of vision loss. As part of this investigation, FDA collected finished product samples of Artificial Tears and Artificial Eye Ointment batches that were manufactured by your facility, and we sent the samples for sterility testing at FDA laboratories. Our analysis of intact (unopened) units found that 18 batches of Artificial Tears were non-sterile. In addition, we also sampled a batch of your Artificial Eye Ointment product, and this batch was also found to be non-sterile. The testing of these intact units revealed that your ophthalmic drug products were intrinsically contaminated with microorganisms. Microbiological isolates from the non-sterile samples were further characterized using whole genome sequencing and compared to isolates in a national database.2 Pseudomonas aeruginosa isolates from three different batches of intact Artificial Tears samples collected by FDA were found to be close genetic matches to more than 85 clinical isolates associated with this outbreak. These test results demonstrate that these lots are adulterated under section 501(a)(1) of the FD&C Act, in that they have been contaminated with filth, and rendered injurious to health.\n\nSignificantly, the pervasive contamination of your drug products, as indicated by FDA sample results, also demonstrates that all drugs made at your facility are adulterated under section 501(a)(2)(A) of the FD&C Act as they have been manufactured under insanitary conditions.\n\nIn addition, two intact samples of Artificial Tears from different batches were found to contain visible, foreign particles.\n\nCGMP Violations\n\nWe reviewed your March 22, 2023, response to our Form FDA 483 in detail. During our inspection, our investigators observed specific violations including, but not limited to, the following.\n\n1. Your firm failed to establish and follow appropriate written procedures that are designed to prevent microbiological contamination of drug products purporting to be sterile, and that include validation of all aseptic and sterilization processes (21 CFR 211.113(b)).\n\nInadequate Equipment and Processes\n\nA. You lacked adequate scientific evidence that the aseptic filling machine used for manufacture of Artificial Tears was suitable for its intended use. Your qualification report was inadequate, including a lack of data on any batches filled as part of the qualification study. Further, all batches of Artificial Tears distributed to the U.S. market were manufactured using filling machine parameters that were outside the design specifications of the equipment.\n\nB. You lacked validation of the processes used to manufacture your aseptically filled Artificial Tears, for example:\n\n• You failed to validate methods that were intended to render your ophthalmic drug products sterile. Specifically, you lacked a study to show the (b)(4) performed on your Artificial Tears product using a (b)(4) can reliably achieve sterilization.\n\n• Your media fill program lacked assurance that aseptic processing operations are appropriately performed to prevent microbial contamination. Our inspection found that you failed to perform appropriate and sufficient media fills studies, for example:\n\no Your media fills failed to adequately simulate the commercial aseptic manufacturing operation. Interventions were not simulated sufficiently or accurately. In addition, you have a manually intensive line with minimal barrier protection where the possibility of contamination is greater. Despite this, you filled (b)(4)-(b)(4)% of the production batch size during media fills.\n\no Manufacturing lines used to produce the Artificial Tears and Artificial Eye Ointment products were not qualified by three successful media fills.\n\no You removed integral units (i.e., units with intact container-closure systems) from media fills without adequate justification and failed to incubate all integral units for the full (b)(4) period.\n\no The personnel responsible for visual inspection of media-filled units lacked appropriate training and qualification.\n\nC. You lacked meaningful airflow pattern studies for your aseptic processing lines. The studies were not performed under dynamic conditions and lacked simulation of interventions and other routine activities that occur during aseptic manufacturing operations.\n\nD. Your firm also shipped an ointment product to the United States that was manufactured using a (b)(4) sterilization process. You failed to ensure the (b)(4) process employed by your contractor to sterilize your Artificial Eye Ointment was validated.\n\nYour response is inadequate, including the following:\n\n• You lack details of your internal investigation into the product contamination. Your investigation is not comprehensive, including but not limited to, a lack of descriptions of the activities performed and root cause analysis. You also lack details on sampling and laboratory methods used for environmental and other tests.\n\n• There is a lack of detail relating to future dynamic airflow pattern studies; heating, ventilation, and air conditioning (HVAC) system qualification; or media fill procedural revisions.\n\n• You also fail to include a commitment to validate the (b)(4) sterilization process and sterility test methods for the Artificial Eye Ointment products.\n\nLack of Container Closure Integrity\n\nYou lacked evidence of reliable container closure integrity for your multi-use ophthalmic products that purport to be sterile. While visual inspections revealed leakers during batch manufacture, there was no assurance that your visual inspection procedure was adequate.\n\nYour product distributors received complaints of leaking Artificial Tears and Artificial Eye Ointment units. FDA’s laboratory performed container closure integrity testing of Artificial Eye Ointment, batch H29, manufactured at your facility. FDA tested 20 units, and 1 unit was found to allow microbiological ingress, which further confirmed that your container-closure system lacks integrity and is insufficient for maintaining sterility. Notably, batch H29 was also found to be non-sterile through FDA testing.\n\nAll sterile drugs must be packaged using a container-closure system that protects product integrity for the duration of its shelf-life. Maintenance of product integrity throughout stresses of its manufacture, storage, distribution, and consumer use is critical to product quality and safety. Loss of container-closure integrity is a direct cause of non-sterility of medicines.\n\nIn your response, you state you will perform container-closure integrity testing using a dye ingress method for your Artificial Tears product and a comprehensive sterility assessment. Your response is inadequate because your container-closure integrity testing protocol does not extend to Artificial Eye Ointment. In addition, you do not sufficiently address the sensitivity of your dye ingress method. The sensitivity of the method to be employed for your study is unclear, and you do not indicate whether it is capable of correlating with detection of bacteria comparable in size to Pseudomonas aeruginosa. Furthermore, your response does not include details on the comprehensive sterility assessment.\n\nInadequate Formulation for Artificial Tears and Artificial Eye Ointment\n\nYou manufactured multi-dose, over-the-counter (OTC) ophthalmic drug products for the product owners, EzriCare LLC, and Delsam Pharma LLC. These products lacked antimicrobial properties to preserve the formulation. Significantly, your firm also marketed this multi-dose product without performing antimicrobial effectiveness studies. It is essential that multi-dose ophthalmic drug products contain one or more suitable substances that will preserve the product and minimize the hazard of injury resulting from incidental contamination during use.\n\nIn your response, you state that antimicrobial effectiveness testing (AET) will be initiated for your Artificial Tears product, and you will use these studies to determine if a suitable preservative will be added to the formulation. Your response is inadequate because you do not explain why you failed to perform AET studies prior to launch of your drug product, and how you will correct such fundamental flaws in your product development program. You also make no commitment to conduct AET for the Artificial Eye Ointment formulation. In addition, although your protocol indicates that you follow the United States Pharmacopeia (USP), the acceptance criteria in the Artificial Tears protocol is less stringent and not in alignment with USP \u003C51> Antimicrobial Effectiveness Testing.\n\nInadequate Gowning Practices & Operator Qualification\n\nCleanroom operators lacked adequate gowning and qualification for performing aseptic operations. Your deficient practices and procedures placed products at high risk for contamination, for example:\n\nA. A gowning demonstration revealed that cleanroom operators do not don sterile goggles and therefore have exposed skin around their eyes during aseptic operations.\n\nB. Cleanroom garments were not suitable for their intended use. For example, garments indicated to be clean were observed to be stained, worn out, and stored improperly. In addition, your firm re-used cleanroom garments for an unspecified number of times without tracking or validation.\n\nC. You lacked written procedures and a training program on proper aseptic behavior and gowning for cleanroom operators. You also lacked evidence that all cleanroom operators are qualified through participation in a media fill, and the microbiological limit set in your gowning validation procedure is unsuitable for aseptic operations.\n\nD. You lacked written procedures and a training program on proper aseptic behavior and gowning for cleanroom operators. You also lacked evidence that all cleanroom operators were qualified through participation in a media fill and justification for the microbiological limits used in your aseptic processing operator gowning qualification procedure (i.e., no more than (NMT) (b)(4) colony forming units (cfu) for each gowning location). You also lacked a commitment to systematically review staff qualifications and competencies throughout your operation, including but not limited to, ensuring an effective CGMP training program.\n\nIn your response, you state that gowning qualification will be performed through media fills, and an in-house study will evaluate the impact of repeated sterilization cycles on cleanroom garments to establish an acceptable number of sterilization cycles. Your response is inadequate. You lack a comprehensive review of all aspects of personnel gowning, the qualification program, aseptic technique, cleanroom behavior, and an examination of the role of people as a contamination hazard in your processes. To further illustrate, you continue to lack substantive actions to implement sterile goggles, enhance practices to prevent sterile gown contamination, gowning qualification criteria (e.g., sampling requirements, location descriptions, acceptance limits with justifications), and many other basic elements of a compliant sterile facility. Your response also fails to address how your inadequate gowning practices impacted your sterile drug products.\n\nSee FDA’s guidance document Sterile Drug Products Produced by Aseptic Processing—Current Good Manufacturing Practice to help you meet the CGMP requirements when manufacturing sterile drugs using aseptic processing at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71026\u002Fdownload.\n\nIn response to this letter, provide the following:\n\n• Comprehensive risk assessment of all contamination hazards with respect to your aseptic processes, equipment, and facilities, including an independent assessment that includes, but is not limited to:\n\no All human interactions within the ISO 5 area\n\no Equipment placement and ergonomics\n\no Air quality in the ISO 5 area and surrounding room\n\no Facility layout\n\no Personnel Flows and Material Flows (throughout all rooms used to conduct and support sterile operations)\n\n• A detailed remediation plan with timelines to address the findings of the independent contamination hazards risk assessment. Describe specific tangible improvements to be made to aseptic processing operation design and control at your facility. Explain how your corrective action and preventive action (CAPA) will robustly remediate your deficient sterile manufacturing operation. Also describe your plans for qualification and validation of your comprehensively remediated facility, processes and equipment.\n\n• A remediation plan that better assures ongoing management oversight throughout the manufacturing lifecycle of all drug products. Provide a more data-driven and scientifically sound program that identifies sources of process variability and assures that manufacturing (including both production and packaging) operations meet appropriate parameters and quality standards. This includes, but is not limited to, evaluating suitability of equipment for its intended use, ensuring quality of input materials, determining the capability and reliability of each manufacturing process step and its controls, and vigilant ongoing monitoring of process performance and product quality.\n\n• Your CAPA plan to implement routine, vigilant operations management oversight of facilities and equipment. This plan should ensure, among other things, prompt detection of equipment\u002Ffacilities performance issues, effective execution of repairs, adherence to appropriate preventive maintenance schedules, timely technological upgrades to the equipment\u002Ffacility infrastructure, and improved systems for ongoing management review.\n\n• Your plan to ensure that inspection and other quality control methods for container-closure systems, including but not limited to opaque bottles and ointment tubes, can robustly detect integrity breaches.\n\n• A comprehensive, independent assessment of the qualifications and competencies of staff to conduct their job duties throughout your operations, including:\n\no a system that ensures each staff member receives training to enable them to properly perform each of their job duties in advance of performing job tasks\n\no a review of your training curriculum, including courses, timing, frequency, and training effectiveness\n\no supervision to determine ongoing adherence of staff to procedures and proper practices\n\no provisions for retraining in response to deficient performance or, when appropriate, re-evaluating whether the individual has the appropriate qualifications and expertise (training, education, skills) for the type and complexity of their assigned work\n\no training of supervisors and managers in CGMPs\n\n2. Your firm failed to test samples of each component for identity and conformity with all appropriate written specifications for purity, strength, and quality. Your firm also failed to validate and establish the reliability of your component supplier’s test analyses at appropriate intervals (21 CFR 211.84(d)(1) and 211.84(d)(2)).\n\nYou did not ensure that incoming lots of active pharmaceutical ingredient (API) and packaging materials were suitable for use in manufacturing.\n\nYour firm released API for use in drug manufacturing based on a component supplier’s certificate of analysis (COA), although you neither established the reliability of the analysis through appropriate validation nor performed identity testing. Notably, examples included two lots of carboxy methyl cellulose sodium API used to manufacture Artificial Tears batches distributed to the U.S. market.\n\nYou also failed to adequately test primary packaging materials, including caps and plugs, used in the Artificial Tears container-closure system. For example, between 2019 and 2022, you received (b)(4) shipments of caps and plugs supplied as sterile from a vendor and released them for use based on the supplier’s COA without adequate testing.\n\nIdentity testing for each component lot used in drug product manufacturing is required, and you may only rely on COA for other component attributes if you validate the supplier’s test results to ensure their reliability at appropriate intervals.\n\nA drug product produced by aseptic processing can become contaminated not only by unacceptable practices in the manufacturing operation, but also due to the use of one or more defective components, containers, or closures.\n\nYour response is inadequate for reasons that include, but are not limited to, the following:\n\n• You fail to indicate that all existing and new suppliers will be qualified.\n\n• It lacks details on procedural revisions to be made, including how you intend to establish and maintain assurance of the reliability of your supplier’s COA.\n\n• It also lacks details on your retrospective testing, including the scope of materials to be tested, sampling and testing methods, and how you intend to ensure that incoming materials are suitable for their intended use.\n\nWe also note that you listed drug products with FDA as being manufactured at your facility and intended for distribution in the United States, including paracetamol syrup, clotrimazole 1%, and Diaprene Children Maximum Topical Creams, that contain components with a high risk of diethylene glycol (DEG) or ethylene glycol (EG) contamination, such as glycerin and propylene glycol. The use of ingredients contaminated with DEG or EG has resulted in various lethal poisoning incidents in humans worldwide. See FDA’s guidance document Testing of Glycerin, Propylene Glycol, Maltitol Solution, Hydrogenated Starch Hydrolysate, Sorbitol Solution, and Other High-Risk Drug Components for Diethylene Glycol and Ethylene Glycol to help you meet the CGMP requirements when manufacturing drugs containing ingredients at high-risk for DEG or EG contamination (“high-risk drug components”), at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F167974\u002Fdownload.\n\nIn response to this letter, provide the following:\n\n• A comprehensive, independent review of your material system to determine whether all suppliers of components, containers, and closures, are each qualified and the materials are assigned appropriate expiration or retest dates. The review should also determine whether incoming material controls are adequate to prevent use of unsuitable components, containers, and closures.\n\n• The chemical and microbiological quality control specifications you use to test and release each incoming lot of components for use in manufacturing.\n\n• A summary of results obtained from testing all components to evaluate the reliability of the COA from each component manufacturer. Include your standard operating procedure (SOP) that describes this COA validation program.\n\n• A summary of your program for qualifying and overseeing contract facilities that test the drug products you manufacture.\n\n• A commitment to provide DEG and EG test results, no later than 30 calendar days from the date of this letter, from testing retains for all lots of high-risk drug components used in the manufacture of drug products. Alternatively, if a retain of a component lot is unavailable, perform retain sample testing of all potentially affected finished drug product batches for the presence of DEG and EG.\n\n• A full risk assessment for drug products that are within expiry which contain any ingredient at risk for DEG or EG contamination (including but not limited to glycerin). Take prompt and appropriate actions to determine the safety of all lots of the component(s) and any related drug product that could contain DEG or EG, including customer notifications and product recalls for any contaminated lots. Identify additional appropriate corrective actions and preventive actions that secure supply chains in the future, including but not limited to ensuring that all incoming raw material lots are from fully qualified manufacturers and free from unsafe impurities. Detail these actions in your response to this letter.\n\n• A description of how you will test each component lot for conformity with all appropriate specifications for identity, strength, quality, and purity. If you intend to accept any results from your supplier’s COA instead of testing each component lot for strength, quality, and purity, specify how you will robustly establish the reliability of your supplier’s results through initial validation as well as periodic revalidation. In addition, include a commitment to always conduct at least one specific identity test for each incoming component lot. In the case of glycerin, propylene glycol, and certain additional high-risk components we note that this includes the performance of parts A, B, and C of the United States Pharmacopeia (USP) monograph.\n\n3. Your firm failed to establish a system for monitoring environmental conditions in aseptic processing areas and an adequate system for cleaning and disinfecting the room to produce aseptic conditions (21 CFR 211.42(c)(10)(iv) and 211.42(c)(10)(v)).\n\nSterilization and Cleaning\n\nYou failed to adequately sterilize and clean your equipment used for drug product manufacturing, for example:\n\nA. You failed to ensure that all equipment with direct product contact was sterilized. During the inspection, you were not able to provide records showing sterilization of product contact equipment on the “(b)(4) Line,” including the filling (b)(4), (b)(4) tubing, and (b)(4) bowls. Review of sterilization records revealed that you only documented that garments and tools were sterilized. You also lacked written procedures describing sterilization of the manufacturing equipment.\n\nB. You failed to adequately clean the equipment used to aseptically produce Artificial Tears. Significantly, our investigators observed visible grease-like residue on product contact surfaces of your filling machine after they had been cleaned.\n\nYou also lacked written procedures and other documentation describing cleaning of the manufacturing equipment.\n\nC. You lacked cleaning validation studies for the shared manufacturing equipment on the “(b)(4) Line.”\n\nInadequately cleaned and maintained equipment can lead to cross-contamination and poor quality drug products.\n\nYour response is inadequate for reasons that include, but are not limited to, the following:\n\n• You fail to provide cleaning procedures or cleaning validation protocols. In addition, no commitment is made to comprehensively evaluate the suitability of your filling machine and other equipment for the manufacture of sterile drug products.\n\n• You fail to provide details of your proposed testing of retain samples.\n\n• You fail to provide explanations for the conflicting information provided to FDA investigators during the inspection. For example, investigators were initially told that (b)(4) bowls on the filling line were not cleaned or sterilized. These statements were later retracted; however, you were unable to provide sufficient information to support claims that (b)(4) bowls were cleaned and sterilized.\n\nMonitoring Environmental Conditions\n\nYour environmental monitoring (EM) program (including personnel monitoring (PM)) was inadequate for classified areas used to produce sterile ophthalmic drug products. For example, non-viable air samples were not collected inside the Grade A filling zone or the Grade B surrounding areas during active filling, you lacked studies to demonstrate that residual disinfectant would not interfere with the swabs used for viable surface monitoring, and you lacked identification data on isolates recovered from EM and PM sampling.\n\nVigilant and responsive environmental and personnel monitoring programs should be designed to provide meaningful information on the state of control of your aseptic processing environment. Operations that include highly manually intensive aseptic activities warrant a more extensive environmental and personnel monitoring program, including but not limited to, heightened emphasis on well-timed sampling to appropriately monitor batch manufacturing conditions.\n\nIn your response, you mention a limited number of environmental samples taken in January 2023 were sent to a third-party laboratory and these samples did not reveal Pseudomonas aeruginosa in your environment. This response is inadequate. The last batches of Artificial Tears shipped to the United States had been manufactured many months before (in April 2022) your limited sampling was conducted, according to records provided by your firm. Environmental sampling that occurs several months after batch manufacture is of little temporal significance. There is also minimal scientific value in testing sterile drug manufacturing areas solely for the presence of a single microbial species. You also had batch retain samples tested by a third-party laboratory and you reported in your response that these samples did not fail sterility testing. However, it is not unexpected that sterility testing of retains of otherwise contaminated batches may pass sterility testing because of the non-uniform nature of microbiological contamination. As noted above, many of your firm’s batches were found to be non-sterile upon FDA testing and were associated with grave adverse events.\n\nIn response to this letter, provide the following:\n\n• A comprehensive, independent assessment of the design and control of your firm’s manufacturing operations, with a detailed and thorough review of all microbiological hazards.\n\n• A comprehensive, independent retrospective assessment of your cleaning effectiveness to evaluate the scope of cross-contamination hazards. Include the identity of residues, other manufacturing equipment that may have been improperly cleaned, and an assessment whether cross-contaminated products may have been released for distribution. The assessment should identify any inadequacies of cleaning procedures and practices and encompass each piece of manufacturing equipment used to manufacture more than one product.\n\n• A CAPA plan, based on the retrospective assessment of your cleaning and disinfection program, that includes appropriate remediations to your cleaning and disinfection processes and practices, and timelines for completion. Provide a detailed summary of vulnerabilities in your process for lifecycle management of equipment cleaning and disinfection. Describe improvements to your cleaning and disinfection program, including enhancements to cleaning effectiveness; improved ongoing verification of proper cleaning and disinfection execution for all products and equipment; and all other needed remediations.\n\n• Appropriate improvements to your cleaning validation program, with special emphasis on incorporating conditions identified as worst case in your drug manufacturing operation. This should include but not be limited to identification and evaluation of all worst-case:\n\no Drugs with higher toxicities\n\no Drugs with higher drug potencies\n\no Drugs of lower solubility in their cleaning solvents\n\no Drugs with characteristics that make them difficult to clean\n\no Swabbing locations for areas that are most difficult to clean\n\no Maximum hold times before cleaning\n\nIn addition, describe the steps that must be taken in your change management system before introduction of new manufacturing equipment or a new product.\n\n• A summary of updated SOPs that ensure an appropriate program is in place for verification and validation of cleaning procedures for products, processes, and equipment.\n\n• A comprehensive, independent review of your personnel and environmental monitoring programs, including but not limited to, a plan to fully remediate these programs. For example, describe changes to equipment, procedures, and practices that will ensure meaningful ongoing data is collected to promptly detect and respond to emerging risks in your classified areas. Provide an updated timeline for implementation of your program, including a summary of the CAPA steps you will be undertaking to ensure effective remediation.\n\n4. Your firm failed to establish the accuracy, sensitivity, specificity, and reproducibility of its test methods, and you also failed to conduct appropriate laboratory testing to determine whether each batch of drug product purporting to be sterile conforms to such requirements (21 CFR 211.165(e) and 211.167(a)).\n\nYour firm lacked adequate sterility testing, for example:\n\nA. You failed to show that your sterility test method was suitable to detect microorganisms in your ophthalmic drug products.\n\nMethod suitability testing ensures the method can reliably determine the presence of microbial growth in the product. Method validation and verification is necessary to support reliable determinations of identity, strength, quality, purity, and potency of drugs. Without evaluating the validity of methods, you lack the basic assurance that the data provided to customers was an accurate reflection of pharmaceutical product quality and safety.\n\nB. You lacked growth promotion tests of the media used for media fills and personnel monitoring.\n\nThe validity of your microbiological testing cannot be ensured without appropriate testing of media.\n\nIn your response, you make commitments to review your sterility testing and other analytical method validations, initiate sterility method verification, and revise your media preparation procedures. Your response is inadequate because you fail to provide revised procedures and you do not address your failure to perform adequate sterility testing on your distributed finished drug products.\n\nIn response to this letter, provide the following:\n\n• A comprehensive, independent assessment of your laboratory practices, procedures, methods, equipment, documentation, and analyst competencies. Based on this review, provide a detailed plan to remediate and evaluate the effectiveness of your laboratory system.\n\n• A detailed risk assessment addressing the hazards posed by distributing contaminated drug products.\n\n• Complete investigations into all batches with confirmed and potential microbial contamination. The investigations should detail your findings regarding the root causes of the contamination.\n\n• All chemical and microbial test methods used to analyze each of your drug products.\n\n5. Your firm’s quality control unit failed to exercise its responsibility to ensure drug products manufactured are in compliance with CGMP, and meet established specifications for identity, strength, quality, and purity (21 CFR 211.22).\n\nYour firm failed to establish an adequate quality unit (QU) with the responsibilities and authority to oversee the manufacture of your drug products. For example:\n\nA. You failed to perform adequate batch release to ensure the acceptability of all batches of Artificial Tears, prior to release for the U.S. market.\n\nB. Your quality system does not adequately ensure the accuracy and integrity of data to support the quality of the drugs you manufacture. For example, your firm permitted the unacceptable practice of using pre-filled batch release documents.\n\nC. You failed to follow your change management procedure. The impact of the change to the specification for the inner cap (plug) used as part of your Artificial Tears container-closure system to a plug “with prehole” was not evaluated.\n\nIn your response, you state you will perform an impact assessment for all change controls initiated. Your response is inadequate for reasons that include, but are not limited to, the following:\n\n• You do not assess all records potentially affected by lapses in data integrity. You also do not assess how poor documentation practices affected distributed drug product nor how you could strengthen QU oversight. You also do not provide copies of the missing batch release documents you indicated that you have now recovered.\n\n• You do not perform a review and impact assessment for changes made outside of your change management system and not previously evaluated.\n\nIn response to this letter, provide the following:\n\n• A comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\n\no A determination of whether procedures used by your firm are robust and appropriate\n\no Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices\n\no A complete and final review of each batch and its related information before the QU disposition decision\n\no Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products\n\nAlso describe how top management supports quality assurance and reliable operations, including but not limited to, timely provision of resources to proactively address emerging manufacturing\u002Fquality issues and to assure a continuing state of control.\n\n• A comprehensive, independent assessment of your change management system. This assessment should include, but not be limited to, your procedure(s) to ensure changes are justified, reviewed, and approved by your quality unit. Your change management program should also include provisions for determining change effectiveness.\n\n• A complete assessment of documentation systems used throughout your manufacturing and laboratory operations to determine where documentation practices are insufficient. Include a detailed CAPA plan that comprehensively remediates your firm’s documentation practices to ensure you retain attributable, legible, complete, original, accurate, contemporaneous records throughout your operation.\n\nData Integrity Remediation\n\nYour quality system does not adequately ensure the accuracy and integrity of data to support the safety, effectiveness, and quality of the drugs you manufacture. See FDA’s guidance document Data Integrity and Compliance With Drug CGMP: Questions and Answers for guidance on establishing and following CGMP-compliant data integrity practices at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F119267\u002Fdownload.\n\nYour firm should retain a qualified consultant to assist in your remediation. In response to this letter, provide:\n\nA. A comprehensive investigation into the extent of the inaccuracies in data records and reporting including results of the data review for drugs distributed to the United States. Include a detailed description of the scope and root causes of your data integrity lapses.\n\nB. A current risk assessment of the potential effects of the observed failures on the quality of your drugs. Your assessment should include analyses of the risks to patients caused by the release of drugs affected by a lapse of data integrity and analyses of the risks posed by ongoing operations.\n\nC. A management strategy for your firm that includes the details of your global CAPA plan. The detailed corrective action plan should describe how you intend to ensure the reliability and completeness of all data generated by your firm including microbiological and analytical data, manufacturing records, and all data submitted to FDA.\n\nMisbranded Drug Violations\n\nEZRICARE Artificial Tears, Delsam Pharma’s ARTIFICIAL TEARS, and Delsam Pharma’s ARTIFICIAL EYE OINTMENT are “drugs” as defined by section 201(g)(1)(B) of the FD&C Act, 21 U.S.C. 321(g)(1)(B), because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and\u002For under section 201(g)(1)(C) of the FD&C Act, 21 U.S.C. 321(g)(1)(C), because they are intended to affect the structure or any function of the body. Specifically, EZRICARE Artificial Tears and Delsam Pharma’s ARTIFICIAL TEARS are intended for use as ophthalmic demulcents, and Delsam Pharma’s ARTIFICIAL EYE OINTMENT is intended for use as an ophthalmic emollient.\n\nExamples of claims from your product labeling that provide evidence of the intended uses (as defined by 21 CFR 201.128) of your products as drugs include, but may not be limited to, the following:\n\nEZRICARE Artificial Tears\n\n“Drug Facts . . . Uses . . . ■ for use as a protectant against further irritation or to relieve dryness of the eye ■ for the temporary relief of discomfort due to minor irritations of the eye, or to exposure to wind or sun” [from your product’s label]\n\nDelsam Pharma’s ARTIFICIAL TEARS\n\n“Drug Facts . . . Uses . . . ■ for use as a protectant against further irritation or to relieve dryness of the eye ■ for the temporary relief of discomfort due to minor irritations of the eye, or to exposure to wind or sun” [from your product’s label]\n\nDelsam Pharma’s ARTIFICIAL EYE OINTMENT\n\n“Drug Facts . . . Uses . . . For use as a lubricant to prevent further irritation or to relieve dryness of the eyes.” [from your product’s label]\n\nEZRICARE Artificial Tears, Delsam Pharma’s ARTIFICIAL TEARS, and Delsam Pharma’s ARTIFICIAL EYE OINTMENT are misbranded under section 502(j) of the FD&C Act, 21 U.S.C. 352(j), because they are not sterile. 21 CFR 200.50 states that all preparations offered or intended for ophthalmic use should be sterile, and if not are deemed misbranded under section 502(j) of the FD&C Act.3 However, FDA analysis of samples of EZRICARE Artificial Tears, Delsam Pharma’s ARTIFICIAL TEARS, and Delsam Pharma’s ARTIFICIAL EYE OINTMENT determined that these products were contaminated with microorganisms. For example, microorganisms in your products included but were not limited to the following: EZRICARE Artificial Tears contained Pseudomonas species, Delsam Pharma’s ARTIFICIAL TEARS contained Bacillus species, and Delsam Pharma’s ARTIFICIAL EYE OINTMENT contained Burkholderia cepacia complex. There is a reasonable probability that instillation of a bacterially contaminated eye product into the eye may cause a range of ocular infections, from minor to serious, vision-threatening infections which could progress in some cases to life-threatening systemic bacterial infection. Therefore, EZRICARE Artificial Tears, Delsam Pharma’s ARTIFICIAL TEARS, and Delsam Pharma’s ARTIFICIAL EYE OINTMENT are misbranded under section 502(j) of the FD&C Act, 21 U.S.C. 352(j).\n\nIn addition, Delsam Pharma’s ARTIFICIAL EYE OINTMENT is further misbranded under section 502(a) of the FD&C Act, 21 U.S.C 352(a), because its labeling is false or misleading. Specifically, the principal display panel (PDP) of the product label purports the product to be “sterile.” However, FDA analysis of samples of Delsam Pharma’s ARTIFICIAL EYE OINTMENT determined that it was contaminated with microorganisms including Burkholderia cepacia complex. Therefore, the labeling for Delsam Pharma’s ARTIFICIAL EYE OINTMENT is false or misleading, because the product is not in fact sterile for its intended use as an ophthalmic emollient drug product, and thus the product is misbranded under section 502(a) of the FD&C Act, 21 U.S.C. 352(a).\n\nThe introduction or delivery for introduction of a misbranded drug into interstate commerce is prohibited under section 301(a) of the FD&C Act, 21 U.S.C. 331(a).\n\nDrug Recalls\n\nOn January 30, 2023, FDA held a teleconference with you. We recommended you consider removing all batches of EzriCare Artificial Tears and Delsam Pharma’s Artificial Tears in distribution from the U.S. market. On February 2, 2023, you initiated a voluntary recall of EzriCare Artificial Tears and Delsam Pharma’s Artificial Tears based on bacterial contamination and CGMP concerns discussed with your firm. The company announcement was posted to the FDA website: https:\u002F\u002Fwww.fda.gov\u002Fsafety\u002Frecalls-market-withdrawals-safety-alerts\u002Fglobal-pharma-healthcare-issues-voluntary-nationwide-recall-artificial-tears-lubricant-eye-drops-due.\n\nOn February 22, 2023, FDA held another teleconference with you. We recommended you remove batch H29 of Delsam Pharma’s Artificial Eye Ointment in U.S. distribution. On February 24, 2023, you initiated a voluntary recall of Delsam Pharma’s Artificial Eye Ointment due to non-sterility. The company announcement was posted to the FDA website: https:\u002F\u002Fwww.fda.gov\u002Fsafety\u002Frecalls-market-withdrawals-safety-alerts\u002Fglobal-pharma-healthcare-issues-voluntary-nationwide-recall-delsam-pharma-artificial-eye-ointment.\n\nDrug Production Suspended\n\nWe acknowledge your commitment to suspend production of drugs for the U.S. market.\n\nGiven the egregious violations of CGMP at your facility, if you plan to resume drug manufacturing operations for the U.S. market, decide to transfer your ownership, contract out any processes, or move to a new location, notify this office.\n\nBased upon the nature of the violations we identified at your firm, you should engage a consultant qualified as set forth in 21 CFR 211.34, to assist your firm in meeting drug CGMP requirements, if your firm intends to resume manufacturing drugs for the U.S. market. The qualified consultant should also perform a comprehensive six-system audit4 of your entire operation for CGMP compliance and evaluate the completion and efficacy of all corrective actions and preventive actions before you pursue resolution of your firm’s compliance status with FDA.\n\nYour use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\n\nResponsibilities as a Contractor\n\nDrugs must be manufactured in conformance with CGMP. FDA is aware that many drug manufacturers use independent contractors such as production facilities, testing laboratories, packagers, and labelers. FDA regards contractors as extensions of the manufacturer.\n\nYou are responsible for the quality of drugs you produce as a contract facility regardless of agreements in place with product owners. You are required to ensure that drugs are made in accordance with section 501(a)(2)(B) of the FD&C Act for safety, identity, strength, quality, and purity. See FDA’s guidance document Contract Manufacturing Arrangements for Drugs: Quality Agreements at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F86193\u002Fdownload.\n\nIneffective Quality System\n\nSignificant findings in this letter demonstrate that your firm does not operate an effective quality system in accord with CGMP. In addition to a severe lack of effective production oversight of facilities and equipment, we found your quality unit is not enabled to exercise proper authority and has insufficiently implemented its responsibilities. You should immediately and comprehensively assess your company’s global manufacturing operations to ensure that systems, processes, and the products manufactured conform to FDA requirements.\n\nConclusion\n\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\n\nFDA placed your firm on Import Alert 66-40 on January 3, 2023, after your response to our 704(a)(4) Request for Records sent to you on November 15, 2022, demonstrated CGMP violations related to controls for DEG\u002FEG in high-risk components used in your drugs.\n\nThe inspectional findings and sample results detailed above further demonstrate your firm’s noncompliance.\n\nYour firm remains on Import Alert 66-40.\n\nCorrect any violations promptly. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to any violations.\n\nFailure to address any violations may also result in the FDA continuing to refuse admission of articles manufactured at Global Pharma Healthcare Private Limited, A-9 SIDCO Pharmaceutical Complex, Thiruporur, into the United States under section 801(a)(3) of the FD&C Act, 21 U.S.C. 381(a)(3). Articles under this authority that appear to be adulterated or misbranded may be detained or refused admission, in that the methods and controls used in their manufacture do not appear to conform to CGMP within the meaning of section 501(a)(2)(B) of the FD&C Act, 21 U.S.C. 351(a)(2)(B) and are misbranded under section 502 of the FD&C Act, respectively.\n\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion\n\nSend your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3012323885 and ATTN: Carrie Ann Plucinski.\n\nSincerely,\n\n\u002FS\u002F\n\nFrancis Godwin\n\nDirector\n\nOffice of Manufacturing Quality\n\nOffice of Compliance\n\nCenter for Drug Evaluation and Research\n\n____________________\n\n1 21 CFR 200.50(a)(2) states, in relevant part, “…liquid preparations offered or intended for ophthalmic use that are not sterile may be regarded as adulterated…”\n\n2 National Center for Biotechnology Information (NCBI)\n\n3 21 CFR 200.50(a)(2) states, in relevant part, “liquid preparations offered or intended for ophthalmic use that are not sterile…may be deemed misbranded within the meaning of section 502(j) of the FD&C Act. This ruling is extended to affect all preparations for ophthalmic use. By this regulation, this ruling is applicable to ophthalmic preparations that are regulated as drugs.”\n\n4 i.e., Quality System, Facilities & Equipment System, Materials System, Production System, Packaging & Labeling System, and Laboratory Control System per FDA’s guidance document Quality Systems Approach to Pharmaceutical CGMP Regulations.","Global Pharma Healthcare Private Limited","global-pharma-healthcare-private-limited-657325-10202023","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fglobal-pharma-healthcare-private-limited-657325-10202023","2026-10-26T08:08:46.716657+00:00","2023-11-14","657325","Dr. A.R. Venkatesh","2026-08-20T00:31:33.354+00:00","2023-10-20",{"id":218,"raw":219,"subject":224,"body_html":225,"body_text":226,"firm_name":227,"letter_id":228,"created_at":88,"fei_number":20,"letter_url":229,"updated_at":230,"action_type":23,"case_status":24,"posted_date":231,"marcs_cms_no":232,"product_type":27,"closeout_date":20,"issuing_office":11,"recipient_name":20,"body_fetched_at":233,"delivery_method":179,"recipient_title":20,"reference_number":20,"action_taken_date":234,"medical_device_id":20,"response_letter_date":20},96,[220,221,222,11,223,13,13,13],"\u003Ctime datetime=\"2026-06-16T04:00:00Z\">06\u002F16\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2026-06-08T04:00:00Z\">06\u002F08\u002F2026\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Ftrinity-healthcare-supply-llc-dba-altrx-728236-06082026\">Trinity HealthCare Supply, LLC dba altRx\u003C\u002Fa>","False &amp; Misleading Claims\u002FMisbranded (Telehealth)\u003Cbr \u002F>\r\n","False & Misleading Claims\u002FMisbranded (Telehealth)","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA ELECTRONIC MAIL READ\u002FDELIVERY RECEIPT REQUESTED\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\u003C\u002Fdd>\n                    \n            \u003Cdd>Trinity HealthCare Supply, LLC dba altRx\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>3206 NE 2nd Ave, Suite 3013\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Miami\u003C\u002Fspan>, \u003Cspan>FL\u003C\u002Fspan> \u003Cspan>33137\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:help@altrx.com\"> help@altrx.com \u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>June 8, 2026\u003C\u002Fp>\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003Cbr>Reference number: MARCS-CMS 728236\u003C\u002Fp>\u003Cp>To altRx:\u003C\u002Fp>\u003Cp>This warning letter advises you of significant violations identified during a U.S. Food and Drug Administration (FDA) review of your website. Promptly address the violations described herein without delay, including ensuring that appropriate resources are allocated to fully address the violations and prevent their recurrence. The violations cited in this letter are not intended to be an all-inclusive list of violations that may exist in connection with your products. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations. Failure to adequately address any violations may result in legal action without further notice, including, without limitation, seizure and injunction.\u003C\u002Fp>\u003Cp>\u003Cstrong>FDA Review\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Violations were identified and documented during a review of altRx’s website, https:\u002F\u002Fwww.altrx.com, FDA Establishment Identifier (FEI) 3044175714, in May 2026. FDA observed that your website offers compounded drug products, including semaglutide and tirzepatide products.\u003Cem>\u003Cstrong>\u003Csup>1\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> As described below, your website’s false or misleading claims concerning compounded semaglutide and tirzepatide products under sections 502(a) and 502(bb) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) [21 U.S.C. §§ 352(a) and 352(bb)], result in products being introduced or delivered for introduction into interstate commerce in violation of section 301(a) of the FD&amp;C Act [21 U.S.C. § 331(a)]. This review was conducted under FDA’s public health responsibilities to protect the public from unsafe, ineffective, and poor quality drug products.\u003C\u002Fp>\u003Cp>\u003Cstrong>Violations of the Federal Food, Drug, and Cosmetic Act\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The following are violations identified during our review. As a reminder, this is not an all-inclusive list of violations that may exist in connection with your products or operations.\u003C\u002Fp>\u003Cp>Your representations regarding compounded semaglutide and tirzepatide products are false or misleading. Under section 502(a) of the FD&amp;C Act [21 U.S.C. § 352(a)], a drug product is misbranded if its labeling is false or misleading in any particular. Furthermore, under section 502(bb) of the FD&amp;C Act [21 U.S.C. § 352(bb)], a compounded drug product is misbranded if its advertising or promotion is false or misleading in any particular.\u003C\u002Fp>\u003Cp>More specifically,\u003C\u002Fp>\u003Cp>1. The compounded semaglutide and tirzepatide products displayed on your website identify “altRx” on the pictured label, suggesting altRx is the compounder of those drugs when in fact it is not.\u003Cem>\u003Cstrong>\u003Csup>2\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fp>\u003Cp>2. The following claims concerning compounded semaglutide and tirzepatide products appear on your website:\u003C\u002Fp>\u003Cul>\u003Cli>“GLP-1s are clinically proven medications….”\u003C\u002Fli>\u003Cli>“…clinically proven weight loss.”\u003C\u002Fli>\u003C\u002Ful>\u003Cp>Compounded drug products are not FDA-approved. Your claims represent that the compounded drug products you offer have been FDA-approved or otherwise evaluated for safety and effectiveness when they have not.\u003C\u002Fp>\u003Cp>Accordingly, these representations cause your compounded drug products to be misbranded under sections 502(a) and 502(bb) of the FD&amp;C Act [21 U.S.C. §§ 352(a) and (bb)]. The introduction or delivery for introduction into interstate commerce of these misbranded drug products is a prohibited act under section 301(a) of the FD&amp;C Act [21 U.S.C. § 331(a)]. The violations described in this letter put you on notice of our concerns but may not represent an exhaustive list of violations. Please be advised, the receipt in interstate commerce of misbranded drug products, and the delivery or proffered delivery thereof, is also a violation of section 301(c) of the FD&amp;C Act [21 U.S.C. § 331(c)].\u003C\u002Fp>\u003Cp>You are responsible for investigating and determining the root causes of any violations and implementing corrective and preventative measures to ensure future and sustained compliance so that these violations and any others do not occur. It is your responsibility to ensure that your operations comply with all requirements of federal law, including FDA regulations. For example, compounded drug products must meet the conditions in sections 503A or 503B of the FD&amp;C Act [21 U.S.C. §§ 353a or 353b] in order to be exempt from certain requirements under the FD&amp;C Act, including the new drug approval requirements.\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>As previously stated, you are responsible for investigating and determining the root causes of any violations and implementing corrective and preventative measures to ensure future and sustained compliance so that these violations and any others do not occur.\u003C\u002Fp>\u003Cp>Send your written response to the Office of Compounding Quality and Compliance (OCQC) within the Center for Drug Evaluation and Research (CDER)’s Office of Compliance at compoundinginspections@fda.hhs.gov within fifteen (15) business days of receipt of this letter. Identify your written response with reference number MARCS-CMS 728236 and Response to Warning Letter in the subject line of the email. Include the specific steps you have taken to correct any violations, an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. Such steps may include the following:\u003C\u002Fp>\u003Cp>1. Identifying the entities that produce the compounded drug products offered on your website;\u003C\u002Fp>\u003Cp>2. Providing a representative sample of labeling for such drug products; and\u003C\u002Fp>\u003Cp>3. Addressing other website claims that contain false or misleading representations about your compounded drug products or demonstrating that such claims have been modified or removed in light of FD&amp;C Act §§ 502(a) and 502(bb) [21 U.S.C. §§ 352(a) and 352(bb)].\u003C\u002Fp>\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. If you have information that you believe demonstrates that your products are not in violation of the FD&amp;C Act and FDA regulations, include that information for our consideration. If you cannot completely address this matter within fifteen (15) business days, state the reason for the delay and the time within which you will do so.\u003C\u002Fp>\u003Cp>If you are not located in the U.S., please note that drug products that appear to be misbranded may be detained or refused admission. We may advise the appropriate regulatory officials in the country from which you operate that your drug products referenced above appear to be misbranded drug products that cannot be legally sold to consumers in the U.S.\u003C\u002Fp>\u003Cp>Please note FDA posts warning letters on www.FDA.gov.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Matthew J. Lash, JD\u003Cbr>Acting Director\u003Cbr>Office of Compounding Quality and Compliance\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003Cbr>U.S. Food and Drug Administration\u003C\u002Fp>\u003Cp>__________________________\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> The semaglutide and tirzepatide products offered on your website are drugs within the meaning of section 201(g) of the FD&amp;C Act [21 U.S.C. § 321(g)] because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of diseases and\u002For because they are intended to affect the structure or any function of the body. Further, they are “new drugs” within the meaning of section 201(p) of the FD&amp;C Act [21 U.S.C. § 321(p)] because they are not generally recognized as safe and effective for their labeled uses.\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> See 21 C.F.R. § 201.1(h)(2) (“The appearance on a drug product label of a person’s name without qualification is a representation that the named person is the sole manufacturer of the product. That representation is false and misleading, and the drug product is misbranded under section 502(a) of the act, if the person is not the manufacturer of the product in accordance with this section.”); see also FD&amp;C Act § 503(b) [21 U.S.C. § 353(b)], FD&amp;C Act § 503B(a)(10)(A)(ii) [21 U.S.C. § 353b(a)(10)(A)(ii)]. We note that 21 C.F.R. § 201.1(a) does not apply to drug products dispensed in accordance with section 503(b)(1) of the FD&amp;C Act [21 U.S.C. § 353(b)(1)]. However, see 45 Fed. Reg. 25760, 25765 (Apr. 15, 1980) (“…if the label of a prescription drug product dispensed by a pharmacist does contain a representation as to the manufacturer, packer, or distributor, it must comply with all the provisions of § 201.1….”). In addition, the labels of your drug products as depicted on the website do not indicate that they are dispensed under section 503(b)(1) of the FD&amp;C Act [21 U.S.C. § 353(b)(1)], nor do they appear to comply with the requirements of section 503(b)(2) [21 U.S.C. § 353(b)(2)].\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA ELECTRONIC MAIL READ\u002FDELIVERY RECEIPT REQUESTED\n\nProduct:\n\nDrugs\n\nRecipient:\n\nTrinity HealthCare Supply, LLC dba altRx\n\n3206 NE 2nd Ave, Suite 3013\n\nMiami, FL 33137\n\nUnited States\n\nhelp@altrx.com\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nJune 8, 2026\nWARNING LETTER\nReference number: MARCS-CMS 728236\nTo altRx:\nThis warning letter advises you of significant violations identified during a U.S. Food and Drug Administration (FDA) review of your website. Promptly address the violations described herein without delay, including ensuring that appropriate resources are allocated to fully address the violations and prevent their recurrence. The violations cited in this letter are not intended to be an all-inclusive list of violations that may exist in connection with your products. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations. Failure to adequately address any violations may result in legal action without further notice, including, without limitation, seizure and injunction.\nFDA Review\nViolations were identified and documented during a review of altRx’s website, https:\u002F\u002Fwww.altrx.com, FDA Establishment Identifier (FEI) 3044175714, in May 2026. FDA observed that your website offers compounded drug products, including semaglutide and tirzepatide products.1 As described below, your website’s false or misleading claims concerning compounded semaglutide and tirzepatide products under sections 502(a) and 502(bb) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) [21 U.S.C. §§ 352(a) and 352(bb)], result in products being introduced or delivered for introduction into interstate commerce in violation of section 301(a) of the FD&C Act [21 U.S.C. § 331(a)]. This review was conducted under FDA’s public health responsibilities to protect the public from unsafe, ineffective, and poor quality drug products.\nViolations of the Federal Food, Drug, and Cosmetic Act\nThe following are violations identified during our review. As a reminder, this is not an all-inclusive list of violations that may exist in connection with your products or operations.\nYour representations regarding compounded semaglutide and tirzepatide products are false or misleading. Under section 502(a) of the FD&C Act [21 U.S.C. § 352(a)], a drug product is misbranded if its labeling is false or misleading in any particular. Furthermore, under section 502(bb) of the FD&C Act [21 U.S.C. § 352(bb)], a compounded drug product is misbranded if its advertising or promotion is false or misleading in any particular.\nMore specifically,\n1. The compounded semaglutide and tirzepatide products displayed on your website identify “altRx” on the pictured label, suggesting altRx is the compounder of those drugs when in fact it is not.2\n2. The following claims concerning compounded semaglutide and tirzepatide products appear on your website:\n“GLP-1s are clinically proven medications….”\n“…clinically proven weight loss.”\nCompounded drug products are not FDA-approved. Your claims represent that the compounded drug products you offer have been FDA-approved or otherwise evaluated for safety and effectiveness when they have not.\nAccordingly, these representations cause your compounded drug products to be misbranded under sections 502(a) and 502(bb) of the FD&C Act [21 U.S.C. §§ 352(a) and (bb)]. The introduction or delivery for introduction into interstate commerce of these misbranded drug products is a prohibited act under section 301(a) of the FD&C Act [21 U.S.C. § 331(a)]. The violations described in this letter put you on notice of our concerns but may not represent an exhaustive list of violations. Please be advised, the receipt in interstate commerce of misbranded drug products, and the delivery or proffered delivery thereof, is also a violation of section 301(c) of the FD&C Act [21 U.S.C. § 331(c)].\nYou are responsible for investigating and determining the root causes of any violations and implementing corrective and preventative measures to ensure future and sustained compliance so that these violations and any others do not occur. It is your responsibility to ensure that your operations comply with all requirements of federal law, including FDA regulations. For example, compounded drug products must meet the conditions in sections 503A or 503B of the FD&C Act [21 U.S.C. §§ 353a or 353b] in order to be exempt from certain requirements under the FD&C Act, including the new drug approval requirements.\nConclusion\nAs previously stated, you are responsible for investigating and determining the root causes of any violations and implementing corrective and preventative measures to ensure future and sustained compliance so that these violations and any others do not occur.\nSend your written response to the Office of Compounding Quality and Compliance (OCQC) within the Center for Drug Evaluation and Research (CDER)’s Office of Compliance at compoundinginspections@fda.hhs.gov within fifteen (15) business days of receipt of this letter. Identify your written response with reference number MARCS-CMS 728236 and Response to Warning Letter in the subject line of the email. Include the specific steps you have taken to correct any violations, an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. Such steps may include the following:\n1. Identifying the entities that produce the compounded drug products offered on your website;\n2. Providing a representative sample of labeling for such drug products; and\n3. Addressing other website claims that contain false or misleading representations about your compounded drug products or demonstrating that such claims have been modified or removed in light of FD&C Act §§ 502(a) and 502(bb) [21 U.S.C. §§ 352(a) and 352(bb)].\nThis letter notifies you of our concerns and provides you an opportunity to address them. If you have information that you believe demonstrates that your products are not in violation of the FD&C Act and FDA regulations, include that information for our consideration. If you cannot completely address this matter within fifteen (15) business days, state the reason for the delay and the time within which you will do so.\nIf you are not located in the U.S., please note that drug products that appear to be misbranded may be detained or refused admission. We may advise the appropriate regulatory officials in the country from which you operate that your drug products referenced above appear to be misbranded drug products that cannot be legally sold to consumers in the U.S.\nPlease note FDA posts warning letters on www.FDA.gov.\nSincerely,\n\u002FS\u002F\nMatthew J. Lash, JD\nActing Director\nOffice of Compounding Quality and Compliance\nOffice of Compliance\nCenter for Drug Evaluation and Research\nU.S. Food and Drug Administration\n__________________________\n1 The semaglutide and tirzepatide products offered on your website are drugs within the meaning of section 201(g) of the FD&C Act [21 U.S.C. § 321(g)] because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of diseases and\u002For because they are intended to affect the structure or any function of the body. Further, they are “new drugs” within the meaning of section 201(p) of the FD&C Act [21 U.S.C. § 321(p)] because they are not generally recognized as safe and effective for their labeled uses.\n2 See 21 C.F.R. § 201.1(h)(2) (“The appearance on a drug product label of a person’s name without qualification is a representation that the named person is the sole manufacturer of the product. That representation is false and misleading, and the drug product is misbranded under section 502(a) of the act, if the person is not the manufacturer of the product in accordance with this section.”); see also FD&C Act § 503(b) [21 U.S.C. § 353(b)], FD&C Act § 503B(a)(10)(A)(ii) [21 U.S.C. § 353b(a)(10)(A)(ii)]. We note that 21 C.F.R. § 201.1(a) does not apply to drug products dispensed in accordance with section 503(b)(1) of the FD&C Act [21 U.S.C. § 353(b)(1)]. However, see 45 Fed. Reg. 25760, 25765 (Apr. 15, 1980) (“…if the label of a prescription drug product dispensed by a pharmacist does contain a representation as to the manufacturer, packer, or distributor, it must comply with all the provisions of § 201.1….”). In addition, the labels of your drug products as depicted on the website do not indicate that they are dispensed under section 503(b)(1) of the FD&C Act [21 U.S.C. § 353(b)(1)], nor do they appear to comply with the requirements of section 503(b)(2) [21 U.S.C. § 353(b)(2)].","Trinity HealthCare Supply, LLC dba altRx","trinity-healthcare-supply-llc-dba-altrx-728236-06082026","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Ftrinity-healthcare-supply-llc-dba-altrx-728236-06082026","2026-10-26T08:10:14.815507+00:00","2026-06-16","728236","2026-08-19T04:37:00.579+00:00","2026-06-08",{"id":236,"raw":237,"subject":242,"body_html":243,"body_text":244,"firm_name":245,"letter_id":246,"created_at":171,"fei_number":20,"letter_url":247,"updated_at":248,"action_type":23,"case_status":24,"posted_date":249,"marcs_cms_no":250,"product_type":251,"closeout_date":20,"issuing_office":241,"recipient_name":252,"body_fetched_at":253,"delivery_method":30,"recipient_title":20,"reference_number":20,"action_taken_date":254,"medical_device_id":20,"response_letter_date":20},21708,[238,239,240,241,242,13,13,13],"\u003Ctime datetime=\"2026-09-29T04:00:00Z\">09\u002F29\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2026-08-04T04:00:00Z\">08\u002F04\u002F2026\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fstokes-healthcare-inc-dba-epicur-pharma-733243-08042026\">Stokes Healthcare Inc. dba Epicur Pharma\u003C\u002Fa>","Center for Veterinary Medicine","Animal Drugs\u002FAdulterated","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Email\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Animal &amp; Veterinary\u003Cbr>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Michael Tursi\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>CEO\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Stokes Healthcare Inc. dba Epicur Pharma\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>8000 Commerce Parkway, Ste. 600\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Mount Laurel\u003C\u002Fspan>, \u003Cspan>NJ\u003C\u002Fspan> \u003Cspan>08054\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:mtursi@stokespharmacy.com\"> mtursi@stokespharmacy.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Veterinary Medicine\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>August 4, 2026\u003C\u002Fp>\u003Cp>Re: 733243\u003C\u002Fp>\u003Cp>Dear Michael Tursi:\u003C\u002Fp>\u003Cp>This letter is to advise you that the United States Food and Drug Administration (FDA) has reviewed your website https:\u002F\u002Fepicurpharma.com, where you market various compounded animal drugs in violation of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act). As explained further below, the claims on your website concerning your compounded animal drugs, including buprenorphine ER injection solution and omeprazole injection suspension, are false or misleading and the drugs are therefore misbranded under sections 502(a), 502(bb), and 201(n) of the FD&amp;C Act (21 U.S.C. §§ 352(a), 352(bb) and 321(n)). Your statements create a false or misleading impression about the safety and effectiveness of your compounded drugs, which are not FDA-approved or indexed. By encouraging use of these treatments instead of drugs that have been through FDA approval or indexing, you expose patients to unknown risks, including the risk of ineffective treatment.\u003C\u002Fp>\u003Cp>\u003Cstrong>Unsubstantiated Claims\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your compounded drugs are not FDA-approved, conditionally approved, or index listed.\u003Cem>\u003Cstrong>\u003Csup>1\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> Animal drugs produced in human drug outsourcing facilities, registered under section 503B of the Act, are not exempt from the FD&amp;C Act’s requirements for adequate directions for use or approval.\u003Cem>\u003Cstrong>\u003Csup>2\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> Unless a drug is compounded using FDA-approved drugs (i.e., using the approved drug as the source of active ingredients) in compliance with 21 CFR Part 530, it violates the FD&amp;C Act because it is not approved or indexed, and cannot satisfy the FD&amp;C Act’s adequate directions for use provision (which requires, among other things, that a prescription drug have an FDA-approved labeling).\u003Cem>\u003Cstrong>\u003Csup>3\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fp>\u003Cp>Promotional materials misbrand a drug if they contain false or misleading comparisons that represent or suggest that it is safer or more effective than another drug when this has not been demonstrated. You make such claims for the following products:\u003C\u002Fp>\u003Cp>\u003Cu>Compounded Omeprazole Injection Suspension\u003C\u002Fu>\u003C\u002Fp>\u003Cp>Omeprazole is the active ingredient in multiple, FDA approved animal drugs, including GastroGard (NADA 141-123), UlcerGard (NADA 141-227), and Gastrobim (ANADA 200-842). The following are examples of claims made through your website, epicurpharma.com, where you state or imply your unapproved drugs are safe, effective, comparable, and\u002For superior to FDA-approved drugs:\u003C\u002Fp>\u003Cul>\u003Cli>“Changing the game for equine gastric ulcers.”\u003C\u002Fli>\u003Cli>“…an innovative alternative for equine gastric ulcers”\u003C\u002Fli>\u003Cli>“…Epicur is bringing the same unique, proven formulation of omeprazole injection to the U.S. for the treatment of equine gastric ulcers.”\u003C\u002Fli>\u003Cli>“Benefits of this formulation over the traditional oral paste include: …\u003Cbr>o More rapid healing with [Equine Squamous Gastric Disease (ESGD)] healing in 10 days and [Equine Glandular Gastric Disease (EGGD)] in 20 days with the injection, compared to the traditional month of treatment with oral treatment (Sundra T, Kelty E, Rendle D, 2024)”\u003C\u002Fli>\u003C\u002Ful>\u003Cp>Compounded drug products are not FDA-approved or indexed. The claims on your website misleadingly suggest that your compounded omeprazole injection suspension is comparable or superior to FDA-approved omeprazole drugs. FDA-approved drugs have been reviewed to ensure they are safe and effective. Neither the safety nor the effectiveness of your product has been reviewed by FDA. Additionally, the literature cited does not appear to support the statement listed above because the study did not review treatment at 10 days, did not find a significant result for ESGD, and did not review records for horses treated with oral omeprazole drugs. The study by Sundra et al. 2024 reviewed the veterinary records of horses that had received four doses of an injectable omeprazole drug at either 5-day or 7-day dosing intervals. The study compared effectiveness of the two dosing intervals using gastroscopy images collected 5 to 7 days after the fourth dose. The study concluded that 5-day intervals resulted in more horses with EGGD healing compared with 7-day intervals, but did not find a significant difference for ESGD healing. The study did not review records for horses that received oral omeprazole drugs or compare the effectiveness of 5-day vs. 7-day dosing intervals for the oral omeprazole drugs. As a result, these claims are false or misleading and your product is therefore misbranded under sections 502(a), 502(bb) and 201(n) of the FD&amp;C Act.\u003C\u002Fp>\u003Cp>\u003Cu>Compounded Buprenorphine ER Injection Solution\u003C\u002Fu>\u003C\u002Fp>\u003Cp>Buprenorphine is the active ingredient in three drugs on the Index of Legally Marketed Unapproved New Animal Drugs for Minor Species, including one marketed drug, ETHIQA XR (MIF 900-014). The following are examples of claims on your website, epicurpharma.com, where you state or imply your unapproved drugs are safe, effective, comparable and\u002For superior to legally marketed indexed drugs:\u003C\u002Fp>\u003Cul>\u003Cli>“Next-Generation Buprenorphine Analgesia for Rats and Mice”\u003C\u002Fli>\u003Cli>“Meet the new gold standard in lab animal pain relief”\u003C\u002Fli>\u003C\u002Ful>\u003Cp>Comparisons are made between your buprenorphine ER injection solution and “Buprenorphine ER Alternatives” as shown in the table below.\u003C\u002Fp>\u003Cdiv>  \u003Cimg src=\"https:\u002F\u002Fwww.fda.gov\u002Ffiles\u002FStokes%20733243.png\" alt=\"Stokes WL\">\n\n\u003C\u002Fdiv>\n\u003Cp>The claims on your website misleadingly suggest that your compounded buprenorphine ER injection solution is comparable or superior to FDA-indexed drugs. FDA-indexed drugs have had their safety and effectiveness affirmed through an alternative FDA review process. Neither the safety nor the effectiveness of your compounded product has been reviewed by FDA.\u003C\u002Fp>\u003Cp>Furthermore, your claim that “FDA indexing [is] underway” is false or misleading because it implies that you have started the indexing process by submitting information to FDA that is under review by FDA.\u003Cem>\u003Cstrong>\u003Csup>4\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> \u003Cstrong>(b)(4)\u003C\u002Fstrong>. However, as of the date of this letter, you have not opened a file or submitted information to FDA for review for indexing, so “FDA indexing” is not currently underway.\u003C\u002Fp>\u003Cp>You state that the FDA-indexed buprenorphine ER alternative has a 2-month shelf life. This is false. Ethiqa XR™ is a buprenorphine extended-release injectable suspension that is FDA-indexed and is currently marketed. Ethiqa has a 36-month shelf life and its label states “once broached, the multi-dose vial should be discarded after 90 days”.\u003C\u002Fp>\u003Cp>\u003Cstrong>False or Misleading Risk Presentation\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Promotional materials misbrand a drug if they are false or misleading with respect to risk. Among other reasons, promotional material can be misleading due to the representations it makes or suggests.\u003Cem>\u003Cstrong>\u003Csup>5\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> It can also be misleading if it fails to reveal facts that are material when viewed in light of the representations made, including facts related to the potential consequences (e.g., adverse effects) of using the drug either as suggested in the promotion or under the usual conditions of use.\u003C\u002Fp>\u003Cp>The promotional materials for your compounded buprenorphine ER injection solution fail to communicate risk information associated with the product. This is particularly concerning in light of the known risks associated with buprenorphine as explained in the product labeling of the drugs approved and indexed by the FDA that contain buprenorphine. Buprenorphine is classified as a Schedule III narcotic due to human abuse and addiction potential and poses severe human exposure risks, including accidental skin absorption or ingestion dangers. Additionally, your promotional materials for the omeprazole injection suspension drug product do not sufficiently communicate risk information associated with the use of the drug.\u003C\u002Fp>\u003Cp>\u003Cstrong>False and\u002For Misleading Advertising about the FDA and the Legality of Compounded Animal Drugs\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cu>False or Misleading Advertising Regarding FDA’s Animal Drug Compounding Guidance\u003C\u002Fu>\u003C\u002Fp>\u003Cp>Your website states that your buprenorphine ER injection solution is “Compliant with GFI #256” and available for office use. This statement is false. Buprenorphine injectable polymeric matrix solution for use in rodents (e.g., mice and rats) is on the list of \u003Cu>Bulk Drug Substances Reviewed and Not Listed\u003C\u002Fu>. Therefore, buprenorphine ER injection solution compounded for use as office stock in rats and mice is not consistent with the recommendations in GFI #256, and your assertion otherwise is false or misleading.\u003C\u002Fp>\u003Cp>\u003Cu>False or Misleading Advertising About FDA’s Oversight of Compounded Drugs\u003C\u002Fu>\u003C\u002Fp>\u003Cp>On your website, you make the following claim about all of your compounded tablets:\u003C\u002Fp>\u003Cul>\u003Cli>“…All Epicur® tablets are manufactured to FDA specifications”\u003Cbr>This statement is false or misleading because FDA does not review, set, or approve specifications for compounded drugs.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cu>False or Misleading Advertising About the Legality of Compounded Animal Drugs\u003C\u002Fu>\u003C\u002Fp>\u003Cp>On your website, you make the following claims about the legal status of animal drugs (including your drugs) compounded in a human drug outsourcing facility:\u003C\u002Fp>\u003Cul>\u003Cli>“Available for dispensing and unlimited hospital administration FDA Federal SEC. 503B. [21 U.S.C. 353b]”\u003C\u002Fli>\u003C\u002Ful>\u003Cp>This statement suggests that the animal drugs listed on the page are legal for dispensing as office stock under FD&amp;C Act section 503B, which is false, because the exemptions in section 503B do not apply to animal drugs.\u003C\u002Fp>\u003Cul>\u003Cli>“…Buprenorphine Injection is on the \u003Cstrong>do not compound List\u003C\u002Fstrong> for office use under GFI #256 which means you must order compounded Buprenorphine from a 503B like Epicur! Stay FDA &amp; DEA complia\u003Ca>nt…”\u003C\u002Fa>\u003C\u002Fli>\u003C\u002Ful>\u003Cp>This statement suggests Buprenorphine Injection is legal for dispensing as office stock if produced in a 503B human drug outsourcing facility, which is false because the exemptions in section 503B do not apply to animal drugs.\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>This letter notifies you of our concerns and provides you with an opportunity to address them. Failure to address this matter may lead to legal action without further notice, including, without limitation, seizure and injunction.\u003C\u002Fp>\u003Cp>This letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products or operations. It is your responsibility to ensure that your firm complies with all requirements of federal law and FDA’s implementing regulations.\u003C\u002Fp>\u003Cp>Within fifteen (15) working days of receipt of this letter, please notify this office in writing of the specific steps you have taken to correct any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective action within fifteen (15) working days, state the reason for the delay and the time within which you will complete the correction. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\u003Cp>Please direct your response to U.S. Food and Drug Administration, Center for Veterinary Medicine, Office of Surveillance and Compliance, Division of Drug Compliance by email to CVMUnapprovedDrugs@fda.hhs.gov.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Johnetta Walters, Ph.D.\u003Cbr>Acting Division Director\u003Cbr>Division of Drug Compliance\u003Cbr>Office of Surveillance and Compliance\u003Cbr>Center for Veterinary Medicine\u003Cbr>U.S. Food &amp; Drug Administration\u003C\u002Fp>\u003Cp>________________________\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> Sections 512, 571, and 572 of the FD&amp;C Act (21 U.S.C. §§ 360b, 360ccc, 360ccc-1).\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> Section 503B(a) of the FD&amp;C Act exempts human drugs from the new drug approval requirements of section 505, but section 503B(a) (21 U.S.C. § 353b) omits any reference to the new animal drug approval requirements in section 512 of the FD&amp;C Act. The exemptions in section 503B apply only to human drugs.\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem> FD&amp;C Act sections 512(a) and 502(f) (21 U.S.C. §§ 360b(a), 352(f)).\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>4\u003C\u002Fstrong>\u003C\u002Fem> See FD&amp;C Act section 572(c) (21 U.S.C. § 360ccc-1(c)).\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>5\u003C\u002Fstrong>\u003C\u002Fem> See FD&amp;C Act section 201(n), 21 U.S.C. 321(n).\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Email\n\nProduct:\n\nAnimal & Veterinary\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMichael Tursi\n\nRecipient Title\n\nCEO\n\nStokes Healthcare Inc. dba Epicur Pharma\n\n8000 Commerce Parkway, Ste. 600\n\nMount Laurel, NJ 08054\n\nUnited States\n\nmtursi@stokespharmacy.com\n\nIssuing Office:\n\nCenter for Veterinary Medicine\n\nUnited States\n\nWARNING LETTER\nAugust 4, 2026\nRe: 733243\nDear Michael Tursi:\nThis letter is to advise you that the United States Food and Drug Administration (FDA) has reviewed your website https:\u002F\u002Fepicurpharma.com, where you market various compounded animal drugs in violation of the Federal Food, Drug, and Cosmetic Act (FD&C Act). As explained further below, the claims on your website concerning your compounded animal drugs, including buprenorphine ER injection solution and omeprazole injection suspension, are false or misleading and the drugs are therefore misbranded under sections 502(a), 502(bb), and 201(n) of the FD&C Act (21 U.S.C. §§ 352(a), 352(bb) and 321(n)). Your statements create a false or misleading impression about the safety and effectiveness of your compounded drugs, which are not FDA-approved or indexed. By encouraging use of these treatments instead of drugs that have been through FDA approval or indexing, you expose patients to unknown risks, including the risk of ineffective treatment.\nUnsubstantiated Claims\nYour compounded drugs are not FDA-approved, conditionally approved, or index listed.1 Animal drugs produced in human drug outsourcing facilities, registered under section 503B of the Act, are not exempt from the FD&C Act’s requirements for adequate directions for use or approval.2 Unless a drug is compounded using FDA-approved drugs (i.e., using the approved drug as the source of active ingredients) in compliance with 21 CFR Part 530, it violates the FD&C Act because it is not approved or indexed, and cannot satisfy the FD&C Act’s adequate directions for use provision (which requires, among other things, that a prescription drug have an FDA-approved labeling).3\nPromotional materials misbrand a drug if they contain false or misleading comparisons that represent or suggest that it is safer or more effective than another drug when this has not been demonstrated. You make such claims for the following products:\nCompounded Omeprazole Injection Suspension\nOmeprazole is the active ingredient in multiple, FDA approved animal drugs, including GastroGard (NADA 141-123), UlcerGard (NADA 141-227), and Gastrobim (ANADA 200-842). The following are examples of claims made through your website, epicurpharma.com, where you state or imply your unapproved drugs are safe, effective, comparable, and\u002For superior to FDA-approved drugs:\n“Changing the game for equine gastric ulcers.”\n“…an innovative alternative for equine gastric ulcers”\n“…Epicur is bringing the same unique, proven formulation of omeprazole injection to the U.S. for the treatment of equine gastric ulcers.”\n“Benefits of this formulation over the traditional oral paste include: …\no More rapid healing with [Equine Squamous Gastric Disease (ESGD)] healing in 10 days and [Equine Glandular Gastric Disease (EGGD)] in 20 days with the injection, compared to the traditional month of treatment with oral treatment (Sundra T, Kelty E, Rendle D, 2024)”\nCompounded drug products are not FDA-approved or indexed. The claims on your website misleadingly suggest that your compounded omeprazole injection suspension is comparable or superior to FDA-approved omeprazole drugs. FDA-approved drugs have been reviewed to ensure they are safe and effective. Neither the safety nor the effectiveness of your product has been reviewed by FDA. Additionally, the literature cited does not appear to support the statement listed above because the study did not review treatment at 10 days, did not find a significant result for ESGD, and did not review records for horses treated with oral omeprazole drugs. The study by Sundra et al. 2024 reviewed the veterinary records of horses that had received four doses of an injectable omeprazole drug at either 5-day or 7-day dosing intervals. The study compared effectiveness of the two dosing intervals using gastroscopy images collected 5 to 7 days after the fourth dose. The study concluded that 5-day intervals resulted in more horses with EGGD healing compared with 7-day intervals, but did not find a significant difference for ESGD healing. The study did not review records for horses that received oral omeprazole drugs or compare the effectiveness of 5-day vs. 7-day dosing intervals for the oral omeprazole drugs. As a result, these claims are false or misleading and your product is therefore misbranded under sections 502(a), 502(bb) and 201(n) of the FD&C Act.\nCompounded Buprenorphine ER Injection Solution\nBuprenorphine is the active ingredient in three drugs on the Index of Legally Marketed Unapproved New Animal Drugs for Minor Species, including one marketed drug, ETHIQA XR (MIF 900-014). The following are examples of claims on your website, epicurpharma.com, where you state or imply your unapproved drugs are safe, effective, comparable and\u002For superior to legally marketed indexed drugs:\n“Next-Generation Buprenorphine Analgesia for Rats and Mice”\n“Meet the new gold standard in lab animal pain relief”\nComparisons are made between your buprenorphine ER injection solution and “Buprenorphine ER Alternatives” as shown in the table below.\n\nThe claims on your website misleadingly suggest that your compounded buprenorphine ER injection solution is comparable or superior to FDA-indexed drugs. FDA-indexed drugs have had their safety and effectiveness affirmed through an alternative FDA review process. Neither the safety nor the effectiveness of your compounded product has been reviewed by FDA.\nFurthermore, your claim that “FDA indexing [is] underway” is false or misleading because it implies that you have started the indexing process by submitting information to FDA that is under review by FDA.4 (b)(4). However, as of the date of this letter, you have not opened a file or submitted information to FDA for review for indexing, so “FDA indexing” is not currently underway.\nYou state that the FDA-indexed buprenorphine ER alternative has a 2-month shelf life. This is false. Ethiqa XR™ is a buprenorphine extended-release injectable suspension that is FDA-indexed and is currently marketed. Ethiqa has a 36-month shelf life and its label states “once broached, the multi-dose vial should be discarded after 90 days”.\nFalse or Misleading Risk Presentation\nPromotional materials misbrand a drug if they are false or misleading with respect to risk. Among other reasons, promotional material can be misleading due to the representations it makes or suggests.5 It can also be misleading if it fails to reveal facts that are material when viewed in light of the representations made, including facts related to the potential consequences (e.g., adverse effects) of using the drug either as suggested in the promotion or under the usual conditions of use.\nThe promotional materials for your compounded buprenorphine ER injection solution fail to communicate risk information associated with the product. This is particularly concerning in light of the known risks associated with buprenorphine as explained in the product labeling of the drugs approved and indexed by the FDA that contain buprenorphine. Buprenorphine is classified as a Schedule III narcotic due to human abuse and addiction potential and poses severe human exposure risks, including accidental skin absorption or ingestion dangers. Additionally, your promotional materials for the omeprazole injection suspension drug product do not sufficiently communicate risk information associated with the use of the drug.\nFalse and\u002For Misleading Advertising about the FDA and the Legality of Compounded Animal Drugs\nFalse or Misleading Advertising Regarding FDA’s Animal Drug Compounding Guidance\nYour website states that your buprenorphine ER injection solution is “Compliant with GFI #256” and available for office use. This statement is false. Buprenorphine injectable polymeric matrix solution for use in rodents (e.g., mice and rats) is on the list of Bulk Drug Substances Reviewed and Not Listed. Therefore, buprenorphine ER injection solution compounded for use as office stock in rats and mice is not consistent with the recommendations in GFI #256, and your assertion otherwise is false or misleading.\nFalse or Misleading Advertising About FDA’s Oversight of Compounded Drugs\nOn your website, you make the following claim about all of your compounded tablets:\n“…All Epicur® tablets are manufactured to FDA specifications”\nThis statement is false or misleading because FDA does not review, set, or approve specifications for compounded drugs.\nFalse or Misleading Advertising About the Legality of Compounded Animal Drugs\nOn your website, you make the following claims about the legal status of animal drugs (including your drugs) compounded in a human drug outsourcing facility:\n“Available for dispensing and unlimited hospital administration FDA Federal SEC. 503B. [21 U.S.C. 353b]”\nThis statement suggests that the animal drugs listed on the page are legal for dispensing as office stock under FD&C Act section 503B, which is false, because the exemptions in section 503B do not apply to animal drugs.\n“…Buprenorphine Injection is on the do not compound List for office use under GFI #256 which means you must order compounded Buprenorphine from a 503B like Epicur! Stay FDA & DEA compliant…”\nThis statement suggests Buprenorphine Injection is legal for dispensing as office stock if produced in a 503B human drug outsourcing facility, which is false because the exemptions in section 503B do not apply to animal drugs.\nConclusion\nThis letter notifies you of our concerns and provides you with an opportunity to address them. Failure to address this matter may lead to legal action without further notice, including, without limitation, seizure and injunction.\nThis letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products or operations. It is your responsibility to ensure that your firm complies with all requirements of federal law and FDA’s implementing regulations.\nWithin fifteen (15) working days of receipt of this letter, please notify this office in writing of the specific steps you have taken to correct any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective action within fifteen (15) working days, state the reason for the delay and the time within which you will complete the correction. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration.\nPlease direct your response to U.S. Food and Drug Administration, Center for Veterinary Medicine, Office of Surveillance and Compliance, Division of Drug Compliance by email to CVMUnapprovedDrugs@fda.hhs.gov.\nSincerely,\n\u002FS\u002F\nJohnetta Walters, Ph.D.\nActing Division Director\nDivision of Drug Compliance\nOffice of Surveillance and Compliance\nCenter for Veterinary Medicine\nU.S. Food & Drug Administration\n________________________\n1 Sections 512, 571, and 572 of the FD&C Act (21 U.S.C. §§ 360b, 360ccc, 360ccc-1).\n2 Section 503B(a) of the FD&C Act exempts human drugs from the new drug approval requirements of section 505, but section 503B(a) (21 U.S.C. § 353b) omits any reference to the new animal drug approval requirements in section 512 of the FD&C Act. The exemptions in section 503B apply only to human drugs.\n3 FD&C Act sections 512(a) and 502(f) (21 U.S.C. §§ 360b(a), 352(f)).\n4 See FD&C Act section 572(c) (21 U.S.C. § 360ccc-1(c)).\n5 See FD&C Act section 201(n), 21 U.S.C. 321(n).","Stokes Healthcare Inc. dba Epicur Pharma","stokes-healthcare-inc-dba-epicur-pharma-733243-08042026","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fstokes-healthcare-inc-dba-epicur-pharma-733243-08042026","2026-11-10T01:02:16.121874+00:00","2026-09-29","733243","Animal & VeterinaryDrugs","Michael Tursi","2026-10-14T12:35:39.359+00:00","2026-08-04",{"id":256,"raw":257,"subject":262,"body_html":263,"body_text":264,"firm_name":245,"letter_id":265,"created_at":19,"fei_number":20,"letter_url":266,"updated_at":267,"action_type":23,"case_status":24,"posted_date":268,"marcs_cms_no":269,"product_type":27,"closeout_date":20,"issuing_office":261,"recipient_name":252,"body_fetched_at":270,"delivery_method":138,"recipient_title":20,"reference_number":20,"action_taken_date":271,"medical_device_id":20,"response_letter_date":20},1209,[258,259,260,261,262,13,13,13],"\u003Ctime datetime=\"2024-10-22T13:20:00Z\">10\u002F22\u002F2024\u003C\u002Ftime>\n","\u003Ctime datetime=\"2024-04-02T04:00:00Z\">04\u002F02\u002F2024\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fstokes-healthcare-inc-dba-epicur-pharma-677624-04022024\">Stokes Healthcare Inc. dba Epicur Pharma\u003C\u002Fa>","Division of Pharmaceutical Quality Operations I","Compounding Pharmacy\u002FAdulterated Drug Products","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Michael Tursi\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>CEO\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Stokes Healthcare Inc. dba Epicur Pharma\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>8000 Commerce Parkway, Suite 600\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Mount Laurel\u003C\u002Fspan>, \u003Cspan>NJ\u003C\u002Fspan> \u003Cspan>08054-2211\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:mtursi@stokespharmacy.com\"> mtursi@stokespharmacy.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Division of Pharmaceutical Quality Operations I\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER \u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>WL # 677624\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>April 2, 2024\u003C\u002Fp>\n\n\u003Cp>FEI: 3002815949\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Tursi:\u003C\u002Fp>\n\n\u003Cp>You registered your facility with the U.S. Food and Drug Administration (FDA) as an outsourcing facility under section 503B of the Federal Food, Drug, and Cosmetic Act (FDCA) [21 U.S.C. § 353b]\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> on January 30, 2018, and most recently on October 11, 2023. &nbsp;From September 26, 2023, to October 25, 2023, FDA investigators inspected your facility, Stokes Healthcare Inc. dba Epicur Pharma, located at 8000 Commerce Parkway, Suite 600, Mount Laurel, NJ 08054. &nbsp;During the inspection, the investigators collected evidence indicating that drug products you produced failed to meet the conditions of section 503B of the FDCA necessary for drugs produced by an outsourcing facility to qualify for exemptions from certain provisions of the FDCA. &nbsp;In addition, the investigators noted serious deficiencies in your practices for producing drug products intended or expected to be sterile, which put patients at risk. &nbsp; &nbsp;\u003C\u002Fp>\n\n\u003Cp>FDA issued a Form FDA 483 to your facility on October 25, 2023. &nbsp;FDA acknowledges receipt of your facility’s response, dated November 15, 2023. &nbsp;Based on this inspection, it appears you produced drugs that violate the FDCA. &nbsp;\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>A. &nbsp;Compounded Drug Products under the FDCA\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Under section 503B(b) of the FDCA, a compounder can register as an outsourcing facility with FDA. &nbsp;Drug products compounded by or under the direct supervision of a licensed pharmacist in an outsourcing facility qualify for exemptions from the drug approval requirements in section 505 of the FDCA [21 U.S.C. § 355(a)], the requirement in section 502(f)(1) of the FDCA [21 U.S.C. § 352(f)(1)] that labeling bear adequate directions for use and the Drug Supply Chain Security Act requirements in Section 582 of the FDCA [21 U.S.C. § 360eee1] if the conditions in section 503B of the FDCA are met.\u003Csup>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> &nbsp;\u003C\u002Fp>\n\n\u003Cp>An outsourcing facility, which is defined in section 503B(d)(4) of the FDCA [21 U.S.C. § 353b(d)(4)], is a facility at one geographic location or address that — (i) is engaged in the compounding of sterile drugs; (ii) has elected to register as an outsourcing facility; and (iii) complies with all of the requirements of this section. &nbsp;Outsourcing facilities must comply with other applicable provisions of the FDCA, including section 501(a)(2)(B) [21 U.S.C. § 351(a)(2)(B)], regarding current good manufacturing practice (CGMP), and section 501(a)(2)(A) [21 U.S.C. § 351(a)(2)(A)], regarding insanitary conditions. &nbsp;Generally, CGMP requirements for the preparation of drug products are established in Title 21 of the Code of Federal Regulations (CFR) parts 210 and 211.\u003C\u002Fp>\n\n\u003Cp>For a compounded drug product to qualify for the exemptions under section 503B, the labeling of the drug must include certain information (section 503B(a)(10) of the FDCA [21 U.S.C. §353b(a)(10)]). &nbsp;\u003C\u002Fp>\n\n\u003Cp>In addition, for a compounded drug product to qualify for the exemptions under section 503B, it must be compounded in an outsourcing facility that is in compliance with the registration and reporting requirements in section 503B(b), including the requirement to submit adverse event reports to FDA “in accordance with the content and format requirements established through guidance or regulation under section 310.305 of title 21, Code of Federal Regulations (or any successor &nbsp;regulations)” (section 503B(a)(1), (b)(5) of the FDCA [21 U.S.C. § 353b(a)(1), (b)(5)]). &nbsp;\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>B. &nbsp;Failure to Meet the Conditions of Section 503B\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>During the inspection, FDA investigators collected evidence indicating that drug products produced by your facility failed to meet the conditions of section 503B. &nbsp;For example, the investigators collected evidence indicating: &nbsp;\u003C\u002Fp>\n\n\u003Cp>1. Some of your facility’s drug products, such as various strengths of Tacrolimus (Aqueous) Ophthalmic Suspensions did not include the following information on the label: The quantity or proportion of each inactive ingredient. &nbsp;Additionally, some of your facility’s drug products, such as Tacrolimus (AQ) 0.5% Ophthalmic Suspension 10mL and Fluorouracil (AQ) PF 50mg\u002FmL Injection Solution 50ms, did not include the following information on the container: Information to facilitate adverse event reporting: www.fda.gov\u002Fmedwatch and 1-800-FDA-1088.&nbsp;\u003C\u002Fp>\n\n\u003Cp>2. Your facility did not submit adverse event reports to FDA in accordance with the content and format requirements established through guidance or regulation under section 310.305 of title 21, Code of Federal Regulations (or any successor regulations).\u003Csup>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> For example, your documented Standard Operating Procedures (SOPs) for reporting adverse events do not state that a follow-up report is to be submitted to FDA within 15 calendar days of receipt of new information or as requested by FDA (21 CFR 310.305(c)(2)).\u003C\u002Fp>\n\n\u003Cp>Because your compounded drug products have not met all of the conditions of section 503B, they are not eligible for the exemptions in that section from the FDA approval requirements of section 505, the requirement under section 502(f)(1) that labeling bear adequate directions for use, and the Drug Supply Chain Security Act requirements described in section 582 of the FDCA. &nbsp;\u003C\u002Fp>\n\n\u003Cp>Specific violations are described below.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>C. &nbsp;Violations of the FDCA\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Adulterated Drug Products\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>FDA investigators noted that drug products intended or expected to be sterile were prepared, packed, or held under insanitary conditions, whereby they may have become contaminated with filth or rendered injurious to health, causing your drug products to be adulterated under section 501(a)(2)(A) of the FDCA. &nbsp;For example, the investigators observed that:\u003C\u002Fp>\n\n\u003Cp>1. Your firm failed to conduct \u003Cstrong>(b)(4)\u003C\u002Fstrong> testing on \u003Cstrong>(b)(4)\u003C\u002Fstrong> used to sterilize the human drug product Fluorouracil PF. &nbsp;Therefore, you do not have assurance that the \u003Cstrong>(b)(4)\u003C\u002Fstrong> was integral throughout use. &nbsp;\u003C\u002Fp>\n\n\u003Cp>2. Your media fills were not performed under the most challenging or stressful conditions. &nbsp;Therefore, there is a lack of assurance that your firm can aseptically produce drug products within your facility. Specifically, your firm did not include higher risk production steps in your media fills, such as \u003Cstrong>(b)(4)\u003C\u002Fstrong> mixing of drug components in large vessels and \u003Cstrong>(b)(4)\u003C\u002Fstrong> to the finished drug product suspension. Additionally, sealed \u003Cstrong>(b)(4)\u003C\u002Fstrong> were used during media fills to protect media bottles during transfer from the \u003Cstrong>(b)(4)\u003C\u002Fstrong> to the ISO 5 classified critical areas, but these \u003Cstrong>(b)(4)\u003C\u002Fstrong> were not used during human drug production. &nbsp;\u003C\u002Fp>\n\n\u003Cp>3. Your firm failed to perform adequate smoke studies under dynamic conditions to demonstrate unidirectional airflow within the ISO 5 classified critical area, in that you did not include production steps that may impede airflow such as mixing drug lots in \u003Cstrong>(b)(4)\u003C\u002Fstrong> vessels. Therefore, your products intended to be sterile are produced in an environment that may not provide adequate protection against the risk of contamination. &nbsp;\u003C\u002Fp>\n\n\u003Cp>4. Your firm failed to ensure an adequate contact time for your sporicidal agent used to disinfect your aseptic processing areas. &nbsp;According to the \u003Cstrong>(b)(4)\u003C\u002Fstrong> label, the required dwell time for \u003Cstrong>(b)(4)\u003C\u002Fstrong> is \u003Cstrong>(b)(4)\u003C\u002Fstrong>, but your firm's SOP only requires a \u003Cstrong>(b)(4)\u003C\u002Fstrong> dwell time. &nbsp;Further, the investigators observed that a \u003Cstrong>(b)(4)\u003C\u002Fstrong> dwell time is not always achieved during cleaning and disinfection. &nbsp;\u003C\u002Fp>\n\n\u003Cp>FDA investigators also noted CGMP violations at your facility, that caused your drug products to be adulterated within the meaning of section 501(a)(2)(B) of the FDCA. &nbsp;The violations include, for example:\u003C\u002Fp>\n\n\u003Cp>1. Your firm failed to establish written responsibilities and procedures applicable to the quality control unit and to follow such written procedures (21 CFR 211.22(d)).\u003C\u002Fp>\n\n\u003Cp>2. Your firm failed to establish an adequate quality control unit with the responsibility and authority to approve or reject all components, drug product containers, closures, in-process materials, packaging materials, labeling, and drug products (21 CFR 211.22(a)).\u003C\u002Fp>\n\n\u003Cp>3. Your firm’s quality control unit failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).\u003C\u002Fp>\n\n\u003Cp>4. Your firm failed to establish written procedures for production and process control designed to assure that the drug products you manufacture have the identity, strength, quality, and purity they purport or are represented to possess (21 CFR 211.100(a)).\u003C\u002Fp>\n\n\u003Cp>5. Your firm failed to establish laboratory controls that include scientifically sound and appropriate specifications, standards, sampling plans, and test procedures designed to assure that components, drug product containers, closures, in-process materials, labeling, and drug products conform to appropriate standards of identity, strength, quality, and purity (21 CFR 211.160(b)).\u003C\u002Fp>\n\n\u003Cp>6. Your firm failed to establish and follow appropriate written procedures that are designed to prevent microbiological contamination of drug products purporting to be sterile, and that include validation of all aseptic and sterilization processes (21 CFR 211.113(b)).\u003C\u002Fp>\n\n\u003Cp>7. Your firm failed to establish an adequate system for monitoring environmental conditions in aseptic processing areas (21 CFR 211.42(c)(10)(iv)).\u003C\u002Fp>\n\n\u003Cp>8. Your firm failed to establish an adequate air supply filtered through high-efficiency particulate air filters under positive pressure in the aseptic processing areas (21 CFR 211.42(c)(10)(iii)).\u003C\u002Fp>\n\n\u003Cp>9. Your firm failed to establish an adequate system for cleaning and disinfecting the room and equipment to produce aseptic conditions (21 CFR 211.42(c)(10)(v)).\u003C\u002Fp>\n\n\u003Cp>Outsourcing facilities must comply with CGMP requirements under section 501(a)(2)(B) of the FDCA. &nbsp;FDA’s regulations regarding CGMP requirements for the preparation of drug products have been established in 21 CFR parts 210 and 211. &nbsp;FDA intends to promulgate more specific CGMP regulations for outsourcing facilities. &nbsp;FDA has issued a revised draft guidance, \u003Cem>Current Good Manufacturing Practice — Guidance for Human Drug Compounding Outsourcing Facilities under Section 503B of the FD&amp;C Act\u003C\u002Fem>. &nbsp;This draft guidance, when finalized, will describe FDA’s expectations regarding outsourcing facilities and the CGMP requirements in 21 CFR parts 210 and 211 until more specific CGMP regulations for outsourcing facilities are promulgated. &nbsp;\u003C\u002Fp>\n\n\u003Cp>It is a prohibited act under section 301(k) of the FDCA [21 U.S.C. § 331(k)] to do any act with respect to a drug, if such act is done while the drug is held for sale after shipment in interstate commerce and results in the drug being adulterated.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Misbranded Drug Products\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>You compound drug products that are intended for conditions not amenable to self-diagnosis and treatment by individuals who are not medical practitioners; therefore, adequate directions for use cannot be written so that a layman can use these products safely for their intended uses. &nbsp;Consequently, their labeling fails to bear adequate directions for their intended uses causing them to be misbranded under section 502(f)(1) of the FDCA.\u003Csup>\u003Cem>\u003Cstrong>4\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> &nbsp;It is a prohibited act under section 301(k) of the FDCA to do any act with respect to a drug, if such act is done while the drug is held for sale after shipment in interstate commerce and results in the drug being misbranded.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>D. &nbsp;Corrective Actions\u003C\u002Fstrong> &nbsp;\u003C\u002Fp>\n\n\u003Cp>We have reviewed your facility’s responses to the Form FDA 483. &nbsp;\u003C\u002Fp>\n\n\u003Cp>Regarding your responses related to the insanitary conditions and CGMP violations, some of your proposed corrective actions appear adequate. &nbsp;However, the following corrective actions appear deficient:\u003C\u002Fp>\n\n\u003Cp>1. In your response regarding your Quality Unit failing to prevent numerous significant deficiencies, you did not assess the need and develop plans to strengthen quality oversight to ensure deficiencies do not reoccur. &nbsp;\u003C\u002Fp>\n\n\u003Cp>2. Concerning the release of non-conforming human drug products, you did not commit to improving Quality Unit training and oversight to prevent recurrence. &nbsp;Additionally, your response did not consider the unsuitability of:\u003C\u002Fp>\n\n\u003Cp>&nbsp; a. Modifying the potency test method to obtain passing potency results without scientific justification and revalidation, and without assessing the impact of these changes on the accuracy of the potency results for all previously distributed batches within expiry; &nbsp;\u003C\u002Fp>\n\n\u003Cp>&nbsp; b. Invalidating original potency results based on resampling results without scientific justification. &nbsp;\u003C\u002Fp>\n\n\u003Cp>3. Regarding process validation for your human drug products, you stated that you would execute the necessary validations; however, you did not perform a risk assessment to determine the impact of failing to perform process validations on the quality of the drug products that you previously and continue to distribute. &nbsp;Additionally, you did not provide validation plans or executed validation studies for FDA’s evaluation. &nbsp;\u003C\u002Fp>\n\n\u003Cp>4. In your response, you provided an executed potency test method validation protocol for your Tacrolimus AQ human drug products; however, this test method remains unvalidated because the validation study:\u003C\u002Fp>\n\n\u003Cp>&nbsp; a. Lacked scientific rationale to justify establishing some of the relative standard deviations limits at \u003Cstrong>(b)(4)\u003C\u002Fstrong>; &nbsp;\u003C\u002Fp>\n\n\u003Cp>&nbsp; b. Documented significant intra-batch potency variability; &nbsp;\u003C\u002Fp>\n\n\u003Cp>&nbsp; c. Did not record chromatography column temperature information for specificity, limit of quantification, limit of detection, linearity, accuracy, precision, intermediate precision, and stability testing; &nbsp;\u003C\u002Fp>\n\n\u003Cp>&nbsp; d. Concluded that the analytical results meet all acceptance criteria, although some sample results failed to meet specifications. &nbsp;\u003C\u002Fp>\n\n\u003Cp>Additionally, you did not consider the impact of these test method changes on the accuracy of the potency results for all previously distributed batches within expiry. &nbsp;\u003C\u002Fp>\n\n\u003Cp>5. In your response, you commit to completing new media fill studies; however, the provided media fill protocol does not include simulating the high-risk step of \u003Cstrong>(b)(4)\u003C\u002Fstrong> drug product suspension. &nbsp;\u003C\u002Fp>\n\n\u003Cp>6. In your response, you stated that you provided a smoke study capturing the missing production activities cited in the FDA observation. &nbsp;However, our review of this new smoke study finds it to be inadequate because it does not include simulating the higher risk production steps of diluting and mixing the drug components using large volume vessels. &nbsp;\u003C\u002Fp>\n\n\u003Cp>7. Regarding your environmental monitoring program response, you indicated in your response that historical data will be used to justify sampling locations; however, you have not performed a risk assessment to determine if historical sampling sites meaningfully represent high risk operating conditions. &nbsp;Further, you did not provide the referenced change control CC-23-021 or details about your proposed risk assessment. &nbsp;\u003C\u002Fp>\n\n\u003Cp>8. In your response, you stated that your firm’s media fill studies, smoke studies, and environmental monitoring program are supporting indicators that your HEPA filter airflow velocities are adequate; however, the current FDA inspection found deficiencies in each of these areas. As such, you have not provided scientific evidence to demonstrate that the wide ranges of airflow velocities generated by your HEPA filters do not adversely impact the airflow patterns inside your ISO 5 classified critical areas.\u003C\u002Fp>\n\n\u003Cp>9. &nbsp;You did not provide a response regarding your investigations failing to include root cause analysis and extension to other lots that may have been associated.\u003C\u002Fp>\n\n\u003Cp>Additionally, we are unable to fully evaluate some of your corrective actions due to lack of adequate supporting documentation: &nbsp;\u003C\u002Fp>\n\n\u003Cp>1. In your response, you commit to improving the timely closing of your investigations; however, you did not provide the referenced revised standard operating procedures and the Interim Status Report form. &nbsp;\u003C\u002Fp>\n\n\u003Cp>2. In your response, you commit to performing \u003Cstrong>(b)(4)\u003C\u002Fstrong> testing; however, your firm did not provide evidence that you have purchased the referenced \u003Cstrong>(b)(4)\u003C\u002Fstrong> Tester, or revised your standard operating procedures and master batch records. &nbsp;Additionally, while you stated you would perform additional sterility testing, the sterility test in itself is not indicative that the batch is sterile, because when contamination is present, it is not uniformly distributed throughout the batch. &nbsp;Therefore, aseptic processing controls, such as \u003Cstrong>(b)(4)\u003C\u002Fstrong> testing, are critical for ensuring the sterility of the finished drug products. &nbsp;\u003C\u002Fp>\n\n\u003Cp>3. We acknowledge that you commit to performing a disinfection efficacy study; however, you did not provide information about the study goals and the protocol details. &nbsp;\u003C\u002Fp>\n\n\u003Cp>Furthermore, our review of data collected during the inspection revealed that your firm detected an adverse trend of \u003Cem>Mucor circinelloides\u003C\u002Fem> fungal contamination between November 3, 2022, and July 10, 2023, in your ISO 8 classified cleanrooms C715, C711, and C735. &nbsp;The \u003Cstrong>(b)(4)\u003C\u002Fstrong> located in cleanroom C715 is used to sterilize the drug components for Tacrolimus AQ, a human drug product intended to be sterile, which are then transported through C711 and C735 on route to the cleanrooms C704 and C706 where aseptic mixing and filling operations occur. &nbsp;Your Quality Unit did not investigate this adverse trend to determine and correct the root cause of the contamination and the impact the contamination may have had on the human drug product components that were exposed to these cleanrooms, and instead produced and distributed \u003Cstrong>(b)(4)\u003C\u002Fstrong> lots of Tacrolimus AQ during this period. &nbsp;\u003C\u002Fp>\n\n\u003Cp>In addition to the issues discussed above, you should note that CGMP requires the implementation of quality oversight and controls over the manufacture of drugs, including the safety of raw materials, materials used in drug manufacturing, and finished drug products. See section 501 of the FDCA. &nbsp;If you choose to contract with a laboratory to perform some functions required by CGMP, it is essential that you select a qualified contractor and that you maintain sufficient oversight of the contractor’s operations to ensure that it is fully CGMP compliant. &nbsp;Regardless of whether you rely on a contract facility, you are responsible for assuring that drugs you produce are neither adulterated nor misbranded. &nbsp;[See 21 CFR 210.1(b), 21 CFR 200.10(b).]\u003C\u002Fp>\n\n\u003Cp>In addition, regarding observations related to the conditions of section 503B of the FDCA, some of your corrective actions appear adequate: You state that the adverse event reporting information will be added to the packaging for the drug product. &nbsp;\u003C\u002Fp>\n\n\u003Cp>You did not address certain observations related to the conditions of section 503B of the FDCA, for example: You state that you list inactive ingredients proportionally from largest to smallest on your product labels and that each label states “INACTIVE(S) (proportional from largest to smallest amount)”, but such a list does not provide the quantity or proportion of each inactive ingredient. &nbsp;\u003C\u002Fp>\n\n\u003Cp>With respect to your documented SOPs for reporting adverse events, FDA expects to evaluate compliance with section 503B(b)(5) of the FDCA upon reviewing any updated copy of your adverse event reporting SOPs that you submit in response to this letter. &nbsp;\u003C\u002Fp>\n\n\u003Cp>Should you continue to compound and distribute drug products that do not meet the conditions of section 503B, the compounding and distribution of your drugs would be subject to the new drug approval requirement, the requirement to label drug products with adequate directions for use, and the Drug Supply Chain Security Act requirements. &nbsp;\u003C\u002Fp>\n\n\u003Cp>FDA strongly recommends that your management undertake a comprehensive assessment of operations, including facility design, procedures, personnel, processes, maintenance, materials, and systems. &nbsp;In particular, this review should assess your aseptic processing operations. &nbsp;A third-party consultant with relevant sterile drug manufacturing expertise should assist you in conducting this comprehensive evaluation. &nbsp;\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>E. &nbsp;Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The violations cited in this letter are not intended to be an all-inclusive statement of violations at your facility. &nbsp;You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. &nbsp;It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\n\n\u003Cp>You should take prompt action to address any violations. &nbsp;Failure to adequately address any violations may result in legal action without further notice, including, without limitation, seizure and injunction. &nbsp;\u003C\u002Fp>\n\n\u003Cp>Within fifteen (15) working days of receipt of this letter, please notify this office in writing of the specific steps that you have taken to address any violations. &nbsp;Please include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. &nbsp;This letter notifies you of our concerns and provides you an opportunity to address them. &nbsp;If you believe your products are not in violation of the FDCA, include your reasoning and any supporting information for our consideration. &nbsp;If you cannot completely address this matter within fifteen (15) working days, state the reason for the delay and the time within which you will do so. &nbsp;\u003C\u002Fp>\n\n\u003Cp>Your written notification should refer to the Warning Letter Number above (\u003Cstrong>WL #677624\u003C\u002Fstrong>). Please address your reply to: CAPT Liatte Closs, Acting Director of Compliance, orapharm1_responses@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>If you have questions regarding the contents of this letter, please contact Compliance Officer, Juan Jimenez, at orapharm1_responses@fda.hhs.gov and juan.jimenez@fda.hhs.gov or at 973-832-9409. Please identify your communications with \u003Cstrong>FEI: 3002815949\u003C\u002Fstrong>.\u003C\u002Fp>\n\n\u003Cp>We appreciate your acknowledgement in receipt of this communication.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003Cbr>\nLisa Harlan\u003Cbr>\nProgram Division Director\u003Cbr>\nOffice of Pharmaceutical Quality Operations Division I &nbsp;\u003C\u002Fp>\n\n\u003Cp>_________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1&nbsp;\u003C\u002Fstrong>\u003C\u002Fem>See Pub. L. No. 113-54, § 102(a), 127 Stat. 587, 587-588 (2013).\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>2&nbsp;\u003C\u002Fstrong>\u003C\u002Fem>We remind you that there are conditions, other than those discussed in this letter, that must be satisfied to qualify for the exemptions in section 503B of the FDCA.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>3&nbsp;\u003C\u002Fstrong>\u003C\u002Fem>For more information, see, FDA’s guidance, “Adverse Event Reporting for Outsourcing Facilities Under Section 503B of the Federal Food, Drug, and Cosmetic Act,” which can be found at https:\u002F\u002Fwww.fda.gov\u002Fdownloads\u002FDrugs\u002FGuidanceComplianceRegulatoryInformation\u002FGuidances\u002FUCM434188.pdf.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>4&nbsp;\u003C\u002Fstrong>\u003C\u002Fem>Your compounded drug products are not exempted from the requirements of section 502(f)(1) of the FDCA by regulations issued by the FDA (see, e.g., 21 CFR 201.115).\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA Electronic Mail\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMichael Tursi\n\nRecipient Title\n\nCEO\n\nStokes Healthcare Inc. dba Epicur Pharma\n\n8000 Commerce Parkway, Suite 600\n\nMount Laurel, NJ 08054-2211\n\nUnited States\n\nmtursi@stokespharmacy.com\n\nIssuing Office:\n\nDivision of Pharmaceutical Quality Operations I\n\nUnited States\n\nWARNING LETTER\n\nWL # 677624\n\nApril 2, 2024\n\nFEI: 3002815949\n\nDear Mr. Tursi:\n\nYou registered your facility with the U.S. Food and Drug Administration (FDA) as an outsourcing facility under section 503B of the Federal Food, Drug, and Cosmetic Act (FDCA) [21 U.S.C. § 353b]1 on January 30, 2018, and most recently on October 11, 2023. From September 26, 2023, to October 25, 2023, FDA investigators inspected your facility, Stokes Healthcare Inc. dba Epicur Pharma, located at 8000 Commerce Parkway, Suite 600, Mount Laurel, NJ 08054. During the inspection, the investigators collected evidence indicating that drug products you produced failed to meet the conditions of section 503B of the FDCA necessary for drugs produced by an outsourcing facility to qualify for exemptions from certain provisions of the FDCA. In addition, the investigators noted serious deficiencies in your practices for producing drug products intended or expected to be sterile, which put patients at risk.\n\nFDA issued a Form FDA 483 to your facility on October 25, 2023. FDA acknowledges receipt of your facility’s response, dated November 15, 2023. Based on this inspection, it appears you produced drugs that violate the FDCA.\n\nA. Compounded Drug Products under the FDCA\n\nUnder section 503B(b) of the FDCA, a compounder can register as an outsourcing facility with FDA. Drug products compounded by or under the direct supervision of a licensed pharmacist in an outsourcing facility qualify for exemptions from the drug approval requirements in section 505 of the FDCA [21 U.S.C. § 355(a)], the requirement in section 502(f)(1) of the FDCA [21 U.S.C. § 352(f)(1)] that labeling bear adequate directions for use and the Drug Supply Chain Security Act requirements in Section 582 of the FDCA [21 U.S.C. § 360eee1] if the conditions in section 503B of the FDCA are met.2\n\nAn outsourcing facility, which is defined in section 503B(d)(4) of the FDCA [21 U.S.C. § 353b(d)(4)], is a facility at one geographic location or address that — (i) is engaged in the compounding of sterile drugs; (ii) has elected to register as an outsourcing facility; and (iii) complies with all of the requirements of this section. Outsourcing facilities must comply with other applicable provisions of the FDCA, including section 501(a)(2)(B) [21 U.S.C. § 351(a)(2)(B)], regarding current good manufacturing practice (CGMP), and section 501(a)(2)(A) [21 U.S.C. § 351(a)(2)(A)], regarding insanitary conditions. Generally, CGMP requirements for the preparation of drug products are established in Title 21 of the Code of Federal Regulations (CFR) parts 210 and 211.\n\nFor a compounded drug product to qualify for the exemptions under section 503B, the labeling of the drug must include certain information (section 503B(a)(10) of the FDCA [21 U.S.C. §353b(a)(10)]).\n\nIn addition, for a compounded drug product to qualify for the exemptions under section 503B, it must be compounded in an outsourcing facility that is in compliance with the registration and reporting requirements in section 503B(b), including the requirement to submit adverse event reports to FDA “in accordance with the content and format requirements established through guidance or regulation under section 310.305 of title 21, Code of Federal Regulations (or any successor regulations)” (section 503B(a)(1), (b)(5) of the FDCA [21 U.S.C. § 353b(a)(1), (b)(5)]).\n\nB. Failure to Meet the Conditions of Section 503B\n\nDuring the inspection, FDA investigators collected evidence indicating that drug products produced by your facility failed to meet the conditions of section 503B. For example, the investigators collected evidence indicating:\n\n1. Some of your facility’s drug products, such as various strengths of Tacrolimus (Aqueous) Ophthalmic Suspensions did not include the following information on the label: The quantity or proportion of each inactive ingredient. Additionally, some of your facility’s drug products, such as Tacrolimus (AQ) 0.5% Ophthalmic Suspension 10mL and Fluorouracil (AQ) PF 50mg\u002FmL Injection Solution 50ms, did not include the following information on the container: Information to facilitate adverse event reporting: www.fda.gov\u002Fmedwatch and 1-800-FDA-1088.\n\n2. Your facility did not submit adverse event reports to FDA in accordance with the content and format requirements established through guidance or regulation under section 310.305 of title 21, Code of Federal Regulations (or any successor regulations).3 For example, your documented Standard Operating Procedures (SOPs) for reporting adverse events do not state that a follow-up report is to be submitted to FDA within 15 calendar days of receipt of new information or as requested by FDA (21 CFR 310.305(c)(2)).\n\nBecause your compounded drug products have not met all of the conditions of section 503B, they are not eligible for the exemptions in that section from the FDA approval requirements of section 505, the requirement under section 502(f)(1) that labeling bear adequate directions for use, and the Drug Supply Chain Security Act requirements described in section 582 of the FDCA.\n\nSpecific violations are described below.\n\nC. Violations of the FDCA\n\nAdulterated Drug Products\n\nFDA investigators noted that drug products intended or expected to be sterile were prepared, packed, or held under insanitary conditions, whereby they may have become contaminated with filth or rendered injurious to health, causing your drug products to be adulterated under section 501(a)(2)(A) of the FDCA. For example, the investigators observed that:\n\n1. Your firm failed to conduct (b)(4) testing on (b)(4) used to sterilize the human drug product Fluorouracil PF. Therefore, you do not have assurance that the (b)(4) was integral throughout use.\n\n2. Your media fills were not performed under the most challenging or stressful conditions. Therefore, there is a lack of assurance that your firm can aseptically produce drug products within your facility. Specifically, your firm did not include higher risk production steps in your media fills, such as (b)(4) mixing of drug components in large vessels and (b)(4) to the finished drug product suspension. Additionally, sealed (b)(4) were used during media fills to protect media bottles during transfer from the (b)(4) to the ISO 5 classified critical areas, but these (b)(4) were not used during human drug production.\n\n3. Your firm failed to perform adequate smoke studies under dynamic conditions to demonstrate unidirectional airflow within the ISO 5 classified critical area, in that you did not include production steps that may impede airflow such as mixing drug lots in (b)(4) vessels. Therefore, your products intended to be sterile are produced in an environment that may not provide adequate protection against the risk of contamination.\n\n4. Your firm failed to ensure an adequate contact time for your sporicidal agent used to disinfect your aseptic processing areas. According to the (b)(4) label, the required dwell time for (b)(4) is (b)(4), but your firm's SOP only requires a (b)(4) dwell time. Further, the investigators observed that a (b)(4) dwell time is not always achieved during cleaning and disinfection.\n\nFDA investigators also noted CGMP violations at your facility, that caused your drug products to be adulterated within the meaning of section 501(a)(2)(B) of the FDCA. The violations include, for example:\n\n1. Your firm failed to establish written responsibilities and procedures applicable to the quality control unit and to follow such written procedures (21 CFR 211.22(d)).\n\n2. Your firm failed to establish an adequate quality control unit with the responsibility and authority to approve or reject all components, drug product containers, closures, in-process materials, packaging materials, labeling, and drug products (21 CFR 211.22(a)).\n\n3. Your firm’s quality control unit failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).\n\n4. Your firm failed to establish written procedures for production and process control designed to assure that the drug products you manufacture have the identity, strength, quality, and purity they purport or are represented to possess (21 CFR 211.100(a)).\n\n5. Your firm failed to establish laboratory controls that include scientifically sound and appropriate specifications, standards, sampling plans, and test procedures designed to assure that components, drug product containers, closures, in-process materials, labeling, and drug products conform to appropriate standards of identity, strength, quality, and purity (21 CFR 211.160(b)).\n\n6. Your firm failed to establish and follow appropriate written procedures that are designed to prevent microbiological contamination of drug products purporting to be sterile, and that include validation of all aseptic and sterilization processes (21 CFR 211.113(b)).\n\n7. Your firm failed to establish an adequate system for monitoring environmental conditions in aseptic processing areas (21 CFR 211.42(c)(10)(iv)).\n\n8. Your firm failed to establish an adequate air supply filtered through high-efficiency particulate air filters under positive pressure in the aseptic processing areas (21 CFR 211.42(c)(10)(iii)).\n\n9. Your firm failed to establish an adequate system for cleaning and disinfecting the room and equipment to produce aseptic conditions (21 CFR 211.42(c)(10)(v)).\n\nOutsourcing facilities must comply with CGMP requirements under section 501(a)(2)(B) of the FDCA. FDA’s regulations regarding CGMP requirements for the preparation of drug products have been established in 21 CFR parts 210 and 211. FDA intends to promulgate more specific CGMP regulations for outsourcing facilities. FDA has issued a revised draft guidance, Current Good Manufacturing Practice — Guidance for Human Drug Compounding Outsourcing Facilities under Section 503B of the FD&C Act. This draft guidance, when finalized, will describe FDA’s expectations regarding outsourcing facilities and the CGMP requirements in 21 CFR parts 210 and 211 until more specific CGMP regulations for outsourcing facilities are promulgated.\n\nIt is a prohibited act under section 301(k) of the FDCA [21 U.S.C. § 331(k)] to do any act with respect to a drug, if such act is done while the drug is held for sale after shipment in interstate commerce and results in the drug being adulterated.\n\nMisbranded Drug Products\n\nYou compound drug products that are intended for conditions not amenable to self-diagnosis and treatment by individuals who are not medical practitioners; therefore, adequate directions for use cannot be written so that a layman can use these products safely for their intended uses. Consequently, their labeling fails to bear adequate directions for their intended uses causing them to be misbranded under section 502(f)(1) of the FDCA.4 It is a prohibited act under section 301(k) of the FDCA to do any act with respect to a drug, if such act is done while the drug is held for sale after shipment in interstate commerce and results in the drug being misbranded.\n\nD. Corrective Actions\n\nWe have reviewed your facility’s responses to the Form FDA 483.\n\nRegarding your responses related to the insanitary conditions and CGMP violations, some of your proposed corrective actions appear adequate. However, the following corrective actions appear deficient:\n\n1. In your response regarding your Quality Unit failing to prevent numerous significant deficiencies, you did not assess the need and develop plans to strengthen quality oversight to ensure deficiencies do not reoccur.\n\n2. Concerning the release of non-conforming human drug products, you did not commit to improving Quality Unit training and oversight to prevent recurrence. Additionally, your response did not consider the unsuitability of:\n\na. Modifying the potency test method to obtain passing potency results without scientific justification and revalidation, and without assessing the impact of these changes on the accuracy of the potency results for all previously distributed batches within expiry;\n\nb. Invalidating original potency results based on resampling results without scientific justification.\n\n3. Regarding process validation for your human drug products, you stated that you would execute the necessary validations; however, you did not perform a risk assessment to determine the impact of failing to perform process validations on the quality of the drug products that you previously and continue to distribute. Additionally, you did not provide validation plans or executed validation studies for FDA’s evaluation.\n\n4. In your response, you provided an executed potency test method validation protocol for your Tacrolimus AQ human drug products; however, this test method remains unvalidated because the validation study:\n\na. Lacked scientific rationale to justify establishing some of the relative standard deviations limits at (b)(4);\n\nb. Documented significant intra-batch potency variability;\n\nc. Did not record chromatography column temperature information for specificity, limit of quantification, limit of detection, linearity, accuracy, precision, intermediate precision, and stability testing;\n\nd. Concluded that the analytical results meet all acceptance criteria, although some sample results failed to meet specifications.\n\nAdditionally, you did not consider the impact of these test method changes on the accuracy of the potency results for all previously distributed batches within expiry.\n\n5. In your response, you commit to completing new media fill studies; however, the provided media fill protocol does not include simulating the high-risk step of (b)(4) drug product suspension.\n\n6. In your response, you stated that you provided a smoke study capturing the missing production activities cited in the FDA observation. However, our review of this new smoke study finds it to be inadequate because it does not include simulating the higher risk production steps of diluting and mixing the drug components using large volume vessels.\n\n7. Regarding your environmental monitoring program response, you indicated in your response that historical data will be used to justify sampling locations; however, you have not performed a risk assessment to determine if historical sampling sites meaningfully represent high risk operating conditions. Further, you did not provide the referenced change control CC-23-021 or details about your proposed risk assessment.\n\n8. In your response, you stated that your firm’s media fill studies, smoke studies, and environmental monitoring program are supporting indicators that your HEPA filter airflow velocities are adequate; however, the current FDA inspection found deficiencies in each of these areas. As such, you have not provided scientific evidence to demonstrate that the wide ranges of airflow velocities generated by your HEPA filters do not adversely impact the airflow patterns inside your ISO 5 classified critical areas.\n\n9. You did not provide a response regarding your investigations failing to include root cause analysis and extension to other lots that may have been associated.\n\nAdditionally, we are unable to fully evaluate some of your corrective actions due to lack of adequate supporting documentation:\n\n1. In your response, you commit to improving the timely closing of your investigations; however, you did not provide the referenced revised standard operating procedures and the Interim Status Report form.\n\n2. In your response, you commit to performing (b)(4) testing; however, your firm did not provide evidence that you have purchased the referenced (b)(4) Tester, or revised your standard operating procedures and master batch records. Additionally, while you stated you would perform additional sterility testing, the sterility test in itself is not indicative that the batch is sterile, because when contamination is present, it is not uniformly distributed throughout the batch. Therefore, aseptic processing controls, such as (b)(4) testing, are critical for ensuring the sterility of the finished drug products.\n\n3. We acknowledge that you commit to performing a disinfection efficacy study; however, you did not provide information about the study goals and the protocol details.\n\nFurthermore, our review of data collected during the inspection revealed that your firm detected an adverse trend of Mucor circinelloides fungal contamination between November 3, 2022, and July 10, 2023, in your ISO 8 classified cleanrooms C715, C711, and C735. The (b)(4) located in cleanroom C715 is used to sterilize the drug components for Tacrolimus AQ, a human drug product intended to be sterile, which are then transported through C711 and C735 on route to the cleanrooms C704 and C706 where aseptic mixing and filling operations occur. Your Quality Unit did not investigate this adverse trend to determine and correct the root cause of the contamination and the impact the contamination may have had on the human drug product components that were exposed to these cleanrooms, and instead produced and distributed (b)(4) lots of Tacrolimus AQ during this period.\n\nIn addition to the issues discussed above, you should note that CGMP requires the implementation of quality oversight and controls over the manufacture of drugs, including the safety of raw materials, materials used in drug manufacturing, and finished drug products. See section 501 of the FDCA. If you choose to contract with a laboratory to perform some functions required by CGMP, it is essential that you select a qualified contractor and that you maintain sufficient oversight of the contractor’s operations to ensure that it is fully CGMP compliant. Regardless of whether you rely on a contract facility, you are responsible for assuring that drugs you produce are neither adulterated nor misbranded. [See 21 CFR 210.1(b), 21 CFR 200.10(b).]\n\nIn addition, regarding observations related to the conditions of section 503B of the FDCA, some of your corrective actions appear adequate: You state that the adverse event reporting information will be added to the packaging for the drug product.\n\nYou did not address certain observations related to the conditions of section 503B of the FDCA, for example: You state that you list inactive ingredients proportionally from largest to smallest on your product labels and that each label states “INACTIVE(S) (proportional from largest to smallest amount)”, but such a list does not provide the quantity or proportion of each inactive ingredient.\n\nWith respect to your documented SOPs for reporting adverse events, FDA expects to evaluate compliance with section 503B(b)(5) of the FDCA upon reviewing any updated copy of your adverse event reporting SOPs that you submit in response to this letter.\n\nShould you continue to compound and distribute drug products that do not meet the conditions of section 503B, the compounding and distribution of your drugs would be subject to the new drug approval requirement, the requirement to label drug products with adequate directions for use, and the Drug Supply Chain Security Act requirements.\n\nFDA strongly recommends that your management undertake a comprehensive assessment of operations, including facility design, procedures, personnel, processes, maintenance, materials, and systems. In particular, this review should assess your aseptic processing operations. A third-party consultant with relevant sterile drug manufacturing expertise should assist you in conducting this comprehensive evaluation.\n\nE. Conclusion\n\nThe violations cited in this letter are not intended to be an all-inclusive statement of violations at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\n\nYou should take prompt action to address any violations. Failure to adequately address any violations may result in legal action without further notice, including, without limitation, seizure and injunction.\n\nWithin fifteen (15) working days of receipt of this letter, please notify this office in writing of the specific steps that you have taken to address any violations. Please include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. This letter notifies you of our concerns and provides you an opportunity to address them. If you believe your products are not in violation of the FDCA, include your reasoning and any supporting information for our consideration. If you cannot completely address this matter within fifteen (15) working days, state the reason for the delay and the time within which you will do so.\n\nYour written notification should refer to the Warning Letter Number above (WL #677624). Please address your reply to: CAPT Liatte Closs, Acting Director of Compliance, orapharm1_responses@fda.hhs.gov.\n\nIf you have questions regarding the contents of this letter, please contact Compliance Officer, Juan Jimenez, at orapharm1_responses@fda.hhs.gov and juan.jimenez@fda.hhs.gov or at 973-832-9409. Please identify your communications with FEI: 3002815949.\n\nWe appreciate your acknowledgement in receipt of this communication.\n\nSincerely,\n\n\u002FS\u002F\n\nLisa Harlan\n\nProgram Division Director\n\nOffice of Pharmaceutical Quality Operations Division I\n\n_________________\n\n1 See Pub. L. No. 113-54, § 102(a), 127 Stat. 587, 587-588 (2013).\n\n2 We remind you that there are conditions, other than those discussed in this letter, that must be satisfied to qualify for the exemptions in section 503B of the FDCA.\n\n3 For more information, see, FDA’s guidance, “Adverse Event Reporting for Outsourcing Facilities Under Section 503B of the Federal Food, Drug, and Cosmetic Act,” which can be found at https:\u002F\u002Fwww.fda.gov\u002Fdownloads\u002FDrugs\u002FGuidanceComplianceRegulatoryInformation\u002FGuidances\u002FUCM434188.pdf.\n\n4 Your compounded drug products are not exempted from the requirements of section 502(f)(1) of the FDCA by regulations issued by the FDA (see, e.g., 21 CFR 201.115).","stokes-healthcare-inc-dba-epicur-pharma-677624-04022024","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fstokes-healthcare-inc-dba-epicur-pharma-677624-04022024","2026-10-26T08:10:06.14804+00:00","2024-10-22","677624","2026-08-19T22:17:46.429+00:00","2024-04-02",{"id":273,"raw":274,"subject":14,"body_html":277,"body_text":278,"firm_name":279,"letter_id":280,"created_at":171,"fei_number":20,"letter_url":281,"updated_at":248,"action_type":23,"case_status":24,"posted_date":249,"marcs_cms_no":282,"product_type":176,"closeout_date":20,"issuing_office":11,"recipient_name":283,"body_fetched_at":284,"delivery_method":179,"recipient_title":20,"reference_number":285,"action_taken_date":286,"medical_device_id":20,"response_letter_date":20},21706,[238,275,276,11,14,13,13,13],"\u003Ctime datetime=\"2026-09-21T04:00:00Z\">09\u002F21\u002F2026\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fbabikian-healthcare-products-cjsc-730513-09212026\">Babikian Healthcare Products CJSC\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA ELECTRONIC MAIL READ\u002FDELIVERY RECEIPT REQUESTED\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>320-26-128\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n                          \u003Cbr>Over-the-Counter Drugs\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Dr. Dikran Babikian\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Chief Executive Officer \u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Babikian Healthcare Products CJSC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>Gevorg Chaush Highway 90\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>2413\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Proshyan Community\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Kotayk\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Armenia\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:(b)(4)\"> (b)(4)\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>September 21, 2026\u003C\u002Fp>\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003Cbr>Reference number: 320-26-128\u003C\u002Fp>\u003Cp>To Dr. Dikran Babikian:\u003C\u002Fp>\u003Cp>This warning letter advises you of significant violations identified during a U.S. Food and Drug Administration (FDA) review of records submitted from your facility. Promptly address the violations described herein without delay, including ensuring that appropriate resources are allocated to fully address the violations and prevent their recurrence. This is not intended to be an all-inclusive list of the violations that exist at your facility. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations. Failure to adequately address violations may result in regulatory action without further notice.\u003C\u002Fp>\u003Cp>\u003Cstrong>FDA Review\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Violations were identified and documented during review of your drug manufacturing facility, Babikian Healthcare Products CJSC, FDA Establishment Identifier (FEI) 3027526825.\u003Cem>\u003Cstrong>\u003Csup>1\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> This review was conducted under FDA’s statutory authority and public health responsibilities to protect the public from unsafe, ineffective, and poor quality drugs.\u003C\u002Fp>\u003Cp>Your facility is registered with the FDA as a manufacturer of over-the-counter (OTC) drug products. FDA has reviewed the records you submitted in response to our August 12, 2025 request for records and other information pursuant to section 704(a)(4) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) for your facility.\u003C\u002Fp>\u003Cp>This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations, parts 210 and 211 (21 CFR, parts 210 and 211).\u003C\u002Fp>\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding of drugs as described in your response to our 704(a)(4) request do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) (21 U.S.C. 351(a)(2)(B)).\u003C\u002Fp>\u003Cp>\u003Cstrong>Violations of the Federal Food, Drug, and Cosmetic Act\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The following are violations identified during our review. As a reminder, this is not an all-inclusive list of violations at your facility.\u003C\u002Fp>\u003Cp>\u003Cstrong>1. Your firm failed to conduct at least one test to verify the identity of each component of a drug product. Your firm also failed to validate and establish the reliability of your component supplier’s test analyses at appropriate intervals (21 CFR 211.84(d)(1) &amp; 211.84(d)(2)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your firm manufactures OTC drug products, including \u003Cstrong>(b)(4)\u003C\u002Fstrong>, intended for the U.S. market. Your response to our request for records and information under section 704(a)(4) indicated that you do not test the identity of each incoming component, \u003Cstrong>(b)(4)\u003C\u002Fstrong>, used in the manufacture of your drug products prior to manufacturing. Your response also indicated that you accept your suppliers’ certificates of analyses without verifying the test results at appropriate intervals.\u003C\u002Fp>\u003Cp>You also did not provide evidence that \u003Cstrong>(b)(4)\u003C\u002Fstrong>, the active ingredients in your drug products, meet USP limits for \u003Cstrong>(b)(4)\u003C\u002Fstrong>. See FDA’s guidance document \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F173005\u002Fdownload.\">.\u003C\u002Fa>\u003C\u002Fp>\u003Cp>Without adequate testing and verification of supplier results, you do not have scientific evidence that your incoming components conform to appropriate specifications prior to use in the manufacture of your drugs. As a manufacturer, you have a responsibility to sample, test, and examine incoming materials before use in production to assure adequate quality.\u003C\u002Fp>\u003Cp>\u003Cstrong>2. Your firm failed to have, for each batch of drug product, appropriate laboratory determination of satisfactory conformance to final specifications for the drug product, including the identity and strength of each active ingredient, prior to release. Your firm also failed to conduct appropriate laboratory testing, as necessary, for each batch of drug product required to be free of objectionable microorganisms (21 CFR 211.165(a) and 211.165(b)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Based on the records and information you provided, you did not demonstrate that you adequately test your finished OTC drug products prior to release and distribution to the United States. For example, the finished product testing reports you provided did not include appropriate assay testing for the identity and strength of each active ingredient or for impurities prior to release. Additionally, the records you provided failed to demonstrate adequate microbiological testing for each batch of your drug product prior to release.\u003C\u002Fp>\u003Cp>Testing is an essential part of CGMP to ensure that the drug products you manufacture conform to all predetermined quality attributes appropriate for their intended use. Drug products must be tested for identity and strength of the active ingredient, prior to release and distribution. Without adequate testing, you do not have scientific evidence to assure that your drug products conform to appropriate specifications before release.\u003C\u002Fp>\u003Cp>\u003Cstrong>3. Your firm’s quality control unit failed to exercise its responsibility to ensure drug products manufactured are in compliance with CGMP, and meet established specifications for identity, strength, quality, and purity (21 CFR 211.22).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Based on the records and information you provided, you did not demonstrate that your quality unit (QU) adequately exercised its authority and responsibilities for the manufacture of your OTC drug products. For example, your QU failed to ensure the following:\u003C\u002Fp>\u003Cul>\u003Cli>Establishing appropriate written procedures for production and process controls to qualify process performance and for qualification of your \u003Cstrong>(b)(4)\u003C\u002Fstrong> system, which produces \u003Cstrong>(b)(4)\u003C\u002Fstrong> used as a component in your drug products (21 CFR 211.100(a)).\u003C\u002Fli>\u003Cli>Maintaining complete manufacturing information relating to the production and control in batch records (21 CFR 211.188).\u003C\u002Fli>\u003Cli>Providing appropriate stability data to support the labeled drug product expiration date (21 CFR 211.137(a)).\u003C\u002Fli>\u003Cli>Establishing adequate QU authority and procedures (21 CFR 211.22(a) &amp; 211.22(d)).\u003C\u002Fli>\u003C\u002Ful>\u003Cp>Your firm’s quality systems are inadequate. For help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR, parts 210 and 211, see FDA guidance documents \u003Cem>Quality Systems Approach to Pharmaceuticals CGMP Regulations\u003C\u002Fem> at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload.\u003C\u002Fp>\u003Cp>\u003Cstrong>Drug Registration and Listing\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>We note that two separate establishments are referenced in this warning letter. Under section 510(i) of the FD&amp;C Act and 21 CFR 207.17(a) any establishment within any foreign country engaged in the manufacture, preparation, propagation, compounding, or processing of a drug that is imported or offered for import into the United States must be registered with FDA. Under section 301(p) of the FD&amp;C Act, 21 U.S.C. 331(p), it is a prohibited act to fail to register an establishment as required by section 510 of the FD&amp;C Act. Additionally, a drug may be considered misbranded within the meaning of section 502(o) of the FD&amp;C Act, 21 U.S.C. 352(o) if it was manufactured in an establishment not duly registered under section 510 of the FD&amp;C Act. It is your responsibility to ensure that all drugs manufactured at your establishment(s) comply with all establishment registration and drug listing requirements under section 510 of the FD&amp;C Act, 21 U.S.C. 360, 21 CFR Part 207, and all other applicable FDA regulations.\u003C\u002Fp>\u003Cp>\u003Cstrong>CGMP Consultant\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Based upon the nature of the violations we identified in your response, you should engage a consultant qualified as set forth in 21 CFR 211.34 to evaluate your operations and to assist your firm in meeting CGMP requirements. The qualified consultant should also perform a comprehensive six-system audit of your entire operation for CGMP compliance and evaluate the completion and efficacy of your corrective actions and preventive actions before you pursue resolution of your firm’s compliance status with FDA.\u003C\u002Fp>\u003Cp>Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>As previously stated, you are responsible for investigating and determining the root causes of any violations and implementing corrective and preventative measures to ensure future and sustained compliance so that these violations and any others do not occur.\u003C\u002Fp>\u003Cp>FDA placed all drugs and drug products offered for import into the United States from your firms, FEI 3027526825 and FEI 3032638909, on Import Alert 66-40 on June 22, 2026.\u003C\u002Fp>\u003Cp>FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may inspect to verify that you have completed corrective actions to any violations.\u003C\u002Fp>\u003Cp>Failure to address any violations may also result in the FDA continuing to refuse admission of articles manufactured at Babikian Healthcare Products CJSC, Gevorg Chaush Highway 90, Proshyan Community, Kotayk 2413 Armenia into the United States under section 801(a)(3) of the FD&amp;C Act, 21 U.S.C. 381(a)(3). Articles under this authority that appear to be adulterated may be detained or refused admission, in that the methods and controls used in their manufacture do not appear to conform to CGMP within the meaning of section 501(a)(2)(B) of the FD&amp;C Act, 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\u003Cp>Send your written response to CDER-OC-OMQ-Communications@fda.hhs.gov within fifteen (15) business days of receipt of this letter. Identify your written response with FEI 3027526825 and ATTN: Christina Capacci-Daniel in the letter or in the subject line of the email.\u003C\u002Fp>\u003Cp>If you have information that you believe demonstrates that your products are not in violation of the FD&amp;C Act and FDA regulations, include that information for our consideration.\u003C\u002Fp>\u003Cp>FDA posts warning letters on www.FDA.gov.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Francis Godwin\u003Cbr>Director\u003Cbr>Office of Manufacturing Quality\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003Cbr>U.S. Food and Drug Administration\u003C\u002Fp>\u003Cp>\u002FS\u002F\u003C\u002Fp>\u003Cp>Tina Smith, M.S.\u003Cbr>Captain, U.S. Public Health Service\u003Cbr>Director\u003Cbr>Office of Unapproved Drugs and Labeling Compliance\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003Cbr>Food and Drug Administration\u003C\u002Fp>\u003Cp>cc:\u003Cbr>U.S. Agent: Mr. Michael Sarian\u003Cbr>American Healthcare Systems Corp., Inc.\u003Cbr>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>______________________________\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> We note that Babikian Healthcare Products, 8 North Ave, Apartment 22, Yerevan, FEI 3032638909 was also listed as the manufacturer of record for several shipments to the U.S. but was not a registered FDA manufacturing facility. See the Facility Registration section below for guidance.\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA ELECTRONIC MAIL READ\u002FDELIVERY RECEIPT REQUESTED\n\nReference #:\n\n320-26-128\n\nProduct:\n\nDrugs\n\nOver-the-Counter Drugs\n\nRecipient:\n\nRecipient Name\n\nDr. Dikran Babikian\n\nRecipient Title\n\nChief Executive Officer\n\nBabikian Healthcare Products CJSC\n\nGevorg Chaush Highway 90\n\n2413\n\nProshyan Community\n\nKotayk\n\nArmenia\n\n(b)(4)\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nSeptember 21, 2026\nWARNING LETTER\nReference number: 320-26-128\nTo Dr. Dikran Babikian:\nThis warning letter advises you of significant violations identified during a U.S. Food and Drug Administration (FDA) review of records submitted from your facility. Promptly address the violations described herein without delay, including ensuring that appropriate resources are allocated to fully address the violations and prevent their recurrence. This is not intended to be an all-inclusive list of the violations that exist at your facility. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations. Failure to adequately address violations may result in regulatory action without further notice.\nFDA Review\nViolations were identified and documented during review of your drug manufacturing facility, Babikian Healthcare Products CJSC, FDA Establishment Identifier (FEI) 3027526825.1 This review was conducted under FDA’s statutory authority and public health responsibilities to protect the public from unsafe, ineffective, and poor quality drugs.\nYour facility is registered with the FDA as a manufacturer of over-the-counter (OTC) drug products. FDA has reviewed the records you submitted in response to our August 12, 2025 request for records and other information pursuant to section 704(a)(4) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) for your facility.\nThis warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations, parts 210 and 211 (21 CFR, parts 210 and 211).\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding of drugs as described in your response to our 704(a)(4) request do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. 351(a)(2)(B)).\nViolations of the Federal Food, Drug, and Cosmetic Act\nThe following are violations identified during our review. As a reminder, this is not an all-inclusive list of violations at your facility.\n1. Your firm failed to conduct at least one test to verify the identity of each component of a drug product. Your firm also failed to validate and establish the reliability of your component supplier’s test analyses at appropriate intervals (21 CFR 211.84(d)(1) & 211.84(d)(2)).\nYour firm manufactures OTC drug products, including (b)(4), intended for the U.S. market. Your response to our request for records and information under section 704(a)(4) indicated that you do not test the identity of each incoming component, (b)(4), used in the manufacture of your drug products prior to manufacturing. Your response also indicated that you accept your suppliers’ certificates of analyses without verifying the test results at appropriate intervals.\nYou also did not provide evidence that (b)(4), the active ingredients in your drug products, meet USP limits for (b)(4). See FDA’s guidance document (b)(4).\nWithout adequate testing and verification of supplier results, you do not have scientific evidence that your incoming components conform to appropriate specifications prior to use in the manufacture of your drugs. As a manufacturer, you have a responsibility to sample, test, and examine incoming materials before use in production to assure adequate quality.\n2. Your firm failed to have, for each batch of drug product, appropriate laboratory determination of satisfactory conformance to final specifications for the drug product, including the identity and strength of each active ingredient, prior to release. Your firm also failed to conduct appropriate laboratory testing, as necessary, for each batch of drug product required to be free of objectionable microorganisms (21 CFR 211.165(a) and 211.165(b)).\nBased on the records and information you provided, you did not demonstrate that you adequately test your finished OTC drug products prior to release and distribution to the United States. For example, the finished product testing reports you provided did not include appropriate assay testing for the identity and strength of each active ingredient or for impurities prior to release. Additionally, the records you provided failed to demonstrate adequate microbiological testing for each batch of your drug product prior to release.\nTesting is an essential part of CGMP to ensure that the drug products you manufacture conform to all predetermined quality attributes appropriate for their intended use. Drug products must be tested for identity and strength of the active ingredient, prior to release and distribution. Without adequate testing, you do not have scientific evidence to assure that your drug products conform to appropriate specifications before release.\n3. Your firm’s quality control unit failed to exercise its responsibility to ensure drug products manufactured are in compliance with CGMP, and meet established specifications for identity, strength, quality, and purity (21 CFR 211.22).\nBased on the records and information you provided, you did not demonstrate that your quality unit (QU) adequately exercised its authority and responsibilities for the manufacture of your OTC drug products. For example, your QU failed to ensure the following:\nEstablishing appropriate written procedures for production and process controls to qualify process performance and for qualification of your (b)(4) system, which produces (b)(4) used as a component in your drug products (21 CFR 211.100(a)).\nMaintaining complete manufacturing information relating to the production and control in batch records (21 CFR 211.188).\nProviding appropriate stability data to support the labeled drug product expiration date (21 CFR 211.137(a)).\nEstablishing adequate QU authority and procedures (21 CFR 211.22(a) & 211.22(d)).\nYour firm’s quality systems are inadequate. For help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR, parts 210 and 211, see FDA guidance documents Quality Systems Approach to Pharmaceuticals CGMP Regulations at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload.\nDrug Registration and Listing\nWe note that two separate establishments are referenced in this warning letter. Under section 510(i) of the FD&C Act and 21 CFR 207.17(a) any establishment within any foreign country engaged in the manufacture, preparation, propagation, compounding, or processing of a drug that is imported or offered for import into the United States must be registered with FDA. Under section 301(p) of the FD&C Act, 21 U.S.C. 331(p), it is a prohibited act to fail to register an establishment as required by section 510 of the FD&C Act. Additionally, a drug may be considered misbranded within the meaning of section 502(o) of the FD&C Act, 21 U.S.C. 352(o) if it was manufactured in an establishment not duly registered under section 510 of the FD&C Act. It is your responsibility to ensure that all drugs manufactured at your establishment(s) comply with all establishment registration and drug listing requirements under section 510 of the FD&C Act, 21 U.S.C. 360, 21 CFR Part 207, and all other applicable FDA regulations.\nCGMP Consultant\nBased upon the nature of the violations we identified in your response, you should engage a consultant qualified as set forth in 21 CFR 211.34 to evaluate your operations and to assist your firm in meeting CGMP requirements. The qualified consultant should also perform a comprehensive six-system audit of your entire operation for CGMP compliance and evaluate the completion and efficacy of your corrective actions and preventive actions before you pursue resolution of your firm’s compliance status with FDA.\nYour use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\nConclusion\nAs previously stated, you are responsible for investigating and determining the root causes of any violations and implementing corrective and preventative measures to ensure future and sustained compliance so that these violations and any others do not occur.\nFDA placed all drugs and drug products offered for import into the United States from your firms, FEI 3027526825 and FEI 3032638909, on Import Alert 66-40 on June 22, 2026.\nFDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may inspect to verify that you have completed corrective actions to any violations.\nFailure to address any violations may also result in the FDA continuing to refuse admission of articles manufactured at Babikian Healthcare Products CJSC, Gevorg Chaush Highway 90, Proshyan Community, Kotayk 2413 Armenia into the United States under section 801(a)(3) of the FD&C Act, 21 U.S.C. 381(a)(3). Articles under this authority that appear to be adulterated may be detained or refused admission, in that the methods and controls used in their manufacture do not appear to conform to CGMP within the meaning of section 501(a)(2)(B) of the FD&C Act, 21 U.S.C. 351(a)(2)(B).\nSend your written response to CDER-OC-OMQ-Communications@fda.hhs.gov within fifteen (15) business days of receipt of this letter. Identify your written response with FEI 3027526825 and ATTN: Christina Capacci-Daniel in the letter or in the subject line of the email.\nIf you have information that you believe demonstrates that your products are not in violation of the FD&C Act and FDA regulations, include that information for our consideration.\nFDA posts warning letters on www.FDA.gov.\nSincerely,\n\u002FS\u002F\nFrancis Godwin\nDirector\nOffice of Manufacturing Quality\nOffice of Compliance\nCenter for Drug Evaluation and Research\nU.S. Food and Drug Administration\n\u002FS\u002F\nTina Smith, M.S.\nCaptain, U.S. Public Health Service\nDirector\nOffice of Unapproved Drugs and Labeling Compliance\nOffice of Compliance\nCenter for Drug Evaluation and Research\nFood and Drug Administration\ncc:\nU.S. Agent: Mr. Michael Sarian\nAmerican Healthcare Systems Corp., Inc.\n(b)(4)\n______________________________\n1 We note that Babikian Healthcare Products, 8 North Ave, Apartment 22, Yerevan, FEI 3032638909 was also listed as the manufacturer of record for several shipments to the U.S. but was not a registered FDA manufacturing facility. See the Facility Registration section below for guidance.","Babikian Healthcare Products CJSC","babikian-healthcare-products-cjsc-730513-09212026","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fbabikian-healthcare-products-cjsc-730513-09212026","730513","Dr. Dikran Babikian","2026-10-14T12:34:23.173+00:00","320-26-128","2026-09-21",{"id":288,"raw":289,"subject":14,"body_html":294,"body_text":295,"firm_name":296,"letter_id":297,"created_at":298,"fei_number":20,"letter_url":299,"updated_at":300,"action_type":23,"case_status":24,"posted_date":301,"marcs_cms_no":302,"product_type":27,"closeout_date":20,"issuing_office":293,"recipient_name":303,"body_fetched_at":304,"delivery_method":138,"recipient_title":20,"reference_number":20,"action_taken_date":305,"medical_device_id":20,"response_letter_date":20},2233,[290,291,292,293,14,13,13,13],"\u003Ctime datetime=\"2023-01-31T05:00:00Z\">01\u002F31\u002F2023\u003C\u002Ftime>\n","\u003Ctime datetime=\"2023-01-27T05:00:00Z\">01\u002F27\u002F2023\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fkobayashi-healthcare-international-inc-637313-01272023\">Kobayashi Healthcare International, Inc.\u003C\u002Fa>","Office of Pharmaceutical Quality","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Norikazu Toyoda\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President and CEO\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Kobayashi Healthcare International, Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>245 Kraft Dr.\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Dalton\u003C\u002Fspan>, \u003Cspan>GA\u003C\u002Fspan> \u003Cspan>30721-1502\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Office of Pharmaceutical Quality\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>January 27, 2023\u003C\u002Fp>\n\n\u003Cp>Case #637313\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Toyoda:\u003C\u002Fp>\n\n\u003Cp>The U.S. Food and Drug Administration (FDA) inspected your drug manufacturing facility, Kobayashi America Manufacturing, LLC, FEI 3003079019, at 245 Kraft Drive, Dalton, Georgia, from May 23 to 27, 2022.\u003C\u002Fp>\n\n\u003Cp>This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\u003C\u002Fp>\n\n\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\n\n\u003Cp>In addition, “ZIM’S HYDRO COOLING PAIN RELIEF PATCH” is an unapproved new drug introduced or delivered for introduction into interstate commerce in violation of section 505(a) of the FD&amp;C Act, 21 U.S.C. 355(a), and is misbranded under section 502(ee) of the FD&amp;C Act, 21 U.S.C. 352 (ee). Introduction or delivery for introduction of such a product into interstate commerce is prohibited under sections 301(d) and (a) of the FD&amp;C Act, 21 U.S.C. 331(d) and (a). These violations are described in more detail below.\u003C\u002Fp>\n\n\u003Cp>We reviewed your June 21, 2022, response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\u003C\u002Fp>\n\n\u003Cp>During our inspection, our investigators observed specific violations including, but not limited to, the following.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>1. Your firm failed to conduct, for each batch of drug product, appropriate laboratory testing, as necessary, required to be free of objectionable microorganisms (21 CFR 211.165(b)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your firm released over-the-counter (OTC) drug products, Zim’s Max Freeze Gel, Zim’s Max Freeze Roll-on, and Zim’s Max Freeze Liquid, without testing batches for microbiological quality. For example, Zim’s Max Freeze Roll-on, lot B87695, was released by your quality unit (QU) on January 20, 2022, without undergoing microbiological testing. Your Quality Assurance Director informed our investigators, during the inspection, that microbiological testing is not a part of finished product release testing.\u003C\u002Fp>\n\n\u003Cp>Microbiological testing is essential to ensure each batch of your finished drug products conform to appropriate microbiological specifications. Testing prior to release and throughout the drug product’s life cycle is imperative to accomplish this standard.\u003C\u002Fp>\n\n\u003Cp>In your response, you claimed there was no danger of objectionable microorganisms in the finished drug product as the percentages of alcohol in the products do not support microbial growth or survival. You also indicated that the finished drug products currently on the market are safe.\u003C\u002Fp>\n\n\u003Cp>Your response is inadequate. You did not provide an appropriate scientific basis to support that your finished drug products are free from microbial growth or survival. It is well established that certain microorganisms are known to survive and thrive in alcohol. Additionally, you did not provide any retrospective testing to support the safety of your drug products currently on the market.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A list of microbiological specifications (i.e., total counts, objectionable microorganisms), including test methods, used to analyze each lot of your drug products before a lot disposition decision.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>&nbsp; &nbsp; o An action plan and timelines for conducting full microbiological testing of retain samples to determine the quality of all batches of drug product distributed to the United States that are within expiry as of the date of this letter.\u003Cbr>\n&nbsp; &nbsp; o A summary of all results obtained from testing retain samples from each batch. If such testing reveals substandard quality drug products, take rapid corrective actions, such as notifying customers and product recalls.\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>An independent assessment of the microbiological test methods you plan to use to ensure that they are adequately validated and\u002For verified to be suitable for their intended purposes.\u003C\u002Fli>\n\t\u003Cli>Appropriate scientific studies to evaluate antimicrobial effectiveness testing (AET) for your aqueous multi-dose drug products. AET by USP &lt;51&gt; testing should be performed at a range of preservative concentrations and should be inclusive of concentrations at or below that listed in the formulation for each drug product. In addition to initial USP &lt;51&gt; studies on your formulations, one of the primary batches of the drug product should be tested for antimicrobial preservative effectiveness (in addition to preservative content) at the end of the proposed shelf life. The drug product specification should include a test for preservative content, and this attribute should be tested in all stability studies.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cstrong>2. Your firm’s quality control unit failed to exercise its responsibility to ensure drug products manufactured are in compliance with CGMP, and meet established specifications for identity, strength, quality, and purity (21 CFR 211.22).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your firm lacked an adequate QU. Your QU failed to establish and follow procedures\u003Cbr>\ndescribing its roles, responsibilities, and authorities. Furthermore, your QU’s oversight\u003Cbr>\nof drug manufacturing operations was inadequate. For example:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>Production and control records from your OTC drug product contract manufacturer were not reviewed or approved prior to release and distribution.\u003C\u002Fli>\n\t\u003Cli>Zim’s Max Freeze S, lot B77086 was intended for the \u003Cstrong>(b)(4)\u003C\u002Fstrong>, but you relabeled the lot for the \u003Cstrong>(b)(4)\u003C\u002Fstrong> without review and approval of manufacturing, packaging, and testing records to assure it met \u003Cstrong>(b)(4)\u003C\u002Fstrong> standards.\u003C\u002Fli>\n\t\u003Cli>There was a failure to establish adequate procedures for maintaining and investigating customer complaints.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>In your response, you stated that your batch record review and complaint investigation deficiencies were due to the lack of QU documentation and sufficient detail.\u003C\u002Fp>\n\n\u003Cp>Your response is inadequate. Your response failed to provide an adequate retrospective review of production records to ensure all batches currently on the market were manufactured to your established specifications.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>&nbsp; &nbsp; o A determination of whether procedures used by your firm are robust and appropriate\u003Cbr>\n&nbsp; &nbsp; o Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices\u003Cbr>\n&nbsp; &nbsp; o A complete and final review of each batch and its related information before the QU disposition decision\u003Cbr>\n&nbsp; &nbsp; o Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>Also describe how top management supports quality assurance and reliable operations, including, but not limited to, timely provision of resources to proactively address emerging manufacturing\u002Fquality issues and to assure a continuing state of control.\u003C\u002Fli>\n\t\u003Cli>A retrospective review of each batch currently on the market and its related information to determine if all established specifications were met before the QU disposition decision.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cstrong>Quality Systems\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your firm’s quality systems are inadequate. See FDA’s guidance document \u003Cem>Quality&nbsp;\u003C\u002Fem>\u003Cem>Systems Approach to Pharmaceutical CGMP Regulations\u003C\u002Fem> for help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR, parts 210 and 211 at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Use of Contract Manufacturers\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Drugs must be manufactured in conformance with CGMP. FDA is aware that many drug manufacturers use independent contractors such as production facilities, testing laboratories, packagers, and labelers. FDA regards contractors as extensions of the manufacturer.\u003C\u002Fp>\n\n\u003Cp>You are responsible for the quality of your drugs, regardless of agreements in place with your CMOs. You are required to ensure that drugs are made in accordance with section 501(a)(2)(B) of the FD&amp;C Act to ensure safety, identity, strength, quality, and purity. See FDA’s guidance document \u003Cem>Contract Manufacturing Arrangements for Drugs: Quality Agreements\u003C\u002Fem> at https:\u002F\u002Fwww.fda.gov\u002Fdownloads\u002Fdrugs\u002Fguidances\u002Fucm353925.pdf.\u003Cbr>\n\u003Cbr>\n\u003Cstrong>Consultant Recommended\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>We strongly recommend engaging a consultant as set forth in 21 CFR 211.34 to assist your firm in meeting CGMP requirements. Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\u003C\u002Fp>\n\n\u003Cp>\u003Cu>\u003Cstrong>Unapproved New Drug and Misbranding Violations\u003C\u002Fstrong>\u003C\u002Fu>\u003C\u002Fp>\n\n\u003Cp>“ZIM’S HYDRO COOLING PAIN RELIEF PATCH” is a “drug” as defined by section 201(g)(1)(B) of the FD&amp;C Act, 21 U.S.C. 321(g)(1)(B), because it is intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and\u002For under section 201(g)(1)(C) of the FD&amp;C Act, 21 U.S.C. 321(g)(1)(C), because it is intended to affect the structure or any function of the body. Specifically, this product is intended for use as an external analgesic.\u003C\u002Fp>\n\n\u003Cp>Examples of claims from the product’s labeling, including the website listed on product label, that provide evidence of the intended uses (as defined in 21 CFR 201.128) of the product include, but may not be limited to, the following:\u003C\u002Fp>\n\n\u003Cp>&nbsp; “BACK, Hip, Neck, Shoulder, Knee . . . \u003Cem>Drug Facts\u003C\u002Fem> . . . \u003Cem>Uses\u003C\u002Fem> . . . For the temporary relief of pain” [from your product’s outer carton]\u003C\u002Fp>\n\n\u003Cp>&nbsp; “Zim’s Max Freeze Hydro Cooling Pain Relief Patches provide immediate cooling relief . . . ready to use anywhere and anytime you need deep penetrating pain relief. Gently adheres to back, hips, neck, shoulders, and knees. . . . targeted pain relief that penetrates to the source of your discomfort.” [amazon.com\u002FZims-Max-Lidocaine-Cooling-P251220\u002Fdp\u002FBOB33B3ZKM?ref_=ast+sto_dp] [from the website of one of your retailers, Amazon.com; your website “WHERE TO BUY” provides a direct link to this and other retailers].\u003C\u002Fp>\n\n\u003Cp>“ZIM’S HYDRO COOLING PAIN RELIEF PATCH” is a topical external analgesic drug subject to section 505G of the FD&amp;C Act, 21 U.S.C. 355h, which governs nonprescription drugs marketed without an approved application. Under section 505G(a)(1) of the of the FD&amp;C Act, 21 U.S.C. 355h(a)(1), category I drugs that were subject to the tentative final monograph (TFM) that is the most recently applicable proposal or determination for such drug issued under 21 CFR Part 330 are deemed to be GRASE and not “new drugs,” as long as they are in conformity with the relevant conditions of use outlined in the applicable TFM and comply with all other applicable requirements. We note that OTC topical external analgesic products were addressed in the TFM for External Analgesic Drug Products for Over-the-Counter Human Use (external analgesic TFM; 48 FR 5852, February 8, 1983) and subsequent rulemakings. Under section 505G(b)(8) of the FD&amp;C Act, the 1983 external analgesic TFM, in combination with subsequent rulemakings, was deemed to be a final administrative order.\u003C\u002Fp>\n\n\u003Cp>This final administrative order addresses counterirritants, analgesic\u002Fanesthetics, and antipruritics, and it identifies active ingredients, dosage strengths, and indications for use corresponding to each of these categories of external analgesic drug products. Your “ZIM’S HYDRO COOLING PAIN RELIEF PATCH,” product does not conform to the conditions of use specified in the final administrative order, as described below.\u003C\u002Fp>\n\n\u003Cp>Your “ZIM’S HYDRO COOLING PAIN RELIEF PATCH” is labeled for use as a counterirritant external analgesic drug product because it includes claims related to the relief of pain in muscles and joints. For example, your product is labeled with the indication “For the temporary relief of pain,” and it identifies the back, hip, neck, shoulder, and knee. The labeling thus conveys that the product is intended for use in the temporary relief of pain in muscles and joints, including the back, hip, neck, shoulder, and knee. Further, the outer carton describes “deep penetrating” and “cooling” relief, and the product’s name includes the term “cooling.” The final administrative order requires the statement of indication for counterirritant external analgesic drug products include the phrase, “For the temporary relief of minor aches and pains of muscles and joints,” and it allows certain other statements including “penetrating pain relief” and “cooling pain relief.” Other categories of products addressed in the final administrative order, including analgesic and anesthetic drug products, are not permitted to include such an indication or statements in their labeling.\u003C\u002Fp>\n\n\u003Cp>However, your “ZIM’S HYDRO COOLING PAIN RELIEF PATCH” is not formulated as a counterirritant external analgesic drug product consistent with the final administrative order. The product is labeled to contain the active ingredients lidocaine at a dosage strength of 4% and menthol at a dosage strength of 1%. Lidocaine is not included as an active ingredient in the final administrative order for an external analgesic counterirritant drug product. Further, the final administrative order includes menthol in a dosage range of 1.25 – 16% for counterirritant external analgesic drug products. Therefore, even if menthol was the sole active ingredient, at a dosage of 1%, it falls below the allowable dosage strength range of 1.25 – 16% for menthol used in counterirritant external analgesic drug products.\u003C\u002Fp>\n\n\u003Cp>We note that, pursuant to the final administrative order, analgesic and anesthetic drug products may contain lidocaine at a dosage strength of 0.5% to 4% and menthol at a dosage strength of 0.1% to 1%. However, as noted above, your “ZIM’S HYDRO COOLING PAIN RELIEF PATCH” is not labeled with statements that the final administrative order permits for analgesic or anesthetic drug products (not counterirritants).\u003C\u002Fp>\n\n\u003Cp>FDA is not aware of any adequate and well-controlled clinical studies in the published literature that support a determination that “ZIM’S HYDRO COOLING PAIN RELIEF PATCH” drug product is GRASE for use under the conditions prescribed, recommended, or suggested in its labeling. Moreover, there is no evident basis under the FD&amp;C Act under which this product would be legally marketed without an approved application. Accordingly, “ZIM’S HYDRO COOLING PAIN RELIEF PATCH” is an unapproved new drug marketed in violation of section 505(a) of the FD&amp;C Act, 21 U.S.C 355(a). Introduction or delivery for introduction of such a product into interstate commerce is prohibited under section 301(d) of the FD&amp;C Act, 21 U.S.C. 331(d).\u003C\u002Fp>\n\n\u003Cp>Lastly, this product is misbranded under section 502(ee) of the FD&amp;C Act, 21 U.S.C. 352(ee), because “ZIM’S HYDRO COOLING PAIN RELIEF PATCH” is a nonprescription drug subject to section 505G of the FD&amp;C Act, 21 U.S.C. 355h, but does not comply with the requirements for marketing under that section and is not the subject of an application approved under section 505 of the FD&amp;C Act, 21 U.S.C. 355.\u003C\u002Fp>\n\n\u003Cp>The introduction or delivery for introduction of a misbranded drug into interstate commerce is prohibited under section 301(a) of the FD&amp;C Act, 21 U.S.C. 331(a).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\u003C\u002Fp>\n\n\u003Cp>Correct any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure, and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\u003C\u002Fp>\n\n\u003Cp>Failure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\n\n\u003Cp>Your written notification should refer to the Warning Letter Number above (\u003Cstrong>Case #637313\u003C\u002Fstrong>). Please electronically submit your signed reply on your firm’s letterhead to Ronda R. Loyd-Jones, Director, Compliance Branch, at email to: Ronda.Loyd-Jones@fda.hhs.gov and orapharm2_responses@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>If you have questions regarding the contents of this letter, you may contact Mr. Thao Ta, Compliance Officer, via phone at 214-253-5217 or e-mail at thao.ta@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Monica R. Maxwell\u003Cbr>\nDivision Director\u003Cbr>\nOffice of Pharmaceutical Quality Operation\u003Cbr>\nDivision II\u003C\u002Fp>\n\n\u003Cp>cc: Via Electronic Mail\u003Cbr>\nMr. Hajime Furuie\u003Cbr>\nQuality Assurance\u002FRegulatory Affairs Director\u003Cbr>\nKobayashi Healthcare International, Inc.\u003Cbr>\n245 Kraft Drive\u003Cbr>\nDalton, GA 30721\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA Electronic Mail\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMr. Norikazu Toyoda\n\nRecipient Title\n\nPresident and CEO\n\nKobayashi Healthcare International, Inc.\n\n245 Kraft Dr.\n\nDalton, GA 30721-1502\n\nUnited States\n\nIssuing Office:\n\nOffice of Pharmaceutical Quality\n\nUnited States\n\nJanuary 27, 2023\n\nCase #637313\n\nWARNING LETTER\n\nDear Mr. Toyoda:\n\nThe U.S. Food and Drug Administration (FDA) inspected your drug manufacturing facility, Kobayashi America Manufacturing, LLC, FEI 3003079019, at 245 Kraft Drive, Dalton, Georgia, from May 23 to 27, 2022.\n\nThis warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\n\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B).\n\nIn addition, “ZIM’S HYDRO COOLING PAIN RELIEF PATCH” is an unapproved new drug introduced or delivered for introduction into interstate commerce in violation of section 505(a) of the FD&C Act, 21 U.S.C. 355(a), and is misbranded under section 502(ee) of the FD&C Act, 21 U.S.C. 352 (ee). Introduction or delivery for introduction of such a product into interstate commerce is prohibited under sections 301(d) and (a) of the FD&C Act, 21 U.S.C. 331(d) and (a). These violations are described in more detail below.\n\nWe reviewed your June 21, 2022, response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\n\nDuring our inspection, our investigators observed specific violations including, but not limited to, the following.\n\n1. Your firm failed to conduct, for each batch of drug product, appropriate laboratory testing, as necessary, required to be free of objectionable microorganisms (21 CFR 211.165(b)).\n\nYour firm released over-the-counter (OTC) drug products, Zim’s Max Freeze Gel, Zim’s Max Freeze Roll-on, and Zim’s Max Freeze Liquid, without testing batches for microbiological quality. For example, Zim’s Max Freeze Roll-on, lot B87695, was released by your quality unit (QU) on January 20, 2022, without undergoing microbiological testing. Your Quality Assurance Director informed our investigators, during the inspection, that microbiological testing is not a part of finished product release testing.\n\nMicrobiological testing is essential to ensure each batch of your finished drug products conform to appropriate microbiological specifications. Testing prior to release and throughout the drug product’s life cycle is imperative to accomplish this standard.\n\nIn your response, you claimed there was no danger of objectionable microorganisms in the finished drug product as the percentages of alcohol in the products do not support microbial growth or survival. You also indicated that the finished drug products currently on the market are safe.\n\nYour response is inadequate. You did not provide an appropriate scientific basis to support that your finished drug products are free from microbial growth or survival. It is well established that certain microorganisms are known to survive and thrive in alcohol. Additionally, you did not provide any retrospective testing to support the safety of your drug products currently on the market.\n\nIn response to this letter, provide:\n\nA list of microbiological specifications (i.e., total counts, objectionable microorganisms), including test methods, used to analyze each lot of your drug products before a lot disposition decision.\n\no An action plan and timelines for conducting full microbiological testing of retain samples to determine the quality of all batches of drug product distributed to the United States that are within expiry as of the date of this letter.\n\no A summary of all results obtained from testing retain samples from each batch. If such testing reveals substandard quality drug products, take rapid corrective actions, such as notifying customers and product recalls.\n\nAn independent assessment of the microbiological test methods you plan to use to ensure that they are adequately validated and\u002For verified to be suitable for their intended purposes.\n\nAppropriate scientific studies to evaluate antimicrobial effectiveness testing (AET) for your aqueous multi-dose drug products. AET by USP \u003C51> testing should be performed at a range of preservative concentrations and should be inclusive of concentrations at or below that listed in the formulation for each drug product. In addition to initial USP \u003C51> studies on your formulations, one of the primary batches of the drug product should be tested for antimicrobial preservative effectiveness (in addition to preservative content) at the end of the proposed shelf life. The drug product specification should include a test for preservative content, and this attribute should be tested in all stability studies.\n\n2. Your firm’s quality control unit failed to exercise its responsibility to ensure drug products manufactured are in compliance with CGMP, and meet established specifications for identity, strength, quality, and purity (21 CFR 211.22).\n\nYour firm lacked an adequate QU. Your QU failed to establish and follow procedures\n\ndescribing its roles, responsibilities, and authorities. Furthermore, your QU’s oversight\n\nof drug manufacturing operations was inadequate. For example:\n\nProduction and control records from your OTC drug product contract manufacturer were not reviewed or approved prior to release and distribution.\n\nZim’s Max Freeze S, lot B77086 was intended for the (b)(4), but you relabeled the lot for the (b)(4) without review and approval of manufacturing, packaging, and testing records to assure it met (b)(4) standards.\n\nThere was a failure to establish adequate procedures for maintaining and investigating customer complaints.\n\nIn your response, you stated that your batch record review and complaint investigation deficiencies were due to the lack of QU documentation and sufficient detail.\n\nYour response is inadequate. Your response failed to provide an adequate retrospective review of production records to ensure all batches currently on the market were manufactured to your established specifications.\n\nIn response to this letter, provide:\n\nA comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\n\no A determination of whether procedures used by your firm are robust and appropriate\n\no Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices\n\no A complete and final review of each batch and its related information before the QU disposition decision\n\no Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products\n\nAlso describe how top management supports quality assurance and reliable operations, including, but not limited to, timely provision of resources to proactively address emerging manufacturing\u002Fquality issues and to assure a continuing state of control.\n\nA retrospective review of each batch currently on the market and its related information to determine if all established specifications were met before the QU disposition decision.\n\nQuality Systems\n\nYour firm’s quality systems are inadequate. See FDA’s guidance document Quality Systems Approach to Pharmaceutical CGMP Regulations for help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR, parts 210 and 211 at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload.\n\nUse of Contract Manufacturers\n\nDrugs must be manufactured in conformance with CGMP. FDA is aware that many drug manufacturers use independent contractors such as production facilities, testing laboratories, packagers, and labelers. FDA regards contractors as extensions of the manufacturer.\n\nYou are responsible for the quality of your drugs, regardless of agreements in place with your CMOs. You are required to ensure that drugs are made in accordance with section 501(a)(2)(B) of the FD&C Act to ensure safety, identity, strength, quality, and purity. See FDA’s guidance document Contract Manufacturing Arrangements for Drugs: Quality Agreements at https:\u002F\u002Fwww.fda.gov\u002Fdownloads\u002Fdrugs\u002Fguidances\u002Fucm353925.pdf.\n\nConsultant Recommended\n\nWe strongly recommend engaging a consultant as set forth in 21 CFR 211.34 to assist your firm in meeting CGMP requirements. Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\n\nUnapproved New Drug and Misbranding Violations\n\n“ZIM’S HYDRO COOLING PAIN RELIEF PATCH” is a “drug” as defined by section 201(g)(1)(B) of the FD&C Act, 21 U.S.C. 321(g)(1)(B), because it is intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and\u002For under section 201(g)(1)(C) of the FD&C Act, 21 U.S.C. 321(g)(1)(C), because it is intended to affect the structure or any function of the body. Specifically, this product is intended for use as an external analgesic.\n\nExamples of claims from the product’s labeling, including the website listed on product label, that provide evidence of the intended uses (as defined in 21 CFR 201.128) of the product include, but may not be limited to, the following:\n\n“BACK, Hip, Neck, Shoulder, Knee . . . Drug Facts . . . Uses . . . For the temporary relief of pain” [from your product’s outer carton]\n\n“Zim’s Max Freeze Hydro Cooling Pain Relief Patches provide immediate cooling relief . . . ready to use anywhere and anytime you need deep penetrating pain relief. Gently adheres to back, hips, neck, shoulders, and knees. . . . targeted pain relief that penetrates to the source of your discomfort.” [amazon.com\u002FZims-Max-Lidocaine-Cooling-P251220\u002Fdp\u002FBOB33B3ZKM?ref_=ast+sto_dp] [from the website of one of your retailers, Amazon.com; your website “WHERE TO BUY” provides a direct link to this and other retailers].\n\n“ZIM’S HYDRO COOLING PAIN RELIEF PATCH” is a topical external analgesic drug subject to section 505G of the FD&C Act, 21 U.S.C. 355h, which governs nonprescription drugs marketed without an approved application. Under section 505G(a)(1) of the of the FD&C Act, 21 U.S.C. 355h(a)(1), category I drugs that were subject to the tentative final monograph (TFM) that is the most recently applicable proposal or determination for such drug issued under 21 CFR Part 330 are deemed to be GRASE and not “new drugs,” as long as they are in conformity with the relevant conditions of use outlined in the applicable TFM and comply with all other applicable requirements. We note that OTC topical external analgesic products were addressed in the TFM for External Analgesic Drug Products for Over-the-Counter Human Use (external analgesic TFM; 48 FR 5852, February 8, 1983) and subsequent rulemakings. Under section 505G(b)(8) of the FD&C Act, the 1983 external analgesic TFM, in combination with subsequent rulemakings, was deemed to be a final administrative order.\n\nThis final administrative order addresses counterirritants, analgesic\u002Fanesthetics, and antipruritics, and it identifies active ingredients, dosage strengths, and indications for use corresponding to each of these categories of external analgesic drug products. Your “ZIM’S HYDRO COOLING PAIN RELIEF PATCH,” product does not conform to the conditions of use specified in the final administrative order, as described below.\n\nYour “ZIM’S HYDRO COOLING PAIN RELIEF PATCH” is labeled for use as a counterirritant external analgesic drug product because it includes claims related to the relief of pain in muscles and joints. For example, your product is labeled with the indication “For the temporary relief of pain,” and it identifies the back, hip, neck, shoulder, and knee. The labeling thus conveys that the product is intended for use in the temporary relief of pain in muscles and joints, including the back, hip, neck, shoulder, and knee. Further, the outer carton describes “deep penetrating” and “cooling” relief, and the product’s name includes the term “cooling.” The final administrative order requires the statement of indication for counterirritant external analgesic drug products include the phrase, “For the temporary relief of minor aches and pains of muscles and joints,” and it allows certain other statements including “penetrating pain relief” and “cooling pain relief.” Other categories of products addressed in the final administrative order, including analgesic and anesthetic drug products, are not permitted to include such an indication or statements in their labeling.\n\nHowever, your “ZIM’S HYDRO COOLING PAIN RELIEF PATCH” is not formulated as a counterirritant external analgesic drug product consistent with the final administrative order. The product is labeled to contain the active ingredients lidocaine at a dosage strength of 4% and menthol at a dosage strength of 1%. Lidocaine is not included as an active ingredient in the final administrative order for an external analgesic counterirritant drug product. Further, the final administrative order includes menthol in a dosage range of 1.25 – 16% for counterirritant external analgesic drug products. Therefore, even if menthol was the sole active ingredient, at a dosage of 1%, it falls below the allowable dosage strength range of 1.25 – 16% for menthol used in counterirritant external analgesic drug products.\n\nWe note that, pursuant to the final administrative order, analgesic and anesthetic drug products may contain lidocaine at a dosage strength of 0.5% to 4% and menthol at a dosage strength of 0.1% to 1%. However, as noted above, your “ZIM’S HYDRO COOLING PAIN RELIEF PATCH” is not labeled with statements that the final administrative order permits for analgesic or anesthetic drug products (not counterirritants).\n\nFDA is not aware of any adequate and well-controlled clinical studies in the published literature that support a determination that “ZIM’S HYDRO COOLING PAIN RELIEF PATCH” drug product is GRASE for use under the conditions prescribed, recommended, or suggested in its labeling. Moreover, there is no evident basis under the FD&C Act under which this product would be legally marketed without an approved application. Accordingly, “ZIM’S HYDRO COOLING PAIN RELIEF PATCH” is an unapproved new drug marketed in violation of section 505(a) of the FD&C Act, 21 U.S.C 355(a). Introduction or delivery for introduction of such a product into interstate commerce is prohibited under section 301(d) of the FD&C Act, 21 U.S.C. 331(d).\n\nLastly, this product is misbranded under section 502(ee) of the FD&C Act, 21 U.S.C. 352(ee), because “ZIM’S HYDRO COOLING PAIN RELIEF PATCH” is a nonprescription drug subject to section 505G of the FD&C Act, 21 U.S.C. 355h, but does not comply with the requirements for marketing under that section and is not the subject of an application approved under section 505 of the FD&C Act, 21 U.S.C. 355.\n\nThe introduction or delivery for introduction of a misbranded drug into interstate commerce is prohibited under section 301(a) of the FD&C Act, 21 U.S.C. 331(a).\n\nConclusion\n\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\n\nCorrect any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure, and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\n\nFailure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\n\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\n\nYour written notification should refer to the Warning Letter Number above (Case #637313). Please electronically submit your signed reply on your firm’s letterhead to Ronda R. Loyd-Jones, Director, Compliance Branch, at email to: Ronda.Loyd-Jones@fda.hhs.gov and orapharm2_responses@fda.hhs.gov.\n\nIf you have questions regarding the contents of this letter, you may contact Mr. Thao Ta, Compliance Officer, via phone at 214-253-5217 or e-mail at thao.ta@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nMonica R. Maxwell\n\nDivision Director\n\nOffice of Pharmaceutical Quality Operation\n\nDivision II\n\ncc: Via Electronic Mail\n\nMr. Hajime Furuie\n\nQuality Assurance\u002FRegulatory Affairs Director\n\nKobayashi Healthcare International, Inc.\n\n245 Kraft Drive\n\nDalton, GA 30721","Kobayashi Healthcare International, Inc.","kobayashi-healthcare-international-inc-637313-01272023","2026-08-18T06:42:29.145918+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fkobayashi-healthcare-international-inc-637313-01272023","2026-10-26T08:09:09.897874+00:00","2023-01-31","637313","Mr. Norikazu Toyoda","2026-08-20T01:16:59.473+00:00","2023-01-27",{"id":307,"raw":308,"subject":187,"body_html":312,"body_text":313,"firm_name":314,"letter_id":315,"created_at":19,"fei_number":20,"letter_url":316,"updated_at":317,"action_type":23,"case_status":24,"posted_date":318,"marcs_cms_no":319,"product_type":27,"closeout_date":20,"issuing_office":11,"recipient_name":320,"body_fetched_at":321,"delivery_method":138,"recipient_title":20,"reference_number":322,"action_taken_date":323,"medical_device_id":20,"response_letter_date":20},1053,[309,310,311,11,187,13,13,13],"\u003Ctime datetime=\"2025-02-18T05:00:00Z\">02\u002F18\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-02-10T05:00:00Z\">02\u002F10\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fmarshalls-traditional-healthcare-cc-697697-02102025\">Marshalls Traditional Healthcare CC\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>320-25-43\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Vick Maharaj\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Chief Executive Officer \u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Marshalls Traditional Healthcare CC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>560 Main Reef Road\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Germiston\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Gauteng\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>1400\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>South Africa\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>Warning Letter\u003C\u002Fstrong> 320-25-43\u003C\u002Fp>\u003Cp>February 10, 2025\u003C\u002Fp>\u003Cp>Dear Mr. Maharaj:\u003C\u002Fp>\u003Cp>The U.S. Food and Drug Administration (FDA) inspected your drug manufacturing facility, Marshalls Traditional Healthcare CC, FEI 3014740544, at 560 Main Reef Road, Germiston, from September 19 to 23, 2024.\u003C\u002Fp>\u003Cp>This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\u003C\u002Fp>\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug product is adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\u003Cp>We reviewed your October 11, 2024, response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\u003C\u002Fp>\u003Cp>\u003Cstrong>CGMP Violations\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cstrong>1. Your firm failed to have, for each batch of drug product, appropriate laboratory determination of satisfactory conformance to final specifications for the drug product, including the identity and strength of each active ingredient, prior to release. Your firm also failed to conduct, for each batch of drug product, appropriate laboratory testing, as necessary, required to be free of objectionable microorganisms (21 CFR 211.165(a) and 211.165(b)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your firm manufactures an over-the-counter (OTC) \u003Cstrong>(b)(4)\u003C\u002Fstrong> drug product. Your firm failed to conduct adequate finished product release testing for each batch of your drug product, including but not limited to, testing the identity and strength of the active ingredient, \u003Cstrong>(b)(4)\u003C\u002Fstrong> and testing for objectionable microorganisms.\u003C\u002Fp>\u003Cp>In your response, you state that you developed and validated an updated test method, and updated release specifications, for the labeled active ingredient, \u003Cstrong>(b)(4)\u003C\u002Fstrong>. You also state that you will perform all appropriate USP &lt;61&gt; and &lt;62&gt; testing for your finished drug products. Your response is inadequate as you did not provide sufficient details regarding the specific tests to be performed for each batch of finished drug product. You also did not consider a risk assessment or retrospective review of products that have been released without appropriate testing.\u003C\u002Fp>\u003Cp>Without adequate finished product release testing, you do not have scientific evidence that each batch of drug product conforms to appropriate specifications before release.\u003C\u002Fp>\u003Cp>In your response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A comprehensive, independent assessment of your laboratory practices, procedures, methods, equipment, documentation, and analyst competencies. Based on this review, provide a detailed plan to remediate and evaluate the effectiveness of your laboratory system.\u003C\u002Fli>\u003Cli>A list of chemical and microbial specifications, including test methods, used to analyze each lot of your drug products before a lot disposition decision.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>2. Your firm failed to establish adequate written procedures for production and process control designed to assure that the drug products you manufacture have the identity, strength, quality, and purity they purport or are represented to possess, and to follow all of your written production and process control procedures (21 CFR 211.100(a) and 211.100(b)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cem>Inadequate Process Validation\u003C\u002Fem>\u003C\u002Fp>\u003Cp>You did not have data to demonstrate that you adequately validate your manufacturing processes used to manufacture your OTC drug products and demonstrate that your processes are reproducible and controlled to consistently yield drugs of uniform character and quality. For example, your validation plan, “VALIDATOIN MASTER PLAN (VMP),” describes requirements for process validation and hold time studies. However, the protocol implementing your validation planed, “PROCESS VALIDATION PROTOCOL,” failed to include operating parameters, such as bulk hold times, or processing limits, such as acceptance criteria for process parameters.\u003C\u002Fp>\u003Cp>In your response, you provided your updated process validation protocol. Your response is inadequate as it did not include hold times and lacked appropriate details such as adequate sampling instructions. The updated protocol also did not include the batch production record associated with the first validation batch.\u003C\u002Fp>\u003Cp>Process validation evaluates the soundness of design and state of control of a process throughout its lifecycle. Each significant stage of a manufacturing process must be designed appropriately and assure the quality of raw material inputs, in-process materials, and finished drugs. Process qualification studies determine whether an initial state of control has been established. Successful process qualification studies are necessary before commercial distribution. Thereafter, ongoing vigilant oversight of process performance and product quality is necessary to ensure you maintain a stable manufacturing operation throughout the product lifecycle.\u003C\u002Fp>\u003Cp>See FDA's guidance for industry, Process Validation: General Principles and Practices for general principles and approaches that FDA considers appropriate elements of process validation at \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71021\u002Fdownload.\">https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71021\u002Fdownload.\u003C\u002Fa>\u003C\u002Fp>\u003Cp>\u003Cem>Inadequate Control of \u003Cstrong>(b)(4)\u003C\u002Fstrong> System\u003C\u002Fem>\u003C\u002Fp>\u003Cp>Your firm uses \u003Cstrong>(b)(4)\u003C\u002Fstrong> as a component to manufacture your OTC drug product. You failed to ensure that your \u003Cstrong>(b)(4)\u003C\u002Fstrong> system is suitable for producing \u003Cstrong>(b)(4)\u003C\u002Fstrong> used in the formulation of your drug product. For example, you turned your \u003Cstrong>(b)(4)\u003C\u002Fstrong> system off when not in use, stopping its circulation, which deviates from its design use as a continuously recirculating system. In addition, you failed to demonstrate that your \u003Cstrong>(b)(4)\u003C\u002Fstrong> system is adequately monitored to ensure it consistently produces \u003Cstrong>(b)(4)\u003C\u002Fstrong> that meets appropriate chemical and microbial attributes.\u003C\u002Fp>\u003Cp>In your response, you state that your \u003Cstrong>(b)(4)\u003C\u002Fstrong> system will continuously \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Your response is inadequate. You did not address the adequacy of your overall \u003Cstrong>(b)(4)\u003C\u002Fstrong> system design to ensure that your \u003Cstrong>(b)(4)\u003C\u002Fstrong> meets, at a minimum, the USP \u003Cstrong>(b)(4)\u003C\u002Fstrong> monograph and appropriate microbial limits. You also did not provide interim measures and assess the impact of using \u003Cstrong>(b)(4)\u003C\u002Fstrong> from an inadequately validated \u003Cstrong>(b)(4)\u003C\u002Fstrong> system on the quality of drug products you manufacture.\u003C\u002Fp>\u003Cp>Pharmaceutical \u003Cstrong>(b)(4)\u003C\u002Fstrong> must be suitable for its intended use and routinely tested to ensure ongoing conformance with appropriate chemical and microbiological attributes. Routine monitoring of microbial counts and identity of contamination in the system is integral to maintaining a state of control and suitability of \u003Cstrong>(b)(4)\u003C\u002Fstrong> for use in manufacturing operations.\u003C\u002Fp>\u003Cp>In your response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A detailed summary of your validation program for ensuring a state of control throughout the product lifecycle, along with associated procedures. Describe your program for process performance qualification (PPQ), and ongoing monitoring of both intra-batch and inter-batch variation to ensure a continuing state of control.\u003C\u002Fli>\u003Cli>A timeline for performing appropriate PPQ for each of your marketed drug products.\u003C\u002Fli>\u003Cli>Process performance protocol(s), and written procedures for qualification of equipment and facilities.\u003C\u002Fli>\u003Cli>A detailed program for designing, validating, maintaining, controlling and monitoring each of your manufacturing processes that includes vigilant monitoring of intra-batch and inter-batch variation to ensure an ongoing state of control. Also, include your program for qualification of your equipment and facility.\u003C\u002Fli>\u003Cli>A comprehensive remediation plan for the design, control, and maintenance of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> system.\u003C\u002Fli>\u003Cli>A \u003Cstrong>(b)(4)\u003C\u002Fstrong> system validation report. Also include the summary of any improvements made to system design and to the program for ongoing control and maintenance.\u003C\u002Fli>\u003Cli>Your total microbial count limits to monitor whether this system is producing \u003Cstrong>(b)(4)\u003C\u002Fstrong> suitable for the intended uses for each of your products.\u003C\u002Fli>\u003Cli>A detailed risk assessment addressing the potential effects of the observed \u003Cstrong>(b)(4)\u003C\u002Fstrong> system failures on the quality of all drug product lots currently in U.S. distribution. Specify actions that you will take in response to the risk assessment, such as customer notifications and product recalls.\u003C\u002Fli>\u003Cli>A procedure for your \u003Cstrong>(b)(4)\u003C\u002Fstrong> system monitoring that specifies routine microbial testing of \u003Cstrong>(b)(4)\u003C\u002Fstrong> to ensure its acceptability for use in each batch of drug products produced by your firm.\u003C\u002Fli>\u003Cli>A procedure governing your program for ongoing control, maintenance, and monitoring that ensures the remediated system consistently produces \u003Cstrong>(b)(4)\u003C\u002Fstrong> that meets \u003Cstrong>(b)(4)\u003C\u002Fstrong>, USP monograph specifications and appropriate microbial limits.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>Drug Production Suspended\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>We acknowledge that you delisted your OTC drug product with FDA. In response to this letter, clarify whether you intend to resume manufacturing drugs for the U.S. market at this facility in the future.\u003C\u002Fp>\u003Cp>If you plan to resume any manufacturing operations regulated under the FD&amp;C Act, notify this office before resuming your drug manufacturing operations. You are responsible for resolving all deficiencies and systemic flaws to ensure your firm is capable of ongoing CGMP compliance. In your notification to the Agency, provide a summary of your remediations to demonstrate that you have appropriately completed all corrective actions and preventive actions (CAPAs).\u003C\u002Fp>\u003Cp>\u003Cstrong>CGMP Consultant Recommended\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Based upon the nature of the violations we identified at your firm, you should engage a consultant qualified as set forth in 21 CFR 211.34 to assist your firm in meeting CGMP requirements. The qualified consultant should also perform a comprehensive six-system audit of your entire operation for CGMP compliance and evaluate the completion and efficacy of your corrective actions and preventive actions before you pursue resolution of your firm’s compliance status with FDA. Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\u003C\u002Fp>\u003Cp>See FDA’s guidance document \u003Cem>Quality Systems Approach to Pharmaceutical CGMP Regulations\u003C\u002Fem> for help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR, parts 210 and 211 at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload.\u003C\u002Fp>\u003Cp>\u003Cstrong>Cosmetics Manufactured for Distribution in the United States\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>In addition, we note that some of the products you manufacture may be regulated as cosmetics, as defined in section 201(i) of the FD&amp;C Act [21 U.S.C. 321(i)]. Any cosmetics you manufacture must comply with applicable statutory and regulatory requirements, including the FD&amp;C Act. Under section 301(a) of the FD&amp;C Act [21 U.S.C. 331(a)], it is a prohibited act to introduce or deliver for introduction into interstate commerce a cosmetic that is adulterated or misbranded.\u003C\u002Fp>\u003Cp>Further, your facility may be subject to requirements of the Modernization of Cosmetics Regulation Act of 2022 (MoCRA). Information on MoCRA requirements may be found at\u003Cbr>https:\u002F\u002Fwww.fda.gov\u002Fcosmetics\u002Fcosmetics-laws-regulations\u002Fmodernization-cosmetics-regulation-act-2022-mocra.\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\u003C\u002Fp>\u003Cp>Correct any violations promptly. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to any violations.\u003C\u002Fp>\u003Cp>Failure to address any violations may also result in the FDA refusing admission of articles manufactured at Marshalls Traditional Healthcare CC, FEI 3014740544, at 560 Main Reef Road, Germiston, Gauteng 1400, South Africa, into the United States under section 801(a)(3) of the FD&amp;C Act, 21 U.S.C. 381(a)(3). Articles under this authority that appear to be adulterated may be detained or refused admission, in that the methods and controls used in their manufacture do not appear to conform to CGMP within the meaning of section 501(a)(2)(B) of the FD&amp;C Act, 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\u003Cp>Send your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3014740544 and ATTN: Christopher M. Jenner.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Francis Godwin\u003Cbr>Director\u003Cbr>Office of Manufacturing Quality\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA Electronic Mail\n\nReference #:\n\n320-25-43\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMr. Vick Maharaj\n\nRecipient Title\n\nChief Executive Officer\n\nMarshalls Traditional Healthcare CC\n\n560 Main Reef Road\n\nGermiston\n\nGauteng\n\n1400\n\nSouth Africa\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nWarning Letter 320-25-43\nFebruary 10, 2025\nDear Mr. Maharaj:\nThe U.S. Food and Drug Administration (FDA) inspected your drug manufacturing facility, Marshalls Traditional Healthcare CC, FEI 3014740544, at 560 Main Reef Road, Germiston, from September 19 to 23, 2024.\nThis warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug product is adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B).\nWe reviewed your October 11, 2024, response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\nCGMP Violations\n1. Your firm failed to have, for each batch of drug product, appropriate laboratory determination of satisfactory conformance to final specifications for the drug product, including the identity and strength of each active ingredient, prior to release. Your firm also failed to conduct, for each batch of drug product, appropriate laboratory testing, as necessary, required to be free of objectionable microorganisms (21 CFR 211.165(a) and 211.165(b)).\nYour firm manufactures an over-the-counter (OTC) (b)(4) drug product. Your firm failed to conduct adequate finished product release testing for each batch of your drug product, including but not limited to, testing the identity and strength of the active ingredient, (b)(4) and testing for objectionable microorganisms.\nIn your response, you state that you developed and validated an updated test method, and updated release specifications, for the labeled active ingredient, (b)(4). You also state that you will perform all appropriate USP \u003C61> and \u003C62> testing for your finished drug products. Your response is inadequate as you did not provide sufficient details regarding the specific tests to be performed for each batch of finished drug product. You also did not consider a risk assessment or retrospective review of products that have been released without appropriate testing.\nWithout adequate finished product release testing, you do not have scientific evidence that each batch of drug product conforms to appropriate specifications before release.\nIn your response to this letter, provide:\nA comprehensive, independent assessment of your laboratory practices, procedures, methods, equipment, documentation, and analyst competencies. Based on this review, provide a detailed plan to remediate and evaluate the effectiveness of your laboratory system.\nA list of chemical and microbial specifications, including test methods, used to analyze each lot of your drug products before a lot disposition decision.\n2. Your firm failed to establish adequate written procedures for production and process control designed to assure that the drug products you manufacture have the identity, strength, quality, and purity they purport or are represented to possess, and to follow all of your written production and process control procedures (21 CFR 211.100(a) and 211.100(b)).\nInadequate Process Validation\nYou did not have data to demonstrate that you adequately validate your manufacturing processes used to manufacture your OTC drug products and demonstrate that your processes are reproducible and controlled to consistently yield drugs of uniform character and quality. For example, your validation plan, “VALIDATOIN MASTER PLAN (VMP),” describes requirements for process validation and hold time studies. However, the protocol implementing your validation planed, “PROCESS VALIDATION PROTOCOL,” failed to include operating parameters, such as bulk hold times, or processing limits, such as acceptance criteria for process parameters.\nIn your response, you provided your updated process validation protocol. Your response is inadequate as it did not include hold times and lacked appropriate details such as adequate sampling instructions. The updated protocol also did not include the batch production record associated with the first validation batch.\nProcess validation evaluates the soundness of design and state of control of a process throughout its lifecycle. Each significant stage of a manufacturing process must be designed appropriately and assure the quality of raw material inputs, in-process materials, and finished drugs. Process qualification studies determine whether an initial state of control has been established. Successful process qualification studies are necessary before commercial distribution. Thereafter, ongoing vigilant oversight of process performance and product quality is necessary to ensure you maintain a stable manufacturing operation throughout the product lifecycle.\nSee FDA's guidance for industry, Process Validation: General Principles and Practices for general principles and approaches that FDA considers appropriate elements of process validation at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71021\u002Fdownload.\nInadequate Control of (b)(4) System\nYour firm uses (b)(4) as a component to manufacture your OTC drug product. You failed to ensure that your (b)(4) system is suitable for producing (b)(4) used in the formulation of your drug product. For example, you turned your (b)(4) system off when not in use, stopping its circulation, which deviates from its design use as a continuously recirculating system. In addition, you failed to demonstrate that your (b)(4) system is adequately monitored to ensure it consistently produces (b)(4) that meets appropriate chemical and microbial attributes.\nIn your response, you state that your (b)(4) system will continuously (b)(4). Your response is inadequate. You did not address the adequacy of your overall (b)(4) system design to ensure that your (b)(4) meets, at a minimum, the USP (b)(4) monograph and appropriate microbial limits. You also did not provide interim measures and assess the impact of using (b)(4) from an inadequately validated (b)(4) system on the quality of drug products you manufacture.\nPharmaceutical (b)(4) must be suitable for its intended use and routinely tested to ensure ongoing conformance with appropriate chemical and microbiological attributes. Routine monitoring of microbial counts and identity of contamination in the system is integral to maintaining a state of control and suitability of (b)(4) for use in manufacturing operations.\nIn your response to this letter, provide:\nA detailed summary of your validation program for ensuring a state of control throughout the product lifecycle, along with associated procedures. Describe your program for process performance qualification (PPQ), and ongoing monitoring of both intra-batch and inter-batch variation to ensure a continuing state of control.\nA timeline for performing appropriate PPQ for each of your marketed drug products.\nProcess performance protocol(s), and written procedures for qualification of equipment and facilities.\nA detailed program for designing, validating, maintaining, controlling and monitoring each of your manufacturing processes that includes vigilant monitoring of intra-batch and inter-batch variation to ensure an ongoing state of control. Also, include your program for qualification of your equipment and facility.\nA comprehensive remediation plan for the design, control, and maintenance of the (b)(4) system.\nA (b)(4) system validation report. Also include the summary of any improvements made to system design and to the program for ongoing control and maintenance.\nYour total microbial count limits to monitor whether this system is producing (b)(4) suitable for the intended uses for each of your products.\nA detailed risk assessment addressing the potential effects of the observed (b)(4) system failures on the quality of all drug product lots currently in U.S. distribution. Specify actions that you will take in response to the risk assessment, such as customer notifications and product recalls.\nA procedure for your (b)(4) system monitoring that specifies routine microbial testing of (b)(4) to ensure its acceptability for use in each batch of drug products produced by your firm.\nA procedure governing your program for ongoing control, maintenance, and monitoring that ensures the remediated system consistently produces (b)(4) that meets (b)(4), USP monograph specifications and appropriate microbial limits.\nDrug Production Suspended\nWe acknowledge that you delisted your OTC drug product with FDA. In response to this letter, clarify whether you intend to resume manufacturing drugs for the U.S. market at this facility in the future.\nIf you plan to resume any manufacturing operations regulated under the FD&C Act, notify this office before resuming your drug manufacturing operations. You are responsible for resolving all deficiencies and systemic flaws to ensure your firm is capable of ongoing CGMP compliance. In your notification to the Agency, provide a summary of your remediations to demonstrate that you have appropriately completed all corrective actions and preventive actions (CAPAs).\nCGMP Consultant Recommended\nBased upon the nature of the violations we identified at your firm, you should engage a consultant qualified as set forth in 21 CFR 211.34 to assist your firm in meeting CGMP requirements. The qualified consultant should also perform a comprehensive six-system audit of your entire operation for CGMP compliance and evaluate the completion and efficacy of your corrective actions and preventive actions before you pursue resolution of your firm’s compliance status with FDA. Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\nSee FDA’s guidance document Quality Systems Approach to Pharmaceutical CGMP Regulations for help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR, parts 210 and 211 at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload.\nCosmetics Manufactured for Distribution in the United States\nIn addition, we note that some of the products you manufacture may be regulated as cosmetics, as defined in section 201(i) of the FD&C Act [21 U.S.C. 321(i)]. Any cosmetics you manufacture must comply with applicable statutory and regulatory requirements, including the FD&C Act. Under section 301(a) of the FD&C Act [21 U.S.C. 331(a)], it is a prohibited act to introduce or deliver for introduction into interstate commerce a cosmetic that is adulterated or misbranded.\nFurther, your facility may be subject to requirements of the Modernization of Cosmetics Regulation Act of 2022 (MoCRA). Information on MoCRA requirements may be found at\nhttps:\u002F\u002Fwww.fda.gov\u002Fcosmetics\u002Fcosmetics-laws-regulations\u002Fmodernization-cosmetics-regulation-act-2022-mocra.\nConclusion\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\nCorrect any violations promptly. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to any violations.\nFailure to address any violations may also result in the FDA refusing admission of articles manufactured at Marshalls Traditional Healthcare CC, FEI 3014740544, at 560 Main Reef Road, Germiston, Gauteng 1400, South Africa, into the United States under section 801(a)(3) of the FD&C Act, 21 U.S.C. 381(a)(3). Articles under this authority that appear to be adulterated may be detained or refused admission, in that the methods and controls used in their manufacture do not appear to conform to CGMP within the meaning of section 501(a)(2)(B) of the FD&C Act, 21 U.S.C. 351(a)(2)(B).\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\nSend your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3014740544 and ATTN: Christopher M. Jenner.\nSincerely,\n\u002FS\u002F\nFrancis Godwin\nDirector\nOffice of Manufacturing Quality\nOffice of Compliance\nCenter for Drug Evaluation and Research","Marshalls Traditional Healthcare CC","marshalls-traditional-healthcare-cc-697697-02102025","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fmarshalls-traditional-healthcare-cc-697697-02102025","2026-10-26T08:09:20.909625+00:00","2025-02-18","697697","Mr. Vick Maharaj","2026-08-19T17:01:31.89+00:00","320-25-43","2025-02-10",{"id":325,"raw":326,"subject":330,"body_html":331,"body_text":332,"firm_name":333,"letter_id":334,"created_at":173,"fei_number":20,"letter_url":335,"updated_at":336,"action_type":23,"case_status":24,"posted_date":337,"marcs_cms_no":338,"product_type":176,"closeout_date":20,"issuing_office":11,"recipient_name":339,"body_fetched_at":340,"delivery_method":179,"recipient_title":20,"reference_number":341,"action_taken_date":342,"medical_device_id":20,"response_letter_date":20},22203,[327,328,329,11,330,13,13,13],"\u003Ctime datetime=\"2026-11-10T05:00:00Z\">11\u002F10\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2026-10-29T04:00:00Z\">10\u002F29\u002F2026\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Ftianjin-healthcare-medical-technology-co-ltd-736415-10292026\">Tianjin Healthcare Medical Technology Co., Ltd.\u003C\u002Fa>","Refusal to Provide Access to and Copying of Records","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA ELECTRONIC MAIL READ\u002FDELIVERY RECEIPT REQUESTED\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>320-27-15\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n                          \u003Cbr>Over-the-Counter Drugs\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Jianyu Zhao\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Firm Contact\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Tianjin Healthcare Medical Technology Co., Ltd.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>2-2066, No 88 HuanHe South Road\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Tianjin Free Trade Pilot Zone\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>KongGang Economic Zone\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Tianjin Shi\u003C\u002Fspan>, \u003Cspan>300000\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>China\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:(b)(6)\"> (b)(6)\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>October 29, 2026\u003Cbr>&nbsp;\u003C\u002Fp>\u003Cp>WARNING LETTER\u003Cbr>Reference number: 320-27-15\u003C\u002Fp>\u003Cp>To Jianyu Zhao:\u003C\u002Fp>\u003Cp>This warning letter advises you of a significant violation identified during a U.S. Food and Drug Administration (FDA) review of records from your facility and provides you the opportunity to address them. This is not intended to be an all-inclusive list of violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations. Failure to adequately address any violations may result in regulatory action without further notice.\u003C\u002Fp>\u003Cp>Your facility, Tianjin Healthcare Medical Technology Co., Ltd. (hereafter THM), FDA Establishment Identifier (FEI) # 3015495180 at 2-2066, No 88 HuanHe South Road, Tianjin Free Trade Pilot Zone, KongGang Economic Zone, Tianjin is registered with the FDA as a manufacturer of active pharmaceutical ingredients (APIs).\u003C\u002Fp>\u003Cp>A review of import records showed multiple shipments of APIs intended for pharmacy compounding into the U.S., which declared THM, as the drug manufacturer. The FDA sent requests for records and other information, pursuant to section 704(a)(4) of the Federal Food, Drug and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 374(a)(4), to the contact email address provided in your registration file. Your firm refused to provide the duly requested records.\u003C\u002Fp>\u003Cp>It is a prohibited act under section 301(e) of the FD&amp;C Act (21 U.S.C. 331(e)) to refuse to permit access to or copying of any record as required by section 704(a). Because your firm failed to respond to the section 704(a)(4) records requests and associated communication attempts, we have no indication of the level of quality assurance for drugs listed as manufactured at your facility.\u003C\u002Fp>\u003Cp>\u003Cstrong>Refusal to Provide Records\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>On June 17, 2026, the FDA sent an electronic records request to the contact email address provided in your registration file. You replied on June 24, 2026, that you would “discontinue the production of relevant \u003Cstrong>(b)(4)\u003C\u002Fstrong> products” for the U.S. market and refused to provide the requested documents. A follow up request was sent on June 25, 2026, informing you that APIs your firm manufactured were imported to the U.S. market and were still within expiry. Therefore, the requested records were still required. You responded that you would not provide the requested records.\u003C\u002Fp>\u003Cp>Simply ceasing commercial distribution or expressing an intent to stop production does not retroactively relieve you of your regulatory obligations.\u003C\u002Fp>\u003Cp>FDA placed all drugs and drug products offered for import into the U.S. from your firm on Import Alert 66-79 on August 25, 2026.\u003C\u002Fp>\u003Cp>If you no longer intend to manufacture or distribute drug products for the U.S. market, you must formally update your registration and drug listings to reflect this change in operations. Pursuant to 21 CFR 207.29(a)(3), an establishment must update its registration within 30 calendar days of ceasing operations.\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The violation cited in this letter is not intended to be an all-inclusive list of violations at your facility.\u003C\u002Fp>\u003Cp>Until FDA is able to confirm compliance with CGMP and other applicable requirements, we may withhold approval of any new applications or supplements listing your firm as a drug manufacturer. In addition, shipments of articles manufactured at THM, 2-2066, No 88 HuanHe South Road, Tianjin Free Trade Pilot Zone, KongGang Economic Zone, Tianjin into the U.S. that appear to be adulterated or misbranded are subject to being detained or refused admission pursuant to section 801(a)(3) of the FD&amp;C Act, 21 U.S.C. 381(a)(3).\u003C\u002Fp>\u003Cp>In response to this letter, you may submit a request to schedule an FDA inspection.\u003C\u002Fp>\u003Cp>Send your written response to CDER-OC-OMQ-Communications@fda.hhs.gov within fifteen (15) business days of receipt of this letter. Identify your written response with FEI 3015495180 and ATTN: Marva Taylor in the letter in the subject line of the email.\u003C\u002Fp>\u003Cp>If you have information that you believe demonstrates that your products are not in violation of the FD&amp;C Act and FDA regulations, include that information for our consideration.\u003C\u002Fp>\u003Cp>FDA posts warning letters to www.FDA.gov.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Francis Godwin\u003Cbr>Director\u003Cbr>Office of Manufacturing Quality\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003Cbr>U.S. Food and Drug Administration\u003C\u002Fp>\u003Cp>cc: U.S. agent\u003Cbr>\u003Cstrong>(b)(6)\u003C\u002Fstrong>\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA ELECTRONIC MAIL READ\u002FDELIVERY RECEIPT REQUESTED\n\nReference #:\n\n320-27-15\n\nProduct:\n\nDrugs\n\nOver-the-Counter Drugs\n\nRecipient:\n\nRecipient Name\n\nJianyu Zhao\n\nRecipient Title\n\nFirm Contact\n\nTianjin Healthcare Medical Technology Co., Ltd.\n\n2-2066, No 88 HuanHe South Road\n\nTianjin Free Trade Pilot Zone\n\nKongGang Economic Zone\n\nTianjin Shi, 300000\n\nChina\n\n(b)(6)\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nOctober 29, 2026\n\nWARNING LETTER\nReference number: 320-27-15\nTo Jianyu Zhao:\nThis warning letter advises you of a significant violation identified during a U.S. Food and Drug Administration (FDA) review of records from your facility and provides you the opportunity to address them. This is not intended to be an all-inclusive list of violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations. Failure to adequately address any violations may result in regulatory action without further notice.\nYour facility, Tianjin Healthcare Medical Technology Co., Ltd. (hereafter THM), FDA Establishment Identifier (FEI) # 3015495180 at 2-2066, No 88 HuanHe South Road, Tianjin Free Trade Pilot Zone, KongGang Economic Zone, Tianjin is registered with the FDA as a manufacturer of active pharmaceutical ingredients (APIs).\nA review of import records showed multiple shipments of APIs intended for pharmacy compounding into the U.S., which declared THM, as the drug manufacturer. The FDA sent requests for records and other information, pursuant to section 704(a)(4) of the Federal Food, Drug and Cosmetic Act (FD&C Act), 21 U.S.C. 374(a)(4), to the contact email address provided in your registration file. Your firm refused to provide the duly requested records.\nIt is a prohibited act under section 301(e) of the FD&C Act (21 U.S.C. 331(e)) to refuse to permit access to or copying of any record as required by section 704(a). Because your firm failed to respond to the section 704(a)(4) records requests and associated communication attempts, we have no indication of the level of quality assurance for drugs listed as manufactured at your facility.\nRefusal to Provide Records\nOn June 17, 2026, the FDA sent an electronic records request to the contact email address provided in your registration file. You replied on June 24, 2026, that you would “discontinue the production of relevant (b)(4) products” for the U.S. market and refused to provide the requested documents. A follow up request was sent on June 25, 2026, informing you that APIs your firm manufactured were imported to the U.S. market and were still within expiry. Therefore, the requested records were still required. You responded that you would not provide the requested records.\nSimply ceasing commercial distribution or expressing an intent to stop production does not retroactively relieve you of your regulatory obligations.\nFDA placed all drugs and drug products offered for import into the U.S. from your firm on Import Alert 66-79 on August 25, 2026.\nIf you no longer intend to manufacture or distribute drug products for the U.S. market, you must formally update your registration and drug listings to reflect this change in operations. Pursuant to 21 CFR 207.29(a)(3), an establishment must update its registration within 30 calendar days of ceasing operations.\nConclusion\nThe violation cited in this letter is not intended to be an all-inclusive list of violations at your facility.\nUntil FDA is able to confirm compliance with CGMP and other applicable requirements, we may withhold approval of any new applications or supplements listing your firm as a drug manufacturer. In addition, shipments of articles manufactured at THM, 2-2066, No 88 HuanHe South Road, Tianjin Free Trade Pilot Zone, KongGang Economic Zone, Tianjin into the U.S. that appear to be adulterated or misbranded are subject to being detained or refused admission pursuant to section 801(a)(3) of the FD&C Act, 21 U.S.C. 381(a)(3).\nIn response to this letter, you may submit a request to schedule an FDA inspection.\nSend your written response to CDER-OC-OMQ-Communications@fda.hhs.gov within fifteen (15) business days of receipt of this letter. Identify your written response with FEI 3015495180 and ATTN: Marva Taylor in the letter in the subject line of the email.\nIf you have information that you believe demonstrates that your products are not in violation of the FD&C Act and FDA regulations, include that information for our consideration.\nFDA posts warning letters to www.FDA.gov.\nSincerely,\n\u002FS\u002F\nFrancis Godwin\nDirector\nOffice of Manufacturing Quality\nOffice of Compliance\nCenter for Drug Evaluation and Research\nU.S. Food and Drug Administration\ncc: U.S. agent\n(b)(6)","Tianjin Healthcare Medical Technology Co., Ltd.","tianjin-healthcare-medical-technology-co-ltd-736415-10292026","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Ftianjin-healthcare-medical-technology-co-ltd-736415-10292026","2026-11-17T01:02:49.409207+00:00","2026-11-10","736415","Jianyu Zhao","2026-11-17T01:02:49.249+00:00","320-27-15","2026-10-29",17,{"510k":345,"classification":346,"enforcement":347,"event":348,"event_backfill":349,"pma":350,"warning_letter":351},"2026-11-16T02:00:55.89+00:00","2026-11-16T02:00:41.999+00:00","2026-11-16T02:00:49.415+00:00","2026-11-17T04:00:34.414+00:00","2026-09-07T05:17:28.839+00:00","2026-11-16T02:01:03.155+00:00","2026-11-17T01:02:55.859+00:00"]